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Abstract
The effect o f  psychoactive drugs on sleep is traditionally evaluated with polysomnography 
(PSG) whereas daytime effects are conventionally assessed with psychometric tests to 
measure changes in daytime cognition and psychomotor functioning. This thesis examines 
whether the actigraph, a non-invasive tool, that records rest-activity patterns has the ability to 
measure drug-induced changes in daytime activity patterns and in sleep.
Two studies were designed to assess the acute effects o f  psychoactive drugs on daytime 
activity levels and sleep in a controlled laboratory environment with healthy participants. In 
the first study participants were randomised to a double-blind, placebo-controlled, crossover 
trial with lorazepam (LZP), a benzodiazepine sedating hypnotic. Actigraphic activity levels
were significantly reduced following LZP dosing (2.5 mg) and these changes were reflected 
by impairment o f cognitive and psychomotor performance.
Participants in the second laboratory study were randomised to a double-blind, placebo- 
controlled, crossover trial with the sedating antihistamine promethazine. Reduced activity 
levels reflected changes in significant impairment o f  cognitive and psychomotor 
performance. Actigraphy therefore appeared to be sensitive to acute sedating effects and was 
able to detect changes in sleep behaviour.
Since antidepressants arc only effective after chronic adm inistration the effects o f treatment 
was investigated in a third field study. Depressed patients were random ised to a doublc- 
blind, parallel group, multi-centre, 14 week study o f the antidepressants paroxetine, 
fluoxetine or sertraline, including abrupt discontinuation. Activity was recorded continuously 
throughout the whole study. Significant improvement in patients' subjective mood scales, as 
depression was alleviated, was reflected in changes in actigraphic sleep and activity profiles.
The findings provide an indication o f  the usefulness o f  actigraphy as a diagnostic tool to 
measure psychoactive drug-induced changes following medication. Further work should 
concentrate on standardising procedures, study design and algorithms. Actigraphy may thus 
be a useful sensitive tool in assessing the psychopharmacology o f  psychoactive medication.
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CHAPTER 1 INTRODUCTION
1.1. Introduction
Actigraphy is an objective measure o f the sleep wake cycle and is measured by the 
continuous measurement o f activity using an actigraph usually worn on the non-dominant 
wrist. The development o f actigraphy has allowed rest-activity patterns to be measured in 
different population groups and it provides a more accurate representation o f  sleep timing 
and patterns than sleep logs or diaries (Girschik e/ a/., 2012). Whilst polysomnography 
(PSG) remains the gold standard for assessing sleep, actigraphy has offered a cheaper, less 
invasive alternative, which has the added advantage o f  being able to monitor rest and activity 
patterns for longer periods o f  time in situations where an intensive in-house assessment o f  
sleep would be difficult. In addition changes in activity can be observed and m easured 
following intervention where other methods would be inappropriate.
1.2. Actigraphy
1.2.1. Uses
Actigraphy is widely accepted as a non-invasive tool for assessing sleep-wake patterns in 
reviews o f a number o f  different groups (reviewed in Sadeh gr a/., 1995; Ancoli-Israel a/.,
2003; Littner et a l, 2003), including, but not exclusive, sleep medicine (Sadeh, 2011), 
insomnia (Hauri and W isbey, 1992; Lichstein et a l,  2006), sleep-related breathing (Acebo 
and LeBourgeois, 2006), children (Acebo gt a/., 2005), restless legs (King gt a/., 2005), 
depression (Royant-Parola et a l,  1986; Raoux et a l,  1994) and circadian rhythm  disorders 
(Lockley a/., 1999; Ancoli-Israel et a/., 2003).
The use o f  actigraphy has been reviewed extensively for clinical and non-clinical use, 
including assessment o f sleep-wake patterns in non-sleep related chronic conditions for 
patients such as those with poor mental health i.e. A lzheim er’s disease (Van Someren et al.,
1999) and psychiatric disorders (Teicher, 1995) as well as patients suffering with cancer 
(Chevalier et a l, 2003). Actigraphy has been specifically used for sleep medicine in various 
different populations and patient groups as described in the review by Sadeh, (2011) who 
also outlined many o f  the issues surroimding the technology including the assessment o f  
'wake' in the sleep period for insomniacs in particular and the different devices and 
algorithms for calculating the sleep variables. In addition actigraphy has been applied to the 
sports related field with its use as an activity m onitor for daytime activities (reviewed in 
Matthews a/., 2012).
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Diagnosis and treatment o f  circadian rhythm disorders benefit particularly from the use o f
actigraphy. Long term analysis o f  the profiles leads to a better understanding o f  the 24 h 
pattern o f  these and other psychiatric diseases as seen in review (M orgenthaler et a l,  2007b) 
and different methodological approaches have been described (Calogiuri e/ a/., 2013).
1.2.2. History and development
Sleep-wake patterns were historically recorded by observation or through Electro- 
Encephalograph (EEG) or Polysomnography (PSG) with full body kit by attaching 
electrodes to the scalp to measure changes in electrical activity, however, these assessments 
are expensive, time consuming and only offer snapshots o f  time. The m easurem ent o f 
activity w ith mechanical monitors, which began in the late 1950’s, was developed to study 
human activity and sleep-wake patterns with self-winding wrist watches. The first solid state 
actigraph was described as '/f» wz^ /z .yoW ZMe/zzozy' in a
study by Colburn ez' a/. (1976) and was used to measure movement over 24 h to assess the 
differences in activity levels in manic-depressives in different episodes o f  depression. 
Activity was recorded via a piezo-electric accelerometer which recorded a voltage every 
time a m ovement was made which was converted to an activity count and stored in the 
memory. The accumulated data were downloaded for analysis.
Actigraphs were developed for the purpose o f  recording continuous activity data and it was 
shown that low level activity could be manually scored as 'sleep-like' in comparison to EEG 
(Mullaney a/., 1980). This was taken further by Cole g/ a/. (1992) who developed an 
automatic algorithm which could discriminate between sleep and wake and this enabled the 
actigraphs to be seen as cheaper alternatives to EEG recording.
The early versions were large and cumbersome and recorded activity for short periods o f 
time. However, these devices have been constantly refined over the years to become the 
small inexpensive models now available. With the advent o f  better memory storage and 
battery life they can record for longer periods up to 180 days depending on the epoch 
employed. By recording continuously, lower activity levels occurring during the day, which 
may be associated with naps, tiredness or sedation, can also be detected. These devices have 
been further developed and coupled to other portable sensors or monitors that also record 
light, heart rate, sleep, respiration and core body temperature.
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1.2.3. Actigraph types
The generic term for an activity m onitor is an actigraph; there are many types on the market 
w ith various brand names to denote their specificity. All types o f  actigraphs basically consist 
o f  a small device worn on the non-dom inant wrist which contains a motion sensor. The 
sensor or piezo-electric accelerom eter generates a signal voltage every time it is moved and 
this is stored as a count in the memory and recorded as activity. Dedicated software 
programs are associated with each device and the collection and interpretation o f the data. 
Currently there are devices which have been developed for a variety o f  specialised uses 
including monitoring activity and exercise, calorific output and non-movement in bed in the 
care home scenario as well as prom pting the user to respond to commands and subjective 
ratings. The two most commonly used actigraphs produced are the M ini-M otionlogger and 
the Actiwatch and these are discussed in more detail (Sections 1.2.3.1 and 1.2.3.2).
1.2.3.1. M ini-M otionlogger
This device, m anufactured by Am bulatory M onitoring Inc. (AMI), (731 Saw M ill River 
Road, P.O. 609, Ardsley, New York. 10502-0609) (Figure 1.1) was originally developed in 
conjunction with the US Army to m onitor fatigue in soldiers. It contains a piezo-electric 
accelerom eter which generates a signal voltage for every movement, this voltage is then 
compared with a reference signal and the num ber o f  times where the movem ent crosses the 
reference Zero Crossing M ode (ZCM ) or is above the threshold Time Above Threshold 
(TAT) during a defined epoch is recorded. This reflects the num ber o f  movements but not 
the intensity. This count is stored in the m em ory unit and the data are downloaded onto a 
com puter and analysed with the ‘A ction4’ software program. They are available with 
different type faces as shown. A typical actogram activity plot from the Action4 software is 
shown in Figure 1.2.
Figure 1.1: New versions of the Mini-Motionlogger (2009 catalogue)
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Figure 1.2: Windows version of Action4 circadian rhythm and research software activity plot 
1.2.3.2. Actiwatch
Developed by Cambridge Neurotechnology Ltd (CNT) (Upper Pendrill Court, Enuine Street 
North, Papworth Everard, Cambridge, CB3 8UY), this device, now obsolete, was known as 
the original Actiwatch (Figure 1.3). It houses a piezo-electric accelerometer which digitally 
integrates the intensity, am ount and duration o f movement for each epoch and stores this as 
an activity count, data are downloaded onto a com puter and analysed using the proprietary 
software ‘Sleepwatch’.
iriSTIjEBEl
Figure 1.3: Actiwatch 4 Series used in this thesis
The electronics in the device check the amplitude o f the signal generated by the 
accelerometer thirty two times a second and records the highest count in that second, the 
num ber o f  counts being proportional to the intensity. A  diagrammatic view to show the 
mechanism is shown in Figure 1.4. The sum o f the highest counts for each individual 1-
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second interval is then logged and presented as the number o f counts in the epoch period 
defined by the user. A  screen view o f the activity plot as an actogram is shown in Figure 1.5.
This Actiwatch 4 Series as described above was used for the studies in this thesis. Since then 
the rights to the Actiwatch were sold to Philips Respironics (Section 1.2.3.4) who retain the 
name. Cambridge Neurotechnology has since rebranded as CamNtech ® and developed a 
new er version called the M otionW atch 8 which is briefly described in the following section 
(Section 1.2.3.3).
Accelerometer 
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Figure 1.4; Diagrammatic view to show the mechanism of the Actiwatch piezo-electric accelerometer
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Figure 1.5: Actogram double plot showing the activity screen using the Actiwatch software
1.2.3.3. M otionW atch 8
This device from CamNtech, as shown in Figure 1.6, works o ff the same principles as the 
Actiwatch but with a m odem  style and with extended battery and memory it is able to store
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data for up to 180 days. It connects to a com puter via a USB port. A screen view o f  the 
activity plot as an actogram is shown in Figure 1.7.
Figure 1.6: MotionWatch 8
^ N3 H li INILGRTTY CHKK CAtiimVHa*»d Smith'JWdmantsVUI RûCSVB'.MûUyiWaltt* 8
nie Vie# Tocts
22 2C12
S d c c t  S d c c t  S d e c t
All nay(R ) Any
19-CQ 00 W
iu .i i j i j iy i  I
'  la.oo 00»
ocoo
0000 Ttiu12.np
ili
II
0 6 »  Sat-M Apr
Figure 1.7: MotionWatch 8 Actogram screen view
1.2.3.4. Actiwatch 2 and spectrum (Philips)
The devices from Philips are shown in Figure 1.8, they are more stylish than the original 
Actiwatch and have an inbuilt marker and light sensor. The ‘'integrated light sensors in the 
Spectrum provide irradiance and luminous flux recordings in red, gf'een, and blue colour 
bands and a white light measurement in lux' as taken from their brochure.
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Figure 1.8: Actiwatch 2 and Spectrum (Philips)
1.2.3.5. Other devices
Early research was conducted using the Gaehwiler M onitor (Hoinbrechtikon, Zurich, 
Switzerland). This Swiss actigraph was one o f the first commercial devices developed 
however it is no longer available. There are a num ber o f  other devices relatively new to the 
market including GENEActive Sleep (Unit 11, Harvard Industrial Estate, Kimbolton, 
Cambs, PE28 ONJ), Somnowatch (SOM NOmedics, GmbH & Co. KG, Nonnengarten 8, D- 
97270. Gemiany), Body Bug (BodyM edia, Inc., 4 Smithfield Street, 11* Floor, Pittsburgh, 
PA 15222), ActiGraph (Actigraph, EEC, 709 Anchors Street, NW , Fort W alton Beach, 
Florida. FL 32528), ActiTrac (IMSystems, 1055 Taylor Avenue, Suite 300, Baltimore, MD 
21286) and Vivago (1ST, International Security Technology, M elkonkatu 16A, FI-00210 
Helsinki, Finland.) to name but a few and these devices essentially work in the same way as 
those previously discussed. However, there are very little published data on these devices 
and their performance; most research papers quote the use o f  Actiwatch or Actigraph. Newer 
versions have been introduced into the daytime activity arena for measuring sport and 
exercise science related performance and data from  their analysis packages have not been 
published for clinical research.
1.2.4. M easurem ent o f activity with the Actiwatch
Activity is recorded continuously, using various epoch lengths ranging from 0.25 to epochs 
in excess o f  10 minutes. As there is a finite storage capacity in the memory o f  the Actiwatch 
used in this thesis, the range o f  epochs enables the user to store data for different lengths o f 
time from 11 days using the 0.25 min epoch to 90 days using the 2 minute epoch. The 
shorter 0.25 epoch allows greater differentiation o f the m ovement and to record activity that 
is high in num ber o f movements such as those seen in Parkinson’s or restless legs syndrome 
(RLS) (King et a l, 2005). The longer 1-2 min epoch is useful for studying activity and sleep 
wake patterns in relation to circadian activity rhythms to define and indicate circadian phase 
(Ancoli-Israel et a l, 2003; Arendt et a l,  2006).
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The most common epoch setting employed for activity information with the Actiwatch is 
that o f  1 minute where the user can study a continuous pattern o f  24 h o f  rest and wake 
activity for up to 45 days. For the analysis o f  sleep and wake in comparison to PSG a 30 sec 
epoch setting can be used. However, this reduces the overall recording capacity o f  the 
memory to 22 days. An epoch setting o f  2 minutes can be deployed if  a longer recording 
time is required which will provide reliable rest-activity data for records up to 90 days.
The sensitivity settings can also be altered in the Actiwatch. Medium sensitivity is the 
default setting which is set at a total score o f  40 counts for a 1-minute epoch and is the 
num ber o f counts to enable the epoch to be scored as ‘aw ake’. Counts lower than 40 in an 
epoch may be scored as ‘sleep’ depending on the algorithm. Low sensitivity settings double 
the activity count in any epoch whereas high sensitivity half the activities count. The 
Actiwatch is set up via a dedicated reader station connected to a personal computer and 
following recording data are then downloaded using the reader and the data are stored in the 
computer, as shown in Figure 1.9.
1.2.5. Algorithms
Traditionally sleep is assessed by PSG which involves attaching electrodes to the scalp, 
recording and then scoring the brain’s electrical activity to determine the different stages o f 
sleep. However, this is an expensive technique which requires access to sleep laboratories 
and specialist training, and is therefore very expensive. In order to assess whether sleep 
could be determined merely by measuring activity levels, PSG recordings were correlated 
with movement measured by activity monitors throughout the sleep period (Mullaney a/., 
1980). By manually scoring each epoch from the activity monitor against the PSG output it 
was found possible to differentiate between sleep and wake. However, this was very time 
consuming and in addition periods o f ‘quiet wake’ were also difficult to interpret. An 
automatic algorithm was developed in order to classify whether each individual epoch was 
scored as wake or sleep, by correlating activity data with PSG recordings and comparing the 
activity counts o f  each 1 minute epoch with 4 epochs before and 2 epochs after, (Cole er a/., 
1992). Nevertheless, this did not account for periods o f  ‘quiet wake’, where the activity level 
was very low or the device had been removed which may confound the results. Various 
scoring algorithms have since been developed which are dedicated to the specific devices 
and software programs.
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Figure 1.9: Diagrammatic view of the Actiwatch set up
1.2.6. Sleep-like minutes
Data recorded during the daytime using the Actiwatch system registers the activity count per 
epoch. In addition, each activity count is scored by the algorithm when sleep is analysed by 
the software as either ‘sleep’ or ‘w ake’. W hen the activity count for an epoch o f 1 minute 
falls below 40 counts, using the medium sensitivity setting, it is scored as a ‘sleep’ epoch. 
Periods o f low activity during the day may therefore be scored as ‘sleep-like’ where the 
activity level is very low. This may be the result o f a nap, reduced activity as a result o f 
sedation or removal o f the device. However few studies have reported on this aspect in 
clinical trials. A study on the effect o f antidepressants on healthy volunteers (n = 12) by 
Stanley and Hindmarch, (1997) showed reductions in actigraphic daytime activity due to the 
sedating effect o f  a single dose o f dothiepin 75 mg even at the hourly psychometric test 
points. Stanley, (1997) also showed a significant reduction in daytime activity in a study 
using a single dose o f  the antihistamine prom ethazine 25 mg in healthy volunteers (n = 24) 
as well as the time course o f  its sedating effect over 6 h even w ith the alerting effects o f 
perfonning psychometric tests, compared with non-sedating antihistam ines and placebo. The 
sedative effect o f  both o f these studies was evident as a reduction in the activity and not an 
increase in ‘sleep-like’ minutes.
1.2.7. Actigraphic sleep variables
The Actiwatch Sleepwatch software analyses the data and provides a summary o f the 
standard sleep variables common to comparable parameters in PSG, as shown in a screen 
shot o f  one analysed sleep period (Figure 1.10). Once the bedtime and wake-up times are set, 
either automatically using the event marker buttons or by a trained operator, the analysis 
program provides the various sleep parameters within the sleep period calculated by the
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dedicated algorithm. If the markers are not set or the bedtimes are not restricted as in clinical 
trials participants sleep diaries may also be used to provide the sleep onset and offset. The 
main sleep variables are described in full in Section 2.4.1.
Although the sleep start and end times are calculated differently by the dedicated algorithm 
for each device and therefore the resultant data parameters are different, a comparison o f the 
two devices, Actiwatch L and M ini-M otionlogger, found total sleep time (TST), referred to 
as actual sleep time (AST), to be correlated strongly (Benson et a l,  2004).
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Figure 1.10: Windows view of the Sleep Analysis profile 
1.2.8. Acti graph comparison with PSG
The first study to compare the two m ost popular actigraphs against PSG was conducted with 
healthy participants (n = 12) without sleep disorders who simultaneously wore the Basic 
M ini-M otionlogger (MML, AMI) and the Actiwatch ® (AW 4, CNT) whilst PSG was 
recorded (Tonetti et a l, 2008). The M M L data were scored and analysed according to the 
algorithm  developed by Cole et a l (1992) and ‘AW  Action fV-2® version 3.23 software 
(AMI). W hilst AW  data were analysed by Actiwatch Activity & Sleep Analysis 5® version 
5.32 software’, and analysed according to the mathematical model developed and validated 
by Oakley, (1997). Analysis was conducted for sleep onset latency / sleep latency (SOL/SL), 
TST, wake after sleep onset / actual wake time (W ASO/AW T) and sleep efficiency (SE). 
The authors concluded that both devices perform ed similarly to each other and PSG on the 
sleep variables except for SOL which they both underestimated.
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The Actiwatch, (Respironics) Sleepwatch (AMI) and Actical (Respironics) an actigraph 
worn round the waist were compared with PSG in a sleep study with healthy participants 
(n =  30, m ale=  19, female = 11) (W eiss a/., 2010). There was a significant correlation 
between the different devices and PSG for sleep efficiency as shown in Figure 1.11.
However all devices underestimated the amount o f wake compared with PSG which is 
particularly important for calculating WASO and TST.
A  further comparison study o f  the basic Motionlogger Watch (AMI) and Acti watch-64
(M ini-M itter) to PSG was conducted in young healthy participants (n = 29) and showed that 
both devices perform ed as well as each other but that both devices underestim ated sleep 
latency com pared with PSG (Rupp and Balkin, 2011). M oreover the researchers stated that 
they were both zzW vaW  eva/wa/g parazMg/ery '.
A  direct comparison o f  Actiwatch-L (AWL, Mini-Mitter) and Mini-Motionlogger (MML,
AMI) the two most common com mercially available actigraphs was conducted in a study 
with 20 healthy participants who wore both devices on their non-dominant wrist
simultaneously for 2 nights. The AW L correlated with the M M L at all the sensitivity settings 
for TST, how ever where wake measurement is a factor, correlation was poorer for WASO, 
SL and SE. (Benson et a l, 2004).
Although there are limitations, since actigraphy measures activity and not sleep, algorithms 
have been developed to calculate variables that are similar to both PSG and actigraphy. 
M oreover actigraphy was positively correlated with PSG in a sleep study o f  depressed 
insomniac patients and was validated against PSG (McCall and McCall, 2012). According to 
the Martin and Hakim, (2011) review a foo/ybr
ybr over penoùk q /  rime m r/ze zza^zzra/ 5 /^eep
eMvzmzzmezz/j^  azzri appear.  ^ /o pz"ovzrie a va/zri e.yrimafe j^ /eep percezzrage, azzri
 azzri czz"carizazz z-/^ f/zzzz .y/eep riz.yoz-riez".y’. (Wilson a/., 2004b) demonstrated
how actigraphy was used to evaluate the effects o f two weeks o f  the hypnotic temazepam 20 
mg/day in insomniacs in outcomes o f actigraphic sleep variables; significant changes were 
recorded in fragmentation index, actual sleep time %, actual sleep time and sleep efficiency.
1.2.9. Advantages and disadvantages o f  actigraphic assessment
The gold standard for sleep recording is PSG, however this has its limitations, it provides a
snapshot o f  one period o f  sleep usually in a sleep laboratory but also with ambulatory
recorders in participant’s homes. W hilst the sleep is an accurate account o f the sleep
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architecture it does not provide how this fits into a 24 h day, or even over a number o f  days 
or weeks. To be wired up for sleep takes 20-30 minutes depending on the number o f  
electrodes by a sleep technician. The electrodes can be uncomfortable to wear and can
impact on sleep latency whilst the participant acclimatises to them, often participants feel 
restricted wearing them when in bed. In addition perform ing PSG in a sleep laboratory is in 
unusual surroundings and may also impact on the quality w hist participants become 
familiarised. W hen performing clinical studies it is wise to include an acclimation night to 
remove first night effects. Actigraphy in contrast is imobtrusive, records continuously for 24 
hours and allows the participants or patients to sleep unrestricted in their own natural 
environment over extended time periods than one night (M artin and Hakim, 2011).
Tabk 3—Pearson correlation coefficients for sleep efficiency 
from polysomnography (PSG) and actigraphy devices^
N = 30 PSG Sleepwatch Actiwatch Actical
PSG 0.619"* 0.651" 0 348
Sleepwatch 0.619" 0.653" 0.405*
Actiwatch 0.651" 0.653" 0.820"
AcUcal 0.348 0.405" 0.820"
"p < 0.05; "p < 0.001; ^Sleepwatch, Sleepwatch achgraph (Ambulatofy 
Monitoring, Inc., Ardsley, NY); Actiwatch, Actiwatch actigraph (Respironics, 
Pittsburgh, PA); Actical, Actical actigraph (Respironics, Pittsburgh, PA)
Figure 1.11: Comparison o f different actigraphs with PSG (Weiss eZ a/., 2010)
Actigraphs facilitate the long term  continuous objective assessm ent o f changes in rest and 
activity patterns. Which is one o f  the reasons why its appeal has grown and it has become a 
useful at^unct to sleep research with an increase in publications (Sadeh, 2011). The use o f  
actigraphy leads itself to opportunities in which PSG would be expensive and inconvenient 
as they are non-invasive and are therefore useful for observing changes in sleep wake 
patterns or sleep profiles following various interventions. These may be drug induced in the 
case o f  depression and insomnia; or when using a Continuous Positive Airway Pressure 
(CPAP) machine in the case o f  patients suffering from sleep problems associated with sleep 
apnoea; or for measuring the effectiveness o f  sleep hygiene advice or cognitive behavioural 
therapy. An actigraphic study o f  the rest-activity cycle o f  psychiatric patients revealed 
differences and showed that schizophrenics had a more disturbed 24 h pattern with both 
lower daytime and night-time activity levels than did depressed patients (Berle g/ zz/., 2010). 
Without actigraphy this type o f  study would not be possible.
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Depressed patients (n = 12) were treated with fluvoxamine, home sleep recordings were
conducted at baseline and weeks 3 and 12. HAM D and M ADRS scores showed patient 
perceived improvement from baseline following treatment, but objective sleep parameters in 
increased number o f  awakenings paradoxically worsened for responders (Wilson er a/.,
2000), i f  used actigraphy could have provided a continuous record o f  changes. A  further 
study was conducted comparing subjective diaries and objective PSG on depressed patients 
(n =  40) treated with nefazodone or paroxetine over 8 weeks (Argyropoulos gr a/., 2003). 
Sleep was recorded on four occasions at baseline, days 3 and 10, then week 8 at patients’ 
homes. There was a reasonable correlation between the measures o f  TST and SOL but not 
num ber o f awakenings. The study was not continuous so unable to report on the effect o f 
medication from day 10 to week 8, whereas actigraphy would have provided a continuous 
assessment.
Actigraphy is also useful for studying circadian rhythms and disorders such as Delayed 
and/or Advanced Sleep Phase Syndrome (DSPS and ASPS) (Morgenthaler gr a/., 2007b), 
particularly where the use o f  a diary is cumbersome and compliance is an issue. With the 
actigraph m arker button a participant m erely depresses the marker when they have turned off 
the lights and are trying to fall asleep as opposed to completing a diary the following day 
which could lead to error. A diary is useful as it enhances the information obtained by 
actigraphy, so where possible both should be used. In clinical research where participants are 
advised to follow strict time regimes during the screening period and wash-out phase o f  a 
drug trial they are extremely useful for confirming compliance.
Actigraphy has its limitations, as discussed in review by Sadeh, (2011) the biggest 
disadvantage is that it does not measure sleep, it measures activity which is interpreted as 
being ‘wake’ or ‘sleep’ depending on the level o f  activity in each epoch and may therefore 
present a false indication o f  sleep since ‘quiet wake’ periods may be scored as sleep. Despite 
the development o f  algorithms to minimise the risk o f  ‘quiet wake’ being incorrectly scored 
as sleep it is impossible to eradicate this completely and therefore caution is advised when 
interpreting data from patients/participants where ‘quiet wake’ is seen e.g. in insomnia 
patients (Hauri and Wisbey, 1992).
There is also variability between activity monitors within the same manufacturer, since each 
device contains a unique sensor; therefore no one device gives identical results to another. 
The inbuilt sensors can deteriorate so it is necessary to calibrate the devices regularly to 
ensure validity o f  results. For clinical research, in cross-over studies, it is therefore important
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to minimise this variation and use the same actigraph for each participant during each 
treatment period to reduce errors.
One o f  the main criticisms with actigraphy is with sleep latency however the use o f  the 
marker button to indicate lights out as an indicator o f  intention to sleep is valuable for 
assessing this and observing difficulty in falling asleep. Although actigraphy does not 
measure PSG variables it has advantages over sleep diaries which merely measure 
participant’s perception o f  sleep timings, number o f  awakenings and how long it took to get 
to sleep. Studies have shown that actigraphy closely resembled PSG in terms o f  sleep 
disruption, and reported that actigraphy was better than diaries w ith similar values to PSG 
for SOL and num ber o f awakenings (Lichstein et a l, 2006) in a study o f 57 insomniacs. 
Similar findings were reported in a different study o f  54 insomniacs, actigraphy reasonably 
correlated with PSG in all variables except sleep latency, but sleep logs again recorded worse 
reports o f  longer SOL com pared with PSG, participant’s perception o f sleep was poorer than 
it actually was (M cCall and M cCall, 2012).
Diaries are useful for guiding analysis to the correct lights out times if  no markers are used 
or i f  the marker has been erroneously pressed, and they provide an opportunity to gain 
further information about the sleep quality and subjective sleep with reasons for poor sleep. 
Actigraphy showed that in a study o f  older nocturia patients, participants men (n = 55) and 
women (n = 92), o f  nocturnal bathroom visits, sleep efficiency derived ftom the actigraph 
was worse than the self-report logs (Zeitzer gr a/., 2013). Although the sleep logs recorded 
the subjective disruption, actigraphy recorded reduced sleep efficiency with an increase in 
num ber o f sleep bouts associated w ith the higher num ber o f  night time voids.
Daytime sedation is traditionally m easured with a sleep test known as the M ultiple Sleep 
Latency Test (MSLT) which measures how sleepy an individual is when given the 
opportunity to sleep which is performed in a sleep laboratory. Actigraphy offers an 
alternative by measuring reduced daytime activity as naps or the accumulation o f  low level
activity below the threshold o f  wake as explained in Section 1.2.6.
Despite its limitations o f  recording activity and not sleep, researchers (Morgenthaler er a/., 
2007a) in the Practice Parameters for the Use o f  Actigraphy, encourage the use o f  actigraphy 
in depressed patients and concludes that a mer/zori /o
c/zarac/enzg czrcarizazz r/zyr/zzzz /zarierzzj or riz.y^ z/r6azzcg.y zzz zzzrizvzriwoZy wz//z zmozzzzzzo, 
zzzc/zzrizzzg zzz.yozzzzzzo wri/z rieprej.yzozz” and "vfcrigrqp/zy z^  ^ zzjq/zz/ybr evo/zzorizzg r/ze
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rgjpowe ro /rgo/zMg/zr /7arigzz/.y wriri z».yozM/zzo, mc/wrimg m^ yozMMzo oj^ j^ oczo/eri wri/z 
rieprg.y:yzvg rizj^orriez-. "^.
1.3. Psychopharm acology and CNS drugs
1.3.1. Introduction
Currently the evaluation o f psychoactive drug effects has been conducted with healthy 
participants utilising psychometric test batteries to assess impairments in daytime cognition 
and psychomotor functioning (Hindmarch, 1980; Fairweather er oA, 1996; Kerr or o/., 1996; 
Hindmarch et a l, 2005). Tracking and reaction time tasks in particular, are known to be 
reliable and sensitive to drug effects, and are related to impairment o f driving ability 
(Hindmarch, 1980; Patat, 1998; Ridout er 6z/., 2003a). Night-time sleep following 
administration o f  psychoactive drugs is still often evaluated with PSG to assess changes in 
sleep architecture. This type o f study design is possible in Phase I and II studies but the data 
are limited to a relatively small num ber o f  volunteers and may not be relevant to the general 
population and in particular to the patient groups intended to receive the medication. 
A lthough it is not economical or logistically possible to conduct comprehensive in-house 
assessments in Phase III studies, actigraphy may be o f  use in the assessment o f  drug-induced 
changes in night-time sleep and in daytime activity in large scale patient studies. For 
example reduction in daytime activity levels may reflect increased sedation, a common side 
effect o f some centrally acting compounds. Psychometric assessments have shown that a 
num ber o f  cognitive functions are adversely affected by increased sedation including 
information processing, memory and attention (Patat g/ a/., 1987; Hindmarch a/., 2001b; 
Soo-ampon et a l, 2004). However, psychom etric tests merely provide indications o f 
im pairment at specific time points, often to cover the time o f m axim um  impact o f  the 
medication and any hangover effect, but where it is not feasible to measure the continuous 
effects.
Actigraphy has enabled the continuous m easurem ent o f activity in relation to the assessment 
o f  a drug and its effbct on changes in activity and sleep patterns. It may be useful to reveal 
that a reduction or change in activity levels following dosing is related to the sedating effect 
o f the medication as indicated in studies examining the effects o f  psychoactive compounds 
(M attmann et a l, 1982; Borbély, 1984; Stanley and Hindmarch, 1997). However, there are 
relatively little data available to show the time-course o f  drug action. There are also limited 
data to show that actigraphy can reliably measure the daytime and night-time characteristics 
o f  a CNS drug. Whether actigraph technology is sensitive to the sedating effects o f
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medication and how accurately actigraphy is able to track drug pharmacokinetics and 
pharmacodynamics remains to be determined.
Previous research has assessed the effect o f  different drugs on actigraphic sleep and daytime 
behaviour in small scale studies including sedatives (M attmann et a l, 1982; Borbély et al., 
1988), anti-depressants (Fairweather er a /.,1996; Stanley and Hindmarch, 1997; Stanley er 
a/., 1999), hypnotics (Borbély ef a/,, 1983; Takahashi er a/., 2003), antihistamines 
(Hindmarch et a l, 1999; Roehrs et a l, 2000; Shamsi et a l,  2001) and stimulants 
(Hindmarch gr a/., 2000b). The classes o f  drugs which are prescribed for inducing sleep, 
reducing anxiety or reducing a histaminic response have well docum ented side effects 
including reduction in activity during wake (Borbély e/ a/., 1983; Takahashi e/ a/., 2003) and 
impairment o f mental ability and alertness in the acute phase following drug administration 
(Kawahara gr a/., 2002; Kiang er a/., 2003). Drug-induced reduction in activity has been 
studied in ‘spontaneous’ activity (Kiang gr a/., 2003) and there are some data to suggest that 
actigraphy is able to detect “hangover effects” (Borbély, 1984; Borbély et al., 1988; Stanley, 
1997; O’Neill er a/., 2000; Klôsch gr a/., 2001; Kawahara er a/., 2002; Takahashi e/ a/., 
2003). Most o f  these studies, however, have employed different actigraphs and not the 
Actiwatch system. There are im portant differences between the devices and the algorithms 
that are utilized (Section 1.2.5) which means that confirmatory studies using the Actiwatch 
are required to assess further the utility o f  ‘actigraphy’ as a tool in psychopharmacology.
Although studies have been conducted on the effects o f  drugs on sleep and activity, many o f
these include assessments on patient groups with sleep related disorders. Therefore the 
studies which have been reviewed in Sections 1.4 Sedative Hypnotics and 1.5 
Antihistamines have been limited to include only those which have assessed sleep/wake 
activity patterns in normal healthy male and female participants. Whereas Section 1.6 
Antidepressants reviews studies related to the acute effect o f  medication on healthy 
participants and chronic use in depressed patient groups.
1.4. Sedative-hypnotics
Drugs in the benzodiazepine class which act on the CNS are classed as hypnotics to induce 
sleep or anxiolytics to induce calm and have a sedative effect depending on their duration o f  
action. The shorter acting compounds (e.g. loprazolam, temazepam, nitrazepam) have poorer 
efficacy but minimal residual effects and are mainly used in the treatment o f  insomnia 
(Beaumont, 2000; Nicholson, 2000), whereas the longer acting ones (e.g. alprazolam, 
diazepam) have good efficacy and are mainly prescribed to treat anxiety (Williams and 
Smith, 2000).
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1.4.1. M echanism o f  action
The benzodiazepines (BZD) act on the GABA receptor to increase GABA function and thus 
promote sedation and sleep. They vary in their duration o f  action and can be short acting 
with a T% o f 2-4 h as in the case o f the hypnotic midazolam, or T% 8-12 h for lorazepam 
(LZP) known as an anxiolytic hypnotic, and longer acting T% 20-40 h for diazepam used as 
an anxiolytic, for insomnia and panic attacks. Overall this group o f  compounds reduce 
anxiety, induce sedation and reduce the time taken to get to sleep. However caution is 
advised as they are addictive and should only be used for short-term resolution o f  sleep 
problems.
1.4.2. Side effects o f  sedative-hypnotics
The main side effects o f these compounds are sedation and impaired coordination even with 
the relatively short acting compounds used to treat anxiety resulting in increased risk o f  
motor accidents or when operating machinery. Sedation can be observed as an objective 
measure with increases in reaction times, reductions in MSLT time or a delay in observation 
and recognition. Side effects may also be reported as increases in the subjective rating o f  the 
sedation component o f  the Line Analogue Rating Scale (LARS) where participants rate 
feelings o f  drowsiness, or not feeling alert the following morning on the awakening from 
sleep (AFS) and behaviour following wake (BFW) components o f  Leeds Sleep Evaluation 
Questionnaire (LSEQ) (Sections 2.6.1 and 2.6.2). Lack o f coordination m ay result in poor 
performance in psychometric tests and driving skills.
1.4.3. Sedative-hypnotics and cognition and psychom otor function
It is a recognised side effect o f  psychoactive drugs that they cause impairment o f  
psychom otor function with a lack o f coordination and reduced processing ability. The 
particular tests used in this thesis the Critical Flicker Fusion (CFF), Choice Reaction Task 
(CRT), and Continuous Tracking Task (CTT) amongst others, are recognised as being 
/o a wzù^ z-zzzzge q/" /z.syc/zoacrive cozzzpozzzzriy' and are suitable for measuring 
changes in ‘.yezzjorz-zzzoroz' pez^ozizzazzce' (reviewed in Hindmarch, 1980). These cognitive 
tests, described in full in Section 2.5, are important when measuring effects as they provide 
useful information on how the psychoactive compoimds might impair everyday functions 
like driving and are used as objective measures o f  sedation (Sherwood and Kerr, 1993). 
Subjective questionnaires LSEQ and LARS are used to rate participant’s opinion on the 
effect o f  sedating compounds on sleep and sleepiness.
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1.4.3.1. Objective psychometric tests
A  study was conducted with the short acting benzodiazepine, midazolam, (T,y; 2-4 h), 
compared with placebo. Healthy participants (n = 12) were treated with 4 different doses o f  
midazolam 5, 10, 15 and 20 mg and CFF and CRT were assessed (Gudgeon and Hindmarch, 
1983). With respect to CRT all doses o f  midazolam increased reaction time with peak 
impairment at 1 h post dose compared with placebo but only the 20 mg dose continued to 
have an effect 4 h post dose, and there was no hangover effect at 7 h post dose. The 10, 15 
and 20 mg doses caused significant impairment in CFF at 1 h post dose and the 15 and 20 
mg doses continued to significantly affect CFF to 4 h post dose, as with CRT no impairment 
was seen at 7 h post dose.
The effect o f  the medium term acting benzodiazepines LZP 1 mg (Ty^  8-12 h) and buspirone 
5 mg and 10 mg (Ty^  2-3 h) were compared with clobazam 1 mg a non-benzodiazepine 
anxiolytic (T,  ^ 18 h) and placebo in a 5 way crossover study with healthy female participants
(n = 10). Although LZP decreased CFF scores compared with placebo following acute 
dosing at 1.5 h post dose this was not significant (Alford gr a/., 1991). Buspirone and LZP
both significantly increased the total reaction time o f  CRT at 1.5 h post dose and LZP 
increased total reaction time overall for 1.5 -  5 h post dose.
Diazepam 10 mg (Ty^  20-40 h), a longer acting benzodiazepine, was compared with LZP 2.5 
mg and medazepam 15 mg (T,/^  36-200 h), a benzodiazepine derivative, and placebo in a 
cross-over study to compare the effects o f  single doses on performance tasks related to 
driving with healthy participants (n = 10) (Seppala er zz/., 1976). Compared with placebo, 
LZP (Ty^  8-12 h) significantly impaired reaction times and CFF up to 12 h, whereas there 
was no impairment following diazepam  and medazepam administration after 5 h. The 
authors concluded that patients would be safe to drive 5-7 h after diazepam  or medazepam 
administration but not safe for 24 h after LZP.
1.4.3.2. Subjective ratings and sleep questionnaires
The LSEQ and LARS are questionnaires useful for subjective ratings o f  sleepiness and 
sedation, and are described in detail in Section 2.6. Sedative-hypnotics are prescribed for 
insomnia and also for their calming effect in anxiety. A  review o f  studies o f  benzodiazepines 
effect on LSEQ by Hindmarch, (1984) showed the usefulness o f  the scale for measuring drug 
effects on subjective sleep. LZP 2 mg, used as a sedative hypnotic control, induced feelings 
o f sedation up to 9 h post dose, compared with placebo in a study o f  the effect o f  
antipsychotics on healthy participants on LARS (Hindmarch and Tiplady, 1994). Participants
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felt significantly fatigued as a side effect o f  LZP 2.5 mg at 7 h post dose compared with 
placebo (Seppala e/ a/., 1976) in the subjective assessment.
Participants (n = 18) rated their feelings o f  sedation as being ‘groggy ' the morning following 
treatment with flunitrazepam 2 mg, a longer acting benzodiazepine (Ty^  18-26 h), compared
with placebo, with associated significant residual drug effects in reduced activity (M attmann 
gt oA, 1982). Temazepam 30 mg also induced ‘groggm gjj' the following morning and at 
midday after a bedtime dose com pared with placebo in healthy participants (n = 14) (Borbély 
er oA, 1984). In contrast in a similar study with healthy participants (n =  15) with the short 
acting benzodiazepines midazolam and triazolam no such effects o f residual sedation were 
reported the following day (Borbély et a l, 1983).
1.4.4. Sedative-hypnotics effect on sleep, actigraphic sleep and daytime activity
1.4.4.1. Sleep
This group o f  compounds aids sleep in general by reducing SOL thereby enabling patients to 
get to sleep faster. They affect sleep architecture by increasing TST and REM  latency, 
reducing Stage 1, and increasing Stage 2. Healthy participants were each dosed on 2 
consecutive nights with flurazepam 30 mg (T% 40-50 h), LZP 4 mg (Ty^  8-12 h) or triazolam 
0.5 mg were (Ty^  2-4 h) in a 4 way crossover study with placebo (Roth er aA, 1980). PSG was 
recorded and the data for the 2 nights was pooled. All m edications significantly affected 
sleep architecture with decreased stage 1, increased stage 2 but no change in stages 3-4, LZP 
alone significantly reduced % REM. Participants subjectively felt that they were able to get 
to sleep significantly faster after flurazepam and LZP, but all treatments significantly 
improved quality o f  sleep with less reports o f awakenings.
LZP is often used as a verum in com parison clinical studies because o f its well-known 
properties. A  study compared LZP with suriclone, a non-benzodiazepine anxiolytic and their 
effect on sleep architecture, Saletu 6zA (1990) confirmed previous research (Roth er aA, 
1980). In a further study LZP was shown to alter sleep architecture as determined by PSG by 
reducing sleep latency, number o f  awakenings. Stage 1 sleep % and REM, whilst increasing 
TST and Stage 2 sleep in a controlled study with healthy participants. Sleep was recorded 
over 3 nights and LZP 2.5 mg was administered on night 2 (Grozinger g/ aA, 1998).
1.4.4.2. Actigraphy
The action o f  benzodiazepines on ‘activity during sleep’ has been assessed using actigraphy
in a num ber o f  studies (M attmann et a l, 1982; Borbély, 1984; W alsh et a l, 1991) as well as
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other hypnotic non-benzodiazepines compounds (Borbély a/., 1988; Daurat e/ a/., 2000;
Denise, 2003).
The hypnotic action o f  midazolam 7.5 mg and 15 mg on actigraphic activity during the night 
taken 30 min before bedtime was compared with triazolam 0.25 mg and 0.5 mg, (Borbély er
a l, 1983). These researchers found that activity was reduced on all treatments compared 
with placebo and that this reduction in activity was m ainly limited to the first h a lf o f the 
night. In addition there was no significant difference in the levels o f  spontaneous activity 
during the first 4 h after waking.
Using a solid state actigraph, hypnotics with a long half-life (flunitrazepam 2 mg, flurazepam 
30 mg, temazepam 20 and 30 mg) were compared with those with a short half-life 
(midazolam 7.5 mg and 15 mg, triazolam 0.25 mg and 0.5 mg) (Borbély, 1984). Following
administration 30 min before bedtime, all treatments caused a marked reduction in activity 
for the first half o f  the sleep period whereas flunitrazepam and flurazepam reduced m otor 
activity during the whole o f  the sleep period com pared with placebo. In another study 
(Borbély gr a/., 1984) the effect o f  temazepam (20 mg and 30 mg) on actigraphic sleep and 
on activity levels after waking was studied, although both doses reduced activity during 
sleep, there was no difference in activity levels during the first 8 h after waking.
The residual effect o f  three benzodiazepines was studied in a placebo-controlled trial 
(Mattmann er a/., 1982) with a solid state Swiss-type actigraph. Night time activity was 
significantly reduced for all treatments (triazolam 0.25 mg, triazolam 0.5 mg, triazolam 1.0 
mg, nitrazepam  10 mg) com pared with placebo. The overall activity level for a 6 h period the 
following day was found to be significantly reduced by all treatments except for the 
triazolam 0.25 mg. The hangover effects o f  triazolam 0.25 mg, flunitrazepam 1.0 mg and 
quazepam 15 mg were also evaluated in a single-blind study (Takahashi a/., 2003) by 
recording mean activity levels in 6 h periods with the ActiTrac (IM Systems, Baltimore, 
MD,USA) wrist actigraph. Significant effect o f  treatment was shown as a reduction in 
activity levels for the afternoon block (12:00-18:00 h) following administration with 
quazepam compared with flunitrazepam and triazolam. In contrast the effect o f  triazolam on 
daytime sleep was measured in a study using the wrist activity monitor (AMI actigraph) in a 
placebo-controlled trial following triazolam 0.25 mg and 0.5 mg dosing after a simulated 
night shift (Walsh er a/., 1991). Total Sleep Time (TST) as measured by actigraphy was 
significantly increased for participants taking triazolam com pared with placebo.
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With regard to non-benzodiazepine hypnotics, the effect o f  zolpidem 10 mg and 20 mg on 
activity during sleep was compared (Borbély er a/., 1988) using a solid state actigraph in a 
placebo-controlled study and found that only zolpidem 20 mg, a higher dose than normally 
prescribed, significantly reduced activity during sleep. No reduction in activity for the first 
4 h in the daytime following the sleep period was observed. Moreover, activity during sleep 
was significantly reduced com pared with placebo in a study to examine the effects o f 
zopiclone 7.5 mg taken after a westward flight (Daurat er 6z/., 2000). Further work on the 
effect o f  zolpidem 10 mg, zopiclone 7.5 mg and flunitrazepam 1 mg on activity during the 
night in a placebo-controlled crossover study using the Gaehwiler actigraph was studied 
(Denise, 2003). Activity levels were significantly reduced after treatment on all medications 
compared with placebo.
These studies have shown that actigraphy is useful when looking at global effects but no 
studies have been conducted to assess the subtle time-course o f action in the benzodiazepine 
group o f  compounds combined with the effect on night-time sleep and following daytime 
activity.
1.5. Antihistam ines
This class o f compounds is used for treating allergic reactions including allergic rhinitis and 
urticaria; as an antiemetic for travel sickness; and for their sedative action. Some o f  the 
earlier antihistamines were prescribed for their sedative properties and could be purchased in 
over the counter sleep remedies.
1.5.1. M echanism  o f action
Allergic reactions have traditionally been treated with the antihistamine class o f  drugs 
known as H, receptor antagonists which alleviate the symptoms associated with this 
condition by blocking Hi histamine receptors. Earlier first generation antihistamines 
(promethazine, diphenhydramine and chlorpheniramine) pass through the blood-brain barrier 
and are associated with unwanted side effects which cause reduced alertness, drowsiness and 
psychomotor impairment (Roehrs 6z/., 1984; Roth er a/., 1987; Hindmarch er a/., 1999). 
These side effects are due predominantly to their ability to cross the blood-brain barrier and 
thus block central HI receptors, involved in arousal. Second generation antihistamines 
(loratadine and cetirizine) however slightly cross the blood brain barrier and unwanted side 
effects o f  sedation and impaired function are reduced. Newer 3"^  ^ generation antihistamines 
(fexofenadine, levocetirizine and desloratadine) have since been developed which do not 
cross the blood-brain barrier and are relatively free from sedative side effects. The first
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generation antihistamines vary in their duration o f  action; diphenhydramine has a plasm a 
half-life o f 7 h, promethazine 16-19 h, and chlorpheniramine 23 h. In comparison cetirizine 
has a plasma half-life o f  8.3 h and loratadine 8 h, whereas the third generation non-sedating 
antihistamines levocetirizine, fexofenadine and desloratadine have half-lives o f  6-10 h, 14.4
h and 27 h respectively.
1.5.2. Side effects o f antihistamines
The first generation antihistamines cause the most side effects o f  drowsiness and 
psychomotor impairment. One such antihistamine is promethazine, which is known to induce 
central nervous system side effects including psychom otor and cognitive impairment as well 
as possessing sedative effects. Studies have shown that cognitive and psychomotor 
performance are significantly impaired by promethazine (Clarke and Nicholson, 1978; 
Parrott and Wesnes, 1987; Hindmarch gr a/., 1999, 2001a; Nicholson ef a/., 2003).
1.5.3. Antihistamines and cognitive and psychom otor function
A  review o f  the different antihistamines and their effect on subjective and objective 
psychometric tests combined enabled indices to be calculated o f  their relative effects overall
as a Proportional Impairment Ratio (M cDonald, et al 2008). As a comparison the PIR ’s for a 
range o f  the different generations o f antihistamines is shown in Table 1.1.
Table 1.1 : Comparative FIR ratios for antihistamines
1^  Generation FIR 2"^  ^Generation FIR 3'^ '^  Generation FIR
d%)henhydramii]e 1.616 cetirizine 0.193 levocetirizine 0
chlorpheniramine 1.956 loratadine 0.357 fèxoÈnadine 0.021
promethazine 2.207 desloratadine 0.14
Comparison the PIR’s for a range o f the different generations o f antihistamines Proportional 
Impairment Ratio comparison
1.5.3.1. Obj ective psychometric tests
The psychometric tests CFF and CRT were used to compare possible impairing effects o f  
levocetirizine 5 mg with diphenhydramine 50 mg (as positive control) and placebo in a 3- 
way, cross-over, repeated measures, study, with healthy participants (n = 18). Treatment was 
administered each morning for 5 days. Tests were conducted at 1, 2, 3, 5, 12 and 24 h on 
Day 1 and repeated on Day 5. There was a significant impairment o f  CFF following
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diphenhydramine adm inistration at 1, 2 and 3 h post dose but no effect following 
levocetirizine. CRT was not impaired for any treatment although reaction times improved 
following levocetirizine which the authors (Gandon and Allain, 2002) concluded was due to 
its slight alerting effect which was consistent with the alertness scale on the Bond and
Lader’s VAS.
The effect o f  fexofenadine high dose 360 mg was compared with promethazine and placebo, 
in a 3-way cross-over study (Hindmarch er a/., 2002). Healthy participants (n = 15) received 
fexofenadine 360 mg, promethazine 30 mg and placebo and the psychometric tests CFF,
CRT and CTT were conducted at 1, 3, 5 and 7 h post dose. All tests were significantly 
impaired following prom ethazine administration up to 7 h post dose with respect to placebo 
however there was no effect on performance following fexofenadine administration. 
Moreover promethazine also significantly increased the sedation component o f  LARS up 
to 7 h.
1.5.3.2. Subj ective ratings and sleep questionnaires
Subjective sedation is com posed o f  the mean scores o f ratings o f  “tiredness” , “drowsiness” 
and “alertness”, as described in full in Section 2.6.2, from the components o f  LARS. A  
significant effect o f treatm ent was recorded following prom ethazine 25 mg treatment up to 
6 h post dose compared with placebo with healthy participants (n = 24) feeling sedated, in an 
eight-way, cross-over study o f  loratadine (10, 20 and 40 mg) and cetirizine (2.5, 5.0 and 10 
mg) with promethazine as the active control (Shamsi er a/., 2001).
1.5.4. Antihistamines effect on sleep, actigraphic sleep and daytime activity
1.5.4.1. Sleep
Roth and colleagues (1987) conducted sleep and MSLT studies on healthy participants 
(n = 1 6 )  following administration with loratadine (10 and 40 mg in the morning), 
diphenhydramine (50 mg three times a day) and placebo in a Latin square cross-over design. 
There was a 5 day wash out between treatments. PSG was averaged over 2 days o f  treatment. 
Daytime sleepiness was m easured as subjective sleep with the Stanford Sleepiness Scale and 
the participants sleep latency o f  the 5 MSLT’s which were conducted every 2 hours. 
D iphenhydram ine significantly reduced latency to sleep on all M SLT’s except the second at 
11:00. The mean o f the 5 ratings o f  sleepiness was significantly different fi"om loratadine and 
placebo with the diphenhydramine participants being sleepier. There was no significant 
difference between treatments in nocturnal sleep.
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1.5.4.2. Actigraphy
The effect o f  antihistamines on actigraphic activity comparing the sedative properties o f  
promethazine 25 mg, a first generation antihistamine, with the newer generation o f  
antihistamines cetirizine (2.5, 5 and 10 mg) and loratadine (10, 20 and 40 mg) have been 
studied using the AMI actigraph (Stanley, 1997). Promethazine was found to induce a 
significant reduction in activity at 5 h post dose compared with all other drugs tested and 
placebo. There was also a significant overall increase in reaction time in CRT showing 
impairment on performance with prom ethazine compared with the other treatments. 
Actigraphic sleep however was not recorded.
Activity levels were monitored for 24 h with AMI actigraphs following dosing in a study 
comparing the effects o f fexofenadine 80, 120 and 180 mg, loratadine 10 mg, promethazine 
30 mg and placebo. The percentage ‘sleep’ and ‘w ake’ for the 24 h period including the 
sleep period was calculated as was the daytime activity until lights out. During the daytime 
there was a significant increase in the number o f  epochs scored as ‘sleep’ with promethazine 
as well as significant impairments in psychomotor performance (Hindmarch ef a/., 1999). 
There was also a significantly higher percentage o f  sleep for the whole period during 
promethazine treatment compared with the other treatments although there was no 
significant difference in the amount o f  sleep during the night.
The effect o f  diphenhydramine 50 mg, a first generation sedating antihistamine, was found to 
increase daytime inactivity in a study using AMI actigraphs comparing sleepiness induced 
by the drug or sleep restriction (Roehrs e/ a/., 2000). These above studies indicate that whilst 
actigraphy was designed to investigate ‘sleep’ and ‘wakefulness’ the technology was also 
useful to assess changes in daytime activity following administration o f sedating compounds.
1.6. Antidepressants
Compounds used to treat m ajor depressive disorder (M DD) are known as antidepressants. 
There are three main groups: tricyclic antidepressants (TCAs), selective serotonin reuptake 
inhibitors (SSRIs), and monoamine oxidase inhibitors (MAOIs). This thesis is focused on the 
effect o f  three SSRI antidepressants paroxetine, fluoxetine and sertraline on depressed 
patients with the same variables used to assess the effect o f  sedative hypnotics and 
antihistamines.
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1.6.1. Depression
Hippocrates, 460-377 BC defined depression as “Gnq/" yèar, w/zeM /rnggrmg, /zrovo&e 
/Mg/a/7c/zoria ". Depression is associated with a multitude o f  underlying negative symptoms 
including feelings o f  low mood and self-esteem, anxiety with a loss o f  interest in daily 
activities, loss o f  appetite, coupled with reduced daytime activity and poor sleep. A q/"
/ow o r moo(^
/ow gMgrgy oryôrigwe' (Wong and Licinio, 2001). In the context o f this thesis it is important 
to review depression as a disease / disorder as depressed patients suffer symptoms which are 
alleviated with antidepressants and one o f the main focuses o f  this thesis is the chronic effect 
o f  treatment on depression by the psychoactive SSRIs.
1.6.1.1. Depression and sleep
Poor sleep quality is a core symptom o f  depression with patient complaints o f  difficulty 
falling asleep, disturbed sleep, and waking early reported in over 90% o f patients (Benca and 
Peterson, 2008; van Mill et a l, 2010; W ichniak et a l,  2012). These sleep problems are 
similar to the side effects caused by SSRI antidepressants as will be discussed later. Indeed 
in many cases as reported in reviews by (Benca and Peterson, 2008) and (Santos Moraes e/ 
a/., 2011) depression is often associated with insomnia and can be a precursor to and 
predictor o f  depression (Baglioni er a/., 2011; Baglioni and Riemann, 2012). Depression is 
also associated with daytime somnolence and reduced daytime activity as detailed in a 
review by (Burton et a l, 2013), as well as subjective reports o f  reduced mood and lethargy 
(Armitage gr a/., 1997a; Rotenberg gr a/., 2000; Argyropoulos 6/ <3/., 2003; Bixler er a/.,
2005) have all also studied the relationship between objective and subjective sleep o f  
patients and found correlation in the sleep duration, sleep latency and num ber o f  awakenings.
Typical complaints o f  depressed patients are about
zMonzmg (Wichniak gr a/., 2012). Alteration in the sleep-
wake cycle e.g. loss o f  job, may w/zzcA z?z rzzm
zzzqy /eari ro /z}{qor/ze.9z.y’ according to Monteleone and M ^, (2008).
The effect o f  depression on sleep architecture and the effect o f  the SSRI antidepressant 
treatment in particular on the sleep architecture o f  depressed patients have been thoroughly 
investigated in reviews (Sharpley and Cowen, 1995; Argyropoulos and Wilson, 2005; 
W ilson and Argyropoulos, 2005; Holshoe, 2009; Mendlewicz, 2009). Studies have shown 
that depression is associated with increased sleep latency, increased sleep disruption and 
fragmentation with more WASO, REM latency and changes in REM distribution as well as
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reduction in slow wave sleep in depressed patients compared with healthy controls 
(Rotenberg gf a/., 2000; Argyropoulos er a/., 2003; Tsuno a/., 2005; Benca and Peterson, 
2008; Quera-Salva er a/., 2010). The effect o f  depression on sleep architecture was reviewed
in W inokur et al. (2001) and tabulated in Figure 1.12.
TABLE I. Patterns and polysomnographlc features of 
sleep in patients w ith clinical depression
NREAf 
Decreased slow-wave sleep 
Decreased delta sleep in XREM-I NREAI-2 
REA!
Reduced REAt latcnc)'
Increased REA! during first half of night 
Increased REA! density 
Sleep continuity 
Increased sleep latency 
Increased wake time
Early morning awakenings______________________________
'AfjRE.W, gv mpid Q r marrmrmf.
Figure 1.12: Sleep parameters o f depressed patients (Winokur eZ a/., 2001)
The comparison o f sleep architecture o f  healthy participants and depressed patients is 
tabulated in Figure 1.13. Studies have produced conflicting results however, differences in 
PSG between healthy participants and depressed patients were found but depressed patients 
subjective sleep did not correlate as well with PSG sleep as the healthy controls (Rotenberg 
et al., 2000). It was reported that depressed patients underestim ated the num ber o f 
awakenings. Whereas a study by Argyropoulos et a l, 2003 showed that depressed patients 
subjective sleep did correlate with objective sleep specifically in TST and SOL.
Depression is linked with insomnia which has been suggested is a risk factor for depression. 
A  study o f  insomniacs and depressed patients reported that the only differences between 
their sleep was the latency and % o f  REM sleep (Benca and Peterson, 2008). Therefore it has
been postulated that to improve sleep in depressed patients would hopefully improve 
depression. Such studies have focused on PSG recordings o f  single or multiple nights 
however, less research has investigated the course o f  depression longer term and the effect 
on sleep in ambulatory field conditions. An actigraphy study o f m otor activity during the day 
and at night showed that depressed hospitalised in-patients who had subjectively rated poorer 
sleep using the Pittsburgh Sleep Quality Index PSQI questionnaire recorded more nocturnal 
activity than patients who rated their sleep good (Lemke er a/., 1999). It was suggested that
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although PSG may be best for m easuring objective sleep, an actigraph might be useful for an 
extended length o f time.
Table 1
Sleep variables in healthy subjccts and in depressed patients
Groups Healthy
subjects
Depressed
subjects
Nights 20 68
Total sleep time (min) 412(43) 347(100)
Sleep eHiciency (%) 0.98 (0.3) 0.89(0.14)*
Sleep latency (min) 3 J (1 1 ) 26(48)*
Slow wave sleep (%) 14 j  (6.8) 10.9(6.8)
SWS, I cycle (min) 262(123) 14(30)
SWS, 2 (ycle (min) 22.6(132) 10(15)
SWS, 3 cycle (min) 66(8.7) 9(18)
SWS, 4 (y de (min) 4.8(86) 4.8(72)
REM sleep latency (min) 89.4 (33.7) 78(72)
REM sleep (%) 192(3.7) 23(5.6)
REM sleep 1 cycle (min) 7.9(42) 22 (18)*
REM sleep 2 cycle (min) 19.7(92) 22(17)
REM sleep 3 <ytle (min) 22.4(112) 19(17)
REM sleep 4 cycle (min) 23.0(122) 19(13)
EM density, 1 cycle (min) 2 0 (2 2 ) 6 (4)**'
EM density, 2 cydc (min) 3.8 (1.9) 5 2  (32)**
EM density, 3 cycle (min) 5.1 (26) 5.8(52)
EM density, 4 cyeic (min) 5.4 (3.2) 6.4(52)
Awakening 1.0(10) 3(3)
< 0.05. 
<0.02. 
<0.01.
Figure 1.13: Sleep variable comparison between healthy and depressed patients (Rotenberg ef a/., 
2000)
A  review o f  studies (reviewed in Kronfeld-Schor and Einat, 2012) suggested that there is a 
link between circadian rhythm, sleep and depression as it was shown that a large percentage 
o f  the general population with sleep problems were depressed. A  further review by 
Monteleone gr a/. (2011) highlighted the links between circadian rhythms in depression with 
changes in mood and sleep-wake cycle. Activity levels were inversely correlated to severity 
o f  depression symptoms, patients experienced a significant worsening o f  depressed mood in 
the m orning com pared to the evening although their activity levels were significantly higher 
in the morning compared to the evening according to Lemke er a/. (1997).
The main treatment o f  MDD is drug therapy and a review to explain the current rise in 
prescriptions was conducted by Moore er a/. (2009). 'TTze Mwmrigr q/"
m 2072 waj- 50,767,207 ybr a// q/^  wp 7.5 per cezzr OM 2077
(wrigM rora/y were 46,677,^7.^. 7%e eoj^ q/^<3Mri6%7rej.yaM^prejcrzprio/z E277,745,455 m
2072. TTeari/z azzri Eoe/aZ Care 7q/brmarioM Ce/z^re, fre^^erÿfriozzy Dzjpezz.yeri zzz r/ze
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E/zg/a/zri (2002-2072 [) The World Health Organisation predicts 
that by 2020, depression will be the second leading cause o f  disability throughout the world.
Clinical trials provide a standardised controlled environment in which to study the acute 
effect o f  a drug reviewed in Kirsch et al. (2008) and Sussman, (2007), and have often been 
used to assess the effects o f  different classes o f  antidepressants on sleep reviewed by Mayers 
and Baldwin, (2005), including the SSRIs.
1.6.2. Selective serotonin reuptake inhibitors (SSRIs) and treatment o f depression
Selective serotonin reuptake inhibitors (SSRIs) are widely recognised as treatments for mild 
to moderate depression. There is evidence to suggest from various reviews that this group o f  
antidepressants affect PSG sleep in laboratory settings (Wilson and Argyropoulos, 2005; 
Mendlewicz, 2009; Holshoe, 2009) (Table 1.2). Less work however has investigated the long 
term effect on sleep and activity in ambulatory field conditions with antidepressants (Kasper 
gf a/., 2010). The effect o f  the respective SSRIs on PSG sleep variables is shown in Table 1.2 
in comparison with the effect o f  depression on sleep, data from (Winokur gr a/., 2001).
Some antidepressants such as the TCAs prom ote sleep reviewed in M ayers and Baldwin. 
(2005) whereas the SSRIs are associated with reductions in sleep efficiency, increased 
latency and sleep disruption. Most antidepressants affect the distribution o f  REM throughout 
the night (reviewed in W ilson and Argyropoulos, 2005). The 3 SSRIs listed in Table 1.2 
have slightly different profiles and mechanisms o f  action as well as side effects.
Table 1.2: Effect o f SSRI antidepressants paroxetine, fluoxetine and sertraline on sleep variables
T r e a t m e n t P a r o x e t i n e  2 0  m g / d a y
F l u o x e t i n e  
2 0  m g / d a y
S e r t r a l i n e  
5 0  m g / d a y
D e p r e s s e d
p a t i e n t s
S l e e p  l a t e n c y Î Î Î Î
S l e e p  e f f i c i e n c y i i i i
S l o w  w a v e  s l e e p i i i
R E M i Î
R E M  L a t e n c y Î Î Î i
The effect o f antidepressant treatment and direction o f  change on sleep variables is shown by the 
arrows, f  = increased, f  = decreased, for the antidepressants paroxetine, fluoxetine and sertraline 
compared with the effect o f depression on sleep variables in patients. The SSRI antidepressants reduce 
REM and increased REM latency (Winokur et al, 2001).
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1.6.3. M echanism o f  action o f selective serotonin reuptake inhibitors (SSRIs)
Lam. (2008) proposed that ‘azz Wga/ Azg/z j/zorri/grm c/mzca/
g^^cacy Tbr acw/g pAa^g ri"ga^ mgM/ wriri goori /oMg-rgnzz g^cacy azzri (o/gra6z/z(y /hr (Ag 
maintenance phase'. Paroxetine, fluoxetine and sertraline belong to the complex group o f 
antidepressants known as the selective serotonin reuptake inhibitors SSRIs which according 
to (Hiemke and Hârtter, 2000) have a ‘rizgA (o g^roz'ozzzzz rgz^p/aAg jz/g2 , /ow q/yzzzzzy (o
zzoz-arirgzza/zzzg .yzfg^ ’. However, they have varying affinities for these sites with differing 
lengths o f action which might explain the efficacy differences between them. Fluoxetine has 
a half-life up to 4 days, whereas paroxetine and sertraline both have comparatively short 
half-lives o f 1 day, moreover, fluoxetine has an active metabolite which continues to be 
active for 7-15 days whereas sertraline has a low activity m etabolite o f  66 h, and paroxetine 
has no active metabolite (Preskhom, 1996; Nutt g( a/., 1999; Vaswani et al., 2003).
According to the literature however, four weeks or more o f  treatment are required to reach 
steady state following com m encem ent o f  treatment with fluoxetine, com pared with 7-14 
days for sertraline and 10-14 days for paroxetine due to their half-lives (Preskhom, 1996; 
Hiemke and Hârtter, 2000). Moreover, dosing with fluoxetine with its active metabolite and 
extended half-life, can allow for missed or sporadic doses as steady state levels are still 
reached according to (Preskom, 1994; Preskhom, 1996). With regards to wash-out time, 
worth considering when choosing an SSRI, fluoxetine due to the long half-life o f  its 
metabolite is slower to be cleared, taking several weeks. Whereas, the rapid clearance o f  
sertraline and paroxetine o f  95% in less than 1 week could therefore account for the higher 
numbers o f  reports o f  discontinuation symptoms associated with rapid withdrawal (Price gz' 
a/., 1996; Haddad and Anderson, 2007). This might therefore lead to the assumption that for 
fluoxetine, whilst taking longer to reach maximal effect, having a slower decline also 
decreases severity o f  withdrawal and successful end o f treatment.
1.6.4. Side effects o f  selective serotonin reuptake inhibitors (SSRIs)
Nausea, disturbed sleep, dry mouth, changes in appetite and sexual dysfunction are all 
reported side effects o f this group o f antidepressants (Ferguson, 2001) however, compared 
with the other main group o f  prescribed antidepressants the TCAs, they are well tolerated 
and do not commonly cause the side effect o f daytime sedation which is common to the 
TCAs. Although malaise and tiredness are some o f  the most frequently reported side effects 
in the first month o f treatment (Mackay g/ a/., 1999).
46
It is estimated that up to 44% patients stop taking medication within the first 3 months o f  
treatment due to the side effects (Bull g( a/., 2002); and between 20-50% are non-compliant 
and stop taking medication for short periods o f time (Rosenbaum gr a/., 1998). Neither the 
incidence o f adverse side effects nor the use o f concurrent m edication has been included in 
this thesis.
1.6.5. Cognitive and psychomotor function and selective serotonin reuptake inhibitors 
(SSRIs)
The DSM-IV is a coding system used for the diagnosis o f  depression and comprises 9
symptoms mainly dealing with mood and according to Kerr and Hindmarch, (1996) do not 
stress the cognitive aspects o f  major depression although ‘zzz^ azrzMgMr q/"p^ygriozzzofor s/zggri 
azzri rizj^ zT/qriozz q/^  zz^zTzzariozz pz-ocgj^zzzg' are ‘jzgzzz^gazz/ ^ga/wz-g  ^ q/^  zzzq/oz' riepz-ga^ s^ zvg 
illness ’, with 70% o f elderly having 'measurable cognitive deficits'. The symptoms that deal 
with the cognitive or psychomotor aspects are Vzzzzzzzz^ /zgri a6z/z(y /o Z/zzzzA: oz- cozzcgzzz'z'arg’ 
and 'psychomotor agitation or retardation'. Fava, (2003) also stated that 'fatigue and 
cogzzzrivg/gxggwrzvg ü^ V^ zzgZ'zozz az-g cozzzzzzozz syzz^ Z'ozzz^  zzz /zarigzzr  ^ wri/z MDD w/zzc/z zzzqy 
gzr/zgz" /zgz"2 Z2 r z7z/g (o r/zg riTyoz-rigz- rig^prig g^^crivg azzririgqz"gj.yazz/ rz"ga(zzzgzzr oz" gzzzgrgg aj a 
2 zrig g;^g^ q/^  z"/zg azzriz%zz-g2 2azzr p-garzzzgzz/ ris^g^, (MDD = major depressive disorder). 
Cognitive and psychomotor retardation manifested in depression has been recognised for 
m any years according to (W idlocher, 1983) and is associated with depressed mood and 
melancholia. In his review into the ‘g /^c /2  q /  azzz'zzA^ z-gJs^ azz/^  ozz cogzzzrivg yhzzcz'zozz’ 
(Amado-Boccara et a l, 1995) stated that it should be considered that there are less adverse 
effects in long-term antidepressant treatment administration to depressed patients compared 
w ith short term effects in healthy volunteers. Also that clinical im provem ent usually appears 
in the third week o f  treatment so to measure improvement in performance in depressed 
patients might be an indicator o f  improvement in depression.
W hilst change in depressed mood is diagnosed through questionnaires such as M ontgomery- 
Asberg Depression Rating Scale (MADRS), Hamilton Depression Rating Scale (HAMD) 
and ZUNG, changes in psychomotor agitation or cognitive retardation may be measured by 
changes in performance o f cognitive and psychometric tests. In recent reviews (Lee g( a/., 
2012) concluded that cognitive functioning was reduced in patients in their first episode o f 
depression and that early recognition and treatment may alleviate relapse and (Marazziti g/ 
a/., 2010) that impairments in attention and executive function are key disturbances o f  MDD  
which occur in all ages. The tests used to determine the effect o f  SSRIs on objective 
cognitive effects in the study conducted in Chapter 5 were CFF and CRT.
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1.6.5.1. Objective psychometric tests Critical Flicker Fusion (CFF) and Choice
Reaction Time (CRT)
It is important to evaluate impact o f  cognitive function, as patients age their cognitive ability 
deteriorates so it is important to consider which antidepressants to use when treating the 
elderly, according to Variend and Gopal, (2008) some elderly patients develop their first 
depressive episode as late-onset depression so it is important to prescribe medications that 
will not have a negative effect on everyday activities. Lane and O ’Hanlon, (1999) discuss 
how SSRIs might affect the depressed elderly and various factors to consider when 
associated with the cognitive decline related to aging and suggest that more studies are 
required to assess the effect on this relevant population.
The objective psychomotor tasks relevant to ^zzcriozz azzri /z^yc/zoacriva
rinzg.y’(Hindmarch, 1980), the Critical Flicker Fusion (CFF) (Hindmarch, 1982) and Choice 
Reaction Time (CRT) (Sherwood and Kerr, 1993) were used in Chapter 5 to determine the 
effect o f  12 weeks treatment, on cognitive function. The CFF is a measure o f  behavioural 
arousal, with a decrease in threshold indicating an impairment o f  information processing, 
and the CRT is a measure o f  sensorimotor performance (Hindmarch, 1998). These tasks are 
useful, sensitive, reliable, valid and commonly used tests (Sherwood and Kerr, 1993) which 
are sensitive to changes in the brain o f  integrative functioning and reaction time and have 
been used extensively in research into the effects o f  CNS drugs.
In single dose acute studies with healthy volunteers, the SSRIs assessed in the study reported 
in Chapter 5 have been extensively studied in healthy participants and showed improved 
cognitive function. The comparable behavioural toxicity value o f a range o f  antidepressants, 
including SSRIs and TCAs was calculated by Hindmarch, (1999) and Kerr and Hindmarch, 
(1996) ftom a number o f  individual healthy volunteer studies by quantitative comparison o f  
administration o f a single dose compared with placebo, the relative effect sizes were reported 
in comparison with placebo. The individual studies with single dose effects were reported in 
Hindmarch and Harrison, (1988) for paroxetine 30 mg in females (n = 10) mean age 38 
years, Hindmarch, (1987) for fluoxetine 40 mg in females (n = 8) mean age 37 years and in 
Hindmarch and Bhatti, (1988) for sertraline 100 mg in females (n = 10) mean age 34 years.
CFF was significantly elevated for all treatments compared with placebo, which indicated
improvements in cognitive function and increased arousal following administration.
Sertraline (100 mg/day) showed the greatest increase followed by paroxetine (30 mg/day)
and fluoxetine (40 mg/day). The relative values for the medications were documented as
paroxetine 1.153, fluoxetine 0.895 and sertraline 1.769, with these compoimds producing a
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significant elevation o f CFF compared with zero for placebo, although the doses were higher
than those administered to the patients in Chapter 5 study (Kerr and Hindmarch, 1996; 
Hindmarch, 1999).
Data from several healthy volunteer studies have provided similar relative drug effect values 
for CRT, for the medication were documented as paroxetine (30 mg/day) 0.276, fluoxetine 
(40 mg/day) -0.432 and sertraline (100 mg/day) 0.802 with a significant ‘qwzcAezzmg' for 
sertraline and paroxetine compared with zero for placebo suggesting that they have an 
arousing effect (Kerr and Hindmarch, 1996; Hindmarch, 1999). Although these healthy 
volunteer studies were not conducted at the same time as double-blind crossover studies, 
comparisons can be compared, as these are relative effect sizes. W hat is evident is that the 
SSRIs have a stimulating effect improving cognitive function which can be measured with 
the CFF and CRT, and that these tasks, loosely related to driving ability, may be useful in 
determining driving impairment or improvement. This aspect was also discussed by 
Brunnauer e/ a/. (2006) who showed an association between driving, psychomotor tests and 
antidepressants in depressed patients and indicated that SSRIs are preferable to TCAs.
The CFF and CRT were 2 o f the tests applied in the review by Amado-Boccara er a/. (1995) 
to compare the effects on cognition o f  various antidepressant medications. It was concluded
that in similar doses to the study in Chapter 5, in single dose healthy volunteer studies, the 
antidepressants paroxetine and sertraline have a cogzzzrive zmpacri. Paroxetine (20
mg/day) raised CFF threshold and decreased reaction time on CRT, that sertraline (50
mg/day) significantly increased CFF threshold but fluoxetine had no cognitive effect. The 
long term effects o f  the medications administered to depressed patients were not reported.
There are relatively few studies which have reported on the chronic long term effects o f  the 
SSRI antidepressant treatments assessed in Chapter 5 on the CFF and CRT cognitive and 
psychomotor tests on depressed patients. Gorenstein et al. (2006), in a study comparing 
chronic use o f  sertraline and fluoxetine with other antidepressants in depressed patients 
treated for > 6 months did .yomg zzz^ azrzzzgzzr a / //zgzr r/zgrqpgwric riojg’ in reaction
times on a similar test to CRT, the visual Foundations I, PSS reaction task, but this was not 
significant.
A  study comparing fluoxetine (20 mg/day) with amitriptyline (75 mg/day), in depressed 
elderly patients (n = 54) on stable dosing, Kerr g/ a/. (1993) reported that CFF was 
significantly improved with increased thresholds following fluoxetine treatment from 
baseline for 6 weeks o f  medication whilst depression scores were significantly reduced with
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both MADRS and HAM D scores. CRT was also significantly improved by week 1 following 
fluoxetine treatment compared with amitriptyline with a reduction in reaction times. In a 
similar study comparing dothiepin (75 mg/day) and fluoxetine (20 mg/day) in depressed 
patients (n = 64) mean age 44, study duration o f  6 weeks, Fairweather a/. (1999) found 
significantly greater improvement in CFF scores following treatment with fluoxetine than in 
patients treated with dothiepin, no reaction tests were conducted.
A  study from Fairweather e/ a/. (1993) in depressed elderly (n = 60) (mean age 70) 
compared fluoxetine (20 mg/day) with amitriptyline (75 mg/day) over 6 weeks found that
there was a significant improvement in CFF scores from patients on fluoxetine from week 1 
compared with amitriptyline and a significant reduction in reaction times w ith CRT. 
Improvement was also reflected in the HAMD and M ADRS scores and quality o f sleep from 
LSEQ variables although not significantly different from amitriptyline.
Hindmarch and Kerr, (1994) adm inistered paroxetine (20 mg/day increasing to 30 mg/day) 
over 6 weeks to depressed patients (19-65 years) following 1 week placebo washout, CFF 
threshold was significantly elevated after 2 weeks o f  treatment and the improvement was 
m aintained for the study duration, CRT was not conducted. Ravindran et al. (1995) 
compared placebo, and dose escalated treatments with sertraline and desipramine in mild to 
moderately depressed patients (n = 103) (18 - 6 5  years) over 6 weeks treatment following 2 
weeks placebo wash out. A lthough there was a trend for improvements in CRT following 
sertraline administration it was not statistically different from placebo or desipramine.
With respect to paroxetine Alexander a/. (1997) conducted a study in depressed patients
compared with dothiepin in an escalated dose regime over 6 weeks. W hilst the HAM D 
scores were significantly reduced for both medications, there were significant differences 
between paroxetine and dothiepin recorded for CFF threshold with paroxetine producing a 
significant improvement in the first 2 weeks following paroxetine treatment. Sleep was also 
rated significantly better on QOS (LSEQ) com pared with dothiepin, but there was no 
significant difference in reaction times between the treatments.
It is important to consider cognitive side-effects o f antidepressants in depressed patients and 
particularly in the elderly as the consequences o f  negative cognitive and behavioural side 
effects can be exacerbated with the likelihood o f  reduced compliance o f  treatment and 
increased accident and injury risk. The older generation o f  antidepressants the TCAs have 
known adverse side effects including a sedative action and the comparison studies discussed
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above with some o f  the TCAs have shown that the SSRI antidepressants used in the current 
study have more positive outcomes in terms o f  cognitive and psychometric tests.
Although the tests used in the current study have not been correlated with driving 
performance, according to Verster and Roth, (2012), a tenuous link exists between SSRIs in 
general and impaired driving ability in depressed patients (Brunnauer er a/., 2006; Wingen ef 
a/., 2006), and Ravera e/ a/. (2012) commented that in an epidemiological review o f  motor 
accidents that there was a wz^ /z '. It was concluded
that the impairment seen in driving performance in depressed patients could be attributed to 
Vgj^ z^ fzza/ 6%?z"g.yjzvg rather than the effect o f  the antidepressant (Wingen e/ a/.,
2006). Nevertheless Ramaekers, (2003) suggested that psychometric tests are important as 
they can provide an early indication and direction o f  action. They are im portant measures in 
regards to drugs that might interfere with CNS activity and impact on safety when patients 
are taking daily medication. Moreover, although tests are a mere snapshot at any one time- 
point, to measure response over a long period o f  time would give an indication o f the 
direction and stability o f  change and as depressed patients are cognitively impaired treatment 
should improve and not exaggerate symptoms.
1.6.5.2. Subjective ratings and depression questionnaires
Few studies have reported on the daytime sedating effect o f  SSRIs, and as SSRIs are known 
to be activating compounds (reviewed in Wichniak er zzA, 2012), less daytime sedation as 
treatment progresses is expected. However some patients do experience Maytime sleepiness' 
but whether this equates to sleepiness or fatigue has not been determined (reviewed in 
Wilson and Argyropoulos, 2005). A  specific adverse event which suggests daytime sedation 
is reported as somnolence (Fava et a l,  2000, 2002). Additionally there were almost 3 times 
as many reports o f  sedation occurring in the first month following paroxetine treatment than 
there were for fluoxetine or sertraline in a report on the Mozz^araZzz/zzT q/" z^o/em6z/z(y' 
(Mackay er a/., 1999). The questionnaires used to determine the subjective effect o f  SSRIs 
on daytime sedation are LSEQ and LARS and the M ADRS and HAM D questionnaires are 
used to determine depression severity and progress and also contain items related to sleep. 
The MADRS and HAMD are physician administered questionnaires and a similar self- 
completion questionnaire is the ZUNG.
The LSEQ is an effective tool used to assess the subjective effects o f  a psychoactive 
compound on quality o f sleep and related behaviour; full details are in Section 2.6.1. The 
LSEQ has been shown to be an effective assessment tool when used to quantify subjective 
sleep effects (Parrott and Hindmarch, 1980; Hindmarch, 1984; Zisapel and Laudon, 2003).
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Two o f the most recognised and widely used diagnostic assessments by clinicians in 
determining depression severity are the depression rating scales o f M ontgomery-Âsberg 
Depression Rating Scale (MADRS) and Hamilton Depression Rating Scale (HAMD). 
Changes in these scales are used to measure the effect o f  treatm ent and im provem ent in the 
symptoms o f the disease. Studies have shown that there is good correlation between the 2 
scales (Kearns g/ a/., 1982; Carmody e/ ûf/., 2006). The MADRS is reported to be more 
sensitive overtime to changes in symptoms (M ulder et a l,  2003) and comparable to 
identifying placebo to drug differences than HAMD (Khan er a/., 2002). Moreover the 
MADRS was preferred being better for estimating depression symptoms and for clinical 
trials (Carmody et a l,  2006). The H A M D -17 was developed for inpatients and contained 
several items less suitable for out-patients such as Tack o f  insight’ and ‘agitation’ interpreted 
as anxiety and was not as useful for the GENDEP study (Ulier et a l,  2008). The MADRS 
questionnaire was related to the mental aspects o f depression such as sadness, tension and 
pessimistic suicidal thoughts. W hereas the emphasis o f  the HAM D was related to 
psychomotor symptoms and somatic mood, such as work and activities, as well as insomnia, 
retardation and mood. However, studies have shown that there is good correlation between 
the 2 scales (Kearns a/., 1982; Carmody a/., 2006)
The criteria for improvement in depression symptoms with the M ADRS and HAM D was 
defined as the Vz/Me the first time point at which a '.y/arz.yrzca/(y jzgnz/zcazz  ^ a
c/zMzca/(y zMgazzzng/ /^ (/z^^rencg’ occurs when there is a reduction o f  > 20% from baseline for 
the first time, and /o /z'ga/TMgnz^ ’ when there is a > 50% reduction in the MADRS
and HAM D scores (Thompson, 2002). In order to compare the outcome scores for the 2 
scales comparable scores have been suggested by (Millier cr a/., 2000; Muller, 2003) as 
shown in Figure 1.14.
T A k  1
Snggeskd sevtnly gm W ons o f Ac HAMD-17 mod MADRS m moden^Écly to scrm ly  dqneaed
Recoraed Mild Miodeimle Maximmni
HAMD-17 0 -7 ' 8 -1 5 ' > 1 6 ' Sis'" 52
MAŒIS 0 -6 ' 9 -17 ' 18'-34" &35' 60
Figure 1.14: Comparable scores for MADRS and HAMD (Muller eZ a/., 2000; Miiller, 2003)
1.6.5.3. Subjective sleep questionnaires Leeds Sleep Evaluation Questionnaire
(LSEQ) and Line Analogue Rating Scale (LARS)
Studies have found similar improvements as those seen in HAM D or M ADRS with LSEQ. 
In a study comparing fluoxetine (20 mg) (n = 51) with dothiepin (120 mg) (n = 56) it was
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reported that over 6 weeks o f  treatment, following 1 week placebo run-in, newly diagnosed 
patients were randomised to be treated with fluoxetine or dothiepin (Stephenson eZ a/., 
2000). All patients improved not only their LSEQ scores for GTS, QOS and AFS scores but 
also the HAMD and MADRS depression rating over the 6 weeks o f  treatment for either 
fluoxetine or dothiepin, indicating that as patients becam e less depressed their sleep 
improved. There was a greater improvement in GTS for the patients treated with fluoxetine, 
whereas the patients treated with dothiepin felt drowsier.
A  trend in favour o f  a sleep improvement with sertraline treatment (50 mg/day) (n = 88) was 
shown in a randomised study o f  newly diagnosed depressed patients compared with 
fluoxetine (20 mg/day) (n = 79), during the 18 and 24 weeks analysis o f  treatment on the 
LSEQ (Sechter gZ a/., 1999). This outcome corresponded with the significant improvement in 
HAM D scores, however no data or different aspects o f  the LSEQ were reported. Whilst 
Bennie et al. (1995) found sim ilar improvements in both LSEQ components and HAM D 
sleep disturbance in a double-blind study in depressed patients treated with fluoxetine (20 
mg/day) (n = 140) or sertraline (50 mg/day) (n = 140). Patients treated with sertraline 
experienced less difficulty in GTS, but patients treated with fluoxetine felt better on AFS at 
the end o f  the 6 week study.
A 6-week double-blind study was conducted in 100 depressed patients (final numbers not 
reported) treated with paroxetine (20 mg/day) or dothiepin (75 mg/day) with escalated 
dosing (Alexander eZ a/., 1997). The overall HAMD scale showed that both treatments 
produced a significant improvement at week 6, with a greater improvement in the patients 
treated with paroxetine. M oreover the sedative action o f dothiepin was more evident in the 
elevated scores for GTS indicating that patients got to sleep quicker, whilst the elevated 
scores for QOS and AFS scores for paroxetine indicated better sleep and improved waking.
Improvements in subjective sleep have also been reported following paroxetine treatment 
(Dorman, 1992; Kerr eZ a/., 1997). Newly depressed patients were randomised to receive 
paroxetine (20 mg) or dothiepin (75 mg) over 5 weeks following 1 week placebo run-in 
(Kerr gZ a/., 1997). Results showed that although both treatments improved GTS, QOS and 
AFS, there was a significant difference between treatments for GTS with dothiepin, a TCA, 
treated patients getting to sleep quicker, and a trend for greater improvement in QOS with 
paroxetine. On the other hand, in a 6 week double-blind study in 60 depressed unipolar 
patients treated with paroxetine (n = 24) (15 mg/day) or mianserin (n = 25) (30 mg/day) 
reportedly slept better (Dorman, 1992). The HAMD for both groups showed improvement in 
the depression scores although there was a greater improvement in the paroxetine treated
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patients from week 2 onwards. Results for the LSEQ sleep moreover showed that patients 
treated with paroxetine reported significantly improved GTS, QOS and AFS compared with 
mianserin.
Studies conducted on the effect o f  fluoxetine on LSEQ components (Fairweather eZ a/., 
1993; Stephenson eZ a/., 2000) have reported on improvements on depressed patients, 
following fluoxetine treatment. Fairweather cZ a/. (1993) compared the effect o f  fluoxetine 
(20 mg/day) and amitriptyline (75 mg/day) on elderly depressed patients (n = 66) for 6 
weeks. Significant improvements were recorded for the MADRS and HAM D scores with 
both treatments relieving depression. W ith regards to LSEQ both treatments improved QOS 
and AFS. Although GTS improved for both treatments it was significantly shorter with 
patients treated with amitriptyline compared with fluoxetine at week 1, which is likely to be 
the effect o f  its sedating properties. Depressed patients were randomised to receive 
fluoxetine (20 mg/day) (n = 50) or dothiepin (150 mg/day) (n = 56) in a randomised double- 
blind study for 7 weeks reported by (Stephenson et a l, 2000) M ADRS and HAM D showed 
that depression symptoms were equally relieved by both treatments at the end o f the study; 
however GTS was improved with fluoxetine treatment in the first week compared with 
dothiepin, QOS improved gradually for both treatments but there were more reports o f 
disturbed sleep from the dothiepin treated patients.
Sertraline was compared with fluoxetine (Aguglia gZ a/., 1993) in an 8 week double-blind
study in 88 patients. Patients w ith baseline HAMD >18 were random ised to receive 
fluoxetine (20 mg/day) (n = 40) or sertraline (50 mg/day) (n = 48). As discussed in Section 
1.6.5.5 significant improvements in the sleep items for HAM D with patients treated with 
fluoxetine or sertraline were also reported after 56 days compared with baseline which was 
comparable to the general improvements in LSEQ scores for both treatments.
To record the efficacy o f a novel antidepressant agomelatine (Kasper et a l,  2010) conducted 
a randomised double-blind 6-week study comparing depressed patients, with HAMD scores 
> 22, treated with sertraline (50-100 mg/day) (n = 157) to patients treated with agomelatine 
(25-50 mg/day) (n = 150). LSEQ questionnaires were completed at baseline then at 2, 4 and 
6 weeks. HAMD insomnia items significantly decreased between baseline and final visit 
indicating an improvement in sleep. There was a greater improvement in patients treated 
with agomelatine than sertraline at week 2. Similar significant outcomes were recorded for 
the LSEQ items GTS and QOS as well as AFS and BFW  for both treatments with 
agomelatine again showing a significantly faster response o f action at week 2. Improved 
scores were observed in the agomelatine treated patients at week 6 but the difference
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between treatments was not significant. The virtue o f  the use o f  the LSEQ for showing 
improvements in subjective sleep following SSRI treatment, although not sedative in action, 
is highlighted in a review o f  comparable studies which shows that in depressed patient 
studies the SSRIs in the current study all showed improvement in LSEQ variables after a 
number o f  weeks (Zisapel and Laudon, 2003).
The LARS has a series o f  rating scales and is employed as a measure o f  the subjective 
effects o f  psychoactive drugs. The mean components o f  ‘tiredness’, ‘drowsiness’, and 
‘alertness’, presented among several distracter scales, are assessed as a measurement o f  
perceived sedation (Hindmarch and Gudgeon, 1980).
Few studies however have used this scale to indicate daytime sedating effect o f SSRIs 
effects in antidepressant studies. The SSRI paroxetine (20 mg) and noradrenergic and 
specific serotonergic antidepressant (NaSSA) mirtazapine (15 mg/30 md nocte) induced 
healthy participant self-assessed daytime sedation compared with placebo the day following 
dosing in a study comparing their effects on car driving (Ridout eZ a/., 2003a). Dothiepin (75 
mg) a TCA induced self-assessed sedation compared with the SSRI fluvoxamine (50 mg and 
100 mg) and placebo in a healthy participant study (Fairweather gZ a/., 1996; Stanley and 
Hindmarch, 1997). Depressed elderly patients (n = 66) became subjectively less sedated over 
6 weeks o f  medication with either fluoxetine (20 mg/day) or amitriptyline (75 mg/day), 
although fluoxetine treated patients were significantly less sedated than patients treated with 
amitriptyline during the first two weeks (Fairweather eZ a/., 1993).
1.6.5.4. Depression questionnaires Montgomery-Asberg Depression Rating Scale
(M ADRS) and Hamilton Depression Rating Scale (HAM D)
The M ontgomery-Âsberg Depression Rating Scale (M ADRS) and Hamilton Depression 
Rating Scale (HAMD) are valuable questionnaires to assess the progress o f  treatment and 
can provide as estimate o f the onset o f  improvement as well as remission. There are various 
reports on the time taken to the onset o f  effect o f  SSRIs using the HAMD from 3 days 
(Parker gZ a/., 2000) to 2 weeks, with 80% o f studies reporting a greater response in weeks I 
and 2 than later, (Mitchell, 2006). Although Stassen eZ a/. (1997) postulated that abrupt 
response m ight be a placebo response, onset o f effect was defined by W ade et al. (2009) as a 
20% reduction in baseline scores after 2 weeks using the HAM D and ZUNG scales. In a 
systematic review o f  28 trials Taylor eZ a/. (2006) concluded that SSRIs appear to begin to 
have an effect in the first week o f  treatment with a q/"acAzgv/Mg a 50% rez/zzcZzo/z’
in HAMD score as confirmed by Katz cZ a/. (2004), although ‘zzz^mvgzzzezzZ cozzZzzzzze^  ^ aZ a 
z/ecz-gziyzzzg z-aZeybr zzZ /ca^ Z^ 6
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Other review studies showed that using the M ADRS and HAM D the 'time to onset' and 
'response to treatment’ occurred within the first 4 weeks o f  treatm ent when comparing 
various SSRIs (Wade eZ a/., 2009; Thompson, 2002).
Similarly other studies reported significant improvements in HAMD and LSEQ following
long term administration with sertraline or fluoxetine to depressed patients over 24 weeks 
and reported that there was no significant difference between treatments (Sechter eZ a/., 
1999). Significant improvements were also reported in a random ised patient study in primary 
care which determined that following a rapid improvement in symptoms after 4 weeks all 
treatments, (paroxetine, sertraline and fluoxetine) continued to be and
the sleep item in the Medical Outcomes Study scale (MOS) showed equal improvements 
over 3 months o f  treatment (Kroenke, 2001).
A study comparing the efficacy and tolerability o f paroxetine, fluoxetine or placebo on MDD 
patients (Fava et a l, 1998) found no significant difference in 21-item HAM D, although all 
patients improved. However, there were more reports o f  adverse events following paroxetine 
or fluoxetine treatment compared with placebo during the 12 weeks. A further study by 
(Fava et a l, 2000) on paroxetine 20 mg day, sertraline 50 m g/day and fluoxetine 20 mg/day 
treatments in a trial with depressed patients and over 6 weeks, w ith up titration if  necessary 
and found that all treatments produced significant improvements in the HAMD scores from 
baseline to endpoint. In a similar study (Fava eZ a/., 2002) not only found significant 
improvement in overall HAM D but also in the sleep disturbance items with patients 
reporting less insomnia.
1.6.5.5. Depression questionnaires M ontgomery-Âsberg Depression Rating Scale
(M ADRS) and Hamilton Depression Rating Scale (HAM D) sleep items
The HAMD and MADRS both have questions related to sleep and these are useful when 
comparing PSG studies for subjective effects o f  medication. The HAMD items are related to
the occurrence o f insomnia early, m iddle or late, w ith early insom nia related to patients 
having difficulty in falling asleep, similar to LSEQ GTS. Trivedi eZ a/. (1999) showed that 
HAM D sleep items conversely improved in a study o f  fluoxetine whilst PSG sleep was 
disrupted, study reported in Section 1.6.6.
The MADRS sleep item is related to the amount o f sleep and how fragmented it is. Lader eZ
zz/. (2005) reported that the SSRIs citalopram (20 to 40 mg/day) and escitalopram (10 to 20
mg/day) significantly improved MADRS sleep Item 4 compared with placebo at 6 weeks o f
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treatm ent with depressed patients (n = 1321). In the study, a significant improvement in Item 
4 score in patients was reported from > 4 at the start o f  the study to < 3 at 4 weeks and < 2 at 
8 weeks compared with placebo, assessments were conducted at 1, 2 ,4 , 6 ad 8 weeks.
1.6.5.6. ZUNG Depression Inventory
The ZUNG Depression Inventory questionnaire was designed by W illiam  Zung (ZUNG, 
1965) and published in 1965 to be used as a self-completion tool for assessing depression in 
patients, on the basis that it should be ‘.y/zorZ a/zz/ JzzMq/e, qwazzZzZaZzvg mZAgr 
qwa/zZaZzvg’. It was felt at the time that the scales that were available were too lengthy and 
time consuming for depressed patients and that they were not completed by the patient. The 
ZUNG questionnaire consists o f  20 sentences which the patient completes giving a value 
between 1 and 4, depending on whether the sentence is worded positively or negatively. The 
values, which relate to the current time, are recorded as 1 for M /zZZ/e q/"zAe Zz/zze’, 2 .yome 
q/zAe Zzme’, 3 for M goozf q/ z^Ae Zzme’ and 4 for ‘mojZ q/'zAe Zzme’. The higher the score
the more depressed is the patient with 80 being the m aximum score. The score ranges relate 
to the values 20-44 normal range, 45-59 m ildly depressed, 60-69 moderately depressed and 
70 and above severely depressed.
The ZUNG depression scale was utilised in a study to compare the effect o f  treatment in 
depressed patients (Stassen eZ a/., 1997). Although scores were not reported, 93% o f patients
(n = 44) treated with oxaprotiline, and 98.3% o f  patients (n = 58) treated with amitriptyline 
had improved by day 28. Improvement onset o f  was defined as a reduction o f baseline scores 
by 20% at day 28. There was more than 90% concordance in a comparison between HAMD  
observer rated and Zung patient rated assessments.
1.6.5.7. Cognitive Failures Questionnaire (CFQ)
According to the literature depression is associated with negative thoughts and that 
depressed patients report deficits in cognition and concentration which result in lapses o f 
memory and impaired attention. The Cognitive Failures Questionnaire (CFQ) was developed 
by Broadbent ez a/. (1982) to provide a measure o f  the fi-equency o f  patient’s errors when 
completing everyday tasks, and consisted o f  25 questions associated with the 3 categories o f  
memory, attention and psychom otor function.
Little commercial data is available on CFQ use in pharmacological studies so for comparable 
baseline values other studies were reviewed. A  study o f  SAD patients versus controls by
M ichalon et al. (1997) gave baseline values o f 38 for controls and 57 for SAD patients. CFQ
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scores o f  38 for controls and 59 for depressed patients was recorded in a study o f  depressed 
and normal UK military personnel (Farrin et a l,  2003). These CFQ values provide a basis 
for evaluating improvement in symptoms in the pharmacological studies.
A study comparing the effects o f  fluoxetine and dothiepin on CFQ and other cognitive 
variables on depressed patients (n = 84) was conducted with a series o f  assessment visits 
over 6 weeks o f  treatment by Fairweather eZ <3/. (1999). Patients were randomized to receive 
either fluoxetine (20 mg/day) or dothiepin (75-150 mg/day). Assessments also included 
LSEQ and HAMD. At baseline Day 0 the CFQ scores were 51 and 56 for fluoxetine and 
dothiepin respectively, following 6 weeks o f  treatment scores were 42 and 47 respectively. 
Unfortunately the HAMD results were not reported although it was stated that 36 patients 
responded to treatment with a 50% reduction in HAM D, however the CFQ results included 
all patients.
1.6.6. Effect o f  selective serotonin reuptake inhibitors (SSRIs) on sleep
The group o f SSRI antidepressants do not improve objective sleep, indeed they may actually 
induce a negative effect on sleep in general, by increasing sleep latency, increasing REM 
onset latency, reducing REM  and disrupting sleep as described in reviews o f healthy 
participants and depressed patient studies (Oswald and Adam, 1986; Vasar gZ a/., 1994; 
Feige eZ a/., 2002; Bell gZ a/., 2003; Jindal eZ zz/., 2003; Argyropoulos and Wilson, 2005). A  
significant reduction in REM, and an increase in REM onset latency following acute dosing 
with paroxetine in healthy volunteers was reported (Oswald and Adam, 1986; W ilson et a l, 
2004a). Similar effects have also been reported after a single dose o f  fluoxetine 
administration to healthy volunteers (Feige et a l,  2002). Due to their deleterious effects they 
may be co-prescribed with hypnotics to aid sleep (Jindal and Thase, 2004).
A study reported by Hicks et a l  (2002) showed that moderate to severely depressed patients’ 
treated w ith paroxetine had increased PSG sleep latency on days 3 and 10 and week 8, 
increased num ber o f awakenings on day 10 and reduced sleep efficiency which correlated 
with subjective ratings o f  the St M ary’s Hospital Sleep Questionnaire (SMHSQ).
Following fluoxetine treatment, patients demonstrated significant increases in number o f
awakenings and REM latency with reduced sleep efficiency at week 8 compared with
baseline but with conversely a significant improvement in the HAMD insomnia sleep items
(Gillin eZ zz/., 1997). Trivedi eZ a/. (1999) conducted a study o f  the effects o f  fluoxetine on
EEG on depressed outpatients (n = 58) with HAMD > 17 at inclusion and aged between 18
and 50 years. It was reported that in the acute phase and up to 10 weeks fluoxetine increased
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Stage 1 sleep, REM latency and REM density but decreased total REM and Stage 2 sleep
whilst HAM D and HAM D sleep items conversely improved.
Sertraline was found to increase sleep latency and suppress REM in depressed patients 
following acute dosing at week 2 and week 12 o f  treatment respectively on sertraline which 
resulted in outcomes o f  increased sleep latency, reduced sleep efficiency and a decrease in 
total sleep time. However subjective PSQI scores reported an improvement fiom  baseline to 
week 12 (Jindal eZ a/., 2003).
Although PSG studies report poorer sleep architecture with SSRI administration 
paradoxically patients felt that they slept better. Depressed patients treated with SSRIs 
subjectively felt that their sleep was significantly improved according to LSEQ and HAM D 
sleep item outcomes according to a review o f  antidepressants and their effect on sleep 
(Mayers and Baldwin, 2005). Fava eZ a/. (2002) investigated the HAMD insomnia items in 
(n = 284) depressed untreated patients who had been diagnosed with M DD on the DSM-V  
criteria for at least 1 month. After 10 to 16 weeks o f treatment w ith fluoxetine, sertraline or 
paroxetine patients felt that their insomnia had significantly improved as shown by 
reductions in the HAM D insomnia item scores for all treatments.
1.6.7. Actigraphy and depression
Insomnia co-exists as a symptom o f  depression and has been known as a precursor for a 
number o f  years (reviewed in Baglioni aZ a/., 2011; Baglioni and Riemann, 2012), therefore 
to measure changes in the sleep wake pattern during the course o f  treatment with actigraphy 
m ight provide a non-invasive diagnostic m ethod o f revealing improvements in symptoms. 
These symptoms o f  depression are described as extended sleep latency, increased num ber o f 
awakenings, more time awake after sleep onset and daytime sleepiness (Mendlewicz, 2009), 
which could be determined with actigraphy, as well as alterations in the sleep architecture. 
Over the years various studies have used a variety o f  activity recording devices to compare 
different patient groups.
In his Harvard review Teicher, (1995) discussed the usefulness o f  McZzgrqp/zy /zzoZzo»
in studies in psychiatric disease and summarised the early studies which indicated
that Yej^ Z-acZzvzZy /eveA wgre a/Zcrezf depending on the disorder and that these changes could
be useful in objectively measuring the diagnosis and response to treatment. The early studies
in actigraphy and depression focused on raw activity levels and showed that elevated activity
levels at night were predictors o f  depression (Mendlowicz cZ a/., 1999). Patients wore the
Gaehwiler actigraph for 5 days and depression was correlated with sleep latency, W ASO and
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TST. Foster and Kupfer, (1975) showed that, using an early m otion sensing device, 
actigraphic night-time activity was more disrupted in a group o f hospitalised depressed 
patients where there was an increase in num ber o f  awakenings in sleep coupled with less 
time asleep, com pared with acute cognitive disorganisation (ACD) patients.
The 24 h activity data o f  a group o f melancholic depressed patients (n = 10) who were 
hospitalized for a mean o f 30 days was compared with nornial controls pre and post therapy 
by Ueda et al. (2005). Data were subdivided into 4 periods o f  6 hours. Depressed patients 
pre-therapy exhibited significantly higher activity in the period from 12:00 to 18:00 than 
normal controls. Following imipramine therapy during the re lie f period activity levels were 
significantly reduced com pared with pre-therapy levels, which were similar to the activity 
levels o f  control participants. There was a positive correlation between the activity data and 
the self-depression scale (SDS). Although not significant the data also shows that the 
melancholic patients were less active during the period from 06:00 to 12:00 than pre-therapy.
Volkers et al. (2002) also used the Gaehwiler actigraph and reported an increase in the 
daytime mean, o f  three 24 h days o f ha lf hour activity, o f 25 in-patients treated with the TCA 
imipramine for 4 weeks com pared with before treatment, the increase in activity 
corresponded to an im provement in the HAM D score (Figure 1.15). M oreover there was a 
significant effect o f  increased sleep fragmentation following 4 weeks o f imipramine 
treatment which the authors suggest may be attributed to m ovement disorders or agitation or 
akathisia, which is also a known side-effect o f SSRIs according to Vaswani et al. (2003).
2000
1800
1600
1400
I I
1200
1000
800
6 00
400
200
6 12 18 24 6
24-hour period
Fig. 1. Mean half-hour motor acthit}' counts &r the 24-h period (horn 061X1 h to 06:00 h) of depressed patients before and after treatment ssith 
unipranhne.
Figure 1.15: Plot o f 24 h activity distribution counts between treatment free and imipramine (Volkers 
et a l,  2002)
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Similarly Royant-Parola ür/. (1986) recorded 24h activity to assess clinical improvement
over 30 days in depressed hospitalised patients, (medication not reported) and reported that 
there was an increase in the actigraphy profile o f daytime activity in the last 8 days by the 
end o f hospitalisation which correlated with an improvement in M ADRS and HAMD.
This increase in daytime activity was also reported by Raoux er a/. (1994) who showed that 
in an in-patient study o f 26 patients over 26 days o f  treatment with TCAs daytime activity 
increased between the 3 days at treatment onset to 3 days prior to discharge, again this was
correlated with improvements in M ADRS. Cosinor analysis was also perform ed which 
revealed not only a significant increase in the m esor and amplitude but a delay in the 
acrophase o f  15 min, although not significant. Joffe and colleagues. (1987) also showed that 
the 24 h mean o f  3 days o f  daytime activity levels o f  the depressed patients that responded to
treatm ent increased following carbamazepine escalated dosing (2 0 0 - 1600 mg/day), which 
is used to treat epilepsy and bipolar disorder.
Stanley er a/. (1999) reported that actigraphy could measure the difference in the mean 24 h 
activity between 2 antidepressants, recorded over 10 days. Fourteen depressed out-patients
wore AM I Actigraphs, 7 were treated with fluoxetine 20 m g/day and 7 with dothiepin 75 
mg/day escalating to 150 mg/day after the first week. Activity levels were lower from
patients treated with dothiepin which was attributed to the sedating effect o f medication.
Recent studies, with the advent o f  more sensitive sophisticated actigraphs, have employed 
algorithms to calculate sleep variables which are comparable to PSG sleep variables (McCall 
and McCall, 2012). A  study by Winkler er a/. (2005) used actigraphy in SAD patients treated 
w ith light therapy and demonstrated how useful actigraphy could be in determining the 
benefit o f  treatment and showed that SAD patients normalised to healthy control activity 
levels after 4 weeks o f light treatment and in improved sleep efficiency, increased daytime 
activity, a reduced cosine peak and 1 h phase delay which brought them into line with 
healthy controls.
1.6.8. Actigraphy and antidepressants
Most actigraphic studies o f  the effects o f  antidepressants have recorded snapshots o f  time by 
selecting various weeks or blocks o f  days to compare sleep changes or to show changes in 
activity levels rather than continuous measures. An early study recorded the m otor activity o f 
in-patients receiving a variety o f  antidepressant medications for 72h using the Actometer 
(Zak, Germany) (Lemke ef a/., 1997). This study showed that the activity levels o f  depressed
inpatients was significantly greater in the morning (07:00 to 08:00) compared with the
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evening (20:00 to 21:00) although depressive symptoms were greater in the morning than the 
evening. Lemke ef a/. (1997) also reported that melancholic unipolar depressed patients 
exhibited more activity during the night indicating that their sleep was more disturbed and 
fragmented before treatment. Actigraphy activity data were negatively correlated with 
subjective Multiple Affective Adjective Checklist (MAACL) which measures intensity o f  
subjective symptoms.
Todder a/. (2009) conducted a longitudinal 4 week study o f  quantity and intensity o f
m ovem ent in depressed patients (n = 27) treated with quetiapine (50-100 mg/day dose 
adjusted) and healthy controls (n = 27) in coiyunction with HAMD using Actiwatches. 
Following 2-day baseline, actigraphy was recorded for 2, 7-day periods at period 1 (days 1- 
7) and period 2 (days 22-29). Patients that improved in response to the HAMD were 
included in the analysis. The analysis showed that patients’ locom otor activity levels 
significantly increased during the day (08:00 to 20:00) following 4 weeks treatment to 
normalised healthy controls. The actigraphy sleep variable data were reported by Todder ef 
al. (2006). It was demonstrated that actual sleep time and sleep efficiency were significantly 
higher after 4 weeks o f  treatment with quetiapine in both the clinically improved and non- 
improved patients as well as there being a shorter sleep latency in the clinically improved 
patients. However although it was reported that actiwatches were worn continuously only the 
data for weeks 1 and 4 were reported.
A study o f  female patients (n = 15 aged m atched with n = 15 controls) w ith panic disorder 
were treated w ith the SSRI escitalopram  5 mg/day for 4 weeks (Todder and Baune, 2010). 
Actigraphy data were continuously measured, although only the data for the untreated week  
versus week 4 treated was presented. The data showed that there was a significant 
im provem ent in sleep efficiency at week 4 compared with week 1 w hich was mirrored, 
although not significant, in the improvement in the PSQI. A  trend was detected in patients 
who improved w ith a > 50% reduction in Hamilton Anxiety Scale (HAM -A) and showed a 
reduction in the actigraphic mean activity score in sleep and increase in actual sleep percent.
However very few studies have monitored the long term effects o f antidepressants to track 
the time-course o f  treatment to measure sleep and / or daytime changes in the community 
according to the review by Burton a/. (2013). In fact only the Kasper er a/. (2010) study 
conducted continuously for 6 weeks on patients treated with agomelatine or sertraline shows 
any similarity to the present study in Chapter 5. The study by Kasper ef a/. (2010) reported 
on sleep variables, daytime activity and circadian rhythm in depressed patients. This was a 
randomised parallel, double-blind study o f  depressed patients (HAMD > 22) treated with
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agomelatine (25 -  50 mg/day) (n = 133) or sertraline (50 -  100 mg/day) (n = 129). HAMD  
and LSEQ data were collected weekly. Actiwatches were worn throughout and data were 
analysed for changes in the rest-activity cycle with assessment o f  NPCRA and the 
actigraphic sleep parameters which were calculated weekly. There were significant 
differences between treatments for sleep efficiency, sleep latency and mean length o f  wake 
bouts, but no significant effect o f  time for either treatment was reported. Sleep efficiency 
decreased over time in the sertraline treated patients whilst sleep latency and the number o f  
wake bouts increased over the 6 weeks. The contrasts with the current study will be further 
discussed in Chapter 5.
1.6.9. Circadian analysis
The rest-activity rhythm is associated with the internal circadian timing system which 
conforms to a general stable rhythm. Irregular behaviour such as shift work, or an illness 
such as A lzheim er’s or insomnia affects sleep and alters the circadian structure. Various 
options to reset the rest-activity pattern have been suggested and one o f the mechanisms for 
characterising, measuring, assessing and reviewing restoration o f the rhythm is provided by 
actigraphy. Studies have shown a disrupted rhythm  from A lzheim er’s patients (Van Someren 
er üf/., 1999) and that bright light might be useful in enabling depressed elderly to maintain a 
24 h circadian rhythm (Most ef a/., 2010). Different methods have been used to show  
disruption and resumption o f the circadian rhythms and the two commonly used with 
actigraphy are Cosinor analysis and Non Parametric Rhythm Analysis (NPCRA). The 
cosinor program was developed by Minors gf a/. (1986) and the NPCRA analysis was 
developed by Van Someren a/. (1999). These programs have been used extensively for 
studying circadian timing in a variety o f  conditions but few studies have explored these 
m ethods for the long term  evaluation o f drug effects.
Wehr a/. (1979) hypothesised 'pAayg waAe cyc/e a»
to reset the rhythm but few studies have reported on this aspect. Sleep 
deprivation and light studies to reset the circadian rhythm have been proposed (Benedetti er 
ûr/., 2005). The disturbances in the circadian rhythm in depression are well known and multi­
factored (Germain and Kupfer, 2008) including changes in daytime activity and sleep 
disturbances. In his review paper Gorwood. (2010) suggested that
a Mew maMage To record and review the
progress o f  the circadian rhythm by actigraphy in a non-invasive way therefore would be 
useful in the process o f  normalising and restoring the disruption caused by depression.
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The 24 h activity profile mean o f  3 days following treatment with the antipsychotic 
imipramine was recorded, with the Gaehwiler actigraph, pre and post 4 weeks o f treatment. 
Patients (n = 52) activity was shown to increase during the day and reduce at night compared 
with no treatment (Volkers a/., 2002). Data were also associated with improvement in 
HAMD.
A study reported on rest-activity disturbances in SAD patients (Teicher et a l,  1997) with the 
time o f  the peak o f the circadian rhythm, 1 h delayed in SAD patients compared with 
controls. This was taken a step further whereby SAD patients versus matched normal 
controls, were treated with light therapy (Winkler ef a/., 2005). The acrophase time o f  peak 
activity was significantly phase advanced by almost 1 h after 4 weeks o f  bright light therapy 
(BLT) treatment and almost matched healthy control subjects. Furthermore it has been 
postulated that the simple method o f recording 24 h activity data may be a suitable method to 
evaluate antidepressant efficacy (Benoit et a l, 1985) and test new  therapies, as it has been 
established that depressed patients have a lower 24 h activity and a more fragmented rhythm 
than healthy controls (Berle ef a/., 2010).
Cosinor and NPCRA variables may be a reliable non-invasive method to understand changes
in circadian rhythm icity during treatment and there are m erits to both methods as discussed 
by Calogiuri et al. (2013). Other markers o f  circadian phase include melatonin and cortisol 
but the collection o f  these are more labour intensive relying on timed blood or urine samples
collected over long periods o f time that would impact on the activity pattern o f  individuals 
by controlling events. Further these bio-markers do not give any indication o f  the sleep and 
wake activity pattern.
1.6.9.1. Cosinor analysis
Circadian rhythm activity can be likened to a cosine curve, where there are perfect peaks o f  
activity during the day and troughs o f  activity during the night. These patterns follow a 
rhythmic pattern close to the shape o f  a cosine curve and if  the daily pattern was perfectly 
fitted to this cosine curve, the percentage rhythm would be expressed as 100%. However, as 
activity data are not perfect, estimates for the variation to the best fit are calculated using an 
analysis program based on fitting the data to the cosine curve by the method o f  least means 
squares (Nelson er a/., 1979; Minors gf a/., 1986), the better the fit the more robust the cosine 
rhythm is. Other variables were calculated to provide the peak activity o f  the curve 
(amplitude), the mean activity value o f  the curve (mesor), and the time o f  the peak o f  activity 
(acrophase time). Subtle changes and variations over long periods o f  time could therefore be 
measured.
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Cosinor analysis has been used for many years and Brown et al. (1990) conducted one o f the 
early studies which showed that there was a pattern o f activity throughout the 24 h cycle in 
normal healthy volunteers. A study o f the effect o f one hour o f bright light in the afternoon 
on hospitalised A lzheim er’s patients showed evidence o f  a more stable rhythm  compared 
with controls (Dowling et al., 2005).
1.6.9.2. Non-parametric circadian rhythm analysis (NPCRA)
Non-parametric circadian rhythm analysis (NPCRA) provides an alternative more sensitive 
m ethod o f analysis to cosinor, the data variables are assumed to be more m eaningful as they 
are not fitted to a cosine curve. The NPCRA variables are described in Section 5.4.8 and 
shown in Figure 1.16. The NPCRA developed by Van Someren et al. (1999) has been 
particularly useful in recording the 24 h behaviour o f A lzheim er’s patients and o f depressed 
elderly (M ost et al., 2010). However few studies have been conducted o f  the use o f NPCRA 
in drug studies. The activity is calculated for the m ean activity o f the 6 minute blocks during 
the 10 most active hours (MIO) and the mean activity o f the 6 minute blocks during the 5 
least active hours (L5).
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Figure 1.16: Example of NCPRA rhythm
The profile o f 7 days of activity combined to show a 24 h mean. The 10 h of maximum activity is 
presented as the blue line and the 5 h of least activity as the red line. The time of MIO onset is 07:00 
and the time o f L5 onset is 01:00.
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Circadian activity was recorded with the Actiwatch in a study o f  depressed out-patients 
treated with either agomelatine or sertraline for 6 weeks (Kasper er or/., 2010). Changes in the
NPCRA Relative Amplitude (RA), the MIO and the L5 were reported. RA rem ained fairly 
constant whereas MIO increased and L5 decreased between the baseline and post-baseline 
week 6. N either the data for the individual weeks or the time course was presented. The 
authors reported a faster improvement in circadian variables with outpatients treated with 
agomelatine (25-50 mg/day) (n = 133) compared with sertraline (50-100 mg/day) (n = 129), 
in line with improvement in HAM D (Kasper et a l, 2010).
A lthough a double-blind randomised, placebo controlled study o f  the effect o f 2 weeks 
temazepam 20 mg/day on 38 insomniacs failed to show any significant effect o f  treatment in
m ost o f the NPCRA variables, the significant increase in L5 activity during withdrawal was 
associated with a significant reduction in sleep efficiency com pared with placebo. The 
authors W ilson et al. (2004b) stated that as the participants were in work that it was unlikely 
that obvious changes in NPCRA would be recorded.
Baune gf a/. (2006) studied the effect o f  the antidepressant quetiapine on changes in daytime 
activity in hospitalised unipolar (n = 8) and bi-polar (n = 2) depressed patients and showed
that there was an improvement in activity levels with an increase at week 4 compared with 
week 1 in MIO regardless o f clinical improvement but no difference in L5 activity at night. 
The L5 levels o f  non-responders to treatment however, were higher com pared to the 
responders at both weeks 1 and 4, and they had significantly lower sleep efficiency and TST.
1.6.10. D iscontinuation o f  selective serotonin reuptake inhibitors (SSRIs)
One o f  the many problems associated with any long term treatment is the likelihood o f
patients m issing doses, and the potential for the emergence o f discontinuation symptoms. 
Apart from forgetting to take medication and instances like holidays w ith medication left at 
home, van Geffen ef a/. (2005) found that the main reasons for abrupt discontinuing were
24%  MO ybr 7.5%% in a fbllow-up
questionnaire o f  74 patients discontinuing SSRI treatment. However such is the problem  
with discontinuing that it was classified as a syndrome in 1996 by a panel o f  experts 
(Schatzberg, 1997) with the following definition:
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The problem with abrupt discontinuation is the likelihood o f the emergence o f 
discontinuation symptoms which were well documented in a discontinuation study (Judge et 
o/., 2002) and reviewed in Demyttenaere and Haddad, (2000). These symptom may include 
dizziness, nausea, sleep-disturbances, stomach aches, flu-like symptoms, headache and 
fatigue to name but a few, which can occur shortly after stopping treatment (Haddad, 2001). 
The emergence o f  these symptoms, which differ from the side effects o f  SSRIs, appear to be 
related to the short half-life o f  the treatment, with m any more reports o f  symptoms occurring 
after 1-5 days o f  paroxetine discontinuation (Black et a l, 2000), than with other SSRIs.
Price ef a/. (1996) reported that in a comparison o f  SSRI post marketing safety from the UK  
database o f adverse drug reactions, discontinuation symptoms following paroxetine 
withdrawal accounted for 5% o f the reports compared with < 1% for sertraline and 
fluoxetine. Nevertheless, a review by Montgomery er a/. (1994) reported that in a meta­
analysis it was found that '.yzgzzz/zcz^ zzfZy y^ ez' pa7zezz^ .y wfrTzzTrmv ^ozzz z^ ea^ zzzezzZ' q/^  zzzq/oz" 
(7q5Z"g.9.yzozz wzr/z ^5!7(/9 7/zazz ^ozzz TCWj’. Recognising the symptoms and subsequent 
management o f  discontinuation is a key factor in treating patients (Haddad and Anderson, 
2007) and the use o f tapering and reducing dosages has been suggested by van Geffen et a l 
(2005).
Rosenbaum aZ. (1998) conducted a discontinuation study with 242 depressed patients on 
SSRIs, where the treatment o f patients on maintenance medication was interrupted and 
substituted with 5-8 days o f  placebo. Symptoms were measured with MADRS, HAMD28 
and the Discontinuation-Emergent Signs and Symptoms (DESS) checklist. There were 
significantly higher adverse outcomes following paroxetine and sertraline withdrawal 
compared with fluoxetine, although most symptoms resumed to pre-discontinuation levels on 
re-stabilisation o f  treatment. The incidence o f symptoms was significantly higher with 
patients treated with paroxetine 66% (n = 82) and sertraline 60% (n = 79) compared with 
fluoxetine 14% (n = 81) according to the Discontinuation-Emergent Signs and Symptoms 
questionnaire (DESS). The percentage o f  patients who reported having trouble sleeping from
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DESS, reported by > 10% o f  patients, was greater following paroxetine withdrawal than 
fluoxetine or sertraline with 39, 22 and 9, respectively.
In a sim ilar study with a 5 day placebo substitution, by M ichelson et al. (2000), significantly 
higher numbers o f adverse events were reported with functional im painnent after paroxetine 
withdrawal compared with sertraline or fluoxetine. Patients (n = 77) on long tenn  
antidepressant treatment with the SSRIs and with a HAM D score > 1 0  were recruited. There 
was a significantly shorter onset time o f new symptoms in the Patient Rated Adverse Events 
Scale, occurring within 2 days following paroxetine withdrawal but no significant effect in 
either sertraline or fluoxetine even after 4 days. The 'time to onset o f symptoms’ is shown in 
Figure 1.17 (M ichelson et a l, 2000).
Interestingly M ichelson et al. (2000) also reported on the plasma concentrations at the end o f 
the placebo substitution disruption, the mean percentage reduction o f active treatment was 
29.7% for fluoxetine, 73.5 % for sertraline and 86.7% for paroxetine although this did not 
correlate with the emergence o f new symptoms. W ith respect to these and other reported 
effects o f  discontinuation it has been suggested that tapering instead o f  abrupt withdrawal 
might be preferable (Rosenbaum and Zajecka, 1997; Haddad, 2001).
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Figure 1.17: Time to onset o f discontinuation symptoms (Michelson et al,  2000)
1.6.10.1. Objective tests Critical Flicker Fusion (CFF) and Choice Reaction Times 
(CRT)
Only one study by (Hindmarch et a l, 2000a) has investigated the effect o f  brief 
discontinuation o f  the SSRIs paroxetine, fluoxetine, sertraline or citalopram treatment on 
cognitive functioning o f depressed patients and the effect o f time on CRT and CFF. 
Depressed patients (n -  87) on maintenance therapy for at least 3 months and with a
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MADRS score o f < 12 were recruited. Patients on treatment with either paroxetine, n = 22 
(20 mg/day), fluoxetine, n = 22 (20 mg/day), sertraline n = 22 (50 mg/day) or citalopram, n = 
21 (20 mg/day) had their treatment disrupted for 4-7 days (Hindmarch g7 a/., 2000). 
Cognitive and psychomotor function was assessed with LARS, CFF, CRT, LSEQ and CFQ 
as well as the depression scales o f MADRS and ZUNG at screening Day 0, Day 5 baseline. 
Day 10 post withdrawal and Day 15 after 5 days re-introduction o f SSRI treatment. B rief 
treatment discontinuation o f  4-7 days had no overall effect on CFF for any treatment, 
although a slight non-significant decrease in threshold was observed following paroxetine 
withdrawal (Hindmarch er a/., 2000a). Although reaction time increased on CRT following 
withdrawal o f all treatments, this was only significant for paroxetine.
1.6.10.2. Leeds Sleep Evaluation Questionnaire (LSEQ)
As previously stated only one other study has reported on the effect on (Leeds Sleep 
Evaluation Questionnaire) LSEQ items following withdrawal o f  SSRI treatment (Hindmarch
et a l, 2000a). In the study reported and described in the previous Section 1.6.10.1 there was 
a slight impairment o f sleep assessed with LSEQ items following paroxetine, fluoxetine and 
sertraline withdrawal.
Although all GTS scores increased for all treatments following discontinuation the effect
was not significant. Scores for QOS following paroxetine withdrawal significantly increased 
with a worsening o f symptoms and poorer sleep quality, and QOS scores were also adversely 
affected with fluoxetine withdrawal. Discontinuation from paroxetine or sertraline worsened 
with an increase, but not significant, in scores for AFS, with patients feeling less refreshed, 
whereas scores following fluoxetine withdrawal slightly increased and therefore exerted no 
adverse effect on AFS. The effect o f  discontinuation on BFW  worsened following 
withdrawal from paroxetine, increased scores indicated that patients felt worse upon 
awakening and that their behaviour and functioning was impaired. Data suggests therefore 
that withdrawal from paroxetine caused disruption in GTS, QOS, AFS and BFW, whereas 
discontinuation from fluoxetine or sertraline does not affect patients to the same degree 
(Hindmarch gr a/., 2000a). Rosenbaum g7 a/. (1998) also reported that paroxetine caused 
more 'fatigue’ than either sertraline or fluoxetine during placebo substitution.
1.6.10.3. Line Analogue Rating Scale (LARS)
The trend for a worsening o f  symptoms during abrupt discontinuation from paroxetine was
repeated in the LARS in the previously described Hindmarch et a l (2000a) study, who 
reported an increase in sedation scores following paroxetine withdrawal. Rosenbaum g7 o'/.
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(1998) also reported that paroxetine caused more ‘fatigue’ according to the DESS, than 
either sertraline or fluoxetine during placebo substitution.
1.6.10.4. M ontgomery-Âsberg Depression Rating Scale (M ADRS) and Hamilton 
Depression Rating Scale (HAMD)
In the 4 week multi centre study reported in Section 1.6.10 there was a significant change in 
both M ADRS and HAMD28 scores following inteiTuption in the paroxetine and sertraline 
groups but not in the patients treated with fluoxetine as shown in Figure 1.18 (Rosenbaum et 
a l, 1998). As reported previously, M ichelson et a l (2000) conducted a similar study o f  a 5 
day placebo-blind withdrawal o f SSRIs in patients, there was a statistically significant 
increase at the end o f the withdrawal, in the HAMD21 scores, for patients treated with 
paroxetine which occurred after the 2nd day o f  replacem ent with placebo, but not for patients 
treated with either fluoxetine or sertraline.
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Figure 3. Mean scores for the 2S-item Hamilton Depression 
Rating Scale (HAMD^s). The two interrupted groups were 
pooled and compared before intemçtion. after 1 week of 
interruption, and after 1 week o f restabilization. The three 
treatments showed no difference in mean scores before mterrup- 
tion. Following interruption, the mean score in the fluoxetine- 
treated patients was significantly lower than that in either the 
sertraline-treated (p =  .004) or paioxetine-treated (p <  .001) 
patients. The three treatments showed no difference in means 
after restabihzation.
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Figure 4. Mean scores for Montgomety-Asberg Depression 
Rating Scale (MADRS). The two interrupted groups were pooled 
and compared before interruption, after 1 week of interruption, 
and after 1 week of restabihzation. The thiee treatments showed 
no difference in mean scores before interruption. Following 
interruption, the mean score in the fluoxetine-treated patients w as 
significantly lower than that in either the sertraline-treated (p = 
.019) or paroxetine-treated (p <  .001) patients. The three diug 
treatments showed no difference in means after restabilization.
Figure 1.18: M ontgom ery-Âsberg Depression Rating Scale (M ADRS) and Hamilton 
Depression Rating Scale (HAM D) during discontinuation (Rosenbaum et a l, 1998)
Depression severity was also assessed in the discontinuation study reported in Section 
1.6.10.1 (CFF and CRT) (Hindmarch et a l, 2000a). At screening patients were included with 
a M ADRS score < 12. At the end o f the withdrawal period there was a statistically 
significant increase, in the M ADRS scores, for patients treated with paroxetine but not for 
patients treated with either fluoxetine or sertraline. Results o f  the withdrawal are shown in 
Figure 1.19. This significant effect was also reported following abrupt discontinuation o f 
paroxetine treatment on HAMD.
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Figure 4. Mean change in Montgomery-Asberg Depres­
sion Rating Scale (MADRS) scores following treatment 
discontinuation. Vertical bars represent ±  1 SEM. 
*P  < 0.05 paroxetine versus fluoxetine, sertraline and 
citalopram.
Figure 1.19: Change in MADRS scores following treatment discontinuation (Hindmarch et al,  2000a)
Other researchers, Judge et a l (2002), also found that there was a statistically significant 
increase at the end o f the withdrawal, in the HAMD21 scores, for patients treated with 
paroxetine but not for patients treated with either fluoxetine or sertraline in study with a 3-5 
day placebo abrupt withdrawal o f SSRIs in patients. The differences in the MADRS and 
HAM D scores for the discontinuation period between paroxetine and sertraline or fluoxetine 
are likely to be due to the difference in their pharmacokinetics. As described in Section 1.6.3 
fluoxetine has a longer half-life o f  1-3 days with the half-life o f its metabolite o f 4-16 days, 
concentration levels decline at a slower rate which helps to reduce severity o f  symptoms. 
This contrasts with paroxetine with a short half-life o f  21 h and no active metabolite, and 
sertraline with a half-life o f  26 h and a low activity m etabolite o f  66 h and maybe why more 
discontinuation symptoms are recorded for paroxetine than for the other SSRIs in the current 
study according to reviews (Price et a l, 1996; Black et a l, 2000).
1.6.10.5. ZUNG
The ZUNG scores worsened in self-rated depression following paroxetine withdrawal in the 
study reported by Hindmarch et al. (2000a), a significant discontinuation effect was 
observed. The scores reported increased from 38.3, 40.9 and 38.3 before discontinuation to
48.6, 42.8 and 40.6 after 5 days o f  discontinuation for paroxetine, fluoxetine and sertraline 
respectively, showing that paroxetine had caused a significant effect (Figure 1.20).
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R uaxebne  20  mg 
S e rlra ln e  50  mg 
Paroxew ne 2 0  mg 
CltBlDpram 20  mg
Figure 3. M ean ch an g e  In Zung D epression  Rating S ca le  
s c o re s  following trea tm en t discontinuation. Vertical b a rs  
re p re sen t ±  1 SEM. * P <  0 .05  paroxetine v e rsu s  fluoxe­
tine, sertraline and  citalopram .
Figure 1.20: Effect o f treatment discontinuation on ZUNG questionnaire (Hindmarch et at., 2000a)
1.6.10.6. Cognitive Failures Questionnaire (CFQ)
The study by Hindm arch et al. (2000a), previously reported, also showed a significant 
increase in the CFQ score during the week following abrupt discontinuation from paroxetine 
and a trend for im painnent following sertraline withdrawal as shown in Figure 1.21.
1.7. Aims and Objectives
Since actigraphy measures rest-activity patterns the overall aim o f the studies was to 
investigate whether it is possible using actigraphy to identify and measure drug-induced 
changes in activity following acute administration o f different classes o f  psychoactive drugs 
(sedative hypnotics and antihistamines). The time course o f  action o f these CNS drugs will 
be investigated in relation to the changes in activity patterns in conjunction with changes in 
psychom otor function to detennine whether actigraphy is suitably sensitive to detect drug- 
induced effects.
F lu o x s tn e 2 0 m a
Sertratne 50  m g
Pam xmlfw20m@
CnBlopram 20  mg
Figure 1. M ean change  in Cognitive Failures Q uestion­
naire (CFQ) sco res  following trea tm ent discontinuation. 
Vertical b a rs  re p re s e n t± 1  SEM. * P < 0 .0 5  paroxetine 
versus fluoxetine and  citalopram.
Figure 1.21 : Effect o f treatment discontinuation on CFQ questionnaire (Hindmarch et a l,  2000a)
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W hether actigraphy can be used to measure drug-induced changes in sleep behaviour during 
the sleep period and changes in the sleep profile following drug administration w ill also be 
evaluated. In addition, whether actigraphy can distinguish changes in motor activity the 
following morning and therefore any hangover effect o f  the drug will also be determined.
The sensitivity o f  the actigraph technology to the sedating effects o f  medication and how  
accurately actigraphy is able to track drug phannacokinetics and pharmacodynamics will
also be investigated.
The chronic effects o f antidepressant administration will also be investigated to determine 
the usefulness o f  the actigraphy technology in monitoring patient groups in their own home 
environment following long term adm inistration o f  medication to evaluate changes in 
activity and sleep patterns.
1.8. Hypotheses
Since two different types o f  studies were being conducted, namely the short acting effects o f
psychoactive compounds on healthy volunteers and the longer acting effects o f 
antidepressant treatment on depressed patients the different hypotheses are:
Acute studies:
i. Acute adm inistration o f psychoactive compounds will impair cognition and 
psychomotor performance in healthy participants greater than placebo and these 
sedative changes in activity and sleep will be measurable by actigraphy.
ii. Actigraphy will determine whether the administration o f  psychoactive compounds 
causes m otor impairments throughout the treatment period.
iii. The null hypotheses for acute studies are that the hypnotic sedative lorazepam and 
the antihistamine promethazine will have no effect on arousal, attention, and sleep as 
assessed by the cognitive and psychomotor tests, actigraphy and subjective 
questionnaires.
Chronic study:
i. Changes in activity, the sleep wake and circadian profile o f  depressed patients 
treated with chronic SSRI antidepressants will be measureable by actigraphy.
ii. Changes in the sleep wake and circadian profile o f  depressed patients following 
abrupt discontinuation o f  treatment will be detectable by actigraphy.
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iii. For statistical purposes the null hypotheses for the chronic study is that the SSRI 
antidepressant treatment will have no effect on sleep wake and circadian activity 
o f depressed patients as measured by actigraphy.
For specific hypotheses refer to relevant sections in the respective chapters
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CHAPTER 2 GENERAL METHODS
This thesis reports on three separate studies, methods common to each study are described in 
this chapter, with specific methods o f  each o f  the studies described in the respective 
chapters.
2.1. Participants
Participants, as healthy volunteers or patients, were recruited to the relevant studies, 
according to the strict criteria in the clinical trial protocols and the inclusion/exclusion 
restrictions. Written informed consent was obtained from all participants together with the 
consent o f their medical practitioner to participate in the trials. Participants were sequentially 
randomised to receive study medication. The participants in the studies referred to in 
Chapters 3 sedative hypnotics and Chapter 4 antihistamines were conducted on healthy 
volunteers whereas the participants in the antidepressant study Chapter 5 were depressed 
patients.
2.2. Study Design
The studies were randomised, double-blind investigations into the effects o f treatment on 
actigraphic sleep variables, subjective sleep and aspects o f  cognitive and psychomotor 
performance. The full details o f  each study design are in the relevant chapters. Studies were 
approved by the relevant Ethics Committees.
2.3. Actigraphy
The Actiwatch AW 4 (Cambridge Neurotechnology Ltd., Cambridge, UK) was worn by the
participants continuously on their non-dom inant wrist for the duration o f each study to 
record activity.
2.4. Activity
Actigraphy records activity in counts per epoch so drug-induced changes in activity may be 
observed and measured. Data were recorded in either 1 or 2 minute epochs depending on the 
study. Actiwatches were set up to record using the manufacturer's proprietary default 
medium setting and activity data were stored in 1 minute epochs. Prior to download the 
marker buttons were pressed to confirm that the internal timer was correct against the 
previously checked computer clocks.
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To obtain the actigraphic sleep variables the Actiwatch Activity and Sleep Analysis 
Version 5 (Sleepwatch Version 5.51) (Figure 2.1) was used to calculate the variables from 
lights o ff to lights on. The Sleepwatch proprietary algorithm  was used to compare the 
activity data o f epochs 10 minutes either side and in a series o f linked calculations epochs 
were scored as ‘sleep’ or ‘w ake’. Epochs with a value o f 40 counts per 1 minute or more 
were scored by the algorithm as wake, anything less being scored as sleep.
8^ Sleep analysis
File R eader Actogram Sleep Analysis Activity analysis Nap Analysis Options
Actiwatch Activity  & Sleep Analysis 5
Copyright Cambridge Neurotechnology Ltd.
Version 5.51
Filename C:\Documents and Settings\Actiwatch Analysi$\Desktop\Samples\STUDY.AWD
Start Date |l 2 Apr 1999 User ID jstudy
Start Time 20:20:00 Age 23 Sex M
Logged samples |20126 
Epoch length j o i . O O  Mins
W atch Serial No jV541229
W atch Type jActivity
Figure 2.1: Actiwatch screen view of Version 5.51 
To show version o f software used for analysis.
For each study the sleep start and sleep end times were calculated from the lights out and 
lights on times set by the m arker or operator and checked for consistency. Sleep analysis was 
perfonned using the autom ated proprietary software algorithm  and the sleep variables were 
calculated. Summary data were exported to Excel for statistical analysis.
2.4.1. Actigraphic sleep variables
In each study the actigraphic sleep variables for the sleep period were automatically 
calculated with the internal Sleepwatch algorithm and software. The analysis window was 
set before and after the ‘lights out’ and ‘lights on’ to cover the whole sleep period.
Four o f  the 17 Sleepwatch variables [sleep period time (SPT), wake after sleep onset 
(W ASO), sleep efficiency (SE) and sleep onset latency (SOL)] are common and considered 
to be comparable to PSG (Oakley, 1997). For the purpose o f statistical analysis all times 
were calculated in decimal minutes.
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The validated sleep variables calculated for the purpose o f  the studies com prised the 
following:
• Time in bed (TIB) -  Lights out to lights on
•  Assumed sleep time / Sleep period time (SPT) -  Assumed sleep time from sleep start
to sleep end similar to sleep period time, from sleep start to sleep end including any
wake time
• Actual sleep time / Total sleep time (AST/TST) -  The total amount o f  sleep in the
sleep period minus any wake time
•  Actual awake time / Wake after sleep onset (AWT/WASO) -  The am ount o f  time 
spent awake in the sleep period
• Sleep efficiency (SE) -  The percentage o f  time spent asleep whilst in bed
•  Sleep latency (SOL/SL) -  The latency before sleep onset following bed time, the
time taken to fall asleep from lights out
• Sleep bouts (SB) and wake bouts (W B) -  The num ber o f episodes o f  continuous 
sleep or continuous wake, and therefore the number o f  transitions from sleep to 
wake
• Sleep bout time (SBT) and wake bout time (W BT) -  The mean time o f  an episode o f 
sleep or wake
•  Fragm entation index (FI) -  The addition o f  the percentages o f  moving time and 1 
minute immobility phases, w hich is used as an indicator o f  restlessness.
•  Average wake movement (AWM) -  Mean activity count per epoch during the 
preceding day, from sleep end to sleep start.
• Total activity counts in sleep
2.4.2. Sleep-like activity
A method o f  analysing data for measuring low activity during the day which can be classed 
as ‘sleep-like’ or ‘sedation’ was suggested by Stanley and Hindmarch, (1997). In the current 
studies each epoch was scored as sleep or wake according to the algorithm whereby activity 
epochs with less than 40 counts recorded per 1 min epoch are defined as sleep-like, and over 
40 counts / min as wake. It was therefore possible to determine whether a treatment had 
induced ‘sedation’.
2.4.3. Cosinor analysis
This is described in detail in Sections 1.6.9.1 and 5.4.8.1.
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2.4.4. Non-parametric circadian rhythm analysis (NPCRA)
This is described in detail in Section 5.4.S.3.
2.5. Cognitive and psychomotor tests
Various cognitive and psychometric performance tests were conducted in each o f  the studies. 
For the purpose o f  reference all tests are described in this methods section. The tests 
included Choice Reaction Time (CRT), Continuous Tracking Task (CTT) and Critical 
Flicker Fusion (CFF). These tests are known to be sensitive to the impairing effects o f  
psychotropic compounds (Sherwood and Kerr, 1993; Hindmarch, 1999, 2002; Hindmarch 
a l,  2002, 2005). To standardise the procedure and for calibration and validation purposes the 
tests were put together collectively in a test battery known as the Leeds Psychom otor Tester 
(LPT). Individually they are useful for comparing the pharmacodynamics effects o f  different 
classes o f  medication. Different tests were used in the various studies in this thesis.
2.5.1. Choice Reaction Time (CRT)
The CRT task is sensitive to a variety o f  psychoactive agents (Alford g/ a/., 1991; Baselt, 
2001; Hindmarch, 1981; Hindmarch and Parrott, 1978) and is used as an indicator o f 
sensorimotor performance (Hindmarch, 1975, 1980), assessing the ability to attend and 
respond to a critical stimulus (Sherwood and Kerr, 1993). The CRT equipment is shown in
Figure 2.2. Participants placed the index finger o f  their preferred hand on a central starting
button, and were instructed to extinguish one o f  six equidistant red lights, illuminated at 
random, by pressing the response button immediately in front o f  the light as quickly as 
possible. The mean o f  50 consecutive presentations was recorded as a response measure o f  
three components o f  reaction time; recognition, m otor and total reaction time. Recognition 
reaction time (RRT) is the time it takes for the participant to notice the light, being the time 
between stimulus onset and the participant lifting their finger from the start button. Motor 
reaction time (MRT) indexes the movement component o f  this task, and is the time between 
the participants lifting their finger from the start button and touching the response button. 
Total reaction time (TRT) is the sum o f  RRT and MRT. All results were recorded 
electronically.
2.5.2. Critical Flicker Fusion (CFF)
The CFF task provides an index o f central nervous system activity or "cortical arousal". 
More specifically, the CFF assesses the ability to distinguish between discrete sensory 
events. Participants were required to discriminate flicker from fusion and vice vcr.ya in four 
light emitting diodes (LEDs) arranged in a one-centimetre square on a black background.
78
The participant was instructed to sit one metre away from the diodes. Individual thresholds 
were determined by the psychophysical method o f  limits on four ascending (flicker to 
fusion) and four descending (fusion to flicker) scales (W oodworth and Schlosberg, 1958). 
CFF has been shown to be sensitive to a variety o f  psychoactive compounds (Smith and 
Misiak, 1976; Hindmarch, 1975, 1982, 1994). A decrease in the CFF threshold is indicative 
o f a reduction in the overall integrative activity o f the central nervous system (Fairw eather et 
a l, 1997). M oreover CFF is able to show improvement in cognitive function with an 
increase in the CFF threshold being indicative o f an improvement in overall integrative 
activity (Kerr et a l,  1991, 1993; Alexander et a l, 1997). All results were recorded 
electronically.
Figure 2.2: Choice reaction test platform
2.5.3. Continuous Tracking Task (CTT)
The CTT interactive task o f  psychom otor function entails using a mouse to keep a cursor in 
alignment with a m oving target on a VDU screen. The movement o f the target is a function 
o f an irregular sine wave. The response measure is the mean difference between the centres 
o f target and cursor in pixels, sampled 5 times per second, over the 5-minute test. Lower 
scores are indicative o f  more accurate tracking (CTT-ER). A peripheral awareness task 
(PRT) was included in which the participant responded to a stimulus presented in the 
periphery o f vision, while simultaneously attending to the traeking test. The mean reaction 
(CTT-RT) time in milliseconds to these stimuli over the trial period was taken as the 
response measure for this com ponent o f the divided attention task. Data were captured 
electronically.
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2.6. Questionnaires
A variety o f  questionnaires were used in the studies, the most common were Leeds Sleep 
Evaluation Questionnaire (LSEQ) and Line Analogue Rating Scale (LARS), descriptions o f  
which are provided below. Other questionnaires, M ontgomery-Âsberg Depression Rating 
Scale (MADRS) Appendix I, Hamilton Depression Rating Scale (HAMD) Appendix II, 
ZUNG Appendix III and Cognitive Failures Questionnaire (CFQ) Appendix IV were 
specifically used in the depression study and are described in detail in Chapter 5.
2.6.1. Leeds Sleep Evaluation Questionnaire (LSEQ)
The Leeds Sleep Evaluation Questionnaire LSEQ (Appendix V) assesses the effects o f  
psychoactive compounds on sleep and early morning behaviour (Hindmarch, 1984; Zisapel 
and Laudon, 2003). It has been shown to be an effective assessment tool when used to 
quantify subjective sleep effects (Parrott and Hindmarch, 1980; Hindmarch, 1984; Zisapel 
and Laudon, 2003). The questionnaire consists o f  ten questions on aspects o f subjective sleep 
and early m orning behaviour and is grouped into four categories: ‘getting to sleep’ (GTS), 
‘quality o f  sleep’ (QOS), and any hangover effect the following morning in feelings on 
‘awakening from sleep’ (AES) and ‘behaviour following w ake’ (BFW). It was employed in 
Chapter 5.
Participants marked a series o f  100 unit line analogue scales to indicate the direction and 
magnitude o f changes in sleep following the administration o f  a drug in relation to then- 
normal non-drug performance (Parrott and Hindmarch, 1980). The questionnaire was 
presented in the studies as a paper-based test. The participants m arked each question by 
placing a vertical m ark on the 100 mm line with a pen to indicate the extent o f  the effect they 
were experiencing with regards to a midpoint. This m idpoint represented their normal state 
o f mind before treatment began. The response was scored by measuring the distance in 
millimetres between the left end o f  the line and the participant’s mark.
For the purpose o f  the current studies it was useful to compare objective actigraphic
variables and subjective sleep, and with regards to the LSEQ GTS was compared with sleep 
latency and QOS was compared with sleep efficiency, percentage sleep and movement
within the sleep period.
A LSEQ score o f  50 indicated no change compared with how participants had slept prior to
drug treatment. A lower score (< 50) indicated a perception o f improved sleep, i.e. easier to 
get to sleep, more restful sleep, and improved early morning behaviour, for example easier to
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wake up and feeling less clumsy than usual. A higher score (> 50) indicated a perceived 
worsening in sleep quality or behaviour the next morning.
2.6.2. Line Analogue Rating Scales (LARS).
The Line Analogue Rating Scale (LARS) (Appendix VII) was used to assess patients’ 
present feeling with that before drug treatment by marking on a series o f  100 mm visual 
analogue scales, the midpoint represented their normal state o f  mind. The scale consists o f  
10 components: Dizzy, Clumsy, Anxious, Relaxed, Tired, Drowsy, Alert, Energetic, Sad, 
and Depressed. The mean scores o f  ratings o f  ‘tiredness’, ‘drowsiness’, and ‘alertness’, 
presented among several distracter scales, are taken as a measurement o f  perceived sedation 
(Hindmarch and Gudgeon, 1980). The lower the score (in millimetres), the more alert and 
less tired and drowsy the participant feels. Depending on the study the LARS was completed 
following dosing, in the morning or at the out-patient visits. The response was scored by 
m easuring the distance in mm between the left end o f  the line and the participant’s mark.
2.6.3. Montgomery-Àsberg Depression Rating Scale (MADRS)
This is described in detail in Section 5.4.9.7.
2.6.4. Hamilton Depression Rating Scale (HAMD)
This is described in detail in Section 5.4.9.8.
2.6.5. ZUNG Depression Inventory 
This is described in detail in Section 5.4.9.10.
2.6.6. Cognitive Failures Questionnaire (CFQ)
This is described in detail in Section 5.4.9.11.
2.7. Statistical methods
The data for this thesis were extracted from each o f  the larger respective studies and 
analysed separately. Data were analysed as a two-treatment data set, for the verum and 
placebo data, in the case o f  Chapter 3 Sedative Hypnotics and Chapter 4 Antihistamines or 
as a three-treatment data set for all treatments for Chapter 5 Antidepressants.
The analysis for each study was conducted as an analysis o f  variance with each variable e.g.
mean activity, test or questionnaire as the dependent variable; drug treatment and study
period as fixed effects, and time (within participant and study period) as a repeated measure
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and with spatial power SP(POW) variance-covariance matrix, with participant as a random
effect.
Individual treatment versus placebo or baseline comparisons were performed using the 
LSMEANS option for estimating differences o f SAS PROC MIXED (Statistical Analysis 
Software SAS® PC, Version 9.1, SAS Institute, North Carolina, USA) which provided 
information on estimates, 95% confidence limits, and P-values for each time point. No test 
multiplicity significance ac^ustment was made at any stage in the analysis. The results were 
analysed by the restricted m aximum likelihood ‘REM L’ m ethod in SAS PROC M IXED with 
‘treatment’ and ‘period’ as fixed effects and ‘participant’ as a random effect, whereby any 
non-missing observations for participants with any missing values were used in the 
estimation.
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CHAPTER 3 SEDATIVE HYPNOTICS
3.1. Introduction
Lorazepam (LZP), a second generation hypnotic benzodiazepine, is prescribed to alleviate 
anxiety and aid sleep. LZP is usually prescribed in small doses (1 mg) during the day to 
reduce anxiety and is also given in a single dose at night (2.5 mg) to initiate sleep. The
pharmacokinetics o f LZP show that it is readily absorbed reaching a peak concentration 
approximately 2 h after dosing with an elimination half-life o f about 12 h (Kyriakopoulos et 
a/., 1978). A  dose o f 2.5 mg LZP has been shown to increase total sleep time and change 
sleep architecture at night (Grozinger e/ a/., 1998; Roschke er a/., 2000), induce subjective 
daytime sleepiness (van Laar gr a/., 2001), and reduce anxiety symptoms (Laakmann e/ a/., 
1998). Previous studies have also shown that it impairs daytime psychom otor performance 
and memory (Baselt, 2001).
The effects o f benzodiazepines in healthy participants and patients are detailed in Section
1.4. As the daytime impairment effects o f  LZP have been well docum ented it was considered 
appropriate to use LZP as a tool to assess how well actigraphy maps onto changes in 
cognitive and psychomotor function. Permission was received from Servier to use the 
placebo and LZP verum data.
3.2. Aims
The aim o f  the study was to evaluate the effect o f  a single dose (2.5 mg) o f  LZP, compared 
w ith placebo, on actigraphic m otor activity in association with cognitive and psychom otor 
function in healthy participants kept in laboratory conditions. The ability o f  actigraphy to 
detect LZP-induced changes in both spontaneous and controlled activity was assessed. In 
addition, whether actigraphy could distinguish changes in the sleep profile and any hangover 
effect o f  the drug was also determined.
3.3. Hypotheses
i. Lorazepam will reduce actigraphic activity levels, increase daytime ‘sleep-like 
activity’ and increase actigraphic sleep variables compared with placebo.
ii. Lorazepam will impair cognitive and psychomotor performance compared with
placebo.
iii. The null hypothesis is that compared to placebo, LZP will have no effect on 
cognitive and psychomotor performance, actigraphic activity, or actigraphic sleep
variables.
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3.4. Methods
3.4.1. Study design
Participants were randomised to a double-blind, placebo-controlled, crossover design study 
where each volunteer acted as their own control. The data presented here were taken from a 
larger clinical trial and for the purpose o f this investigation only the results o f  the study 
treatments o f placebo and LZP are presented. Volunteers received either LZP (2.5 mg) or 
placebo on two consecutive days, in a Latin Square design so that each volunteer received 
each treatment. All treatments were supplied in identical capsules and each oral dose was 
taken at 18:00 h on Day 1 and Day 2 o f  each study period as shown in schedule (Figure 3.1). 
Lach o f the study periods was separated by a six day washout.
Day 3
00:00 07:00
A
Day-1 1 Night -1
X
Day 1 Sleep Psychometrics ill' Night 1
X
Day 2 1 Night 2
D
18:00
23:00
24:00
Figure 3.1: Study schedule
Legend, A = Admit participants to unit, X = dosing with placebo or LZP (2.5 mg), D = discharge from 
unit
3.4.2. Participants
Twenty four healthy male and female Caucasian volunteers were recruited onto the study; 
one participant was withdrawn after Night 1. Twenty three participants completed at least 
one o f  the treatments and are therefore are included in the analysis, 21 participants (10 
males, 11 females) com pleted both study treatments. The age (mean ± SD) o f the 23 
participants was 27.3 ± 5.3 years and the mean height, weight and body mass index (BMI) o f 
the participants at screening were 1.72 ± 0.08 m, 70.0 ± 9.7 kg and 23.7 ± 2.2 kg/m^, 
respectively.
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All participants were in good health without any clinical history o f  physical or mental illness 
as assessed by a physician. No participants were taking any concomitant medication (except 
oral contraceptives) likely to interfere with the study measures. Following a medical history, 
participants underwent a medical examination (including 12-lead electrocardiogram, 
urinalysis, haematology, biochemistry, alcohol breath test and drugs o f  abuse screen). 
Written informed consent was obtained ftom all volunteers together with the consent o f  their 
medical practitioner to participate in the trial. The study was approved by the Ethics 
Committee o f the South W est Surrey Health Authority.
Participants were instructed to avoid late-iiights and adhere to their usual bedtime 
(minimum 6 - 8 h sleep) before each o f the study periods. In order to ensure compliance to 
the sleep wake restriction they were required to wear actigraphs continuously from the
screening visit to study completion (maximum 8 weeks). The use o f alcohol, nicotine and 
products containing caffeine were prohibited for 24 h before and on study days.
3.4.3. Study procedures
Participants attended the unit on Day -1, a breath alcohol reading was taken and a urine 
sample obtained for drugs o f  abuse screening. The actigraph was removed, downloaded,
checked for compliance and reattached. Participants were familiarised with the study 
procedures and trained on the standard battery o f  psychom etric tests (Section 2.5) at the start 
o f  the trial in order to minimize learning effects during the study (Parkin et a l, 1997).
The psychometric test battery was performed at 07:00 h on Day 1 o f  each study period in
order to obtain pre-treatment baseline recordings. Treatment (placebo or LZP) was 
administered at 18:00 h. After dosing on Day 1 the standard battery o f psychom otor and 
cognitive tests was conducted at I, 2, 3, 4 and 14 h post dose. During the study periods food 
consumption was strictly controlled and mealtimes were regulated, breakfast was consumed 
at 09:00 h; lunch at 12:00 h; a snack at 16:00 h; and dinner at 20:00 h on Day 1 and at 17:45 
h on Day 2 and Day 3.
Bedtime (participants’ supine in the dark in a standardised controlled environment) was from 
23:00 - 07:00 h and participants were prevented from napping during the day. Blood samples 
were taken hourly at 15 min past the hour ftom 18:00 - 22:00 h on Day 2 to assess the 
pharmacokinetic profile o f  the drug (data not permitted to be presented).
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3.4.4. Actigraphy
Volunteers were required to wear Actiwatches AW 4 (Cambridge Neurotechnology Ltd., 
Cambridge, UK), which were set to record at 1 min epoch, on their non-dominant wrist for
the duration o f  each study period (4 days), to m onitor rest and activity. Actigraphy records 
activity in counts per epoch so drug-induced changes in activity may be observed and 
measured. Actiwatches were also worn from the screening visit to the start o f  the study (up 
to 30 days) and during the washout period o f at least 6 days between each study period to 
ensure volunteer compliance and maintenance o f a regular bedtime.
All procedures were strictly controlled with relation to times. The sleep analysis sleep period 
was set from lights o ff at 23:00 to lights on at 06:59. Sleep analysis was not perform ed when 
participants were out o f  the unit, but the actograms and data were reviewed prior to each 
period to ensure that participants sleep and wake times were within the study protocol
restrictions.
3.4.4.1. Analysis procedure for sleep like minutes and activity
Data were downloaded onto a computer via an Actiwatch Reader Station. The data were then
analysed using the internal Sleepwatch analysis program. The 24 h w indow  o f  analysis for 
sleep was set from 07.00 to 06.59 for all days. Parameters for sleep were set from 23:00 to 
06:59 (in accordance with Tights o f f  and Tights o n ’ times). The resultant activity data for 
Day 1 and Day 2 was then extracted and exported into Excel as activity data, in counts per 
one minute epoch, and sleep data whereby each minute was scored as sleep (S) or wake (W) 
as determined by the Sleepwatch algorithm. The excel files were saved according to the 
Treatm ent Num ber and Period number. The original *.xls files were saved in a folder 
labelled ‘original’.
Data epoch points indicating that the Actiwatch had been removed, w ith a zero in the cell, 
were edited from the excel sheets and replaced with a full stop, to ensure that these times 
were not included in the analysis. These periods correlated to times o f  removal as confirmed 
by the ‘Removal log’ completed by the volunteers, and confirmed by the reviewer. The
edited *.xl data files were saved into a folder labelled ‘edited’.
A  macro was performed which calculated the mean activity and the total number o f sleep 
epochs per half hour. The edited .xl file was saved into a folder labelled ‘macrod’ and the 
resultant spread sheet containing all the relevant data were saved as ‘emsacti.xls’. This
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spread sheet was checked against the original excel files together with the Sleepwatch files. 
The checked spread sheets were initialled and dated.
The mean activity for each 30 min time interval on Day 1 was calculated from dosing at 
18:00 h for 24 h. Each 30 min period before the psychometric tests was classified as
“spontaneous activity” and each 30 min period during which the tests were performed was 
classified as “controlled activity". The evening data on Day 1 consisted o f  5 hours from 
18:00 to 23:00, as all dosing was conducted simultaneously. Dosing on Day 2 was staggered 
so post-dose actigraphy participant data were aligned and covers 4 h post dose. The mean 
activity for each 30 min time interval on Day 1 and Day 2 was calculated from dosing at 
18:00 h for 24 h including the sleep period. The activity for the m orning following dosing on 
both Days 1 and 2 was calculated from 07:00 to 08:30 to measure any hangover effects o f  
the medication.
3.4.4.2. M issing data
A log o f  missing data were compiled for times when the Actiwatch was removed in excess 
o f 30mins including participant removal and faulty data to ensure that it was not included in
the analysis panel.
3.4.4.3. Sleep variables
The actigraphic sleep variables (Section 2.4.1) were automatically calculated w ith the 
internal Sleepwatch algorithm and software. The analysis window was set 15 min before and 
after the Tights out’ and Tights on’ to cover the whole sleep period. The 8 h window o f 
analysis for sleep was from 23:00 to 06:59 for all days. Parameters for sleep were set from 
sleep start at 23:00 to sleep end at 07:00 (in accordance with Tights o f f  and Tights o n ’ 
times). The resultant summary data for Days 1 and 2 was exported into Excel as the sleep 
variables. The resultant excel files were saved according to the Treatment Number and 
Period number and the bespoke SAS program calculated the statistical significance.
3.4.5. Cognitive and psychom otor function
Cognitive and psychomotor performance was measured in a 30 min test battery which  
included Choice Reaction Time (CRT); Continuous Tracking Task (CTT) and paper-based 
Line Analogue Rating Scales (LARS). The test battery was conducted at pre-dose 07:00, 
then 1 h post dose at 19:00, followed hourly at 20:00, 21:00 and 22:00. These tests are 
known to be sensitive to the impairing effects o f  psychotropic compounds (Hindmarch a/., 
2005). Other tests were performed but are not reported.
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3.4.5.1. Choice Reaction Time (CRT)
This test, described in fhll in Section 2.5.1, was used as a reaction task which is sensitive to a 
variety o f  psychoactive agents (Alford a/., 1991; Baselt, 2001; Hindmarch, 1981; 
Hindmarch and Parrott, 1978). Participants were required to place the index finger o f  their 
preferred hand on a central starting button, and were instructed to extinguish one o f six 
equidistant red lights, illuminated at random, by pressing the response button immediately in 
front o f  the light as quickly as possible. The response measure is the time in ms o f each o f  
the three components o f  reaction time: recognition (RRT), motor (MRT) and total reaction 
time (TRT). All results were recorded electronically.
3.4.5.2. Continuous Tracking task (CTT)
This test is described in full in Section 2.5.3. and is a divided attention interactive task o f  
psychomotor performance (Hindmarch, 1987; Kerr er a/., 1996; Parkin e/ a/., 1998). 
Participants were required to keep a cursor in alignment with a m oving target on a computer 
screen using a mouse, whilst simultaneously responding to a peripheral stimulus. The 
response measure o f  the tracking component o f  the task was the mean deviation in pixels, 
w ith lower scores indicative o f more accurate tracking (CTT-ER). The mean reaction time in 
milliseconds was taken as the response measure o f  the peripheral awareness task (RT) 
component. All data were captured electronically.
3.4.5.3. Line Analogue Rating Scale (LARS)
The LARS (Hindmarch, 1980; Hindmarch and Gudgeon, 1980) was employed as a measure 
o f  the subjective effect o f  the medication and is explained in full in Section 2.6.2. Volunteers
were required to indicate their present feeling, where the m id-point on a 10 cm scale 
represented their normal state o f mind before treatment began. The mean scores o f  ratings o f  
the ‘tiredness’, ‘drowsiness’ and ‘alertness’ factors were taken as a measurement o f
perceived sedation. LARS was perform ed on Day 2 at 07:00 h; 17:00 h; 19:00 h; 20:00 h; 
21:00 h and 22:00 h and then on Day 3 at 08:00 h.
3.4.6. Statistical analysis
The data for the placebo and LZP were extracted from the larger four-way treatment study 
and analysed separately as a two-treatm ent data set. Baseline values, taken prior to each 
study period, were used as a covariate to minimise any order effects in the study periods. The 
statistical analysis is described in full in Chapter 2 Methods Section 2.7.
Comparison o f the effect o f LZP and placebo on activity, conducted separately for each day, 
was divided into 3 time intervals, 0 to 5 h (18:00-23:00 h) for acute effects o f the medication, 
5-13 h (23:00-07:00 h) for evaluation during the overnight sleep period and 13-14.5 h 
(07:00-08:30 h) post dose for residual effects.
A Pearson’s Correlation Matrix was produced to identify any relationship between the 
activity levels and the psychomotor performance. As data were taken from a larger four 
treatment study, a test for significance as an explanatory variable o f sequence category effect 
was performed, however no statistical significance was found.
3.5. Results
3.5.1. Participants
One participant removed the actiwatch during night 2, 2 participants completed only one o f  
the treatment periods, 1 each for LZP and placebo; one participant did not complete either 
treatment. The data for 23 participants is included in the analysis.
3.5.2. Actigraphy
The Actiwatch was used to collect activity data. The data were analysed for activity counts, 
sleep-like minutes and sleep variables. Faulty and missing data were removed.
3.5.2.1. W ake activity
There was a significant main effect o f  treatment following dosing (0 to 5 h, 18:00 -  23:00) 
on the first day o f  treatment Day 1 (F(i,g5 4) = 6 .8 6 , P = 0.0104) for LZP compared with 
placebo and a significant effect o f  time (F(9,3i]) = 15.92, P < 0.0001) (Figure 3.2A). 
analysis revealed that there was a significant effect o f  treatment on ‘spontaneous’ activity 
counts per epoch (mean ±  SEM) at 3 h (20:30 -  21:00) post dose, with LZP reducing activity 
compared with placebo (191 ± 8  versus 257 ± 11; P = 0.0061), in the 30 minutes prior to the 
test point at 21:00. There was a trend for significance at 5 h (P = 0.0542) post dose ju st prior 
to bedtime (22:30 -  23:00) w ith LZP reducing activity com pared w ith placebo (272 ± 15 
versus 318 to ±  21). On Day 2, activity levels 0-4 h post dose, were also reduced following 
LZP administration however this effect was not statistically significant (Figure 3.2B).
The morning following Day 1, (residual effects) there was a significant effect o f treatment on 
activity immediately following the 8  h sleep period (F(i 63.3) = 6.55, P = 0.0129) which 
occurred between 13:00 -  14:30 h post dose (07:00 -  08:30) with a significant effect o f  time 
(F(2,82 6) = 8.65, P = 0.0004). Compared with placebo, LZP produced a significant reduction
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in activity in the hours after waking, suggesting a hangover effect after LZP administration 
(Figure 3.2A).
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Figure 3.2; Time course of effect o f placebo (■) and LZP 2.5 mg (□ )  on daytime actigraphic activity 
There was an overall significant effect o f treatment on Day 1 (P < 0.02), post-hoc tests revealed a 
significant effect at 3 h post dose (*P < 0.01) compared with placebo and an overall significant effect 
o f treatment on morning after Day 1 (P < 0.02). A = Day 1, B = Day 2. Data are presented as mean ± 
SEM (n = 23) (# = psychometric test point, controlled activity). Data are presented as mean ± SEM (n 
- 21 ).
Following a second evening dose o f LZP on Day 2, although activity in the morning was 
again reduced there was no overall significant effect o f treatm ent 13:00 -  14:30 h post dose 
(07:00 -  08:30), although there was a significant effect o f time (F(2,72.s) -  13.57, P < 0.0001) 
(Figure 3.2B).
3.5.2.2. ‘Sleep-like’ minutes during wake
Each individual activity epoch was scored as ‘sleep’ or ‘w ake’ by the Sleepwatch algorithm, 
using the Sleepwatch medium sensitivity setting where an activity count o f  less than 40 is 
scored as sleep, ‘sleep-like activity’ was pooled into 30 min blocks. There was a statistically 
significant effect o f time P < 0.0001. Although there was an increase in the num ber o f  sleep­
like epochs overall during the 5 h period following LZP adm inistration on Day 1, this was 
not statistically significant (Figure 3.3).
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Figure 3.3; Time course o f effect o f placebo (■) and LZP 2.5 mg (□ )  on ‘sleep-like’ minutes on 
Day 1.
There was a significant effect o f time P < 0.0001. Data are presented as mean ± SEM (n = 23)
3.5.2.3. Sleep activity
Activity was also continuously m onitored during the 8 h sleep periods (23:00 -  07:00 h) on 
Day/Night 1 and Day 2/Night 2. There was a significant effect o f treatment on N ight 1 
(F(i,i9.4) = 7.11, P = 0.015), LZP reduced half hourly activity com pared with placebo and with 
a significant effect o f time (F(i5 6^30) = 4.66, P < 0.0001). Post-hoc analysis revealed that LZP 
produced a significant reduction in activity at the beginning o f the sleep period at 5.5 h post 
dose compared with placebo (23:00 -  23:50) P = 0.0001, (Figure 3.4A) with LZP reducing 
mean activity counts from 38 ± 4.9 (placebo) to 19 ± 3.1 (LZP).
A similar effect o f  LZP treatm ent was observed on activity levels during the sleep period on 
Night 2, LZP (F (ij47) = 1 1.58, P = 0.0009) reduced ha lf hourly activity compared with 
placebo and with a significant effect o f  time (F(is,534) = 5.28, P < 0.0001). Post-hoc analysis 
revealed that LZP again produced a significant reduction in activity at the beginning o f  the 
sleep period at 5.5 h post dose com pared with placebo (23:00 -  23:50) P < 0.0001 (Figure 
3.4B) with LZP reducing m ean activity counts per epoch from 40 ± 4.7 (placebo) to 16 ± 3.0 
(LZP).
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Figure 3.4; Time course of effect o f placebo (■) and LZP 2.5 mg (□ )  on actigraphic activity at Night 
There was an overall significant effect o f treatment on Night 1 (P = 0.0151),/?o5? -hoc tests revealed a 
significant effect at 5.5 h post dose (**P < 0.001) compared with corresponding placebo. On Night 2 
there was a significant effect o f treatment (P = 0.0009), post-hoc tests also revealed a significant effect 
at 5.5 h post dose (** P <  0.001) compared with corresponding placebo, 5 -  5.5 h post dose 
corresponds to 23:00 -  23:30 h. A = Day 1, B = Day 2. Data are presented as mean ± SEM (n = 23).
3.5.2.4. Actigraphic sleep variables
The effect o f  LZP on the main sleep variables is shown in Table 3.1. Compared with 
placebo, LZP produced a statistically significant reduction in the num ber o f sleep bouts 
(F(i,i8) = 11.63, P = 0.0031), (22 ± 2 versus 28 ±  2, respectively), with longer sleep bout 
times following LZP com pared with placebo (23 ± 2 min compared with placebo 17 ±  2) 
min. There was an indication that LZP reduced fragm entation index, with a trend for a 
significant reduction (F^jg) = 3.92, P = 0.06) on the first night after dosing (26 ± 2 versus 21 
± 2 placebo versus LZP respectively). LZP significantly increased actual sleep percent (F(]jg) 
= 6.73, P = 0.0183) (LZP versus placebo, 91% ± 1 versus 8 8 % ± 1) and had a similar 
significant effect on sleep efficiency (F(ijg) = 12.81, P = 0.002) (LZP versus placebo, 90% ± 
1 versus 8 6 % ± 1 ).
Similarly on the second night after dosing LZP again reduced activity shown as a significant 
reduction in the num ber o f  sleep bouts (F (ij7) = 7.74, P -  0.0128), LZP versus placebo (22 
± 2 versus 27 ± 2 bouts respectively). The sleep bout times were longer following LZP 24 ± 
2 min compared with 18 ± 2 min for LZP versus placebo. However there was no significant 
effect for the fragmentation index on Night 2. LZP significantly increased actual sleep
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percent (F(U7) = 8.03, P = 0.0115) to 92 (± 1) % compared with 89 (± 1) % for placebo and 
sleep efficiency (F(ij7)=  13.44, P = 0.0019) to 91 (± 1) % compared with 87 (± 2) % for 
placebo.
Table 3.1: Effect o f LZP and placebo on the main actigraphic sleep variables
Night 1 Night 2
Variable P lacebo Lorazepam P lacebo Lorazepam
Actual S leep  (%) 88 ± 1 91 ± 1 * 89 ± 1 9 2 ±  1 *
Number of S leep  Bouts 28 ±2 22 ± 2 27 ±2 22 ± 2 *
Fragmentation Index 26 ±2 21 ±2 25 ±3 21 ±2
S leep  Efficiency (%) 86 ± 1 90 ± 1 ** 87 ±2 91 ± 1 "
Mean S leep  Bout Time 
(mins)
17± 1 23 ± 2 " 18±2 24 ±2
S leep  Latency (mins) 9 ± 2 4 ±  1 8 ± 2 3±  1
Sleep variables calculated with Sleepwatch Algorithm and presented as mean ± SEM (n = 23).
* P < 0.05, ** P < 0.01 versus corresponding placebo.
3.5.3. Psychometric tests
Subjective and objective assessments o f  sedation were measured with psychometric tests.
The subjective test was LARS, and the objective assessments CRT (TRT), and CTT. The
effect o f  LZP on those assessments is shown below and presented in Figtire 3.5.
3.5.3.1. Line Analogue Rating Scale (LARS)
The perception o f  sedation was increased, LZP caused a main effect o f  treatment (F(],65.3) =  
4.58, P = 0.0361) when com pared with placebo and a significant treatment by time 
interaction (F(4j 5g)= 3.08, P < 0.0179). analysis revealed a significant effect at 4.5 h
post dose only (P < 0.0001) (mean ± SEM) with subjective sleepiness increasing following 
LZP from (50 ± 2) to (59 ±  2) placebo versus LZP respectively (Figure 3.5A). Participants 
felt drowsier following LZP dosing but this was limited to 4.5 h post dose and subjects this 
was limited to 4.5 h post dose and subjects did not experience any hangover effect the 
following morning.
3.5.3.2. Choice Reaction Time (CRT) and Total Reaction Time (TRT)
Analysis o f  the Total Reaction Time (TRT) component o f  the CRT task revealed that LZP 
caused an overall significant increase in reaction times (F(],53 6)=  39.37, P < 0.0001), with a 
statistically significant effect o f  time (F(4j 50) = 5.87, P = 0.0002), and a treatment by time
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interaction (F(4j 50)= 4.2, P = 0.003). Post-hoc analysis revealed a significant effect o f  LZP 
compared with placebo on the individual time points at 2.5 h (740 ± 34.2, P < 0.0001), 3.5 h 
(774 ± 35.6, P < 0.0001), 4.5 h (776 ± 31.9, P < 0.0001) post dose as well as the following 
m orning at 14.5 h (712 ± 20.8, P = 0.0127) compared with placebo (635 ± 18.6, 648 ± 25.2, 
638 ± 23.0, 651 ± 17.8, at 2.5, 3.5, 4.5 and 14.5 h respectively) (mean ± SEM) as shown in 
Figure 3.5B. LZP impaired reaction times by increasing participant’s time taken to complete 
the task compared with placebo.
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Figure 3.5: Time course of effect o f placebo (■) and LZP 2.5 mg (□ )  on cognitive function
Time course of effect o f placebo (■) and LZP 2.5 mg (□ )  on (A) sedation component of LARS, (B)
total reaction time o f CRT (C) reaction time of CTT and (D) tracking error o f CTT.
* P < 0.05, ** P < 0.02 compared with corresponding placebo. Data are presented as mean ± SEM 
(n = 21)
3.5.3.3. Continuous Tracking Task -  Reaction Time (CTT-RT)
There was a main effect o f treatment w ith an increase in response time to the peripheral 
stimulus component o f  the continuous tracking task (CTT) with LZP (F(i 43.7) = 26.58, P < 
0.0001), a main effect o f time (F(U37) = 6.94, P < 0.0001) and treatment by time interaction
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(F(i,i37)=  5.22, P = 0.0006) compared with placebo. analysis revealed a significant
effect o f LZP com pared with placebo on the individual time points at 2.5 h (628 ± 36.3, P =
0.009), 3.5 h (689 ± 46.1, P < 0.0001), 4.5 h (781 ±  70.2, P < 0.0001) h post dose as well as 
the following morning at 14.5 h (654 ± 47.2, P = 0.026) compared with placebo (502 ± 2 1 .0 , 
505 ± 23.5, 513 ± 20.6, 542 ± 28.3 at 2.5, 3.5, 4.5 and 14.5 h respectively) as shown in 
Figure 3.5C. LZP impaired reaction times by causing a significant increase in time taken 
compared with placebo.
3.5.3.4. Continuous Tracking Task -  Tracking Error (CTT-ERR)
There was a main effect o f  treatment on tracking performance, with impaired tracking 
accuracy increase in CTT-ERR with LZP (F(i,54.4)=  19.83, P < 0.0001), a main effect o f  time 
(F(4,i50) = 4.47, P = 0.0019) and treatment by time interaction (F^j]?) = 5.22, P = 0.0023) 
com pared with placebo. Post-hoc analysis revealed a significant effect o f LZP com pared 
with placebo on the individual time points at 2.5 h (31 ± 5.1, P = 0.0116), 3.5 h (35 ± 5.8, P 
= 0.013), 4.5 h (44 ±  8.1, P < 0.0001) post dose compared with placebo (19 ±  2.1, 19 ±  2.5, 
19 ± 2.0, at 2.5, 3.5, and 4.5 h respectively) (mean ±  SEM) as shown in Figure 3.5D. LZP 
impaired tracking performance by increasing the error in following the moving target.
3.5.4. Correlation o f actigraphic actigraphy with cognitive performance
There was no significant correlation between actigraphic activity at 3 h (20:30 -  21:00) post 
dose where the difference in activity levels was significant and the 3.5 h (21:00 -  21:30) post 
dose time point o f  the cognitive performance tests, as detailed in the Pearson’s Correlation 
Matrix although activity levels and CTT-ERR approached significance (P =  0.08).
3.6. Discussion
There is relatively little literature on the actigraphic profile o f sedative hypnotics. Some 
authors (Roehrs a/., 2000; Kiang er a/., 2003; Takahashi er a/., 2003) have reported that 
the derived actigraph data show significant reductions in activity after dosing w ith various 
compounds, using a variety o f  time blocks ranging from 6 to 24 post dose. Although these 
studies have provided an indication that actigraphy may be able to detect changes in 
behavioural activity following medication, the use o f  large analysis time episodes may not be 
sufficient to provide a discrete profile o f  the drug and o f its time course o f  effect on activity 
and pharmacodynamics.
One o f  the first early studies to investigate the use o f  actigraphy as a new technology
compared the effect o f  3 hypnotic benzodiazepines on subjective sleep, M SLT, psychom otor
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tests and motor activity (Mattmann a/., 1982). The study examined the effects o f triazolam 
(0.25, 0.5 and 1 mg), nitrazepam (10 mg) and flunitrazepam (2 mg) in a double blind 
crossover study on activity at night. Eighteen participants slept in their own homes and 
activity was recorded overnight with an early generation actigraph, subjective sleep was 
assessed by questionnaire and a typing test was employed as a measure o f  psychomotor 
performance. The study showed that nocturnal m otor activity was reduced by all the 
hypnotics w ith a 10% significant reduction after dosing with triazolam 0.25 mg to a 
significant 31% reduction following dosing with triazolam  1 mg relative to placebo. 
Additionally reductions in daytime activity were substantiated by subjective sleepiness and 
impaired performance.
A further study from the same group using a sim ilar protocol (Borbély et a i,  1983) 
examined the hypnotic and residual effects o f  triazolam and midazolam. Activity data were 
again calculated in 7.5 min epochs overnight to 4 h post waking. Night-time activity was 
significantly reduced by > 10% overall compared with placebo after dosing with triazolam 
(0.5 mg) and midazolam (15 mg) most o f  the reduction occurring in the first half o f  the 
night. N either treatment affected daytime activity however psychom otor performance 
(typing test) was significantly impaired after triazolam (0.5 mg). There was no significant 
effect on subjective sleep by either treatment.
These studies reported above used actigraphy periods m uch larger than the current study and 
did not map the half-hourly effect o f  the hypnotic as is reported here where activity was 
recorded in 1 min epochs. Nevertheless they were able to show that actigraphy had the 
potential to identify differences in activity levels and activity in sleep following psychoactive 
medication.
The time intervals for analysis in the current study were such that it was possible to 
differentiate between ‘controlled’ activity during the 30 min test points and ‘spontaneous’ 
activity between the test points thereby removing the stimulating effects o f  the tests and 
avoiding confounding data by including periods where activity levels were dictated by 
protocol required tasks. The reduction in ‘spontaneous’ activity levels during the 5 h period 
after LZP dosing closely followed the cognitive impairment observed in the psychometric 
tests suggesting that actigraphy is able to detect a drug-induced effect. The current data also 
showed that LZP reduced activity levels even whilst tests were being conducted and that 
therefore the ‘sedating’ effect o f LZP was observed even when activity was fairly prescribed.
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LZP (2.5 mg single dose) significantly impaired psychometric and cognitive effects at 4.5 h 
post dose in the current study. This data confirms the findings o f Allen et al. (1993) that LZP 
(2 mg) in healthy participants induced impairment up to 5 h post dose in DSST and pursuit 
rotor performance, the latter being similar to CTT. A  similar study by O ’N eill a/. (2000) 
showed that LZP 0.5 mg/day significantly impaired psychometric performance on the CRT 
at 4 h post dose in healthy subjects.
Daytime actigraphy data may also be interpreted as ‘sleepiness’ or ‘sleep-like’ behaviour by
using the propriety sleep analysis software algorithm to score each epoch as either ‘sleep’ or 
‘wake’. Various studies (Roehrs er a/., 2000; Kawahara g/ a/., 2002; Kiang er a/., 2003) have 
successfully used this method to calculate overall ‘sleep-like’ behaviour during the day. In 
the present study, although no overall significant effect o f  treatment was found on the overall 
number o f  ‘sleep-like’ epochs during the 5 h period post dose, it is worthy to note that there 
was a post-hoc significant difference in the 30 min interval at 4 h, 21:30 -  22:00 post dose. 
This was during the half hour just prior to the 4.5 h 22:00 -  22:30 test point which also 
showed the greatest impairment in performance on the psychometric tests and when the 
subjective rating o f  sedation in the LARS showed that participants actually felt significantly 
more sedated and drowsy.
LZP has been shown to alter sleep architecture as determined by PSG (Grozinger et a l, 
1998; Saletu er a/., 1990) by reducing sleep latency, number o f  awakenings, Stage 1 and 
REM sleep, whilst increasing TST and Stage 2 sleep. W hilst actigraphy is not able to 
identify changes in sleep stages /  architecture the present study showed that the actigraphic 
analysis o f the sleep period revealed significant reductions in the activity levels at the 
beginning and end o f  the sleep period indicating more restful sleep. These findings are 
consistent with previous findings o f  reduced sleep latency and increased TST (Grozinger et 
a/., 1998). The actigraphic sleep parameters confirm this improvement in sleep showing an 
increase in the actual sleep percent and longer mean sleep bout times, reductions in the 
number o f  wake bouts and the fragmentation index. This clearly indicates that the actigraphy 
data were consistent with previous PSG findings o f  the effect o f  LZP and provides a less 
expensive, non-invasive alternative for detecting changes in sleep due to the effect o f  a drug.
Previous studies have used actigraphy for recording activity during sleep and calculating the 
sleep variables which are common to PSG. In a study by Kawahara et al. (2002) 
investigating the effects o f  benzodiazepine and non-benzodiazepine compounds brotizolam 
(0.25 mg) and zopiclone (7.5 mg) showed that sleep time (TST) was significantly longer 
following both hypnotic drugs.
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Actigraphy is a useful non-invasive tool to assess CNS drug effects in the field or in a 
patients natural environment. As psychoactive drugs have varied durations o f  efficacy, it is 
important to establish the maximum duration o f  impairment in order to provide safety data 
when prescribing. If a hypnotic taken to aid sleep has residual or hangover effects in the 
morning clearly this may be a safety hazard. As in the present study reported here previous 
studies (Mattmann e/ a/., 1982; Borbély a/., 1988; Takahashi e/ a/., 2003) have also shown 
that actigraphy is useful in providing data on residual effects through a reduction in activity 
levels following dosing.
In addition to demonstrating reduced activity levels following dosing the present study 
showed that actigraphy is able to detect a significant reduction in activity in the hour 
immediately following the sleep period (first hour o f  wake) therefore suggesting the 
presence o f  residual impairment the morning after dosing known as the ‘hangover’ effect.
This coincided w ith impairment observed by the psychom otor assessments the morning 
following LZP compared with placebo. Interestingly subjective assessments (LARS) did not
show that participants taking LZP felt drowsy in the m orning compared with placebo. This is 
o f  concern as although subjects did not feel impaired their cognitive data suggests significant 
impairment on cognitive and psychom otor tasks.
Similar effects to those described above were seen following a repeated dose o f  LZP. There 
was a significant reduction in activity in the 5 h period immediately following dosing, as 
well as residual effects the following morning. The actigraphic sleep showed a similar 
profile following the second dose o f LZP again with improved sleep and reduced movement.
The present study has endorsed previous findings and shown that psychomotor performance 
impairment and reduced processing skills, and subjective assessment o f sedation are 
mirrored by actigraphy (Stanley, 1997; Stanley and Hindmarch, 1997; Stanley era/., 1999).
3.7. Limitations
The current study has limitations and recommendations for improvement. As the present 
analysis was taken from a larger clinical trial the study was not specifically designed for 
measuring the effect o f  treatment with actigraphy and therefore may not have been 
adequately powered. It was necessary to compartmentalise the actigraphy data to avoid the 
confounding effect o f  the psychometric testing and pharmacokinetic sampling. This may 
have further reduced the statistical power o f the study. Having stated that, the analysis was 
able to show an effect on daytime activity and sleep.
3.8. Conclusion
This study provides evidence that actigraphy is sensitive not only to the sedating effects o f  
LZP, as measured by a reduction in behavioural activity, but also to the residual effects o f 
the drug the morning after dosing. The study also confirms that the actiwatch is able to detect 
the effects o f a hypnotic on sleep and is able to provide an indication o f the clinical effects o f 
medication. Moreover this study, following the recommendation o f  Roehrs and colleagues 
(2000), adds further evidence that actigraphy can provide a reliable and sensitive indicator o f  
the time course o f  action o f  psychoactive drugs.
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CHAPTER 4 ANTIHISTAMINES
4.1. Introduction
First generation antihistamines have well known sedative effects and impair cognitive
function which are reviewed in detail in Section 1.5 (Baselt, 2001; M cDonald et al., 2008). 
These antihistamines, one o f  which is promethazine, are known to induce central nervous 
system side effects including psychomotor and cognitive impairment as well as possessing 
general sedative effects. Promethazine passes through the blood-brain barrier, blocks 
histamine from binding to its receptors and inducing a stimulating effect, causing the central 
side effect o f sedation and reducing wake behaviour.
Studies have shown that cognitive and psychomotor perform ance are significantly impaired 
by promethazine (Clarke and Nicholson, 1978; Parrott and Wesnes, 1987; Hindmarch et a/., 
2001a, 1999; Nicholson et a l,  2003). In addition it has been shown that sedation induced by 
these antihistamines can also be detected as a reduction in wrist actigraphic 'activity' and an 
increase in actigraphic 'sleep-like' minutes (Stanley, 1997; Kamei et a/., 2012). Previous 
work by the author on benzodiazepines has dem onstrated that reductions in actigraphic 
activity mirror impairment o f  psychomotor performance (Dawson et a/., 2008) and 
Chapter 3. The aim o f  this work was to assess whether the algorithm applied to detect LZP 
induced impairment o f activity could be applied to other psychoactive drugs with a different 
mechanism o f action.
A clinical trial, conducted between February and M arch 2005, was used to investigate the 
effects o f three different doses o f a novel antihistamine, against the first generation 
antihistamine promethazine (active control) and placebo. The primary objective o f the study 
was to assess the effect on cognitive and psychom otor function o f the novel antihistamine 
compared with placebo and promethazine. A  secondary objective was to assess the efficacy 
o f  the novel antihistamine on histamine-induced wheal and flare. The placebo and verum 
(promethazine) data from this trial has been extracted for analysis.
Promethazine an impairing antihistamine has a T^ a^  o f  4.39 h (range 2 -  8 h) and T./^  o f  
18.6 h (range 9.5 -  29.7 h) (Strenkoski-Nix a/., 2000). It has been shown to specifically 
impair CTT, CFF and CRT (Baselt, 2001), and induce subjective sleepiness between 2 and 
5.5 h post dose (Clarke and Nicholson, 1978) with a performance decrement profile 3 - 8 h 
post dose (Hindmarch a/., 2001a; Nicholson a/., 2003; Paul et al., 2005).
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4.2. Aims
The purpose o f  the study was to evaluate the appropriateness o f  the Sleepwatch algorithm 
and methods developed by the author to assess the effect o f  a single dose o f  the 
antihistamine promethazine 25 mg compared with placebo on motor activity assessed by
actigraphy in healthy volunteers kept in controlled laboratory conditions. The analysis was 
designed to investigate whether actigraphy could accurately reflect the psychometric
evidence o f sedation associated with promethazine.
4.3. Hypotheses
i. Promethazine will reduce actigraphic activity levels, increase 'sleep-like' minutes
and increase actigraphic sleep variables compared with placebo. Compared with 
placebo, promethazine will impair cognitive and psychomotor performance.
ii. The null hypothesis is that there will be no difference between promethazine and 
placebo in actigraphic activity, actigraphic sleep or cognitive and psychomotor 
performance.
4.4. M ethods
4.4.1. Study design
The original clinical trial was a randomised, double-blind, double dummy, five way 
crossover, single dose study to examine the effects o f  3 different doses o f  a novel 
antihistamine compound on cognitive and psychomotor performance function compared with 
placebo and promethazine. Promethazine 25 mg, is an antihistamine known to produce 
psychomotor and cognitive impairment as well as possessing sedative side effects was used 
as an active control (verum). As the purpose o f  this investigation was the use o f  actigraphy 
and the associated performance tests, only the placebo and promethazine results have been 
used for further/original analysis.
Procedures, including the baseline assessment for psychometric tests, pharmacokinetic 
samples and wheal and flare, were carried out pre-dose and then at selected time points up to 
24 h following administration. Each study treatment period was followed by a wash-out 
period o f  between 6-10 days. The study was approved by a COREC approved Ethics 
Committee and the Quom  Research Review Committee, Quom  Research Review 
Committee, 25 Church Lane, Old Dalby, Leicestershire, LE14 3LB. During the study 
participants were required to w ear an Actiwatch throughout each study treatment period to 
measure their overall m otor activity 0-12 hours post dose and for sleep during the subsequent 
8 hour sleep period, to assess objective measures o f  sedation and actigraphic sleep. Validated
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psychometric tests were performed at +1, +3, +6, +9, +12 h and + 24 h time points to assess 
objective levels and cognitive and psychomotor impairment and at the same test points the 
Line Analogue Rating Scales (LARS) was also conducted to assess subjective levels o f  
sedation.
4.4.2. Participants
Healthy adult males (n = 19) aged 18-45, were randomised to receive the study medication. 
The mean (+ SD) age o f the participants was 28.9 + 6.7 years and the mean height, weight 
and body mass index (BMI) o f the participants at screening were 1.77 ± 0.07 m, 76.00 ± 9.14 
kg and 24.16 + 2.61 kg/m^, respectively.
Following informed consent all participants underwent a full medical screening to ensure 
that they were within the study inclusion/exclusion criteria. The inclusion criteria for the 
study required that participants were healthy males, non-smokers, 18-45, BMI >18 and <30 
kg/m^ o f  minimum 50 kg weight, with normal resting ECG, a positive response to histamine-
induced wheal and flare by skin prick and a normal sleep-wake cycle. Study restrictions 
included abstinence from caffeine containing beverages or food, e.g. coffee, tea, chocolate 
and soft drinks for 24 hours, alcohol for 48 hours and grapefruit and/or grapefruit ju ice for 
72 hours prior to and during the study visit. All participants were tested for alcohol and drugs 
o f abuse at screening and on admission to each treatment period.
4.4.3. Study procedures
Participants were adm itted on Day -1 when a wrist actigraph (Actiwatch®) was attached to 
the participant’s non-dom inant wrist. During the evening prior to the first treatment period 
participants underwent a minimum o f  3 training sessions on the psychometric tests. Bedtime 
(participants’ supine in the dark in a standardised controlled environment) was from 23:00 to 
07:00 h. On Day 1 o f  each study period participants were woken at 07:00 h. Baseline 
m edical checks, including resting 12-lead ECGs, pulse and blood pressure, were performed 
prior to dosing at 07:15 h, and the psychometric tests were conducted at 07:30 h to obtain 
pre-dose baseline levels. A  pre-dose baseline blood sample was also obtained at 07:25 h and 
the wheal and flare test (Section 4.4.7) was administered at 08:00 h with the skin test 
measurement at 08:10 h. Following the baseline procedures during study period 1, 
participants were assigned a randomisation code. Dosing was performed at 08:30 h. Due to 
the complexity o f  the study all procedures were staggered and conducted relative to the drug 
dosing time to allow for management o f  the study procedures by the clinical team.
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Psychometric tests, including the LARS as a measure o f subjective sedation, were conducted 
at +1, +3, +6, +9, +12 h and +24 h post dose each period followed immediately by the wheal 
and flare tests. Blood samples were also obtained for phanuacokinetic analysis at +1, +3, +6, 
+9, +12 h and + 24 h post dose. The principles o f the psychometric tests are described in full 
detail in Chapter 2.
Day -1 Night -1
SleepDay 1 Night 1
P w P w P wP W X P w P w
SleepDay 2
P w
Clock Time
Figure 4.1 : Study design
Plan to illustrate the study protocol. Drug administration, placebo or promethazine 25 mg (X), arrival 
(A), departure (D), sleep period 23:00 -  07:00 h, continuous actigraphy (<-^), psychometric testing (?) 
and wheal and flare (W)
Breakfast was adm inistered at +2 h, lunch at +4.5 h and dinner at +11 h post dose. Lights out 
was at 23:00 h. The following day participants were woken at 07:00 h and the study 
procedures were repeated at +24 h post dose. After thorough medical examination 
participants were required to complete a sleep questionnaire (LSEQ), (data not included), 
and the wrist actigraph was removed and they were discharged from the unit. The study 
design and timing o f  the procedures is shown in Figure 4.1.
4.4.4. Actigraphy
Volunteers were required to wear Actiwatches®, AW 4 (Cambridge Neurotechnology Ltd., 
UK), on their non-dom inant wrist for the duration o f  each study period (2 days) to m onitor 
rest and activity. The Actiwatch was set at the m anufacturer’s default medium setting and 
activity data were captured in 1 min epochs. As dosing was staggered the activity data files 
clock times were adjusted and synclironised to study time and pooled into 15 minute blocks 
to control for the confounding activity o f the study procedures and analysed with means for 
15 mins, 30 mins and 60 mins.
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To investigate the effects o f treatment when activity was unrestricted and spontaneous, 
activity data were identified for the times during which the test procedures were not being 
conducted and the activity o f  the participants was uncontrolled. To ensure consistent 
comparative data o f the hourly effects for up to 12 h post dose, the last 15 minutes o f  activity 
for each hour was extracted and analysed. Data were further subdivided into 4 h sections, 
0-4 h, 5-8 h and 9-12 h post dose so that the time course o f action o f  promethazine could be 
investigated and so that the time period around the Tma% o f promethazine (2 to 8 h) could be 
identified and assessed.
The Sleepwatch algorithm was used to score each individual one minute epoch as either 
'sleep-like’ as 'S ’ whereby activity counts below 40 were designated as sleep, or 'wake’ as 
‘W ’. The addition o f  the 'S ’ minutes provided an estim ation o f the ‘sedative’ effects o f  the 
drug, although it is worth noting that objective psychometric assessments and / or 
actigraphically m easured impairment might not be equivalent to subjective feelings o f 
sedation. As with activity counts, data were pooled into 15 minute blocks and analysed by 15 
mins, 30 mins and 60 mins.
4.4.5. Actigraphic sleep variables
Using the Sleepwatch algorithm the sleep period from 23:00 h to 07:00 h was analysed for
various sleep summary variables including sleep percentage time, sleep efficiency, sleep 
bouts, and fragmentation index (Section 2.4.1).
4.4.6. Cognitive and psychom otor function
Cognitive and psychomotor performances were measured in a test battery, which included 
Choice Reaction Time (CRT); Continuous Tracking Task (CTT) and Line Analogue Rating 
Scales (LARS) Chapter 2 Sections 2.5.1, 2.5.3 and 2.6.2. The mean scores o f ratings o f  the 
'tiredness’, 'drowsiness’ and 'alertness’ factors were taken as a measurement o f  perceived 
sedation (Gudgeon and Hindmarch, 1983). These tests are known to be sensitive to the 
impairing effects o f  psychotropic compounds (Hindmarch a/., 2005). The test battery was 
conducted at pre-dose 07:30, then 1 h post dose, followed by 3 h post dose, 6 h post dose, 9 h 
post dose, 12 h post dose and 24 h post dose the following morning at 08:30. The first two 
subjects were dosed at 08:30 followed by a 15 minute stagger for subsequent pairs o f  
participants.
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4.4.7. W heal and flare
The wheal and flare test was used to assess skin reactivity to histamine. When a small area o f  
skin is injured, there is local vasodilatation which elicits reddening o f  the skin. This is 
followed by a swelling (a wheal) which is localised to the site o f  the injury and its immediate 
surroundings. The original site o f injury is then surrounded by a much wider area o f  less
intense vasodilatation known as the flare.
The wheal and flare test was performed at designated time points for 24 h following drug 
administration to assess the clinical effectiveness o f  the antihistamine. A  drop o f  solution 
containing 10 mg/mL histamine solution was placed on the volar surface o f  the forearm. The 
skin was pricked through the droplet using ALK Lancet (B D Microfine U 100) and then
blotted. After ten minutes the areas o f  the wheal and flare were marked and m easured 
respectively. For the duration o f  each wheal and flare assessment participants were required 
to rest their arms (with underside uppermost) on a table in front o f them, therefore their 
activity was restricted.
4.4.8. Statistics
The data for the placebo and prom ethazine were extracted from a larger five-way treatment 
study and analysed separately as a two-treatment data set. Baseline values, taken prior to 
each study period, were used as a covariate to minimise any order effects in the study 
periods.
Comparison o f  the effect o f  prom ethazine and placebo was conducted separately for each 
day which was separated into 3 time intervals, 0 to 12 h post dose (08:30 - 20:30 h) for acute 
effects o f the medication, 14.5 -  22.5 h post dose (23:00 - 07:00 h) for evaluation during the 
overnight sleep period and 22.5 -  23.5 h post dose (07:00 - 08:00 h) post dose for residual 
effects.
A test for the effect o f  any carryover o f treatment was conducted on the activity data. 
However no statistical significance was found.
4.5. Results
4.5.1. Actigraphy
Wrist actigraphy measured the activity o f the participants 0-12 hours post dose, for the 8
hour sleep period plus the hour after waking. Data from 19 participants were included in the 
analysis, 17 participants completed all treatments, 1 participant completed 4 visits and 1
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participant only 1 visit. As the data were taken from a larger five way crossover study a test 
for a carryover effect was carried out, nonetheless there was no significant effect o f 
carryover for any o f the activity or sleep-like m inute time blocks for 12 h post dose 
(P > 0.25).
The purpose o f the analysis reported here was to investigate the usefulness o f the actigraphy 
device and to detennine whether actigraphy was able to m irror the pharmacodynamics o f a 
drug. Therefore only verum and placebo data are reported. The raw actigraphy files were 
analysed blind according to the algorithm and the subsequent data analysed by the methods 
developed in the previous chapter (Section 3.4.4) and are prescribed as a two-way crossover 
for the comparison between promethazine, the active control, and placebo.
4.5.2. Activity
To account for the interference o f the effect o f  the controlled activity test points, data were 
further divided and analysed in 15, 30 and 60 min time blocks to detennine whether any 
significant effects were evident.
There was no significant main effect o f treatment for prom ethazine compared with placebo 
for the 15, 30 or 60 min activity data blocks 0 - 12 h post dose, neither was there any 
significant effect o f treatment for the sleep period (23:00 -  07:00) nor for residual effects 
following sleep (07:00 -  08:00) for any o f  the time blocks. The activity profile o f  the activity 
counts per minute o f the 60 min blocks for 12 h post dose is shown in Figure 4.2.
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Figure 4.2: Time course of effect of placebo (■) and promethazine 25 mg (□) on 12 h activity 
Activity presented as mean activity counts per 1 min per hour blocks. There was no overall significant 
effect of promethazine versus placebo. Tests were conducted at +1 h, +3 h, +6 h, +9 h and +12 h as 
shown by #. Data are presented as mean ± SEM (n = 19).
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In order to reduce any confounding effect o f  restricted activity periods post-hoc analysis was 
conducted on the last 15 minutes o f activity for each hour, (prior to the test points), when 
activity was spontaneous. Extracted data were further subdivided into 4 h sections, 0-4 h, 5-8 
h and 9-12 h post dose in order to cover the T^ax to T./, post dose o f  promethazine 
(2.5 to 12 h).
There was no overall significant effect o f  treatment for the 12 h analysis with regards to 
reductions in spontaneous activity. Neither was there an effect o f treatment for the time 
sections 0-4 h nor 9-12 h for the last 15 minutes o f  each hour. Analysis o f  the 5-8 h post dose 
period revealed a significant effect o f  treatment with prom ethazine reducing activity (F(i^44.i) 
= 5.72, P = 0.0378). Post-hoc analysis revealed a significant effect o f  treatment at 6 h (P =
0.0112), prom ethazine reduced activity (M ean ± SEM) to 152 (± 19) compared with placebo 
293 (± 78) as shown in Figure 4.3.
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Figure 4.3: Time course o f effect o f placebo (■) and promethazine 25 mg (□) on spontaneous activity 
‘Spontaneous activity’ was taken as the last 15 minutes of every hour, up to and including 12 h post 
dose. There was an overall significant effect o f treatment in the time section 5-8 h post dose 
(P < 0.05). Post-hoc tests revealed a significant effect at 6 h post dose (* P < 0.02) compared with 
placebo. Data are presented as mean ± SEM (n = 19).
There was no effect o f treatment on activity during the sleep period (23:00 -  07:00) or for 
residual effects following sleep (07:00 -  08:00) for any o f  the different time blocks.
4.5.3. Residual effects
There was a significant effect o f  treatment for promethazine com pared with placebo for the 
15 min sleep-like activity data blocks 0 - 12 h post dose (F(i307) = 7.19, P = 0.0077), where
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promethazine increased sleep-like activity relative to placebo. analysis revealed a
significant effect o f  treatment at time point 23, 6.5 -  6.75 h post dose, P = 0.0163, and at 
time point 42, 11.25 -  11.5 h, post dose P = 0.0045.
There was also a significant main effect o f  treatment for promethazine compared with 
placebo for the 30 min sleep-like activity data blocks 0 - 12 h post dose with a significant 
effect o f  treatment (F(i,202) = 4.16, P = 0.0427) with promethazine. analysis revealed
a significant effect o f  treatment at time point 10, 4.5 -  5.0 h post dose, P = 0.0284; at time 
point 12, 6.5 -  7.0 h post dose, P = 0.0257; at time point 21, 10.0 -  10.5 h post dose, 
P = 0.0150; and at time point 23, 11.0 -  11.5 h post dose P = 0.0301, promethazine increased 
sleep-like activity relative to placebo.
There was a similar significant main effect o f  treatment for the 60 min sleep-like activity 
data bins 0 - 12 h post dose (F(, jM) = 4.92, P = 0.0285) with promethazine increasing sleep­
like activity. analysis revealed a significant effect o f  treatment at time point 5, 4.0
to 5.0 h post dose, P = 0.0343; at time point 6, 6.0 -  7.0 h post dose, P = 0.0288; and time 
point 11, 1 1 .0 -  12.0 h post dose, P = 0.0214. Promethazine increased sleep-like minutes at 
time points 5, 6 and 11 to 0.16 (± 0.03), 0.28 (± 0.04) and 0.19 (± 0.4) compared w ith 0.10 
(± 0.2), 0.21 (± 0.4) and 0.11 (± 0.3) compared with placebo respectively (Mean ± SEM) 
(Figure 4.4).
There was no significant effect o f  treatment for sleep-like minutes in any o f  the 4 h blocks up 
to 12 h post dose for the 15 minute periods o f  spontaneous activity.
As with the reduction in activity the data showed that the ‘sleep-like’ activity o f participants 
was significantly increased following prom ethazine treatment com pared with placebo and 
that this occurred between the Tma% and T,/^  2.5 -  12 h post dose.
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Figure 4.4: Time course of effect o f placebo (■) and promethazine 25 mg (□) on sleep-like activity 
Number of sleep-like minutes 12 h post dose in 60 min blocks. There was an overall significant effect 
o f treatment post dose (P < 0.05). Post-hoc tests revealed a significant effect at 5 h, 6 h and 11 h 
(* P < 0.05) compared with placebo. Psychometric tests were conducted at +1 h, +3 h, +6 h, +9 h and 
+12 h as shown by #. Data are presented as mean ± SEM (n=19).
4.5.4. Sleep variables
There was no significant effect o f promethazine on any o f the actigraphic sleep variables 
including percentage sleep, num ber o f sleep bouts, fragmentation index or sleep efficiency 
during the post dose night sleep period from 23:00 to 07:00 hours. The values for each o f the 
variables are shown in Table 4.1.
Table 4.1; Actigraphic sleep variables night one
Variable
Promethazine
25mg
Placebo
Percentage Sleep 8 8 + 1 8 9 + 1
Number of Sleep Bouts 26 ± 2 24 + 2
Fragmentation Index 26 + 2 3 5 + 4
Sleep Efficiency 8 7 + 1 87 + 2
Data are provided as sleep variables calculated with the Sleepwatch Algorithm and presented as mean 
± SEM (n = 19).
4.5.5. Cognitive and psychom otor function
4.5.5.1. Choice Reaction Time (CRT) -  Total Reaction Time (TRT)
There was a significant main effect o f treatment with prom ethazine increasing Total reaction 
time (TRT) com pared with placebo (F(i 48.7) = 30.86, P < 0.0001). Post-hoc analysis revealed 
a significant effect o f prom ethazine 25 mg with an increase in reaction times compared with
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placebo on the individual time points at 1 h (600 ± 36.9, P = 0.0076), 3 h (669 ± 42.7, 
P < 0.0001), and 6 h (617 + 31.4, P < 0.0001) post dose compared with placebo (563 + 23.4, 
558 + 23.2, 552 + 26.2 at 1, 3, and 6 h respectively) (mean + SEM) as shown in Figure 4.5B.
4.5.5.2. Continuous Tracking Task -  Reaction time (CTT-RT)
There was a significant main effect o f  treatment with promethazine increasing the response 
time to the peripheral stimulus component o f  the CTT-RT compared with placebo (F(i,4o g) = 
8.49, P = 0.0058). analysis revealed a significant effect with increased response
times following promethazine 25 mg at the individual time points 3 h (701 + 16.9, P <
0.0001) and 6 h (702 + 19.0, P < 0.0001) post dose compared with placebo (656 + 11.6 and 
663 + 16.1 at 3 and 6 h respectively) (mean + SEM) as shown in Figure 4.5C.
4.5.5.3. Continuous Tracking Task -  Tracking error (CTT-ERR)
There was a significant effect o f  treatment with promethazine increasing the number o f  
tracking error on CTT compared with placebo (F(i 33 9) = 13.57, P = 0.0008). 
analysis revealed a significant effect o f  promethazine compared with placebo with on the 
individual time points at 3 h (15.6 + 3.1, P < 0.0001) and 6 h (13.84 ±  2.2, P < 0.0001) post 
dose compared with placebo (9.1 + 0.9 and 8.9 + 0.8 at 3 and 6 h respectively) (mean + 
SEM) as shown in Figure 4.5D.
4.5.5.4. Line Analogue Rating Scales (LARS).
There was a significant effect o f  treatment on subjective perception o f sedation, with higher 
sedation scores following treatment with promethazine compared with placebo (F(],49 ]) = 
55.14, P < 0.0001). analysis revealed a significant effect o f  promethazine compared
with placebo on the individual time points at 1 h (61.4 ±  2.3, P < 0.0001), 3 h (71.8 ± 2.5, P 
< 0.0001), 6 h (70.7 + 2.6, P < 0.0001) and 9 h (57.4 + 1.4, P = 0.0339) post dose compared 
with placebo (52.8 + 0.9, 55.0 + 2.1, 53.3 + 1.7 and 51.9 + 1.1 at 1, 3, 6 and 9 h respectively) 
(mean + SEM) as shown in Figure 4.5A. Participants treated with promethazine scored 
higher on the sedation component o f  LARS compared with placebo, higher scores indicate 
impairment/sedation.
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Figure 4.5: Time course o f effect o f placebo (■) and promethazine 25 mg (□ ) on cognitive function 
Time course o f effect o f placebo (■) and promethazine 25 mg (□) on (A) sedation component of 
LARS; (B) total reaction time (TRT) o f CRT; (C) response time o f CTT-RT and (D) tracking error 
CTT-ERR. There was an overall significant effect o f treatment on LARS and TRT (P < 0.0001), CTT 
(P < 0.01) and CTT-ERR (P < 0.001) on the psychometric tests. Post-hoc tests revealed significant 
effects for all tests at 3 h and 6 h post dose (*** P < 0.0001, ** P < 0.01, *P < 0.05) compared with 
placebo. Data are presented as mean ± SEM (n=19).
4.6. Discussion
The purpose o f this study was to compare changes in actigraphic activity following a single 
dose o f prom ethazine (25 mg) or placebo with changes in cognition and psychomotor 
performance. The validated cognitive psychom otor or subjective tests used were the CRT 
(Hindmarch, 1980), CTT (Hindmarch et a l, 1983) and LARS (Hindmarch and Gudgeon, 
1980) which are known to be sensitive to the CNS effects o f  the antihistamine promethazine 
(Hindmarch et a l,  2001a, 1999). Prom ethazine is commonly prescribed not only for allergic 
reactions but as an anti-emetic in motion-sickness and as a paediatric sedative at night. The 
side effects associated with this compound are important to note because patients taking 
these compounds may find that it impacts on their daily activities including driving or 
operating m achinery with associated safety risks. In addition it is important to assess whether
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actigraphy can detect daytime sedation / impairment as this might be useful in predicting 
relative safety risks o f  novel, newly developed antihistamine medications.
Psychometric tests were performed at specific time points across the day in order to profile 
the pharmacodynamic effects o f  the drug. However since the tests themselves take time to 
perform the number o f  tests used in the study was limited and this may have excluded 
critical time points o f  interest. In contrast to the psychom etric tests actigraphy provides an 
unobtrusive continuous measurement o f  activity and therefore any changes in activity 
associated with the effects o f  a drug may be measured in a more time-specific manner. 
Previous work has shown that prom ethazine 25 mg reduced daytime activity m easured by 
actigraphy and was associated at 6 h post dose (Stanley, 1997; Hindmarch a/., 1999) with 
significant subjective sedation, as measured by LARS, and decrements in psychomotor 
performance in antihistamines.
In the current study there was evidence o f significant impairment in cognitive and 
psychomotor performance 0 -  9 h following a single dose o f  promethazine (25 mg) 
com pared with placebo. Activity levels were not statistically significantly reduced. However 
when the level o f  'sleep-like minutes', (i.e. 1 min activity epochs < 40 counts assessed by the 
algorithm as 'sleep') were assessed, promethazine was shown to significantly increase the 
amount o f  sleep-like activity during the 0 -  12 h post dose period with significant effects at 
5 h and 6 h post dose (Figure 4.4) coinciding with the T a^x to o f  the drug. The reason for 
this dissociation in time between activity levels and cognitive performance is unclear. It 
could be attributed to the confounding factor o f  restricted activity during the wheal and flare 
assessments and psychometric assessments.
To assess whether the potentially confounding time periods, where the activity o f 
participants was either standardised (psychometric testing) or restricted (wheal and flare), 
impacted on the output, activity was selected &om the data panels when the tests were not 
being performed and activity was not controlled. This enabled 'spontaneous activity', as the 
last 15 minutes o f each hour, to cover the whole o f  the treatm ent period, to be measured. 
Analysis showed that there was a significant reduction in activity levels at 5 -  8 h post dose 
(Figure 4.3).
Prom ethazine is known to effect sleep variables (Adam and Oswald, 1986) when given 1 h 
prior to sleep at night by increasing TST and reducing number o f awakenings. However, no 
effect was observed during the sleep period 23:00 to 07:00 h for any o f  the actigraphic sleep 
variables in the current study. This could be due to the fact that promethazine was
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administered in the morning over 14 h before the sleep period, and past the o f  12 h so any
effect was diminished. There was a reduction in the fragmentation index indicating less 
m ovement during sleep, although this was not statistically significant.
This study clearly demonstrates the importance o f study design when using actigraphy. 
During residential laboratory studies more data are needed to correct for periods when 
activity is controlled or restricted as this can confound results. As with the previous study on 
the benzodiazepine LZP (Chapter 3), actigraphy was able to show reduced activity due to the 
effect o f  the sedating treatment. In the present study only 15 min o f  spontaneous activity was 
available compared with 30 min in the LZP study. However, as actigraphy recording is 
continuous it allows for the investigation o f  times when activity is not restricted or affected 
by other activities unlike cognitive and psychomotor tests that are performed at precise time 
points to try and measure the effect o f  greatest impairment.
Although the length o f assessment at each time-point was greater in this study the frequency 
o f the tests in the current study at +1, +3, +6, +9, and +12 post dose was less compared with 
the LZP study where tests were conducted hourly. This scheduling o f  tests allowed 
participants to have more ‘spontaneous’ time. During this time it was found that activity 
epochs reduced to very low levels which were calculated as being ‘sleep-like’ with under 40 
counts per 1 min epoch. From  the data it was clear that prom ethazine increased the amount 
o f sleep-like behaviour and that this persisted for up to 6 h post dose.
This study confirms previous evidence (Stanley, 1997) that actigraphy is able to measure 
‘sedation’, with significant reductions in activity, up to 6 h post dose following prom ethazine 
administration being observed. Thus actigraphy appears useful for studying the subtle effects 
o f sedating compounds. Furthermore, in the current study significant reductions were also 
observed at 11 h post dose, which might translate to a residual effect o f  medication in the 
morning i f  given at night.
4.7. Limitations
The current study has sim ilar limitations and recommendations for improvement to the 
previous study in Chapter 3. The data for the present analysis were taken from a larger 
clinical trial which was not specifically designed for measuring the effect o f  treatment with 
actigraphy. It was again necessary to compartmentalise the actigraphy data to avoid the 
confounding effect o f  the psychometric testing, wheal and flare assessments and 
pharmacokinetic sampling.
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4.8. Conclusions
As in the previous study the data showed that it was possible to detect changes in daytime 
activity and sleep due to the psychoactive effect o f  medication. Actigraphy appears to be 
useful ac^unct to clinical studies to measure the effect o f  sedating medication on activity 
even when confounding assessments are being performed. This study provides further 
evidence that actigraphy is sensitive not only to the sedating effects o f LZP (Chapter 3) but 
to the effect o f  the sedating antihistamine promethazine as measured by an increase in 
‘sleep-like’ behaviour.
Although psychometric tests were being performed at distinct time-points, actigraphy was 
able to show the time-course o f promethazine in relation to its pharmacokinetic profile. The 
activity profile showed a significant reduction in ‘spontaneous’ activity levels during the 
Tmax to T% o f the drug between 5 to 6 h post dose. In addition, by using the algorithm to score 
the activity epochs as sleep or wake, actigraphy was also able to show a significant increase 
in ‘sleep-like’ behaviour during the T a^x to T% at 6 h post dose. These detrimental changes in 
activity m irrored the significant im pairment observed in the cognitive and psychomotor 
function tests from I to 6 h post dose. Although these effects occurred earlier than the 
activity, they are not continuous but only snapshots o f the impairing effect. Furthermore the 
reduction in activity and the increase in sleep-like activity supported the participants’ 
subjective feeling o f  being sedated as shown by the increase in LARS scores.
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CHAPTER 5 ANTIDEPRESSANTS
5.1. Introduction
5.1.1. Chronic antidepressant administration
Actigraphy, used in a study o f  patients with depression in their own home environment 
would provide a ‘real-life’ assessment o f  the effects o f  a drug on patients. It would be
difficult to evaluate the chronic effect o f antidepressant m edication with patients living in the 
laboratory since this would not only depend on the time taken to reach the stable dose with 
different medications but would also not provide an indication o f  the effect o f  the drug on 
the disease in everyday living.
Due to the reported effects o f  discontinuation o f  SSRI treatment discussed in Section 1.6.10
it was therefore necessary to study not only the early phases o f  the treatment but also the 
long term effects including a discontinuation phase which would highlight the effects o f  
missing or skipping doses.
5.1.2. Selective serotonin reuptake inhibitors (SSRIs) and treatment o f  depression
Selective serotonin reuptake inhibitors (SSRIs) are widely recognised as treatments for mild 
to moderate depression and are discussed in detail in Section 1.6. There is evidence to 
suggest from various reviews that this group o f  antidepressants affect sleep in laboratory
settings with FSG (W ilson and Argyropoulos, 2005; M endlewicz, 2009; Holshoe, 2009) 
(Table 1.2). Less work however has investigated the long term effect on sleep in ambulatory 
field conditions with antidepressants (Kasper a/., 2010). The effect o f  the respective
SSRIs on PSG sleep variables is shown in Table 1.2 in comparison with the effect o f 
depression on sleep, data from (W inokur et al., 2001).
Some antidepressants such as the TCAs promote sleep (Mayers and Baldwin, 2005) whereas 
the SSRIs are associated with reductions in sleep efficiency, increased latency and sleep 
disruption. Most antidepressants affect the distribution o f  REM throughout the night 
(reviewed in Wilson and Argyropoulos, 2005). The 3 SSRIs listed above have slightly 
different profiles and mechanisms o f  action as well as side effects. They also have different 
half-lives; fluoxetine has a half-life up to 4 days, whereas paroxetine and sertraline both have 
comparatively short half-lives o f  1 day. The active metabolite o f  fluoxetine continues to be 
active for 7-15 days, the metabolite o f sertraline is active for 66 h, whereas paroxetine has no 
active metabolite (Nutt er a/., 1999; Vaswani a/., 2003; Preskhom, 1996).
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5.2. Aims
The aim o f  this study was to assess the effect o f  three non-sedating antidepressant SSRI 
antidepressants, paroxetine, fluoxetine and sertraline measured in a 12 week single treatment 
parallel study to assess whether actigraphy could detect changes in activity and sleep
associated with treatment and on a week o f  abrupt discontinuation. The study also explored 
the relationship o f  long term  anti-depressant medication on sleep and activity cycles as well 
as cognitive and psychomotor function and subjective ratings o f  sleep and mood.
To investigate the effect o f  3 SSRI antidepressant treatments (paroxetine, fluoxetine and 
sertraline) on the time course and duration o f  action on actigraphic sleep and wake variables,
subjective sleep quality, depression rating and psychom otor and cognitive performance in 
depressed patients.
5.3. Hypotheses
i. Paroxetine, fluoxetine and sertraline will affect actigraphic daytime activity,
actigraphic sleep, the sleep wake cycle and circadian activity equally for 12 weeks o f
treatment, and during treatment discontinuation.
ii. Paroxetine, fluoxetine and sertraline will improve depression rating and cognitive 
and psychomotor performance up to 12 weeks o f  treatment, and during treatment 
discontinuation.
iii. The null hypothesis is that paroxetine, fluoxetine and sertraline will have no effect 
on actigraphic daytime activity, actigraphic sleep, the sleep wake cycle and circadian 
activity up to 12 weeks o f  treatment, and during treatment discontinuation.
iv. The null hypothesis is that paroxetine, fluoxetine and sertraline will have no effect 
on depression rating or cognitive and psychomotor performance up to 12 weeks o f  
treatment, and during treatment discontinuation.
5.4. M ethods
5.4.1. Design
This was a phase IV, randomised, double-blind, parallel group, multi-centre study in which 
depressed patients Montgomery-Àsberg Depression Rating Scale (MADRS >20) diagnosed 
as requiring antidepressant treatment were randomised to receive either paroxetine, 
fluoxetine or sertraline antidepressants.
The study was given a favourable ethical opinion from the local ethics committees o f South
West Surrey and the University o f  Surrey, together with the Cornwall Local Research Ethics
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Committee which covered the area o f  the GP investigators in the Cornwall Clinical Research 
Group who carried out the study. Following study initiation GPs were trained to ensure 
consistency o f  scoring the MADRS and other questionnaires, study administration, actigraph 
set up and psychometric procedures.
The MADRS, designed to be sensitive to the changes and treatment effects (M ontgomery 
and Asberg, 1979) o f  antidepressants, was used to assess eligibility in this study by the GP at 
the clinical interview visit 1, to record depression scores prior to randomisation. Baseline 
scores, whereby patients rated with a score o f  > 20, and matched the inclusion eligibility 
criteria were entered into the study.
5.4.2. Patients
Patients (n = 99) (18 years and over) diagnosed with depression, defined as requiring 
treatment for depression on clinical grounds with a M ontgomery-Àsberg Depression Rating 
Scale (MADRS) score o f  > 20 (moderate-severe) (Snaith er a/., 1986) at screening Visit 1 
(Day 0), were recruited onto the study provided that the patients were able and willing to 
give informed consent, and were willing to fulfil the study obligations and restrictions 
including attending all the study visits, performing all the assessments and wearing an 
Actiwatch throughout.
Recruitment was conducted over 5 months at 9 centres by approximately 12 general 
practitioners (GPs) as local site investigators. The number o f patients ranged from 1 to 24 at 
each centre. It was anticipated that to obtain 75 com pleted patients, 100 patients would be 
required to ensure 25 patients in each treatment group to test the null hypothesis that 
paroxetine, fluoxetine and sertraline have the same effects on rest-activity up to 12 weeks o f  
treatment and upon discontinuation.
Patients were excluded from recruitm ent if  they had received drug treatment for depression 
within the previous 3 months, had a history o f  drug allergy, or serious cardiovascular 
disease, serious psychological or neurological disorders, history o f  cancer, were shift­
workers or were any patient that the physician or investigator felt was unsuitable.
5.4.3. Study design
The study was a randomised, double-blind, parallel group, multi-centre investigation 
conducted in general practice. There was no baseline period as patients were randomised to 
treatment at the first visit (Visit 1). There was no placebo dosing comparator as it was
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considered unethical not to dose patients with active drug when efficacious treatments were 
available.
Cognitive and psychomotor assessments were conducted at each visit throughout the study 
and are described in detail in section 2.5. Patients were required to wear an Actiwatch (AW4 
Cambridge Neurotechnology) continuously throughout the study to measure their rest- 
activity patterns. At a pre-determined time, from Visit 12 to Visit 13, treatment was 
discontinued abruptly for 7 days with the substitution o f placebo for the active drug to 
compare the effect o f  each medication discontinuation. The timing o f  the discontinuation 
was blind both to the investigators and patients. All visits were scheduled to occur at 
approximately the same time o f day and patients were advised to take their medication at the 
same time each day, morning or evening.
Patients were assessed at 14 visits on Days 0, 1 , 2 ,  3, 5, 7, 10 and 14 for Visits 1 to 8, and 
then at weeks 4, 8, 11, 12, 13 and 14 for Visits 9, 10, 11, 12, 13 and 14, respectively. The
study visit schedule is shown in Figure 5.1. Cognitive and psychomotor tests, questionnaires 
and depression rating scales were assessed at each visit as well as clinical efficacy, safety, 
and quality o f  life measures. To ensure patients were assessed according to the visit schedule 
there were allowable windows for each visit from week 2 Visit 8 o f  ± 2 days.
During routine clinic appointments, patients suffering from depression were identified as 
potential participants in the study by their GP and given the informed consent document to 
review. If  following due consideration they were willing to participate in the study they were 
invited to return and attend Visit 1 for informed consent. At this visit eligibility was 
confirmed with the inclusion/exclusion criteria and baseline assessments were performed. A  
unique patient num ber was assigned, the investigational m edication kit was allocated and the 
first Actiwatch, set to record at 1 min epoch was dispensed.
Further packs o f  medication were dispensed at Visits 6, 8, 9, 10, 11, 12 and 13. For 12 weeks 
the patients received the allocated medication, this was followed by a one week period when 
they received placebo followed by a further week when they again received study 
medication. Neither the patient nor the investigator was aware o f  which medication the 
patient was receiving or the timing o f  the placebo treatment.
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Actiwatch 1 Actiwatch 2 Actiwatch 3
1 min ep och  2 min ep och  1 min ep och
Visit 1 7 8 9 10 11 12 13 14
Day 0 7 14 28 56 77 84 91 98
I I I I I I I I I I I I I I I 
W eek  0 1 2 3 4  5 6 7 8 9 10 11 12 13 14
Discontinuation  
Figure 5.1: Study visit schedule
To show the relationship o f study duration with number o f days, weeks and visits in relation to the 
Actiwatch schedule and discontinuation/withdrawal of treatment phase. Actiwatch 1, set at 1 min 
epoch, was dispensed at Visit 1 and worn for 4 weeks from Visit 1 to Visit 9; Actiwatch 2, set at 2 
min epoch, was worn for 8 weeks from Visit 9 to Visit 12; and Actiwatch 3, set at 1 min epoch was 
worn for 2 weeks from Visit 12 to Visit 14. The medication was discontinued abruptly and replaced 
by placebo from Visit 12 to Visit 13, weeks 12 to 13.
5.4.4. Study medication
Study m edication consisted o f fluoxetine (20mg capsules), paroxetine (20mg capsules) or 
sertraline (50mg capsules), together with matching placebo for the discontinuation phase. 
The treatment pack for each patient contained 8 boxes one o f  each to be dispensed at Visits 
1, 6, 8, 9, 10, 11, 12 and 13 (Weeks 0, 1, 2, 4, 8, 11, 12 and 13). Each box contained blister
strips o f  medication for oral administration. Patients were to take their m edication on a daily 
basis at the same time each day.
At the first visit patients were sequentially randomised to receive fluoxetine (20 mg/day), 
paroxetine (20 mg/day) or sertraline (50 mg/day). The patient and investigator were not 
informed o f the timing o f  the 7-day placebo substitution period, which took place between 
visits 12 and 13, i.e. placebo treatment started after all assessments had been completed at 
Visit 12. At Visit 12 (Week 12) patients were dispensed with a pack o f  placebo to replace 
medication to simulate one week o f  abrupt discontinuation.
5.4.5. Study measures
To investigate the effects o f  paroxetine, fluoxetine and sertraline on aspects o f  actigraphic 
sleep, wake and mood depression rating scales, quality o f  sleep questionnaires and cognitive 
and psychomotor performance assessments were conducted. The assessments to measure the 
effects o f  medication on cognitive function and psychomotor performance included Critical 
Flicker Fusion (CFF) (Section 5.4.9.2), Choice Reaction Time (CRT) (Section 5.4.9.1), 
Cognitive Failures Questioimaire (CFQ) (Section 5.4.9.11), and Line Analogue Rating Scale 
(LARS) (Section 5.4.9.5). These tests are referred to in more detail in Chapter 2. Objective
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actigraphic sleep was assessed using the Actiwatch (Sections 5.4.6 and 5.4.7) and the Leeds 
Sleep Evaluation Questionnaire (LSEQ) (Sections 2.6.1 and 5.4.9.4) was used to assess
subjective quality o f sleep. Depression severity was m easured by the physician w ith the 
MADRS (Section 5.4.9.7) and the Hamilton Depression Scale (HAM D) (Section 5.4.9.8) 
and the patient-rated ZUNG Depression Inventory (Section 5.4.9.10). At the final assessment 
(Visit 14) the investigator was required to determine whether continuation o f  treatment with 
an SSRI was warranted and i f  so an antidepressant o f  choice was prescribed.
5.4.6. Actigraphy
Patients were required to wear Actiwatches AW4 (Cambridge Neurotechnology Ltd.,
Cambridge, UK) on their non-dom inant wrist for the duration o f  the study to m onitor rest 
and activity. Actigraphy records activity in counts per epoch so changes in activity may be 
observed and measured and therefore provides a continuous measure. The maximum storage 
o f  the Actiwatch was 45 days at 1 m inute epoch. As the duration o f the study was 98 days 
actigraphy was recorded in three separate files.
W hen a suitable patient was screened and consented, an appointm ent for V isit 1 was made. 
A request was placed by the prescribing GP for the first Actiwatch (A W l) to be set up and 
sent same day from one o f  the two GP set-up surgeries, for dispensing and attached at Visit
1. A fter 4 weeks at Visit 9, A W l was returned to the GP by the patient (week 4). Actiwatch 
(AW 2), set to record at 2 min epoch, was set up and sent to the GP from University o f  Surrey 
to coincide with Visit 9. At the end o f  8 weeks at Visit 12, AW 2 was returned to the GP by 
the patient (week 12). Actiwatch (AW 3) sent from University o f  Surrey, set to record at 1 
min epoch, was attached. AW3 was returned at the final visit. V isit 14. A t the end o f  each 
phase the Actiwatches were sent back to the University o f  Surrey from the investigator site 
to be downloaded (Figure 5.1).
In order to cover the study duration with as few Actiwatches as possible different epochs 
were used. To cover the critical periods during the first 4 weeks o f medication and the 
discontinuation phase o f  the last 2 weeks the Actiwatch epoch was set at 1 minute. Since the 
maximum data storage duration set at 1 min epoch was 45 days, to reduce the number o f  
changes and cover the middle period, the epoch was set at 2 min to cover the 8 weeks from 
week 4 to week 12 (Visits 9-12).
As the patients were living at home not in a controlled environment, and they slept to their
own habitual bedtimes, they were requested to press the event marker on the Actiwatch to
record when they put the lights out to go to sleep in the evening and again in the morning
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when they woke up to indicate the end o f  their sleep period. They were advised to remove 
the Actiwatch when bathing. Patients were required to complete a daily diary (Appendix 
VIII) which was a simple log to record bedtimes and wake times and also daytime activities.
The Actiwatches were purchased specifically for the study and were calibrated prior to 
delivery. If the Actiwatch failed to download or the actogram when downloaded appeared to 
exhibit an abnormal reduction o f overall activity or unusual activity patterns, then the
Actiwatches were returned to the m anufacturer for data retrieval or validity and verification. 
Any obvious data considered not suitable for inclusion in the analysis was rejected, this 
included sensor faults. Data were captured electronically.
5.4.7. Actigraphy analysis
5.4.7.1. Data download and preparation procedures
Prior to download to ensure that the actual times registered were correct the com puter clock 
at the University o f  Surrey was synchronised to the correct real time (GMT or BST) using a 
radio controlled clock. As a check to determine whether the internal clock o f the Actiwatch 
was accurate the event marker was pressed and the time was recorded in a log, after a few
minutes the data from the Actiwatch was downloaded and the event m arker check time was 
com pared with the actual time o f pressing the marker, differences were noted in the 
individual participant logs.
Following download the actogram was reviewed for any obvious discrepancies and these 
irregularities were noted in a log including any marker time errors. These observations 
included non-compliance issues such as shift work patterns, missing data and abnormal 
activity related to an Actiwatch sensor fault. The actograms and event marker record were 
printed off, signed and dated. The actograms were also reviewed for the overall sleep 
window to determine the sleep analysis start and end times. By checking the marker at 
download it was discovered that the internal com puter clocks at the 2 surgeries, where the 
first Actiwatches (A W l) were set up, were incorrect. One surgery, organised to set up most 
o f the Actiwatches, was approximately 1.5 hours in advance o f  real time and the other 
surgery was approximately 1 hour in advance. It was therefore necessary prior to analysis to 
at^ust the start times o f  the *.awd data files to correct the time errors by opening the file in 
notepad and amending the start time.
Prior to analysis the epochs o f  the first and third *.awd data files were changed to 2 min 
epoch in order to harmonize and analyse all data files with the same epoch length, for
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accurate comparison o f  outputs across the datasets and not to introduce errors by forcing the 
2 minute data into 1 minute epochs. The activity and sleep/wake variables were 
automatically calculated using the Sleepwatch® software (version 5.51) set at the 
manufacturer’s default medium setting. In addition where necessary, to ac^ust for clock time 
changes from Greenwich Mean Time (GMT) to British Summer Time (BST) to ensure that 
data files were correct to actual time, separate *.awd data files were created for pre and post 
the clock change.
5.4.7.2. Sleepwatch analysis procedures
The Sleep Analysis window was opened, then from the Sleep Diary dropdown menu the 
analysis w indow was set to broadly cover the patient’s sleep period w ith all the sleep start 
and end times, as pre-determined by visual inspection o f the actogram. The ‘read markers’ 
button was activated and the markers, i f  set by the patient, were selected and the automatic 
calculation o f the sleep variables was conducted using the internal algorithm. Following the 
automatic analysis each day was visually checked to confirm the presented analysis, or 
manually ac^usted by resetting the sleep and end times and recalculated i f  markers were not 
set or not appropriate. The manual sleep start and sleep end times were captured as observed 
by a reduction in activity prior to sleep start and the resumption o f activity after waking. 
Nights when the Actiwatch was not worn were not included.
The panel o f  sleep variables for each o f  the sleep files were saved as an AWS summary file
and each summary was exported to Excel 2003. The three summary files for A W l, AW 2 and 
AW3 were amalgamated into one Excel workbook, and then joined to form one worksheet 
where the study and visit days from Visit 1 Day 1 to Visit 14 Day 96 were identified. Some 
Actiwatches were attached after Visit 1, therefore the excel files were ac^usted to take 
account o f  this by inserting blank nights to ensure that visit dates corresponded to dates from 
the excel output to allow accurate statistical analysis from Day 1 V isit 1. The extracted 
sheets were checked to confirm that all days were included in the summary, since the 
program just exported analysed nights. Extra blank nights were inserted i f  there were 
missing data to ensure that all dates were included and the file continuous. Extra rows were 
added to convert the values presented from clock time to decimal time for ease o f  analysis, 
so when the times occurred after midnight, the midnight value as 00:00 h was converted to 
24.00 h and 01:30 h converted to 25.50 h.
The data for the first 24 h in each panel were adopted as the baseline in order to assess
change across time. The excel data panel for each participant was extracted to a SAS data
file and a SAS program (SAS®Version 9.1 Statistical Analysis Software, SAS Institute,
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North Carolina, USA) written by Dr Sigurd Johnsen (University o f  Surrey) was used to 
extract the weekly means for each individual variable. This resulted in an output file for each 
o f  the treatments for each variable calculated as weekly means. A further SAS program 
calculated the statistical significance between the treatments, and between the study weeks.
5.4.7.3. Sleepwatch variables
The variables analysed for this study are as fully described in Section 2.4.1. The variables
calculated for this study with the 2 m inute epoch were:
•  Time in bed (TIB)
• Assum ed sleep time / Sleep period time (SPT)
• Actual sleep time / Total sleep time(AST/TST)
• Actual awake time / Wake after sleep onset (AW T/W ASO)
•  Sleep efficiency (SE)
•  Sleep latency (SOL/SL)
•  Sleep bouts (SB)
•  Sleep bout time (SBT)
•  Total activity counts in sleep
• Average wake movement (AW M)
5.4.8. Circadian rhythm analysis
Circadian rhythm activity was determined by 2 methods namely Cosinor analysis (Nelson g/ 
al., 1979) and Non-parametric circadian rhythm  analysis (NPCRA) (Van Someren et a l, 
1999). For both analyses the first Actiwatch files were a(^usted for the clock error by editing 
the start time o f  the recording by opening the text file in the ‘Notepad’ program and 
amending the time. Since the Actiwatch files were o f different epochs and lengths all 
Actiwatch files were also converted to a common 1 minute epoch. In addition files were 
ac^usted for GMT and BST time, and separate files created where necessary.
5.4.8.1. Cosinor analysis
Cosinor analysis is explained in full in Section 1.6.9.1 (Dowling gr a/., 2005; Calogiuri a/., 
2013). The values calculated were:
•  Amplitude: Difference between the m esor and peak activity
• Mesor: M ean activity value
•  Rhythm %: Percentage o f data points that fit the cosine curve
•  Acrophase time: Time o f peak activity during the biological day
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5.4.8.2. Cosinor analysis procedure
A macro provided by Dr Rob M eadows (University o f Surrey) was used to extract the 24 h 
mean activity values for each day for each o f  the Actiwatch awd files. Data cells were 
excluded where the Actiwatch had been removed and the mean hour values were ac^usted to 
account for the clock change from Greenwich M ean Time (GM T) to British Summer Time 
(BST) where the Actiwatch had been worn across the time change weekend. The mean hour 
values were grouped into weeks, aligned with the visit dates, if  there was a visit deviation, 
and then averaged. The averaged data were then fitted to a cosinor model using a program 
provided by Dr D Minors (Nelson et al 1979; Minors and Waterhouse, 1989), and the 
circadian rhythm variables, as described in Section 5.4.8.1 for activity, were calculated.
5.4.8.3. Non-param etric circadian rhythm analysis (NPCRA)
Non-parametric circadian rhythm  analysis (NPCRA) is explained in Section 1.6.9.2. The 
following NPCRA variables for activity were calculated:
• Average: The mean activity o f  the 6 minute blocks over the 24 h period.
• Amplitude: The difference between the daily averages for the activity during the 10 
hours with the most activity (MIO) and the 5 hours with the least activity (L5). This 
provides an indication o f  the circadian rhythm.
• Interdaily Stability (IS): The stability o f the rhythm  which ranges from 0 to 1. If  a 
patient had the same schedule every day with activities and rest at exactly the same 
times the stability would be 1. A normal value is considered to be approximately 0.6.
• Intradaily Variability (IV): Provides an indication o f  the fragmentation o f the rhythm 
ranging from 0 to 2 where 2 is indicative o f an unstable rhythm. The normal value 
would be approximately 1.
• MIO: M ean activity o f  the 6 minute blocks during the 10 m ost active hours.
•  MIO onset time: the start time o f  the 10 hours o f  maximum activity (MIO).
•  L5: Mean activity o f  the 6 minute blocks during the 5 least active hours.
•  L5 onset time: the start time o f  the 5 hours o f  least activity (L5).
• Relative Amplitude: Calculated by dividing the amplitude with the sum o f MIO and
L5, provides a range from 0 to 1 where higher values are indicative o f  a higher
amplitude (Kasper e/ ar/., 2010).
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5.4.8.4. Non-parametric circadian rhythm analysis (NPCRA) analysis procedure
The Actiwatch files were ac^usted for the clock error by editing the start time o f  the
recording by opening the text file in the ‘N otepad’ program  and changing the time. All 
Actiwatch files were then converted to a common 1 minute epoch. As the macro was not 
written for files longer than 30 days the 8 week files were split into manageable 30 day sub­
files. The activity data were then analysed in weekly blocks using an excel macro (provided 
by Prof. Eus Van Someren) whereby the start dates and times were entered. Any days or 
parts identified as unreliable or missing, e.g. due to non-compliance where patients had 
om itted to wear the Actiwatches, were entered in whole 24 h periods and were removed from 
the analysis.
5.4.9. Cognitive and psychom otor function
Cognitive and psychomotor performance was measured by the Leeds Psychomotor Tester, 
which comprised the Choice Reaction Time (CRT) and Critical Flicker Fusion (CFF). These 
tests are known to be sensitive to the impairing effects o f  psychotropic compounds (Roschke 
er a/., 2000; Hindmarch er a/., 2005). CRT and CFF tests have previously been described in 
Sections 2.5.1 and 2.5.2, respectively. The patients completed the tests at all Visits 1 to 14, 
however, only the data h"om Visits where depression was also assessed are presented which 
were Visits 1 (baseline), 7, 8, 9, 10, 11, 12, 13 and 14 (corresponding to study weeks 0, 1 ,2 , 
4, 8, 1 1 ,1 2 ,1 3  and 14).
5.4.9.1. Choice Reaction Time (CRT)
The CRT, as described in detail in Section 2.5.1, was conducted at each visit. The
components o f the test. Recognition Reaction Time (RRT) and M otor Reaction Time (MRT) 
were individually m easured and com bined to provide the Total Reaction Time (TRT).
5.4.9.2. Critical Flicker Fusion (CFF)
The CFF, as described in detail in Section 2.5.2, was conducted at each visit. Patients were 
required to discriminate flicker from fusion, and vice in a set o f  four light emitting
diodes arranged in a one centimetre square.
5.4.9.3. Questionnaires
Questionnaires were used to evaluate patients’ subjective ratings o f the effects o f  the
antidepressants. The Line Analogue Rating Scale (LARS) (Appendix VI) was employed to
measure perceived daytime sedation. The mean scores o f  ratings o f ‘tiredness’, ‘drowsiness’, 
and ‘alertness’, presented among several distracter scales, were taken as a measurement o f
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perceived sedation. Subjective sleep quality was assessed using the Leeds Sleep Evaluation 
Questionnaire (LSEQ) (Appendix V), cognitive impact was assessed with the Cognitive 
Failures Questionnaire (CFQ) (Appendix IV), and depression with the ZUNG (Appendix 
III). Depression rating was also evaluated using the physician rated depression scales o f  
MADRS (Appendix I) and HAMD (Appendix II) as detailed in the following sub-sections.
5.4.9.4. Leeds Sleep Evaluation Questionnaire (LSEQ)
The LSEQ, described in detail in Section 2.6.1, was used to assess the subjective rating o f  
sleep o f  the patients and was completed at each visit by the patient to record changes in 
perceived sleep quality. At Visit 1, for the baseline night, patients were required to compare
their sleep for ‘last night’ with ‘sleep in the past w eek’. The polarity o f  some o f  the
individual lines was reversed to ensure that patients read the scales correctly. For all 
subsequent Visits patients were required to compare their sleep ‘using the m edication’ to 
norm ally ‘without the m edication’. The questionnaire was completed by the patients at all 
visits but only the data for weeks 0, 1, 2 ,4 , 8, 1 1 ,1 2 ,1 3  and 14 were used in the analysis.
5.4.9.5. Line Analogue Rating Scale (LARS)
The LARS as described in detail in Section 2.6.2 was used to assess patients’ present
feelings with that before treatment. Subjective evaluation o f  perceived sedation was obtained 
from the mean scores o f  ratings o f  “tiredness”, “drowsiness” and “alertness”. The 
questionnaire was completed by the patients at all visits but only the data for weeks 0, 1 ,2 , 
4, 7, 8, 11 ,12, 13 and 14 were used in the analysis.
5.4.9.6. Depression scales
Three depression rating scales MADRS, HAMD and ZUNG were used in the study to assess 
the subjective effect o f SSRI treatment on patients’ depression and subsequent improvement.
The M ADRS and HAMD were com pleted by the GP and the ZUNG by the patient. The
questionnaires were completed at weeks 0 (baseline), 1, 2, 4, 8, 11, 12, 13 and 14
(corresponding to visits 7, 8, 9, 10, 11, 12, 13 and 14) to m onitor the level o f  depression and 
efficacy o f treatment. During the first weeks there were frequent assessments to cover the 
early onset o f the relief o f depressive symptoms from visit 1 prior to treatment, then at 1, 2 
and 4 weeks. Questionnaires were administered at week 13 following the discontinuation 
week and at week 14, following one week o f  treatment resumption.
The MADRS, designed to be sensitive to the changes and treatment effects (Montgomery 
and Asberg, 1979) o f  antidepressants, was used to assess eligibility in the current study by
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the GP at the clinical interview visit 1, to record depression scores prior to randomisation. 
The HAMD was shorter in time to administer than the MADRS. To improve inter-rater 
variability the GPs were trained on administering the questionnaires during the study 
initiation. In addition, as the study was a clinical trial patients were their own control and 
therefore change across the study and within each patient was measured.
It was important to monitor and capture the outcomes o f these questionnaires during the first 
4 weeks o f  treatment on the current study more intensely to determine when the onset and 
response o f treatment occurred.
5.4.9.7. Montgomery-Àsberg Depression Rating Scale (MADRS)
The M ADRS questionnaire was originally designed as a rating scale to be sensitive to 
change and treatment effects (Montgomery and Asberg, 1979) and was related to the mental 
aspects o f  depression such as sadness, tension and pessimistic suicidal thoughts. The 
M ADRS (Appendix I) consists o f  10 items related to depressive feelings (apparent sadness, 
reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, 
lassitude, inability to feel, pessimistic thought and suicidal thoughts) with each item graded 0 
to 6.
The ratings were based on a clinical interview completed by the same GP at each visit. The 
total o f  the scores for the ten items was an indicator o f the severity o f  depression, 0 to 6 
normal to recovered, 7 to 19 mild, 20 to 34 moderate and 35 to 60 severe (Bhatt et a l, 2011). 
A  subset o f  item 4 for reduced sleep which represented the experience o f reduced duration or 
depth o f  sleep compared with patient’s own pattern when well was also evaluated. Baseline 
scores, whereby patients rated with a score o f  > 20, and m atched the inclusion eligibility 
criteria were entered into the study. Patients were included in the study i f  their score was >  
20 at baseline Visit 1.
The sleep subset o f  Question 4, on reduced sleep (Lader et a l, 2005) was used in the 
analysis to specifically review changes in perceived sleep duration, the subset was marked 
out o f  6 whereby 0 was scored for no change, 1 -2 slight difficulty dropping o ff to sleep or 
slightly reduced, 3-4 indicated reduced sleep by at least 2 hours and 5-6 indicated less than 
2-3 h sleep (Appendix I MADRS).
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5.4.9.8. Hamilton Depression Rating Scale (HAM D)
The Hamilton Depression Rating Scale (Hamilton, 1960) (Appendix II) was designed to 
measure the severity o f  depression in patients already diagnosed as suffering from depressive 
illness. The HAM D scale was completed by the same GP at each o f the study visits 1, 7, 8, 
9, 10, 11, 12, 13 and 14, and was used to assess the state o f  the patient’s current condition 
with that over the preceding few days. There are various versions o f  the HAMD which 
originated in 1960 (Hamilton, 1960) and in this study the 17 item version o f  the 
questionnaire was used. According to the scoring patients severity is assessed fi-om 0-7 
normal, 8-13 mild, 14-18 moderate, 19-22 severe, > 23 very severe depression.
The HAMD consists o f  17 items which relate to depressive feelings (mood, guilt, suicide, 
insomnia, work and activities, retardation, agitation, anxiety, somatic symptoms, loss o f  
libido, hypochondriasis, weight loss and insight), with the items being rated according to 
severity either on a 0-2 point or a 0-4 point scale. The total o f  the scores for the 17 items was 
used in the analyses. In addition further analysis o f the sleep questions was conducted. A 
sleep subset o f  items 4-6 relating to insomnia (difficulty getting to sleep, restlessness, 
waking in the night and waking early) and a further subset for item 4 relating to insomnia 
occurring early in the night (difficulty getting to sleep) was evaluated.
5.4.9.9. M ADRS and HAM D sleep items
As previously stated poor sleep or insomnia is a m ^or factor in depression (Benca and 
Peterson, 2008) and both o f  the depression questionnaires have scales related to questions on
sleep which is useful for comparison with other objective and subjective ratings o f  sleep 
duration or quality. The sleep question in M ADRS Item 4, comprised a scale o f  1 to 6 on 
aspects o f  sleep duration or ‘reduced sleep’ from 0 = sleep as usual, through to ‘slight 
difficulty dropping o f f  or ‘fitful sleep’ = 2, ‘sleep broken or reduced by 2 hours’ = 4 to the 
extreme ‘less than 2 or 3 hours sleep’ = 6. ‘Sleep disturbance’ according to previous 
literature is a score o f  2 or more 917 (W illiam son et a l,  2006) in bipolar patients. The full 
questionnaire is shown in Appendix I.
The HAMD sleep questions relate to issues o f  insomnia. Question 4 relates to insomnia 
occurring early in the night rated as 0 = ‘no difficulty falling asleep’ = 0, ‘occasional 
difficulty’ -  1 and ‘nightly difficulty’ = 2. Similarly for question 5 which relates to middle o f  
the night insomnia where ‘patient complains o f  being restless and disturbed’ = 1, and waking 
during the night and getting out o f  bed’ = 2. Question 6 relates to early waking, ‘waking in 
early hours but gets back to sleep’ = 1 and ‘waking but unable to fall back to sleep again’ =
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2. The maximum score for insomnia occurring early, middle and late was therefore 6 (Fava 
gr a/., 2002). The full questionnaire is shown in Appendix II.
5.4.9.10. ZUNG Depression Inventory
The ZUNG Depression Inventory (ZUNG, 1965) (Appendix III) was a subjective 
questionnaire completed by the patient in contrast to the MADRS and HAMD which were 
completed by the GP. It was developed to be self-completed by the patient to indicate then- 
own feelings during drug treatment and consisted o f  20 sentences which the patient scored 
out o f  4 quantitative terms: ‘none or a little o f  the tim e’, ‘some o f  the time’, ‘good part o f the 
time’, ‘most or all o f  the time’. The 20 sentences related to mood, somatic symptoms, 
irritability and agitation, indecisiveness, suicide, worthlessness, fatigue and weight changes. 
The answers were scored 1 - 4 ,  the lower the score the better the outcome for that sentence, 
80 being the worst overall score. The total o f  the scores for the 20 sentences was used in the 
analysis. The questionnaires were completed by the patients at weeks 0, 1, 2, 4, 8, 10, 11, 
12, 13 and 14, corresponding to study visits 1, 7, 8, 9, 10, 11, 12, 13 and 14. Values for 
depression severity were < 50 (normal), 50 to 59 (mild), 60 to 69 (moderate), and > 69 
(severe) (Passik er a/., 2002) with most people with depression scoring between 50 and 69 
(Cusin gr a/., 2010).
5.4.9.11. Cognitive Failures Questionnaire (CFQ)
To measure the effects o f  treatment in the present study patients were also required to rate 
their feelings for self-reported, cognitive failures in perception, memory and motor function 
in everyday activities using the CFQ. The Cognitive Failures Questionnaire (CFQ) was a 
measure o f self-reported cognitive failure in perception, memory and motor function, 
developed by (Broadbent e/ a/., 1982) comprising 25 possible failures covering the three 
general areas (Appendix IV).
Participants self-rated how often they had experienced each problem  since the last visit, 
using a five point scale ranging from ‘never’ (0) to ‘very often’ (4). The lower the score the 
better, the maximum impairment score for cognitive failures was 100. Higher scores have 
been shown to correlate significantly with depressive symptoms (Hohman et a l, 2011; 
Farrin a/., 2003) with values o f  38 for controls and 59 for depressed patients, lower values 
indicating less anxiety. The questionnaire was completed by the patients at weeks 1, 2, 4, 8, 
11, 12, 13 and 14 corresponding to study visits 1, 7, 8, 9, 10, 11, 12, 13 and 14.
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5.4.10. Statistical analysis
All results were analysed using a linear mixed model (SAS®Version 9.1) with fixed effects 
for participant and treatment, and time as a repeated measure. Tests were used to determine 
which times or treatments were significantly different. Pairs o f  treatments were statistically 
contrasted within visits, where appropriate, estimates, 95% confidence limits and P-values, 
unac^usted for test multiplicity, being examined. Pairs o f  visits were also statistically 
contrasted within treatments, estimates, 95% confidence limits and P-values, unac^usted for 
test multiplicity, being examined. A trend towards statistical significance was shown by 
i f  the P-value was < 0 .1 .
5.5. Results
The data presented here were taken from the larger clinical trial and for the purpose o f  this
investigation only the results o f  those participants that com pleted the study and consistently 
wore the Actiwatch were analysed and are presented. The data were analysed using the 
m ethods developed in Chapter 2 to determine whether there were any statistically significant 
effects o f  the SSRIs on the time course o f  treatment o f the variables measured; whether there 
was any statistical difference between treatments; and to determine whether actigraphy was 
sensitive enough to measuring the effect o f  the SSRIs on activity and sleep. The results are 
presented in sub-sections for the full study weeks 0 to 14, for the treatment period weeks 1 to 
12 and for the withdrawal and discontinuation period weeks 12 and 13.
5.5.1. Demographics
The total number o f  patients that were randomised to the study was 99 with 33 patients in 
each treatment group. Vital signs (blood pressure and heart rate), weight, date o f  birth and
sex were recorded and com pleted on the Informed Consent page in the Case Report Foim  
(CRF) at Visit 1. The average age o f  all patients in the study (n = 99) was 43.5 (± SEM 1.3) 
years, with a range o f  19 - 84 years. The mean MADRS score overall was 29.3 (± SEM 0.8)
with a score range from 20.0 to 40.0, a score o f 7 to 19 being mild, 20 to 34 moderate and 35 
to 60 severe (Table 5.1).
For the purpose o f  this study in order to compare actigraphy data with cognitive and 
psychomotor assessments and depression rating scales only patients (n = 56) that completed 
either the whole study o f  14 weeks (n = 54) or up to and including the discontinuation week 
o f 13 weeks (n = 2) and consistently wore the Actiwatch were eligible and therefore analysed 
(Table 5.2). Fifty six patients were included in the final analysis having completed at least 13 
visits, including the discontinuation phase Visits 12 to 13. In order to be included patients
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were also required to have been compliant with wearing the Actiwatch for the duration o f  the 
study. Patients were not included in the analysis if  they were withdrawn due to adverse event 
or did not complete all visits (n = 8, n = 7, n = 10 for paroxetine, fluoxetine and sertraline, 
respectively) as shown in study flow chart Figure 5.2. Further, patients were excluded if  they 
had not consistently worn the Actiwatch, were shift workers or had unusual sleep/wake 
patterns (n = 5, n = 8, n = 5 for paroxetine, fluoxetine and sertraline, respectively).
Table 5.1: Summary of demographics for the full data set at randomisation before treatment
Full data set
Paroxetine 
20 mg/day
Fluoxetine 
20 mg/day
Sertraline 
50 mg/day
All
treatments
N = 33 N = 33 N = 33 N = 99
Gender
Males 11 6 13 30
Females 22 27 20 69
Mean
(SEM) 44.9 (2.3) 43.6 (2.5) 42.0 (2.2) 43 .5(1 .3)
Age
(years) Min 19 20 19 19
Max 76 84 74 84
Mean
(SEM) 29.0 (0.8) 29.0 (0.8) 29.7 (0.7) 29.3 (0.8)
MADRS
score Min 20.0 20.0 24.0 20.0
Max 37.0 37.0 40.0 40.0
Patients were required to have a physician rated MADRS score > 20 at screening, in order to be 
included in the study, a score of 7 to 19 = mild; 20 to 34 = moderate; and 35 to 60 = severe 
depression. MADRS = Montgomery-Àsberg Depression Rating Scale
The average age o f all patients in the coiupleter’s dataset was 46.0 ±12 .1  years, w ith a range 
o f  21.4 -  83.6 years. The deiuographics o f these patients are presented in Table 5.2.The 
luean age in the three treatiuent groups was 48.1 ± 9.9, 45.2 ± 13.4 and 44.6 ± 1 3 .3  years for 
paroxetine (20 tug/day), fluoxetine (20 mg/day) and sertraline (50 mg/day), respectively. O f 
those, 20 patients (6 male) received paroxetine, 18 (1 male) received fluoxetine and 18 (5 
male) received sertraline. Two patients (1 luale, 1 feiuale) from the paroxetine group who 
com pleted up to and including Visit 13 week 13 were also included in the analysis. The 
study flow chart o f  patient randomisation is shown in Figure 5.2.
The mean M ADRS score overall was 28.7 (± 0.6), and in the three treatment groups was 
28.8 (± 1.1), 28.3 (± 1.1) and 29.0 (± 0.9) for paroxetine 20 mg/day, fluoxetine 20 mg/day 
and sertraline 50 mg/day, respectively.
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Table 5.2: Patient randomisation demographics and numbers for dataset of completers
Completers dataset
Paroxetine 
20 mg/day
N = 20
Fluoxetine 
20 mg/day
N = 18
Sertraline 
50 mg/day
N = 18
All
treatments
N = 56
Gender
Males 6 1 5 12
Females 14 17 13 44
Age
(years)
Mean
(SEM) 48.1 (2.2) 45.2 (3.2) 44.5 (3.1) 46.0(1.6)
Min 33 29 21 21
Max 65 84 74 84
MADRS
score
Mean
(SEM) 27.9(1.7) 24.9(1.8) 26.5(1.8) 26.5(1.8)
Min 20.0 20.0 24.0 20.0
Max 37.0 37.0 34.0 37.0
Patients were required to have a physician rated MADRS score > 20 at screening, in order to be 
included in the study, a score o f 7 to 19 = mild; 20 to 34 = moderate; and 35 to 60 = severe 
depression. MADRS = Montgomery-Àsberg Depression Rating Scale
W ithd raw n  (n = 13) 
A dverse e v e n t /  
DNF(n = 8) 
Protocol dev ia tion  
(n = 5)
Fluoxetine 
{n = 33)
C om pleted  
(n = 18)
S ertraline  
(n = 33)
C om pleted  
(n = 18)
Paroxetine  
(n = 33)
C om ple ted  
(n = 20)
W ithdraw n (n = 15) 
A dverse e v e n t /  
DNF(n = 7) 
Protocol dev iation  
(n = 8)
W ithdraw n (n = 15 
A dverse e v en t /  
DNF(n = 10) 
Protocol dev ia tion  
(n = 5)
Pa tien ts  en ro lled  and  random ised  
(n = 99)
Figure 5.2: Study flow chart o f patient randomisation and completion numbers 
Patients who did not finish treatment (DNF)
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5.5.2. Analysis rationale
Sleep variables were analysed for the full 14 weeks o f  the study using Visit 1 (Day 1 / 
Night 1) as the baseline and results are presented as change relative to this baseline. The first 
night o f  the study, however, might not be medication-ffee, given that the time o f  dosing was 
not recorded. Patients were provided with medication to commence &om the very first day 
and consequently could have dosed either in the evening before the first night or the 
following morning. The first night was therefore included in the 14 week analysis as one 
baseline night for comparison, as there was no placebo control or placebo run-in for the 
study. All other weeks were analysed as the mean o f  7 days. The 14 week study moreover 
included one week discontinuation.
To take account o f this anomaly, and for clarity for direction o f  change, the sleep variables 
were further analysed without using the first night as baseline for the 12 weeks o f  chronic 
medication. The results for the 12 week study are therefore presented as relative to week 1.
Further analysis was conducted for weeks 12 and 13 separately, which was the week prior to
and the discontinuation week. Only statistically significant results are presented. For both 
cosinor and NPCRA the analysis was conducted using the weekly means with the first day 
included in the first week, results are therefore presented as change relative to week 1.
The cognitive and psychometric tests and rating scales were conducted on Day 1 Visit 1 
prior to treatment and were therefore medication free, these results were analysed both as 
relative to, and change from. Visit 1 baseline.
5.5.3. Actigraphy
The overall Sleepwatch mean values and significance results for weeks 0 to 14 are 
summarised by week and treatment group, differences between weeks, and on 
discontinuation withdrawal and re-introduction o f treatment in Tables 5.3 and 5.4, and in 
Figures 5.3 -  5.7. The Actiwatch activity sleep analysis is based on the completers dataset 
n = 56, (those compliant with wearing actiwatch and completing discontinuation) with 
paroxetine, fluoxetine and sertraline n = 20, n = 18 and n = 18 respectively. The first values 
for each treatment and variable were recorded as week 0 the night o f Visit 1 for all the sleep 
variables or the day following Visit 1 for the average wake movement. Analysis showed no 
significant difference between the three treatment groups, or treatment by time interaction 
for any o f  the Sleepwatch variables. There were, however, overall significant effects o f  time 
for some o f  the Sleepwatch variables as detailed in the relevant sub-sections.
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The analysis for the actigraphy variables from week 1 to week 12 was conducted on the 7 
day weekly means excluding Night 1, as previously stated, it was not documented when 
patients took their first dose o f  medication and i f  taken on the first night could have affected 
the sleep data. The different antidepressant treatments were further analysed for the effect o f  
time, and for each week relative to week 1 for weeks 1 to 12, the chronic treatment phase. 
Further analysis was conducted for the effect o f  the withdrawal o f  medication during the 
discontinuation period, from week 12 to week 13, between the means for weeks 12 and 13, 
the week before discontinuation on stable treatment and the week o f  abrupt discontinuation. 
An example o f  each o f  the Actograms for a single patient covering the full treatment period 
is shown in Appendix (VfX).
5.5.4. Actigraphic sleep variables
5.5.4.1. Sleep time - time in bed
The mean (± SEM) time in bed (TIB) for each treatment recorded on the night o f  Visit 1 was 
509 (± 14), 484 (± 22), and 489 (± 24) minutes (8h28m, 8h04m and 8h09m) for paroxetine, 
fluoxetine and sertraline, respectively. Analysis o f  TIB showed no statistically significant 
difference between the treatment groups, however, there was a significant effect o f  time 
(F(i4, 7i8) 3.49, P < 0.0001). All three treatments showed an increase in TIB (Figure 5.3A). 
For paroxetine there was a significant effect o f  time (F(M, 257) = 1.84 P < 0.05) with increases 
in the TIB for weeks 1, 2, 3, 4, 6, 7, 8, 9, 11 and 14 compared with week 0 Visit 1. 
Fluoxetine showed a trend approaching significance over time (F(]4, 224) = 1.63 P = 0.07). 
f  ojf-Aoc analysis revealed that for sertraline there was a significant effect o f  time (F(,4, 237) = 
2.36 P < 0.05) for weeks 1 ,2 , 3 ,4 , 5, 6, 7, 8, 10, 11, 12 and 14 compared with Visit 1.
Analysis o f  the TIB from week 1 to week 12, i.e. to the end o f the 12 week treatment phase, 
showed no significant difference between the three treatment groups or across time. There 
was however a statistically significant effect o f  time between week 12 compared with week  
13, during discontinuation, with a reduction in TIB for all treatments (F(i,52.5)=5.89, P < 
0.05). analysis showed that this was significant for sertraline (F(U7) =
5.84, P < 0.05).
5.5.4.2. Sleep time -  sleep period time
The mean (± SEM) sleep period time (SPT) (duration o f  time from sleep start to sleep end, 
also known as actigraphic assumed sleep time) for each treatment recorded at Visit 1 was 
485 (± 15), 448 (± 23) and 461 (± 23) minutes (8h05m, 7h28m and 7h41m) for paroxetine,
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fluoxetine and sertraline, respectively. There was an overall significant effect o f  time (F(]4  ^
718) = 2.14, P < 0.01), with an increase in sleep duration (Table 5.4 and Figure 5.3B). Post- 
hoc analysis revealed that there was a significant effect o f  time for sertraline (F(i4,237) = 1.75, 
P < 0.05) for weeks 1, 2, 3, 4, 5, 6, 7, 8, 10, 11 and 12 com pared with Visit 1.
The mean (± SEM) SPT for each treatment recorded for week 1 was 510 (± 18), 463 (± 12) 
and 479 (± 9) minutes for paroxetine, fluoxetine and sertraline, respectively. Analysis o f  the 
SPT from week 1 to week 12, showed no significant difference between the tliree treatment 
groups nor a significant effect o f  time. There was however, a significant difference between 
week 12 compared with week 13 during discontinuation overall w ith a reduction in SPT for 
all treatments (F(i, 52.4) = 4.52, P < 0.05). Post-hoc analysis showed that this was statistically 
significant for sertraline (F(i, n) = 6.71, P < 0.05).
A. B.
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Figure 5.3: Effect o f antidepressant treatment on actigraphic TIB and SPT.
The effect of paroxetine (■) (n = 20), fluoxetine ( • )  (n = 18) and sertraline (A) (n = 18) on 
actigraphic sleep variables (mean ± SEM) on A. TIB and B. SPT. Week 0 is the value recorded on the 
night o f Visit 1.
5.5.4.3. Sleep time -  total sleep time
The mean (± SEM) total sleep time (TST) (sleep start to sleep end, less any wake time) for 
each treatment recorded at V isit 1 was 424 (± 16), 397 (± 2 1 )  and 398 (± 22) minutes 
(7h04m, 6h37m and 6h38m) for paroxetine, fluoxetine and sertraline, respectively (Table 5.3 
and Figure 5.4A), there was no significant difference between the three treatment groups, 
however was there a trend towards a significant effect o f time, (F(,4  ^7,g) = 1.61, P = 0.07), 
with sleep time reducing. Patients on paroxetine, also exhibited a trend towards a significant 
reduction in m inutes (F(i4, 257)= 1.62, P = 0.07). There was also a significant reduction in TST 
for patients on paroxetine for the 12 week analysis (F(n,204)= 2.13, P > 0.05).
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5.5.4.4. Sleep efficiency %
The mean (± SEM) sleep efficiency % (SE) for each treatment recorded at V isit 1 was 83.4 
(± 2.1), 81.8 (± 1.7) and 81.9 (± 2.7) % for paroxetine, fluoxetine and sertraline, respectively 
(Figure 5.4B and Table 5.3). There was also an overall significant effect o f  time (F(M_ 718) = 
2.37, P < 0.01). For paroxetine there was a significant effect o f  time with a reduction in sleep 
efficiency (F(i4,257) = 2.19, P < 0.01) for weeks 3, 4, 5, 6, 7, 8, 9, 11, 12, 13 and 14 compared 
with Visit 1.
Analysis o f the sleep efficiency from week 1 to week 12 showed a significant effect o f  time 
with a reduction in sleep efficiency overall across time (F(i 1, 566) = 2.21, P < 0.05). The mean 
(± SEM) for each treatment recorded for week 1 was 81.9 (± 1.7), 83.6 (1.1), and 82.1 (2.3) 
% for paroxetine, fluoxetine and sertraline, respectively (Table 5.4). There was a trend 
towards a decrease in sleep efficiency with paroxetine (F(n, 204) = 1.74, P = 0.07) with a 
significant effect at weeks 3, 4, 5, 6, 7, 8, 9, 10 and 12 compared with week 1. Similarly with 
fluoxetine (F(n, 175) = 1.76, P = 0.06) there was a significant effect at weeks 6, 8, 10, 11 
and 12 compared with week 1. There was no significant difference between the three 
treatment groups or effect o f time in sleep efficiency from week 12 to week 13.
A. B.
4 75
•F 4 5 0
3  400,
Tim e (w eek s)
0 1 2 3 4  5 6 7 8 9 10 11 12 13 14 
T im e (w eek s)
Figure 5.4: Effect o f antidepressant treatment on actigraphic TST and SE
The effect o f paroxetine (■) (n = 20), fluoxetine ( # )  (n = 18) and sertraline (A) (n = 18) on 
actigraphic sleep variables (mean ± SEM) on A. TST and B. SE. Week 0 is the value recorded on the 
night o f Visit 1.
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5.5.4.5. Sleep latency
The mean (± SEM) sleep latency (SL) for each treatment recorded at Visit 1 (Table 5.3) was 
16 (± 3), 29 (± 5) and 17 (± 3 ) minutes for paroxetine, fluoxetine and sertraline, respectively. 
There was no significant effect between treatments for sleep latency (Figure 5.5A) however, 
the effect o f  time approached significance (F(i4, ?ig) = 1.56, P = 0.08). For paroxetine there 
was a significant effect o f time with an increase in sleep latency (F(M, 257) ^  1.84, P < 0.05) 
for weeks 3, 4, 5, 7, 9, 10, 11 and 14 com pared with baseline Visit 1. There was no 
significant difference between the three treatment groups nor effect o f time in sleep latency 
from weeks 1 to 12 or from weeks 12 to 13 during discontinuation.
5.5.4.6. Sleep bouts
The mean (± SEM) num ber o f  sleep bouts (SB) for each treatment recorded at V isit 1 was 14 
(± 2), 14 (± 1), and 14 (± 2) for paroxetine, fluoxetine and sertraline, respectively (Table
5.4). There was an overall significant effect o f  time for the num ber o f  sleep bouts 
(F(i4, 718) = 7.4, P < 0.0001) indicating that sleep was more restless with increased sleep 
disturbance. Analysis showed that there were significant effects o f time (Figure 5.5B) with 
increases in the num ber o f  sleep bouts with paroxetine (F(%4  ^257) = 4.80, P < 0.0001) in weeks 
2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14 com pared with Visit 1; w ith fluoxetine (F(,4, 224) = 
3.21, P < 0.001) for weeks 7, 9, 10, 11 12, 13 and 14 compared with Visit 1 and with 
sertraline (F(M, 237) = 1.76, P < 0.05) for weeks 3, 4, 6, 7, 8, 10, 11 12 and 14 compared with 
Visit 1.
A. B.
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Figure 5.5: Effect of antidepressant treatment on actigraphic SOL and sleep bouts.
The effect of paroxetine (■) (n = 20), fluoxetine (# )  (n = 18) and sertraline (A) (n = 18) on 
actigraphic sleep variables (mean ± SEM) on A. SL and B. sleep bouts. Week 0 is the value recorded 
on the night of Visit 1.
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Analysis o f the number o f  sleep bouts for weeks 1 to 12 showed a significant effect o f  time 
(F(ii, 566) = 6.13, P < 0.0001) with an increase in the number o f  sleep bouts indicating more 
restless sleep and increased sleep disturbance. The mean (± SEM) number o f  sleep bouts for 
each treatment recorded for week 1 was 16 (± 1), 14 (± 1), and 14 (± 1) for paroxetine, 
fluoxetine and sertraline, respectively. There was a significant effect o f  time for paroxetine 
(F(ii, 204) = 3.89, P < 0.0001) in weeks 4 to 12 inclusive compared with week 1; for fluoxetine 
(F(ii, 175) = 2.53, P < 0.01) for weeks 5 to 12 inclusive compared with week 1 and for 
sertraline (F(n, ig?) = 2.03, P < 0 .0 5 )  for weeks 2 to 12 inclusive compared with week 1. 
Analysis showed no significant difference between the three treatment groups nor effect o f  
time in num ber o f sleep bouts during the discontinuation from weeks 12 to 13.
5.5.4.7. Sleep bout time
The mean (± SEM) sleep bout time recorded at baseline Visit 1 for each treatment was 38 (± 
5), 34 (± 4) and 37 (± 8) minutes for paroxetine, fluoxetine and sertraline, respectively 
(Table 5.4). Analysis showed no significant difference between the three treatment groups
nor effect o f time on sleep bout time from weeks 0 to 14 during the overall period (Figure 
5.6A), from weeks 1 to 12 the active period, or from weeks 12 to 13 during the 
discontinuation period.
5.5.4.8. Wake after sleep onset
The mean (± SEM) wake after sleep onset time (W ASO) (number o f minutes spent awake 
from sleep start to sleep end) for each treatment recorded at baseline Visit 1 was 61 (± 11), 
51 (± 7 )  and 63 (± 11) minutes for paroxetine, fluoxetine and sertraline, respectively (Table
5.4). The effect o f  time approached significance (F(i4, 71g) = 1.54, P = 0.09) with the number 
o f minutes awake increasing (Figure 5.6B). There was a significant effect o f  time for 
fluoxetine (F(M, 224) = 2.24, P < 0.01) with signiftcant increase in WASO for weeks 7, 10, 11, 
12, 13 and 14 compared with Visit 1. Analysis showed no significant difference between the 
three treatment groups nor effect o f  time on WASO from weeks 1 to 12 or during the period 
o f discontinuation week 1 2  to 13.
5.5.4.9. Total activity counts in sleep
The mean (± SEM) total number o f  activity counts during the SPT for each treatment 
recorded at Visit 1 was 6337 (8h05m) (± 1156), 5024 (7h28m) (± 771) and 5649 (7h41m) (± 
928) for paroxetine, fluoxetine and sertraline respectively (Table 5.4). There was an overall 
significant effect o f  time (F(i4, 71g) = 1.72, P < 0.05) with an increase in the number o f  activity 
counts during sleep indicating restless sleep (Figure 5.7). However, analysis failed
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to reveal an effect o f time for any treatment. Analysis showed no significant difference 
between the three treatment groups nor effect o f time on the num ber o f total activity counts 
in sleep from weeks 1 to 1 2  or from weeks 1 2  to 13 during the discontinuation period.
A. B.
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Figure 5.6: Effect o f antidepressant treatment on actigraphic sleep bout time and WASO.
The effect o f paroxetine (■) (n = 20), fluoxetine ( • )  (n = 18) and sertraline (A) (n = 18) on 
actigraphic sleep variables (mean ± SEM) on A. sleep bout times and B. WASO. Week 0 is the value 
recorded on the night o f Visit 1.
5.5.4.10. Average wake m ovement (AWM)
The mean (± SEM) average wake m ovement calculated as the activity counts per 2 minute 
epoch during the day (sleep end to sleep start), for each treatment recorded on day 2 was 431 
(± 51), 627 (± 77) and 623 (± 75) for paroxetine, fluoxetine and sertraline, respectively 
(Table 5.4). There was an overall significant effect o f  time (F(,4, 718) = 1.77, P < 0.05) with 
wake activity levels increasing over time (Figure 5.7). For paroxetine there was a trend 
approaching significance (F(i4,258)=  1.61, P =  0.07) with significantly increased activity for 
weeks 7, 8 , 9, 10, 11, 12, and 13 com pared with day 2.
Analysis o f the average wake m ovement for weeks 1 to 12 showed a trend towards an 
overall significant effect o f treatm ent (F(2, 5 3 .1) = 2.56, P = 0.09) with lower overall wake 
activity levels for paroxetine during the day. The mean (± SEM) average wake m ovement for 
each treatment recorded for week 1 was 462 (± 52), 651 (± 62) and 616 (± 67) for 
paroxetine, fluoxetine and sertraline, respectively (Table 5.4).
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There was a significant difference between week 12 com pared with week 13 overall w ith an 
increase in daytime wake activity (F(,,5o.7) = 20.11, P < 0.0001) during the discontinuation 
period for all treatments (Figure 5.7B). Analysis showed that there was a significant increase 
in daytime wake activity for fluoxetine (F ( i j5.6)= 21.53, P < 0.01) and a trend towards 
significance for sertraline (F(i, 17)= 4.33, P = 0.05) in week 13.
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Figure 5.7: Effect o f antidepressant treatment on total activity counts and average wake movement.
The effect o f paroxetine (■) (n = 20), fluoxetine ( # )  (n = 18) and sertraline (A) (n = 18) on 
actigraphic sleep variables (mean ± SEM) on A. Total activity counts in sleep (x 10^) and B. Average 
wake movement. Week 0 is the value recorded on the night o f Visit 1.
5.5.4.11. Summary o f  actigraphic sleep variables
A summary o f the direction o f the statistically significant effect o f time o f  antidepressants on 
actigraphic sleep variables for the full study for weeks 0 to 14, the treatment phase for weeks 
1 to 1 2  and for the last week o f treatment week 1 2  compared with the discontinuation 
withdrawal week 13, is presented in Table 5.5. The arrows show the direction o f  change o f 
the variables that were statistically significant w ith f  = increased and f = decreased.
5.5.5. Cosinor
The overall mean cosinor values and significance results are summarised by week and 
treatment group, and differences between weeks, on discontinuation and re-introduction o f 
treatment is shown in Table 5.6 and Figures 5.12 to 5.15. The first chart in each section 
shows the mean scores for each treatment and cosinor variables recorded. The second chart 
shows the change with respect to the first week, week 1 as baseline. There were some
significant effects between treatments, but no treatment by time interaction for any o f  the
cosinor variables. There were significant effects o f  time for some o f the variables as detailed 
in relevant sub-sections. The individual treatments were also analysed for the effect o f time
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overall and for individual weeks com pared with baseline for weeks 1 to 1 2 , the treatment 
phase and a further analysis for weeks 12 and 13, the m aintenance treatment and abrupt 
discontinuation weeks, respectively. The Actiwatch cosinor analysis was conducted on the 
completers dataset n = 56, (those compliant with wearing actiwatch and completing 
discontinuation) with paroxetine, fluoxetine and sertraline n = 2 0 , n = 18 and n = 18 
respectively.
5.5.5.1. Amplitude
The mean (± SEM) amplitude o f activity, at the peak (acrophase) o f activity o f  the cosine 
curve less the mesor, for each treatment recorded at week 1 was 9026 (± 1264), 12658 (± 
1333) and 11863 (± 1315) for paroxetine, fluoxetine and sertraline, respectively (Table 5.6). 
There was a trend towards significance between treatments for amplitude (F(2, 53.2) = 2.70, P = 
0.08); with lower values for paroxetine as shown in Figure 5.8.
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Figure 5.8; Effect o f antidepressant treatment on cosinor amplitude
The effect o f paroxetine (■) (n = 20), fluoxetine ( • )  (n = 18) and sertraline (A) (n = 18) on the 
amplitude cosinor variable (mean ± SEM) on A. Amplitude and B. Amplitude change relative to 
baseline week 1. Data are presented as activity counts x 10 .^ There was a trend towards a significant 
effect o f treatment for amplitude (P < 0.1).
Analysis showed no significant difference between the three treatment groups nor effect o f 
time on the amplitude from weeks 1 to 12. There was a trend towards a significant difference 
between weeks 1 2  and 13 during the discontinuation period with an increase in amplitude 
overall (F(i, 50) = 3.93, P = 0.05) and a trend towards significance for fluoxetine 
(F(i, 14.3)= 3.96, P = 0.07).
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5.5.5.2. M esor
The mean (± SEM) m esor o f activity for each treatment recorded at week 1 was 9499 
(± 1250), 13846 (± 1320) and 12610 (± 1305) (Table 5.6) for paroxetine, fluoxetine and 
sertraline, respectively. There was a significant effect between treatments for the mesor, 
mean level o f activity, (F(2, 53.2) 3.46, P < 0.05) with lower levels o f  activity for paroxetine
com pared with either fluoxetine or sertraline (Figure 5.9).
Analysis showed a significant difference between the three treatment groups for the mesor 
m ean level o f  activity from weeks 1-12, (F(2, 53.4) = 3.21, P < 0.05). There was a trend towards 
a significant difference between weeks 1 2  and 13 during the discontinuation period w ith an 
increase in m esor overall shown as an increase in mean activity (F(,  ^50.4) ^  6.73, P = 0.05) 
and for fluoxetine (F(i, 14.7) = 5.94, P < 0.05).
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Figure 5.9: Effect o f antidepressant treatment on cosinor mesor.
The effect o f paroxetine (■) (n = 20), fluoxetine ( # )  (n = 18) and sertraline (A) (n -  18) on the mesor 
cosinor variable (mean ± SEM) on A. Mesor and B. Mesor change relative to baseline week 1. Data 
are presented as activity counts x 10 .^ There was a significant effect o f treatment for mesor (P < 0.05).
5.5.5.3. Rhythm percentage %
The mean (± SEM) percentage rhythm for each treatment recorded at week 1 was 69.9% (± 
3.0), 74.5% (± 3.1) and 71.8% (± 3.1) for paroxetine, fluoxetine and sertraline, respectively 
(Table 5.6). There was a trend towards significance for the effect o f time (F(i3  ^37.5) = 1.86, P 
= 0.07) with an increase in percentage rhythm with time compared with week 1 as shown in 
Figure 5.10.
Analysis showed a significant effect o f  time overall (F(n, 39.8) = 2.22, P < 0.05) with an 
indication o f an increase in in the percentage rhythm  for the treatment phase weeks 1 to 12.
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There was a significant difference between weeks 12 and 13 for fluoxetine (F(i, 15.8) = 11.75, 
P < 0.01) with an increase in the percentage rhythm  during the abrupt discontinuation week.
5.5.5.4. Acrophase time
The mean (± SEM) time o f the acrophase (peak) o f  the activity rhythm for each treatment 
recorded at baseline week 1 was 13.62 (± 0.26), 13.84 (± 0.27) and 13.46 (± 0.26) hours 
(13:37, 13:50 and 13:27 hh:mm) for paroxetine, fluoxetine and sertraline, respectively (Table 
5.6). There was a trend towards an overall significant effect o f time (F(i3, 36.7) = 1.92, P = 
0.06) with the acrophase time being delayed and occurring slightly later in the biological day 
for the middle weeks (Figure 5.11).
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Figure 5.10: Effect o f anti depressant treatment on cosinor percentage rhythm.
The effect o f paroxetine (■) (n = 20), fluoxetine ( • )  (n = 18) and sertraline (A) (n = 18) on the 
percentage rhythm cosinor variable (mean ± SEM) on A. Percentage rhythm and B. Percentage 
rhythm change relative to baseline week 1. There was a trend towards a significant effect o f time for 
percentage rhythm (P < 0.1).
For the treatment phase weeks 1 to 12, analysis showed that there was a trend towards 
significance for the effect o f time overall (F(n,38.2) = 1.87, P = 0.08) with a slight delay in the 
timing, occurring later in the day during the middle weeks. There was also a trend towards a 
significant difference between weeks 12 and 13 overall w ith a delay in the acrophase time 
occurring later in the biological day (F(i,5i.i) = 9.06, P < 0.01). There was also a significant 
effect o f  time for fluoxetine (F(i  ^15.1)= 7.41, P < 0.05) between weeks 12 and 13.
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Figure 5.11; Effect o f antidepressant treatment on cosinor acrophase time.
The effect o f paroxetine (■) (n = 20), fluoxetine ( • )  (n = 18) and sertraline (A) (n = 18) on the 
acrophase time cosinor variable (mean ± SEM) on A. Acrophase time and B. Acrophase time change 
relative to baseline week 1 is represented as dec.h. There was a trend towards a significant effect o f 
time for acrophase time (P  < 0.1).
5.5.5.5. Summary o f cosinor variables
A summary o f  the direction o f  the statistically significant effect o f  duration o f 
antidepressants on cosinor variables for the full study for weeks 0 to 14, the treatment phase 
for weeks 1 to 12 and for the last week o f  treatment week 12 compared with the 
discontinuation withdrawal week 13, is presented in Table 5.7. The arrows show the 
direction o f change o f the variables that were statistically significant with |  = increased and 
I = decreased. The effect o f  timing on MIO and L5 onset is shown as delayed or advanced.
5.5.6. Non-param etric circadian rhythm  analysis (NPCRA)
The NPCRA mean values and significance results are summarised by week and treatment 
group, differences between weeks, on discontinuation and re-introduction o f  treatment in 
Tables 5.8 and 5.9 and Figures 5.16 to 5.20. The mean scores for each week o f  treatm ent for 
the NPCRA variables were recorded with the first values for the scores recorded during the 
first week o f treatment. The Actiwatch NPCRA analysis was conducted on the completers 
dataset n = 56, (those compliant with wearing actiwatch and completing discontinuation) 
with paroxetine, fluoxetine and sertraline n = 20, n = 18 and n = 18 respectively.
5.5.6.1. Average activity
The mean (± SEM) average activity for each treatment recorded at week 1 was 159 (± 21), 
228 (± 22) and 212 (± 22) for paroxetine, fluoxetine and sertraline, respectively (Table 5.8). 
As shown in Figure 5.12, there was a trend towards a significant effect between treatments
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overall for average activity with paroxetine activity levels lower than fluoxetine or sertraline 
(F(2, 53.2) = 3.03, P = 0.06). There was also an overall significant effect o f time (F(i3, 36.8) =
5.05, P < 0.0001) with an increase in activity over time.
Analysis showed no significant difference between the three treatment groups or effect o f 
time on NPCRA average activity from weeks 1-12. There was a significant effect o f time 
overall on average activity between week 12 and week 13 (F(],49.8) = 1.93, P < 0.01) with an 
increase in activity during the abrupt discontinuation week. There was also a significant 
effect for fluoxetine (F(i, 15.]) = 9.74, P < 0.01) with an increase in activity in week 13 
compared with week 1 2 .
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Figure 5.12: Effect o f antidepressant treatment on NPCRA average activity.
The effect o f paroxetine (■) (n = 20), fluoxetine ( • )  (n = 18) and sertraline (A) (n = 18) on NPCRA 
variables (mean ± SEM) on A. Average activity and B. Average activity change relative to baseline 
week 1. There was significant effect o f time on average activity (P < 0.0001) and a trend towards a 
significant effect o f treatment (P < 0.1).
5.5.6.2. Amplitude
The mean (± SEM) amplitude for each treatment recorded at week 1 was 273 (± 37), 383 (± 
38) and 363 (± 38) for paroxetine, fluoxetine and sertraline, respectively (Table 5.8). There 
was a trend towards a signifieant effeet between treatments (F(2, 5 3 .2 ) = 2.65, P = 0.08) with 
lower overall activity levels for paroxetine com pared with fluoxetine or sertraline (Figure 
5.13). Analysis showed no significant difference between the three treatment groups nor 
effect o f  time on NPCRA amplitude from weeks 1-12.
There was a significant effect o f time overall on amplitude between week 12 and week 13 
(F(i, 49.1) ^  4.04, P = 0.05) with an increase in overall amplitude on week 13. This was also 
seen in the fluoxetine group with a significant effect o f  time (F(i, 14.3) = 7.64, P < 0.05) with
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an increase in amplitude in week 13 in the abrupt discontinuation week com pared with 
week 1 2 .
A. B.
600
500
■o 40 0
E 300
200
100
T im e (w e e k s)
100
0)
T 3
3
CL
I
-50
-100
0 1 2  3 4  5 6 7 8 9 10 11 12 13 14
T im e (w e e k s)
Figure 5.13: Effect o f antidepressant treatment on NPCRA amplitude.
The effect o f paroxetine (■) (n = 20), fluoxetine ( • )  (n = 18) and sertraline (A) (n = 18) on NPCRA 
variables (mean ± SEM) on A. Amplitude and B. Amplitude change relative to baseline week 1. There 
was significant effect o f time on average activity (P < 0.0001) and a trend towards a significant effect 
o f treatment (P < 0.1).
5.5.6 .3. MIG onset time
The mean (± SEM) MIC onset time o f  the 10 hours o f maximum activity for each treatment 
recorded at week 1 was 8.7 (± 0.3), 8.4 (± 0.3) and 8.1 (± 0.3) (08:42, 08:24 and 08:06 
hh:mm) for paroxetine, fluoxetine and sertraline, respectively (Table 5.8). There was a trend 
towards a significant effect o f  time overall, shown in Figure 5.14, for the MIO onset time 
(F (2 , 53.2) = 2.52, P = 0.07) with a delay occurring later in the biological day relative to 
week 1 .
For the treatment phase weeks 1 to 12, there was a trend towards significance for the effect 
o f  time overall on the MIO onset time (F(n, 40.1) -  1.93, P -  0.06) with a slight delay in the 
timing, occurring later in the day. This was also seen in the sertraline group w ith a 
significant effect o f time (F(i 1^ 6,96) = 3.31, P = 0.07) for weeks 2, 5 and 10 com pared with 
week 1. Analysis showed no significant difference between the three treatm ent groups nor 
effect o f  time on MIO onset time between weeks 12 and 13.
5.5.6 .4. MIO average activity
The mean (± SEM) activity o f  the 6  m inute blocks for the 10 hours o f  maximum activity for 
each treatment recorded at week 1 was 286 (± 37), 396 (± 39) and 375 (± 39) for paroxetine, 
fluoxetine and sertraline, respectively (Table 5.8). There was a trend towards a significant
150
effect o f treatment (F(2, 53.2) = 2.52, P = 0.09) with lower activity levels for paroxetine 
compared with fluoxetine and sertraline (Figure 5.15).
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Figure 5.14: Effect o f antidepressant treatment on NPCRA MIO onset time.
The effect o f paroxetine (■) (n = 20), fluoxetine ( • )  (n = 18) and sertraline (A) (n = 18) on NPCRA 
variables (mean ± SEM) on A. MIO onset time and B. MIO onset time change relative to baseline 
week 1. There was a trend towards a significant effect o f time (P <0.1).
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Figure 5.15: Effect o f antidepressant treatment on NPCRA MIO average activity.
The effect o f paroxetine (■) (n -  20), fluoxetine ( # )  (n = 18) and sertraline (A) (n = 18) on NPCRA 
variables (mean ± SEM) on A. MIO activity and B. MIO activity change relative to baseline week 1. 
There was a trend towards a significant effect o f treatment (P < 0.1).
Analysis showed no significant difference between the tliree treatment groups nor effect o f 
time on MIO average activity between weeks 1 and 12. There was a significant effect o f  time 
overall on MIO activity between week 12 and week 13 (F(i, 49) = 4.01, P = 0.05) with an 
increase in MIO overall activity for the 10 hours o f m aximum activity in week 13 compared 
with week 12. This was also seen in the fluoxetine group (F(i, 14.2) = 7.52, P < 0.05) with an 
increase in MIO activity in week 13 discontinuation week com pared with week 12.
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5.5.6.5. L5 onset time
The mean (± SEM) onset time for the 5 hours o f  least activity for each treatment recorded at 
week 1 was 0.8 (± 0.3), 1.0 (± 0.3) and 0.6 (± 0.3), (00:48, 01:00 and 00:36 hh:mm) for 
paroxetine, fluoxetine and sertraline, respectively (Table 5.9) as shown in Figure 5.16. 
However, there was no significant effect for treatment or time for weeks 1 to 14.
Analysis showed that there was no effect o f  treatment nor time on L5 onset time overall for 
weeks 1 to 12. However, there was a significant effect o f  time for paroxetine (F (n ,8.i) = 4.92, 
P < 0.02) with a significant effect at week 7, shown as a delay in timing, L5 onset occurring 
later in the night. There was a significant effect o f time for the L5 onset overall with an 
advance in the L5 onset between week 12 and week 13 occurring earlier in the night (F(i^49.2) 
=  5.7, P < 0.05).
A. B.
■S2
lO
T im e (w e e k s)
0 1 2  3 4  5 6 7  8  9 10 11 12 13 14 
T im e (w e e k s)
Figure 5.16: Effect o f antidepressant treatment on NPCRA L5 onset time.
The effect o f paroxetine (■) (n = 20), fluoxetine ( # )  (n = 18) and sertraline (A)  (n = 18) on NPCRA 
variables (mean ± SEM) on A. L5 onset time and B. L5 onset time change relative to baseline week 1.
5.5.6 .6 . L5 Activity
The mean (± SEM) activity counts per 6  minute epoch for the 5 hours o f least activity, for 
each treatment recorded at week 1, and shown in Figure 5.17, was 13 (± 2), 13(± 2) and 12 
(± 2), for paroxetine, fluoxetine and sertraline, respectively (Table 5.9). Analysis showed 
that there was no significant effect for treatment or time for weeks 1 to 14.
There was no significant effect o f  time or treatment overall on the L5 activity for weeks 1 to 
12, however there was a significant effect o f  time with sertraline causing a reduction in L5 
activity (F(n, 7,1) = 4.08, P < 0.05). Analysis showed no significant difference between the 
three treatment groups nor effect o f  time on L5 mean activity between weeks 12 and 13.
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Figure 5.17: Effect of antidepressant treatment on NPCRA L5 activity.
The effect of paroxetine (■) (n = 20), fluoxetine ( • )  (n = 18) and sertraline (A) (n -  18) on NPCRA 
variables (mean ± SEM) on A. L5 activity and B. L5 activity change relative to baseline week 1.
5.5.6 .7. Interdaily Stability (IS)
The IS value, which is an indication o f the stability o f  the rhythm, ranges in theory between 
values o f O-I, for each treatment, with lower levels indicating less stable rhythm. The mean 
IS value (± SEM) recorded at week 1 was 0.57 (± 0.03), 0.64 (± 0.03) and 0.65 (± 0.03), for 
paroxetine, fluoxetine and sertraline, respectively (Table 5.9). There was no significant effect 
o f  treatment overall or time, during the 14 week study although there were lower values for 
paroxetine, as shown in Figure 5.18, indicating a less stable rhythm. Analysis showed no 
significant effect o f  time on IS between weeks 1 and 12 but there was a significant trend for 
a treatment effect (F(2,5i,7) = 2.72, P = 0.08).
There was a trend towards a significant effect o f  time with a decrease in IS overall between 
week 12 and week 13 with a reduction in IS between week 12 and week 13 (F(i^49.i) = 3.12, P 
= 0.08). This was also seen in the fluoxetine treatment group with a significant effect o f  time 
(F(i, 14.2) = 4.03, P = 0.06) and a reduction in IS in week 13 the abrupt discontinuation week 
compared with week 1 2 .
5.5.6 .8 . Intradaily Variability (IV)
The IV value, which is an indication o f the fragmentation o f the rhythm, ranges in theory 
with values between 0-2 w ith higher values indicates a more fragm ented rhythm. The mean 
IV value (± SEM) for each treatm ent recorded at week 1 was 0.81 (± 0.4), 0.65 (± 0.5) and 
0.70 (± 0.5), for paroxetine, fluoxetine and sertraline, respectively (Table 5.9). There was a 
trend towards a significant difference between treatments (F(2, 52.9) = 2.94, P = 0.06), overall
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there were higher values for paroxetine indieating a more disrupted rhythm  as shown in 
Figure 5.19.
Analysis showed no significant difference between the three treatment groups nor effect o f 
time on IV between weeks 1 to 12. Analysis showed no significant difference between the 
three treatment groups nor effect o f time on IV between weeks 12 to 13.
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Figure 5.18: Effect o f antidepressant treatment on NPCRA IS activity.
The effect o f paroxetine (■) (n = 20), fluoxetine ( • )  (n = 18) and sertraline (A) (n = 18) on NPCRA 
variables (mean ± SEM) on A. IS and B. IS change relative to baseline week 1.
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Figure 5.19: Effect o f anti depressant treatment on NPCRA IV activity.
The effect o f paroxetine (■) (n = 20), fluoxetine ( # )  (n = 18) and sertraline (A) (n = 18) on NPCRA 
variables (mean ± SEM) on A. IV and B. IV change relative to baseline week 1. There was a trend 
towards a significant effect o f treatment (P < 0.1).
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5.5.6 .9. Relative Amplitude (RA)
The RA value, ranges in theory with values between 0-1 with higher values indicating a 
rhythm o f higher amplitude. The mean RA value (± SEM) for each treatm ent recorded at 
baseline week 1 was 0.90 (± 0.1), 0.94 (± 0.1) and 0.93 (± 0.1), for paroxetine, fluoxetine 
and sertraline, respectively (Table 5.9). There was a significant effect, as shown in Figure 
5.20, between treatments (F(2, 53.2) = 3.68, P < 0.05) with lower values for paroxetine overall 
indicating a rhythm with less amplitude.
Analysis showed no significant difference between the three treatm ent groups nor effect o f 
time on RA between weeks 1 to 12. Analysis also showed no significant difference between 
the three treatment groups nor effect o f  time on RA between weeks 12 to 13.
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Figure 5.20: Effect of antidepressant treatment on NPCRA RA.
The effect of paroxetine (■) (n = 20), fluoxetine ( • )  (n = 18) and sertraline (A) (n = 18) on NPCRA 
variables (mean ± SEM) on A. RA and B. RA change relative to baseline week 1. There was a 
significant effect of treatment (P < 0.05).
5.5.6.10. Summary o f NPCRA variables
A summary o f  the direction o f  the statistically significant effect o f duration o f 
antidepressants on NPCRA variables for the full study for weeks 0 to 14, the treatment phase 
for weeks 1 to 12 and for the last week o f treatment week 12 compared with the 
discontinuation withdrawal week 13, is presented in Table 5.10. The arrows show the 
direction o f change o f the variables that were statistically significant with |  = increased and 
I = decreased. The effect o f  timing on MIO and L5 onset is shown as delayed overall for 
weeks 0 - 1 4  and 1 - 1 2 ,  occurring later in the biological day. W hereas the effect o f  tim ing on 
L5 onset time overall was advanced during the abrupt discontinuation between weeks 12 and 
13.
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5.5.7. Cognitive and psychom otor function
The overall mean values and statistical results for the psychometric tests are sum m arised by 
week and treatm ent group, in Tables 5.11 and 5.12 with the mean change from baseline 
shown in Figures 5.21 and 5.22. The mean baseline scores for each treatment and test 
variables were recorded at the first visit and are valid baselines as these results were obtained 
prior to antidepressant dosing. There was no significant effect between treatments, or 
treatment by time interaction for any o f  the test variables for the 14 week period.
5.5.7.1. Choice Reaction Time (CRT)
The CRT results are summarised by visit and treatment group in Table 5.11 for the 
individual components Recognition Reaction Time (RRT); M otor Reaction Time (M RT) and 
Total Reaction Time (TRT) (ms).
At baseline, Visit 1 week 0 the mean RRT (± SEM) was 457 (± 24), 534 (± 25) and 447 (± 
25) ms for paroxetine, fluoxetine and sertraline respectively (Table 5.11). There was a 
significant effect o f  time overall for all treatments (F(g, 45.0) = 3.6 6 , P < 0.01) with an 
improvement in reaction time across time. Analysis showed a trend towards a significant 
effect o f  time for fluoxetine (F(g, lo) = 2.62, P = 0.08) with improved performance at weeks 8  
and 11 compared with baseline Visit 1 week 0 (Figure 5.21 A). Analysis o f  RRT from V isit 1 
to Visit 12, i.e. to the end o f  twelve weeks o f  treatment, showed in general an improvement 
with reductions in reaction time across time. There was a significant effect o f  time overall 
for all treatments (F(6,48.0) = 4.79, P < 0.01) with a trend towards a significant effect o f  time 
for fluoxetine (F(6, 12) = 2.39, P = 0.09) and sertraline (F(6, 12) = 2.61, P = 0.08). Further 
analysis showed no significant difference between the three treatment groups nor effect o f  
time on RRT between weeks 12 and 13 during discontinuation o f  treatment.
At baseline. Visit 1 week 0 the mean MRT (± SEM) was 322 (± 15), 339 (± 16) and 333 (± 
16) ms for paroxetine, fluoxetine and sertraline respectively (Table 5.11). The analysis o f  the 
change in M RT from week 1 to week 14 did not reach significance between the three 
treatment groups (Figure 5 .2IB). Analysis o f  MRT from week 1 to week 12 showed no 
significant difference for time overall however there was a trend towards an overall 
significant effect o f  time for sertraline (F(6, 12) = 2.61, P = 0.08) with a reduction in reaction 
times across time. Further analysis showed no significant difference between the three 
treatment groups or effect o f  time on RRT between weeks 12 and 13.
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Figure 5.21: Effect o f antidepressant treatment on RRT and MRT on change from baseline.
The effect o f paroxetine (■) (n = 20), fluoxetine ( • )  (n = 18) and sertraline (A) (n = 18) on variables 
o f cognitive and psychomotor function (mean ± SEM) on mean change from baseline for A. RRT and 
B. MRT (ms). There was a trend towards a significant effect o f time for RRT for sertraline (P < 0.1).
At baseline the mean TRT (± SEM) was 778 (± 34), 872 (± 36) and 779 (± 36) ms for 
paroxetine, fluoxetine and sertraline, respectively (Table 5.11). There was a significant effect 
o f  time overall for all treatments (F(g^  ^ .^i) = 3.20, P < 0.01) with a reduction in reaction time 
(Figure 5.22A). There was an overall significant effect o f  time for TRT for paroxetine (F(g, 
ii.g) = 3.42, P < 0.05) with a significant reduction for weeks 1, 2, and 4 compared with 
baseline Visit 1 week 0. There were trends toward overall significance o f time for TRT for 
fluoxetine (F(g^  lo.o) = 2.61, P = 0.08) with a significant reduction for weeks 8  and 11 
compared with baseline Visit 1 week 0 and for sertraline (F(g_ lo.o) = 2.44, P = 0.09) with a 
significant reduction for week 2 com pared with baseline Visit 1 week 0. Analysis o f  the 
change in TRT from week 1 to week 12 showed that there was an overall effect o f  time (F(e, 
48.0) =  4.16, P <  0.01) and a trend towards significance for sertraline (F(6, 12) =  2.76, P =  0.06).
Analysis o f  the change in TRT from week 12 to week 13, i.e. during discontinuation o f 
treatment, did not reach statistical significance for all treatments. However, discontinuation 
from paroxetine showed a within group significant decrease with an im painuent during week 
13 com pared with week 12 with an increase in TRT (F(i, ,9) = 4.96, P < 05).
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Figure 5.22: Effect o f antidepressant treatment on TRT and CFF on change from baseline.
The effect o f paroxetine (■) (n = 20), fluoxetine ( • )  (n = 18) and sertraline (A) (n = 18) on variables 
o f cognitive and psychomotor function (mean ± SEM) on mean change from baseline for A. TRT (ms) 
and B. CFF (Hz). There was a trend towards a significant effect o f time for TRT (ms) for sertraline (P 
< 0.1) on change from baseline relative to Day 0. For CFF there was a significant effect o f time 
overall (P = 0.05) and a trend towards a significant effect o f time for fluoxetine and sertraline (P < 
0.1) on change from baseline relative to Day 0.
5.5.12. Critical Flicker Fusion (CFF)
The CFF results are summarised by visit and treatment group in Table 5.11. The mean CFF 
(± SEM) recorded at baseline, Visit 1, for the individual means were 27.8 (± 0.6), 29.3 (± 
0.7) and 27.5 (± 0.7) Hz for paroxetine, fluoxetine and sertraline, respectively. There was a 
significant effect o f  time for all treatments (F(g, 46.]) = 3.00, P < 0.01) with an overall 
improvement in integrative function as m easured by CFF as shown in Figure 5.22B. For 
paroxetine there was an overall significant effect o f time (F(g, n.6) = 6.08, P < 0.01) with a 
significant improvement for weeks 1, 2, 4, 8, 11, 12, 13 and 14 compared with baseline Visit 
1 week 0. For sertraline, there was an overall significant effect o f  time (F(g, lo.o) = 3.19, P < 
0.05), with a significant improvement for weeks 1 4, 8 and 12 com pared with baseline Visit 
1 week 0.
Analysis o f  weeks 1 to 12 showed that CFF was improved overall (F(6, 48.i) = 3.85, P < 0.01) 
for all treatments with an improvement in integrative function over time. There was a 
significant effect o f treatment for paroxetine (F(6, u) =  7.66, P = 0.01), and a trend towards a 
significant effect o f time for fluoxetine (F(6, 12) = 2.85, P = 0.07) and sertraline (F(6, 12.1) = 
2.56, P = 0.08). A higher score indicates improved functioning
Analysis o f the change in CFF from week 12 to w eek 13, i.e. during discontinuation o f 
treatment, did not reach statistical significance for all treatments. Paroxetine and sertraline
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showed a decrease in CFF from Visit 12 to Visit 13, whilst fluoxetine showed an increase 
during this period. However this reduction was only significant in CFF for sertraline (F(i, ]?) 
= 5.43, P < 0.05) at week 13 compared with week 12 showing a within group impairment in 
integrative function during treatment discontinuation.
5.5.7.3. Summary o f cognitive and psychom otor function variables
A summary o f  the direction o f  the statistically significant effect o f  duration o f  
anti depressants on cognitive variables for the full study for weeks 0 to 14, the treatment 
phase for weeks 1 to 12 and for the last week o f  treatment (week 12) compared with the 
discontinuation withdrawal week 13, is presented in Table 5.12. There was a significant 
improvement in RRT, TRT and CFF during the 12 week and 14 week study. However, there 
was a significant worsening o f  TRT following paroxetine withdrawal and CFF following 
sertraline withdrawal during the abrupt discontinuation between weeks 12 and 13.
5.5.7.4. Leeds Sleep Evaluation Questionnaire (LSEQ)
The LSEQ is divided into four sub-sections, getting to sleep (GTS), quality o f  sleep (QOS), 
awakening from sleep (AFS) and behaviour following wake (BFW) which are covered in 
detail below. At Visit 1, for the baseline night, patients were required to compare their sleep 
for ‘last night’ with ‘sleep in the past w eek’. For all further visits in weeks 1 to 14 patients 
were required to compare their sleep ‘with the medication’ to normally ‘without the 
medication’ where a score o f  50 indicates no change.
The individual mean LSEQ scores (± SEM) for GTS recorded at baseline. Visit 1 were 53.8 
(± 3.4), 51.1 (± 3 .6 )  and 49.1 (± 3.6) for paroxetine, fluoxetine and sertraline, respectively 
Table 5.13. Analysis o f  the change in GTS h"om week 0 (Visit 1) to week 14, did not reach 
statistical significance between treatments or for time Figure 5.23A. However, GTS was 
significantly improved overall (F(6, 48) = 2.24, P = 0.055) for the treatment period weeks 
1 to 12.
The individual mean LSEQ scores (± SEM) for QOS recorded at baseline, week 0 Visit 1 for 
the baseline night, when patients were required to compare their sleep for ‘last night’ with 
‘sleep in the past week’ were 63.3 (± 3.7), 51.6 (± 3.9) and 45.5 (± 3.9) for paroxetine, 
fluoxetine and sertraline respectively, where a score greater than 50 indicated poorer sleep 
Table 5.13. For the change from week 0 Visit 1 to week 14, analysis did not reach statistical 
significance between treatments Figure 5.23B. There was, however, a significant effect o f  
time overall for all treatments (F(g, 45 g) = 2.47, P < 0.05) with an improvement in quality o f
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sleep across time. For the treatment period week 1 to week 12 the QOS analysis showed a 
significant improvement across time for all treatments (P(6, 48) = 2.69, P < 0.05) with a 
significant improvement in QOS for paroxetine (F(6, m) = 2.84, P = 0.05).
Analysis did not show an effect o f  treatment for QOS for the discontinuation phase between 
weeks 12 and 13, however there was a trend towards a significant treatment by time 
interaction (F(2, 53) = 2.87, P = 0.07). QOS was significantly improved for fluoxetine (F(i, n) =
5.01, P < 0.05) and a trend was observed for sertraline (F(i, n) = 3.76, P = 0.07) with a 
reduction in QOS scores at week 13 during the discontinuation period compared with week
12 .
The mean LSEQ scores (± SEM) for AFS recorded at baseline. Visit 1, were 50.8 (± 3.9),
49.5 (± 4.1) and 42.3 (± 4.1) for paroxetine, fluoxetine and sertraline, respectively Table 
5.13. Analysis did not show any significant effects o f  treatment or time for the 14 weeks 
study Figure 5.24A, the treatment period from week 1 to week 12 or the abrupt 
discontinuation from week 1 2  to week 13.
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Figure 5.23; Effect o f antidepressant treatment on GTS and QOS on change from baseline.
The effect o f paroxetine (■) (n = 20), fluoxetine ( • )  (n = 18) and sertraline (A) (n = 18) on LSEQ 
components (mean ± SEM) on mean change from baseline for A. Getting to sleep (GTS) and B. 
Quality o f sleep (QOS). There was a significant difference of treatment for QOS (P < 0.05). The 
charts indicate a worsening of effect o f paroxetine on GTS and QOS occurring during the withdrawal 
period (week 13).
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The individual means for LSEQ scores (± SEM) for BFW  recorded at baseline, Visit 1, were 
55.9 (± 3.2), 57.0 (± 3.4) and 53.5 (± 3.4) for paroxetine, fluoxetine and sertraline, 
respectively indicating that the patients were less confused and sleepy after waking than the 
previous week since scores were on average greater than 50 Table 5.13. For the week 1 to 14 
study period, analysis showed a significant trend for improvement over time (F(g, 45 g) = 2.04, 
P = 0.06) with a reduction in scores indicating that the patients felt more refreshed on waking 
(Figure 5.24B). Analysis showed a significant trend o f improvement over time for the 12 
week study period for BFW  (F(6, 48) ^  2.81, P < 0.05) w ith a reduction in scores, and a 
significant trend for paroxetine (F(6, i4> = 2.42, P = 0.08). Analysis did not show any 
significant effect o f treatment nor time for the abrupt discontinuation from week 1 2  to 
week 13.
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Figure 5.24: Effect o f antidepressant treatment on AFS and BFW on change from baseline.
The effect o f paroxetine (■) (n = 20), fluoxetine ( • )  (n = 18) and sertraline (A) (n = 18) on LSEQ 
components (mean ± SEM) on change from baseline for A. Awakening from sleep (AFS) and B. 
Behaviour following wake (BFW).
5.5.7.5. Line Analogue Rating Scale (LARS)
The subjective evaluation o f sedation was obtained from the mean score (in millimetres) for 
the combined ratings o f “tiredness”, “drowsiness” and “alertness” from the LARS 
questionnaire. The individual mean scores (± SEM) for the three treatment groups at baseline 
Visit 1 prior to treatment were 68.1 (± 3.4), 65.7 (± 3.6) and 58.8 (± 3.6) for paroxetine, 
fluoxetine and sertraline, respectively, patients indicated that they felt more sleepy and less 
alert than the previous week (Table 5.13).
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Analysis o f  the 14 week study showed that there was a significant effect o f  time overall for 
all treatments (F(g, 45.7) = 7.10, P < 0.0001), with patients indicating an improvement and 
feeling less drowsy and tired, and more alert as shown in m ean change from baseline in 
Figure 5.25. For paroxetine there was an overall significant effect o f  time (F(g, 11.3) = 5.36, P < 
0.01), with a significant decrease in scores for weeks 1, 2, 4, 8 , 11, 12, 13 and 14 compared 
with baseline Visit 1 week 0. Similarly there was an overall significant effect o f  time (F(g_ lo.o) 
= 4.18, P < 0.05) for fluoxetine, with a significant decrease in scores for weeks 2, 4, 8 , 11, 
12, 13 and 14 compared with baseline Visit 1 week 0.
Analysis for the 12 week treatment period showed a significant effect o f  time overall for all 
treatments (F(6, 48) = 8.92, P < 0.0001), indicating an improvement and in feeling less drowsy 
and tired and more alert with significant improvements for paroxetine (F(6, m) = 6.74, P < 
0.01) and fluoxetine (F(6,12) ^  5.06, P < 0.01). There was a significant trend with an increase 
in scores with paroxetine (F(i  ^ 19) = 4.05, P = 0.06) indicating patients felt more drowsy and 
sedated during the discontinuation week 13 com pared with week 1 2 .
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Figure 5.25; Effect o f antidepressant treatment on LARS on change from baseline.
The effect o f paroxetine (■) (n = 20), fluoxetine ( • )  (n = 18) and sertraline (A) (n = 18) on LARS 
(mean ± SLM) on mean change from baseline. There were no statistically significant effects. The 
chart indicates a worsening o f effect occurring during the withdrawal period week 13 for paroxetine.
5.5.7.6 . Summary o f the sleep questionnaire variables
A summary o f the improvement o f  the statistically significant effect o f  duration o f 
antidepressants on the sleep questionnaire variables for the full study for weeks 0 to 14, the 
treatment phase for weeks 1 to 1 2  and for the last week o f  treatment (week 1 2 ) compared 
with the discontinuation withdrawal week 13, is presented in Table 5.14. There was a 
significant improvement in patient’s perception o f the quality o f their sleep according to the 
LSEQ. M oreover, they felt significantly less drowsy and more alert according to the LARS 
during the 12 week and 14 week study. However, there was a significant worsening o f LARS
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following paroxetine withdrawal during the abrupt discontinuation betw een weeks 12 and
13.
5.5.7.7. Montgomery-Asberg Depression Rating Scale (MADRS)
The overall MADRS results for the 14 week study are summarised by visit and treatment 
group, and differences between visits, on discontinuation and re-introduction o f  treatment in 
Table 5.15. The maximum achievable score for severe depression on the MADRS scale is 60
whereas the mean M ADRS score (± SEM) for each treatment recorded at baseline Visit 1 
was 27.9 (± 1.8), 24.9 (± 1.8) and 26.5 (± 1.8) for paroxetine, fluoxetine and sertraline, 
respectively corresponding to moderate to severe depression MADRS (25-30). There was no 
significant effect between treatments or for treatment by time interaction for the MADRS
score as shown in Figure 5.26. There was, however, an overall significant effect o f  time 
(F(8,45.6) = 32.87, P < 0.0001) with substantial improvements in depression rating.
All treatments showed an improvement in depression rating observed as a decrease in 
MADRS scores. For paroxetine there was a significant effect o f  time (F(g, 1, 2) = 18.9, P < 
0.0001) with a decrease in depression severity for weeks 1, 2, 4, 8 , 11, 12, 13 and 14 
compared with the baseline Visit 1. Fluoxetine showed a significant effect o f  time (F(g, lo o) = 
6.93, P < 0.01) for weeks 1, 2, 4, 8, 11, 12, 13 and 14 compared with the baseline Visit 1. 
For sertraline there was also a significant effect o f  time (F(g, lo.o) ^  31.42, P < 0.0001) with a 
decrease in depression scores for weeks 1, 2, 4, 8 , 11, 12, 13 and 14 compared with the 
baseline Visit 0. Patients improved from being moderately depressed (MADRS 25-30) to not 
being clinically depressed with scores less than 15 (mild depression MADRS 15-24), scoring
7.5 (± 2.0), 8 .8  (± 2.1) and 9.1 (± 2.1), for paroxetine, fluoxetine and sertraline, respectively 
at week 14.
Analysis o f  the 12 week treatment period from week 1 to week 12 showed MADRS 
depression scores were significantly reduced indicating an improvement in depression rating 
overall for MADRS across time (F(6, 48) = 45.34, P < 0.0001). There were significant 
improvements for each treatment with paroxetine (F(6, 14) = 24.88, P < 0.01), fluoxetine 
(F(6, i 2 )  = 9.72, P < 0.01) and sertraline ( F ( 6 j 2 )  = 44.04, P < 0.0001) with a reduction in 
depression scores. Analysis did not show any significant effect o f  treatment nor time during 
the abrupt discontinuation from week 12 to week 13.
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Figure 5.26: Effect o f antidepressant treatment on MADRS on mean change from baseline.
The effect o f paroxetine (■) (n = 20), fluoxetine ( • )  (n = 18) and sertraline (A) (n = 18) on MADRS 
score (mean ± SEM) on change from baseline. There was a significant effect o f time on MADRS 
overall (P < 0.0001), for paroxetine and fluoxetine (P < 0.01), and for sertraline (P < 0.0001). The 
chart indicates a worsening of effect during the withdrawal period week 13 for paroxetine and 
sertraline but a continued improvement for fluoxetine.
5.5.7.8. M ontgomery-Asberg Depression Rating Scale (M ADRS) sleep item
The question relating to the sleep com ponent was analysed independently as a M ADRS sleep 
subset. Results are summarised by week and treatment group, and differences between visits, 
on discontinuation and re-introduction o f  treatment as shown in Table 5.15. The maximum 
score for severe sleep im painuent is 6. The m ean M ADRS sleep component (± SEM) for 
each treatment recorded at baseline Visit 1 was 3.6 (± 0.4), 2.8 (± 0.4) and 2.9 (± 0.4) for 
paroxetine, fluoxetine and sertraline, respectively suggesting that sleep was impaired due to 
the patients’ depression. There was an overall significant effect o f time (F(8, 45.8) ^  7.17, P < 
0.0001) but no significant effect between treatments nor for treatment by time interaction on 
the MADRS sleep subset. Although scores were reduced for all treatments, as shown in 
Figure 5.27 there was only a significant effect o f  time for paroxetine, (F(8, n j)  = 6 . 3 8 , ?  
< 0.01) with significant reductions on the M ADRS sleep score for weeks 1, 2, 4, 8, 11, 12, 
13 and 14 (P < 0.0001) compared with baseline Visit 1.
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Figure 5.27: Effect o f antidepressant treatment on MADRS sleep component on change from baseline. 
The effect o f paroxetine (■) (n = 20), fluoxetine ( • )  (n = 18) and sertraline (A) (n = 18) on MADRS 
sleep component (mean ± SEM) on change from baseline. There was a significant effect o f time on 
MADRS sleep component overall and sertraline (P < 0.01), and a trend for sertraline (P < 0.1). The 
chart indicates a worsening of effect during the withdrawal period week 13 for paroxetine and 
sertraline.
Analysis o f  the 12 w eek treatment period from week 1 to week 12 showed that the MADRS 
sleep com ponent depression scores were significantly reduced indicating an im provem ent in 
the sleep aspect o f depression (F(6, 48) = 9.84, P < 0.0001). There were significant 
improvements for each treatment for M ADRS sleep for paroxetine (F(6, i4) ^  7.18, P < 0.01), 
with a trend towards significance for fluoxetine (F(6, 12) = 2.38, P = 0.09) sertraline and 
(F(6, 12) = 2.97, P = 0.05). Analysis showed a significant effect o f  time during the abrupt 
discontinuation from week 12 to week 13 with a significant increase in the M ADRS sleep 
component scores indicating a deterioration during discontinuation (F(i,53) = 4.77, P < 0.05), 
however, this was significant only for paroxetine (F ( i j9) = 3.57, P = 0.07) and sertraline 
(F(|, n) = 3.57, P = 0.08).
5.5.7.9. Hamilton Depression Rating Scale (HAM D)
The overall HAM D results are summarised by week and treatment group, and differences 
between visits, on discontinuation and re-introduction o f  treatment in Table 5.15. The mean 
HAMD score (± SEM) for each treatment recorded at baseline Visit 1 was 20.7 (± 1.2), 19.8 
(± 1.3) and 20.8 (± 1.3) for paroxetine, fluoxetine and sertraline, respectively being m ild to 
moderate depression (HAM D 18-24). There was no significant effect for treatment nor 
treatment by time for the HAM D score. There was, however, an overall significant effect o f 
time (F(8, 45,8) = 32.17, P < 0.0001). All treatments showed substantial improvements in the 
HAM D depression rating observed as a decrease in scores as shown in Figure 5.28.
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For paroxetine there was a significant effect o f  time (F(8, n.4) = 17.09, P < 0.0001) with a 
decrease in depression severity for weeks 1, 2, 4, 8, 11, 12, 13 and 14 compared with 
baseline Visit 1. Fluoxetine showed a significant effect o f  time (F(8, lo.o) = 8.02, P < 0.01) for 
weeks 1, 2, 4, 8, 11, 12, 13 and 14 com pared with baseline Visit 1. For sertraline there was 
also a significant effect o f  time (F(8, lo.o) = 13.7, P < 0.001) with a decrease in depression 
scores for weeks 1, 2, 4, 8, 11, 12, 13 and 14 compared with baseline Visit 1. Patients 
improved from being moderately depressed (18-24) to being not clinically depressed with 
scores less than 7 (mild depression 7-17), with mean scores o f  5.2 (± 1.2), 5.3 (± 1.2) and 6.6 
(± 1.2), for paroxetine, fluoxetine and sertraline, respectively at week 14.
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Figure 5.28; Effect o f antidepressant treatment on HAMD on change from baseline.
The effect o f paroxetine (■) (n = 20), fluoxetine ( • )  (n = 18) and sertraline (A) (n = 18) on HAMD 
(mean ± SEM) on change from baseline for HAMD score. There was a significant effect o f time on 
HAMD overall (P < 0.0001), and for paroxetine and sertraline (P < 0.05) with a trend for fluoxetine (P 
< 0 . 1).
Analysis o f the 12 week treatment period showed that the HAM D depression scores were 
significantly reduced indicating an im provement in depression rating overall for HAMD 
(P (6,48) -  42.39, P < 0.0001). There were significant improvements for treatments paroxetine 
(F(6, 14) = 24.61, P < 0.0001), fluoxetine (F(6, u) = 9.76, P < 0.001) and sertraline 
(P(6,12) ^  18.43, P < 0.0001). Analysis o f  the HAM D depression scores for weeks 12 to 13 
showed a trend towards a significant increase in scores for paroxetine (F(i, 19) = 3.18, P = 
0.09) from 5.7 (± 1.4) to 7.5 (± 1.4) with a rebound effect on the depression rating during the 
discontinuation period.
5.5.7.10. Hamilton Depression Rating Scale (Insomnia) sleep item
The HAM D sleep subset component for insom nia was made up o f the total score o f the 3 
components o f early, middle and late insomnia, the maximum score for severe insomnia 
being 6 . Results are summarised by week and treatment group, and differences between
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visits, on discontinuation and re-introduction o f treatment in Table 5.15. The mean HAM D 
sleep subset score (± SEM) for each treatment recorded at baseline Visit 1 was 3.7 (± 0.7), 
4.4 (± 0.7) and 3.2 (± 0.7) for paroxetine, fluoxetine and sertraline, respectively indicating 
that patients were experiencing sleep problems. There was no significant effect o f  treatment 
nor treatment by time interaction for the HAM D sleep score. There was, however, an overall 
significant effect o f  time (F(g, 45 0) = 5.32, P < 0.001) as shown in Figure 5.29. All treatments 
showed improvements in the sleep component o f  the depression rating observed as a 
decrease in scores to 1.3, 0.9 and 1.4 for paroxetine, fluoxetine and sertraline, respectively at 
week 14. However, there was only a significant effect o f time for paroxetine (F (g, 10.9) = 4.02, 
P < 0.05) with a decrease in severity on sleep for weeks 1, 2, 4, 8 , 11, 12, 13 and 14 
compared with baseline Visit 1.
0 .-2
Tim e (w eek s)
Figure 5.29: Effect o f antidepressant treatment on HAMD sleep score on change from baseline.
The effect o f paroxetine (■) (n = 20), fluoxetine ( • )  (n = 18) and sertraline (A) (n = 18) on HAMD 
sleep component (mean ± SEM) on change from baseline. There was a trend for a significant effect on 
HAMD sleep component (P < 0.1). The chart indicates a worsening o f effect during the withdrawal 
period week 13 for paroxetine and sertraline.
HAM D sleep scores for the 12 week period were significantly reduced indicating an 
improvement in the sleep component rating overall across time (F(6,48) = 7.35, P < 0.0001). 
There was a significant improvement for paroxetine (F(6, 14) = 5.77, P < 0.01). Analysis o f the 
sleep component showed no significant effect during the discontinuation weeks.
5.5.7.11. Hamilton Depression Rating Scale (Early Insomnia) sleep item
A further component o f  the HAM D was analysed for early insomnia, which is comparable 
with sleep latency, the time taken to get to sleep, the maxim um  score for severe early 
insomnia is 2. Results are summarised by week and treatment group, and differences 
between visits, on discontinuation and re-introduction o f  treatment in Table 5.15. The mean 
HAM D sleep subset score (± SEM) for early insomnia for each treatment recorded at the
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baseline Visit 1 was 1.1 (± 0.2), 0.9 (± 0.2) and 1.0 (± 0.2) for paroxetine, fluoxetine and 
sertraline, respectively indicating occasional difficulty falling asleep o f less than 30 minutes. 
There was an overall significant effect o f time (F(s, 45.4) = 4.69, P < 0.001). For fluoxetine 
there was a significant effect o f  time (F(g, jo.o) = 2.91, P = 0.06) for weeks 1, 2, 4, 8 , 11, 12, 13 
and 14 compared with baseline Visit 1 (Figure 5.30). All treatments showed improvements 
in early insomnia, the sleep latency com ponent o f  the depression rating observed as a 
decrease in scores to 0.2 (± 0.1), 0.3 (± 0.1) and 0.3 (±0.1)  for paroxetine, fluoxetine and 
sertraline, respectively at week 14 indicating little difficulty falling asleep.
-0 .5
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Figure 5.30: Effect o f antidepressant treatment on HAMD early insomnia on change from baseline. 
The effect o f paroxetine (■) (n = 20), fluoxetine ( • )  (n = 18) and sertraline (A) (n = 18) on HAMD 
early insomnia components (mean ± SEM) on change from baseline. The chart indicates a worsening 
of effect during the withdrawal period week 13 for paroxetine and sertraline.
Analysis o f the 12 week period showed that the HAM D scores for the early insomnia aspect 
were significantly reduced (F(6,4g) = 5.93, P < 0.001), indicating an overall improvement with 
a significant improvement for paroxetine (F(6, u) = 4.14, P < 0.05). Analysis o f  the 
discontinuation weeks for early insomnia showed no significant effect, however, there was a 
trend towards a worsening o f  the early insom nia score for sertraline (F(i  ^]?) = 3.4, P = 0.08) 
with an increase in scores between weeks 1 2  and 13 indicating that patients took longer to 
get to sleep during the discontinuation week.
5.5.7.12. ZUNG Depression Inventory
The overall ZUNG results are summarised by week and treatm ent group, and differences 
between visits, on discontinuation and re-introduction o f  treatment in Table 5.16. The 
maximum self-com pleted score for the severest depression is 80. The mean ZUNG score (± 
SEM) for each treatment recorded at baseline Visit 1 was 56.5 (± 1.7), 54.4 (± 1.8) and 53.7 
(± 1 .8 ) for paroxetine, fluoxetine and sertraline, respectively being mild to moderate 
depression (50-59). There was no significant effect between treatments nor treatment by time
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interaction for the ZUNG score; however, there was significant effect o f  time overall (F(8,4s.5) 
= 14.94, P < 0.0001) Figure 5.31. All treatments showed improvements in the depression 
rating observed as a decrease in scores. For paroxetine there was a significant effect o f  time 
(F(8, 11.2) = 5.25, P < 0.01) with a decrease in depression severity at weeks 1 ,2 ,  4, 8, 11, 12, 
13 and 14 compared with the baseline Visit 1. Fluoxetine showed a significant effect o f time 
(F(8, 10.0) = 9.78, P < 0.01) for weeks 1, 2, 4, 8, 11, 12, 13 and 14 compared with baseline 
Visit 1. For sertraline there was also a significant effect o f  time (F(g, lo.o) = 9.91, P < 0.01) 
with a decrease in depression scores for weeks 1, 2, 4, 8, 11, 12, 13 and 14 compared with 
baseline Visit 1. All treatments showed improvements in the depression rating observed as a 
decrease in scores to 35.9 (± 2.4), 36.7 (± 2.5) and 37.5 (± 2.5) for paroxetine, fluoxetine and 
sertraline, respectively at week 14 which is in the normal ZUNG score range o f  20-49.
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Figure 5.31 : Effect o f antidepressant treatment on ZUNG on change from baseline.
The effect o f paroxetine (■) (n = 20), fluoxetine ( • )  (n = 18) and sertraline (A) (n = 18) on ZUNG 
(mean ± SEM) on change from baseline. There was a significant effect o f time on ZUNG score overall 
(P < 0.0001), and for sertraline (P < 0.01), and paroxetine and fluoxetine (P < 0.05).
Analysis o f the 12 week period showed that the ZUNG depression scores were significantly 
reduced indicating an im provement in self-rated depression overall (F(6, 48) = 20.72, P < 
0.0001). There were significant improvements for each treatment, for paroxetine, fluoxetine 
and sertraline (F(6, h) = 7.94, P < 0.01), (F(6, i2)=  10.26, P < 0.01) and (F(6, i2)=  15.47, P < 
0.0001) respectively. Analysis showed no significant effect during the discontinuation weeks 
for the ZUNG depression rating.
5.5.7.13. Cognitive Failures Questionnaire (CFQ)
The overall CFQ is a self-reported questionnaire on failures in perception, memory and 
motor function. The overall CFQ results are summarised by week and treatment group, and 
differences between visits, on discontinuation and re-introduction o f treatment in Table 5.16.
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The maximum score is 100. The mean CFQ score (± SEM) for each treatment recorded at 
baseline Visit 1 was 58.9 (± 3.7), 57.6 (± 3.9) and 66.4 (± 3.9) for paroxetine, fluoxetine and 
sertraline, respectively indicating a m ild level o f  impairment.
There was no significant effect o f treatment nor treatment by time interaction for the CFQ 
score. There was, however, an overall significant effect o f  time (F(g, 45.2) = 7.68, P < 0.0001) 
as shown in Figure 5.32. There was a significant effect o f  time overall for sertraline (F(s, lo) = 
3.76, P < 0.05) with an improvement in cognitive function for weeks 1, 2, 4, 8 , 11, 12, 13 
and 14 compared with baseline Visit 1. W liereas for paroxetine (F(g, n) = 2.39, P = 0.09) and 
fluoxetine (F(g, lo.o) =2.53, P = 0.09) there was a trend towards significance for time overall 
with improvements at weeks 1, 2, 4, 8 , 11, 12, 13 and 14 compared with baseline Visit 1. All 
treatments showed a reduction in perceived failures after 14 weeks, observed as a decrease in 
scores to 35.0 (± 4.5), 39.1 (± 4.8) and 41.1 (± 4.8) for paroxetine, fluoxetine and sertraline, 
respectively at W eek 14 which are within the normal range o f 40-45.
■fc -20
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Figure 5.32: Effect o f antidepressant treatment on CFQ on change from baseline.
The effect o f paroxetine (■) (n = 20), fluoxetine ( # )  (n = 18) and sertraline (A ) (n = 18) on CFQ 
score (mean ± SEM) on change from baseline Day 0. There was a significant effect o f time overall on 
CFQ score change from baseline (P  < 0.01), with a significant effect for sertraline (P  < 0.05).
Analysis o f  the 12 week period showed that CFQ scores were significantly reduced 
indicating an im provement in self-rated cognitive function overall (F(6, 48) = 10.46, P < 
0.0001). There were significant improvements for each treatment individually, for 
paroxetine, fluoxetine and sertraline (F(6, 14) = 3.64, P < 0.05), (F(6, 12) = 3.96, P < 0.05) and 
(F(6, 12) = 5.58, P < 0.01) respectively. Analysis showed no significant effect during the 
discontinuation weeks for the CFQ.
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5.5.7.14. Summary o f  the depression questionnaire variables
A summary o f  the improvement o f  the statistically significant effect o f  duration o f  antidepressants 
on the depression questionnaire variables for the full study for weeks 0 to 14, the treatment phase
for weeks 1 to 12 and for the last week o f treatment (week 12) compared with the discontinuation 
withdrawal week 13, is presented in Table 5.17. There was a significant improvement in the GP's 
and patient’s perception o f the severity o f  their depression according to the M ADRS, HAM D and 
ZUNG during the 12 week and 14 week study. Moreover, they felt significantly less clumsy 
according to the CFQ. However, there was a significant worsening o f  the MADRS sleep and 
HAM D insomnia early following paroxetine withdrawal during the abrupt discontinuation 
between weeks 12 and 13.
5.5.7.15. Overall summary o f  significant variables
For comparison a summary o f the significant variables for weeks 1 to 12 and the discontinuation 
week 12 to 13 is shown in Table 5.18.
5.6. Discussion
5.6.1. Introduction
The treatment o f  depression for the patients in the current study was with the group o f  the most
widely prescribed antidepressants known as the SSRIs, which are prescribed to treat depression 
(Taylor and Stein, 2006). This is the first study to investigate and compare the effect o f  3 SSRI 
antidepressant treatments (paroxetine, fluoxetine and sertraline) on the time course and duration 
o f  action on actigraphic sleep and wake variables, actigraphic circadian variables, subjective sleep 
quality, depression rating and psychomotor and cognitive performance in depressed patients in a 
14 week randomised, double-blind, study. For the purpose o f  comparison with other studies 
reference is made m ainly to the effects o f  the SSRIs detailed in this study on depressed patients 
and not healthy participants, since the effect o f  antidepressants and the mechanism o f  action may 
vary depending on the length o f treatment, their health status and their sleep. Depressed patients 
experience more sleep (W ichniak et a l,  2012) and circadian disruption (Germain and Kupfer, 
2008) than healthy participants, disturbed sleep being one o f  the diagnostic criteria o f  depression 
according to the Diagnostic and Statistical Manual o f  Mental Disorders (DSM-IV) criteria o f  
depression, and with sleep disturbance being reported by > 90% o f patients (W ichniak et a l, 
2012).
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Table 5.18: Summary of the statistically significant variables of antidepressant treatment overall
S le e p  V a ria b le W e e k s  1 to  12 T re a tm e n t  p h a s e W e e k s  12 a n d  13 W ith d ra w a l
Effect of time Overali Paroxetine Fluoxetine Sertraline Overall Paroxetine Ruoxetine Sertraline
T im e in b e d  (m in) 4/P <0.05
4
P <0.05
S le e p  p e r io d  tim e  (m in) 4/P <0.05
4
P <0.05
T o ta l s le e p  tim e  (m in) 4-P<0.05
4/
P <0.05
4
P <0.05
S le e p  e ff ic ien c y  (%) nLP <0.02
4-
P=0.07
4-
P = 0 .07
N u m b er o f  s le e p  b o u ts -TP<0.0001
T
P<0.0001
T
P<0.01
T
P <0.05
A v e ra g e  w a k e  m o v e m e n t TP<0.0001
-T
P<0.01
T'
P =0.05
A m p litu d e -TP <0.05
T
P =0.07
T-
P <0.05
•T
P <0.05
R hythm  % TP <0.05
T
P<0.01
A c ro p h a s e  tim e  (h) D elayedP =0.08
D elayed
P<0.01
Delayed
P <0.05
A v e ra g e  ac tiv ity TP<0.01
T
P<0.01
A m p litu d e -rP =0.05
■T
P <0.05
M10 o n s e t  tim e  (h) DelayedP =0.06
Delayed
P =0.06
M10 ac tiv ity TP=0.05
T'
P <0.05
L5 o n s e t  tim e  (h) DelayedP<0.05
Advanced
P<0.05
Advanced
P =0.08
L5 ac tiv ity 4-P <0.05
IS 4-P=0.08
4
P =0.06
MADRS 
(R an g e  0-60)
Improved
P<0.0001
Improved
P<0.0001
Improved
P<0.01
Improved
P<0.0001
MADRS S le e p  
(R ange  0-6)
Improved
P<0.0001
Improved
P<0.01
Improved
P =0.09
Improved
P <0.05
W orsened
P<0.05
W orsened
P=0.08
W orsened
P =0.08
HAMD
(R ange  0-52)
Improved
P<0.0001
Improved
P<0.0001
Improved
P<0.01
Improved
P<0.0001
W orsened
P=0.09
HAMD S le e p  
(R an g e  0-6)
ImproÆd
P<0.0001
Improved
P<0.01
HAMD In so m n ia  E arly  
(R an g e  0-2)
Improved
P<0.001
Improved
P<0.05
W orsened
P=0 .08
Zung ImprovedP<0.0001
Improved
P<0.001
Improved
P<0.001
Improved
P<0.0001
CFQ ImprovedP<0.0001
Improved
P<0.05
Improved
P <0.05
Improved
P<0.01
LSEQ
G etting  to  s le e p
Improved
P =0.055
LSEQ
Q uality  o f s le e p
Improved
P <0.05
Improved
P =0.05
Improved
P =0.07
Improved
P<0.05
Improved
P =0.07
LSEQ
B e h a v io u r  fo llo w in g  w a k e
Improved
P <0.05
Improved
P =0.08
LARS
(S e d a tio n )
Improved
P<0.0001
Improved
P<0.01
Improved
P<0.01
W orsened
P =0.06
RRT
(ms)
Improved
P<0.01
Improved
P=0.09
Improved
P =0.07
MRT
(ms)
Improved
P =0.05
TRT
(ms)
Improved
P<0.01
Improved
P =0.06
W orsened
P <0.05
OFF
(Hz)
Improved
P<0.01
Improved
P<0.01
Improved
P=0.06
Improved
P =0.07
W orsened
P <0.05
The statistically significant effect o f duration of antidepressant treatment and direction of change on 
all significant variables for the treatment phase weeks 1 to 12; and for the discontinuation withdrawal 
week 12 to 13. A trend towards statistical significance is shown by ‘= ’ if  the P-value was < 0.1. 
indicates direction o f change.
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For the purpose o f  this study patients were treated as whole groups, and not segregated into 
sub-groups, on how well they responded to treatment or whether they were depressed 
anxious and agitated, or depressed melancholic and lethargic, as has been the case in other 
reported studies (Sechter et a l, 1999). This might be an issue when comparing SSRI 
treatments as there are differing response times depending on the type o f  depression, 
according to Nutt et al. (1999) with improvement in depression with SSRI treatment being 
faster than in anxiety disorders.
The present study set out to investigate whether the use o f  actigraphs would provide an
objective measure o f the ‘in the field’ long term chronic effects o f  medication compared with 
the use o f actigraphy for short duration, well-controlled, residential, studies as detailed in 
Chapters 3 and 4, where it was used to show changes in daytime activity and differences in 
sleep variables following one night o f  medication. In order to determine whether actigraphy 
would be able to contribute to the m easurem ent o f  the long term  chronic effects o f 
m edication it was necessary to examine the outcomes o f  the other well-known established 
diagnostic assessments o f antidepressants such as depression and sleep questionnaires as 
well as cognitive and psychom otor assessments. It was im portant to assess whether the 
outcomes described above showed changes with the depression status o f  the patients, and if  
any changes correlated with the actigraphy data.
5.6.2. Effect o f  depression on sleep
As described in Section 1.6.1.1, poor sleep is a core symptom o f  depression, with recognised 
changes in sleep architecture including increased sleep latency, sleep disruption and
fragmentation and in REM distribution.
5.6.3. Effect o f  treatment on depression questionnaires
5.6.3.1. Effect o f  treatment on Montgomery-Asberg Depression Rating Scale
(MADRS) and Hamilton Depression Rating Scale (HAMD)
At baseline, patients were rated as being m oderately depressed on the MADRS questionnaire 
with a mean score o f  26.5 (18-34), which compares with the mean HAMD score at baseline 
o f  20.4 moderate (> 16) using the comparison scores by Millier er a/. (2000). In the current 
study the M ADRS scores showed that all patients responded well to treatment, and a 
significant improvement in depression scores was observed by week 2 with the ‘onset o f  
response’ o f  the antidepressant, as defined as a > 20% both MADRS and HAMD scores 
when compared with baseline scores (Wade ef a/., 2009). This is in agreement with other
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studies (Parker ef a/., 2000; Mitchell, 2006; Wade er a/., 2009; Stassen ef a/., 1997) that also 
found significant improvement at 2 weeks.
By week 8 the M ADRS scores for all treatments were significantly further improved w ith a 
‘response’ o f > 50% reduction to < 18 with scores o f  10.4, 11.9 and 8.0 for paroxetine, 
fluoxetine and sertraline, respectively which signified that patients’ depression scores had 
improved from moderately severe to mild depression (mild depression 18-34). ‘Remission o f  
depression’ with scores < 10 is considered to be the cut o ff for clinical depression severity, 
patients therefore almost reached remission at week 12, with scores o f 7.0, 10.8 and 10.1 for 
paroxetine, fluoxetine and sertraline, respectively.
The HAM D overall depression scores in the present study were similarly improved, from 
-2 0  (mild to moderate 18-24) at baseline to mild < 7 at week 14 with significant reductions 
in depression severity. The ‘onset o f  response’ as defined by Wade e/ a/. (2009) was evident 
by week 2 with a > 20% compared with 6om  baseline, for all treatments. By week 8 
depression scores had decreased by > 50% response with all patients now classified as only 
m ildly depressed M ADRS (< 15). Patients were deemed to be in remission by week 14 with 
a MADRS score < 1 0 , (complete remission MADRS < 5).
Although all three treatment groups showed a significant mean decrease in MADRS and
HAM D scores there was no significant difference between treatments for either M ADRS or 
HAMD. These results are consistent with the findings o f  similar studies by Fava er <2/. (2000; 
2002) in which a comparable three-arm treatment o f  paroxetine (20 mg/day), fluoxetine (20 
mg/day) or sertraline (20 mg/day) was adm inistered to depressed patients for between 10 to 
16 weeks (average 11 weeks). Similarly, although depression severity was significantly 
reduced no differences were found between treatments, with HAM D scores for all treatments 
approximately 25 at baseline, reducing to <10 at study endpoint (Fava er a/., 2000).
The Study reported in this thesis also supports the evidence o f De W ilde et al. (1993) who 
compared the effect o f  paroxetine and fluoxetine on HAMD on depressed patients for 6 
weeks and highlighted that patients treated with paroxetine responded faster than those with 
fluoxetine. A significant difference between the treatments at 3 weeks was reported. A  
similar effect was seen in the current study with a greater response observed on MADRS 
between the paroxetine and fluoxetine treated patients at 4 weeks, and although significantly 
different from baseline, it was not significant between the 2 treatiuents. In contrast, however.
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no difference was observed in the present study on the HAM D, both treatments being 
significantly different A"om baseline at week 4.
Van M offaert et al. (1995) conducted a similar study in patients treated w ith fluoxetine or 
sertraline with baseline MADRS scores o f  28.1 and 29.5 respectively and reported that for 
both the MADRS and HAMD there was a decrease in scores o f  43% and 45% respectively at 
8 weeks compared with baseline. The current study showed a greater response with a >50%  
reduction in scores at week 8 compared with baseline. The reasons for this could be that the 
patients were recruited from 15 psychiatric centres, were removed from psychotropic 
m edication for one week or two if  taking M AOIs, and permitted use o f  chloral hydrate or 
short acting benzodiazepines. In contrast patients in the current study were not and had never 
been prescribed any o f the study drugs and were not permitted to use any psychotropic 
m edication during the study. Therefore the use o f  other psychotropic m edication in the Van 
Moffaert e/ a/. (1995) study could have delayed response.
5.6.3.2. Effect o f  treatment discontinuation on M ADRS and HAMD
As previously discussed the symptoms experienced following abrupt discontinuation were 
defined by (Schatzberg, 1997) and are a recognised outcome o f  SSRI withdrawal. This can 
be quite serious with a rebound effect leading to resumption o f  the depression symptoms, 
and other somatic effects such as nausea, insomnia, dizziness and agitation.
In the current study even though mean M ADRS and HAM D scores increased slightly during 
the abrupt discontinuation week 13 by > 25% for paroxetine and > 5% for sertraline 
compared with week 12 (after 12 weeks o f continuous treatment), analysis did not
reveal any statistically significant effect between treatments or over time. This differs to the 
finding by Rosenbaum er a/. (1998), whereby in a study o f  242 depressed patients on 
continuous antidepressant treatment for > 4 but < 24 months, both the mean M ADRS and 
HAMD scores o f  patients treated with paroxetine or sertraline, after one week treatment 
disruption, were significantly higher compared with fluoxetine. However, as in the present 
study, patients responded to re-introduction as shown by the reduction in M ADRS and 
HAM D scores
A further difference in outcomes was reported by Hindmarch et al. (2000a) with a significant 
effect o f  a 5 day abrupt discontinuation following withdrawal from paroxetine treatment 
whereby scores were at the upper limit o f  the mild depression range with a mean o f  16.5
compared with the current study where the mean was 8.8, pre-discontinuation treatment
186
means for both studies were sim ilar with 6.9 and 7.0 for H indmarch and current studies, 
respectively. The mean scores o f  patients treated with sertraline in both studies was 11.6
after disruption, with 8.7 and 10.1 for H indmarch and the current study, respectively, prior to 
disruption. Interestingly, in the current study, MADRS scores during discontinuation for 
patients treated with fluoxetine continued to improve with a further reduction in scores 
whereas mean scores increased both the other studies (Rosenbaum et a l, 1998; Hindmarch et 
a l, 2000a).
In the current study patients did not show any ‘regression’ as defined by W ade et a l (2009) 
in their M ADRS depression symptoms during discontinuation as the mean scores were still < 
12 and within the low m ild depression cut o ff point o f  scores below 9-17. These scores 
clearly showed that patients were perhaps in remission before discontinuation. Moreover, 
apart fiom the M ADRS score for paroxetine, the mean scores from the present study 
following réintroduction were even lower than those at week 12 and in agreem ent with 
Rosenbaum er a/. (1998) who commented on the q/ier archive
q / ' r r e o r r r n g M r  ' and worthy o f  
further investigation. It has been reported that prompt resumption o f treatment reverses the 
emergence o f  discontinuation symptoms (Haddad and Anderson, 2007).
As seen in M ADRS, post-hoc analysis o f  HAM D revealed that there was a slight increase in 
depression scores during the discontinuation week 13 compared with week 12 for both 
paroxetine and sertraline. Contrary to other findings (Rosenbaum gr a/., 1998), these changes 
were not regarded as clinical deteriorations as depression scores remained within the mild 
depression range (7-17). The current study reported here indicates that there was a rebound 
worsening and increase in HAM D scores during discontinuation following paroxetine and 
sertraline withdrawal. This was, however, not statistically significant, although there was a 
trend towards significance for paroxetine (P = 0.09). In a sim ilar discontinuation study, 
however, it was reported that there was a statistically significant worsening o f  HAM D 
symptoms which occurred after the 2nd day o f  replacement with placebo following 
paroxetine withdrawal compared with that o f  sertraline and fluoxetine (Michelson er a/., 
2000). A study comparing the antidepressant agomelatine with paroxetine (Montgomery er 
(z/., 2004) also reported a significant rise in symptoms o f  depression occurring in the first 
week o f  discontinuation o f  treatment with paroxetine. The reason why there were no 
statistically significant findings in the current study compared with the literature is unclear 
but might be because the other studies referred to were conducted with previously depressed 
patients on long term stable treatment, for at least 4 months when recruited, whereas the
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current study was conducted with recently diagnosed treatment naïve patients. Moreover the 
effect o f  discontinuation was recorded after 7 days which was longer than any o f  the other 
studies reported and it is likely that the effect o f  discontinuation was reducing.
The findings in the current study are also in agreement with the discontinuation study 
reported by Judge er a/. (2002) which also showed that the MADRS revealed a significant 
increase in scores following paroxetine withdrawal compared with fluoxetine. Depressed 
patients (n = 141 completed) who had been on open-label chronic treatment > 4 but < 24 
months were given placebo substitution for 3-5 days. It was suggested that the deterioration 
during the discontinuation may be related to the short half-life o f  paroxetine (t./^  21 h) as the 
period o f discontinuation was 3-5 days compared with 7 days in the current study. Judge g/ 
a/. (2002) also reported on the significant effect o f  paroxetine withdrawal compared with 
fluoxetine on the Discontinuation-Emergent Signs and Symptoms (DESS) questionnaire with 
patients experiencing more discontinuation em ergent symptoms. M oreover, although not 
strictly a sleep questionnaire, Rosenbaum gr a/. (1998) also employed the DESS to record 
symptoms experienced following treatment discontinuation and recorded significantly higher 
numbers o f  patients reporting ‘trouble sleeping’ after 5-8 days o f  paroxetine withdrawal 
compared with fluoxetine or sertraline. In the same study sertraline treated patients reported 
more symptoms than fluoxetine treated patients.
5.Ô.3.3. Effect o f treatment on MADRS and HAMD sleep items
The MADRS has a sleep item  component sim ilar to HAM D but it is not divided into 
different aspects o f  sleep problems, it is merely summarised as ‘reduced sleep’ (Lader gr a/., 
2005). ‘Reduced sleep’ is a reduction in depth and/or duration o f  sleep time com pared with 
the normal time when patients are well. With respect to MADRS sleep in the present study, 
patients’ sleep duration or depth o f  sleep was significantly improved by over 50% by week 8 
and continued to improve significantly for all treatments by week 12. This improvement was 
also significant for paroxetine indicating that patients felt that their sleep duration had 
improved more than the other treatments.
The HAMD sleep item results in the current study indicated that, for the 12 weeks o f  
treatment, although all patients felt that their sleep overall was improved in terms o f  getting 
more sleep and overall sleep duration, this was statistically significant only for paroxetine. A  
sim ilar significant im provem ent in the sleep com ponent o f HAM D in ‘early insom nia’ 
associated with SOL or difficulty falling asleep was seen in the current study for all 
treatments overall, f  o.yr-/?og analysis revealed that this effect was significant for paroxetine.
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The mean HAMD baseline scores o f  > 3 for the 3 combined sleep components were 
significantly reduced overall for all treatments with a > 50% response reduction to a mean o f  
1.5 for the overall sleep component by week 8. The early insomnia component was similarly 
improved with a reduction in scores fiom the mean baseline > 0.9 to > 50% to < 0.4 by week
8. Furthermore, results showed that for fluoxetine there was a significant im provem ent in 
‘early insomnia’ over the full 14 weeks with patients experiencing less difficulty and taking 
a shorter time getting to sleep even during discontinuation o f treatment.
As previously discussed Section 1.6.2 the SSRIs are not prescribed for aiding sleep, but by 
improving depression, as a consequence perception o f  sleep may improve. It is therefore
perhaps not surprising that patients reported improvements in the sleep components o f the 
depression scales. According to the physician rated scales patients in the current study 
reported overall significant improvements in M ADRS and M ADRS ‘sleep’, and HAM D, 
HAMD sleep and HAM D early insomnia. Significant improvements were also reported for 
the individual treatments for the patients treated with paroxetine or sertraline in M ADRS 
‘sleep’; with paroxetine in HAMD ‘sleep’ whilst patients treated with paroxetine also 
reported a significant im provem ent in HAM D early insomnia for the 12 weeks o f treatment. 
These results indicate that patients took less time to get to sleep, and had better quality o f  
sleep if  they were in the paroxetine treated group.
All patients in the present study were included in the current analysis and not differentiated 
into subgroups between high and low insom nia scores, which contrasted with the Fava et a l 
(2002) study whereby patients were divided into subgroups between patients having high or 
low insomnia at baseline. The HAMD was recorded to assess whether there was any 
difference in the sleep items o f  the 284 depressed patients treated with the SSRIs for between 
10 and 16 weeks (Fava gr a/., 2002). The findings in the current study substantiate the 
improvements reported in the Fava gr a/. (2002) study into the effects o f  treatment with 
paroxetine 37 mg/day, fluoxetine 42 mg/day or sertraline 108 mg/day. There was a 
significant im provem ent in sleep items for early, m iddle or late insomnia from baseline to 
endpoint, although there was no difference between treatments or between subgroups within 
treatment. The doses quoted differ to the current study for the patient mean dose being 
higher and almost double those o f  the current study, and were further increased i f  patients 
required up-titration.
Other studies have also reported on the use o f  the HAMD to show improvements in sleep 
following antidepressant treatment. Patients reported significant improvement in the
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physician rated HAMD sleep component score with reduced sleep disturbance, o f  early, 
middle and late insomnia following 8 weeks o f  treatment with fluoxetine compared with 
baseline (Gillin et a l, 1997). This significant improvement in HAM D sleep disturbance was 
also reported at endpoint week 8 by Armitage et al. (1997b). Similar significant 
improvements in the sleep items for ILAMD on patients treated with fluoxetine or sertraline 
were found after 56 days compared with baseline (Aguglia gr a/., 1993).
5.6.3.4. Effect o f  treatment discontinuation on MADRS and HAMD sleep items
During the abrupt discontinuation week 13 compared with week 12, as previously discussed 
in the overall depression ratings (Section 5.6.3.2), scores were significantly increased for the 
MADRS sleep component for paroxetine and sertraline showing a worsening o f  symptoms
with patients feeling that their sleep duration or depth was reduced.
A sim ilar pattern was seen in the raw data for the HAM D perception o f  overall sleep and 
early insomnia components for both paroxetine and sertraline during the discontinuation 
week, with a rebound effect and an increase in scores, indicating that symptoms worsened. 
This did not reach statistical significance, however. Conversely the scores for fluoxetine for 
MADRS sleep and HAMD sleep and early insomnia continued to decline showing that even 
during discontinuation sleep continued to improve and had no adverse impact on the sleep 
components. This direction is sim ilar to the overall MADRS and HAM D and likely to be due 
to the longer half-life o f  fluoxetine o f up to 4 days.
5.6.3.5. Treatment and ZUNG questionnaire
In the current study patients were required to rate their own depression severity compared 
with that o f  the physician using the ZUNG questionnaire. Patient-reported depression gave 
similar reductions in scores to HAMD and MADRS, although not as dramatic, with a 
significant subjective im provem ent in depression symptoms com pared with baseline scores. 
The ZUNG improvement was therefore similar to MADRS and HAM D and showed a 
sim ilar >20% reduction by week 2, from m ild depression >50 (50-59 m ild depression) to 
<50 (normal), and with further reductions at weeks 8 and 12 >35%. There was no significant 
difference between treatments on the ZUNG and all 3 treatments appeared to be efficacious. 
These data show that the physician rated scales o f HAMD and MADRS were corroborated 
by the patient’s own rating and patients did not feel depressed at week 12. A study that used 
both the ZUNG and MADRS to compare the effect o f  the SSRI antidepressants fluoxetine 
and sertraline, reported similar improvements when comparing their outcomes so this self­
com pletion ZUNG questionnaire is comparable to MADRS (Aguglia et a l, 1993).
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5.6.3.6. Effect o f treatment discontinuation on ZUNG
Although not statistically significant there appeared to be a worsening o f depression with an 
increase in the level o f  depression at week 13 following abrupt discontinuation o f paroxetine. 
This confirmed what was seen with the physician rating scales o f M ADRS although in 
HAM D sertraline also showed a slight worsening o f scores. This worsening o f self-rated 
depression following paroxetine withdrawal confirms the results obtained by Hindmarch et 
al. (2000a) whereby a significant discontinuation effect was observed. However, the scores 
for the treatments in the current study at week 13 were m arginally lower than the Visit 3 
post-discontinuation in the Hindmarch et al. (2000a) study and there was also a marked 
increase in the level o f  depression from paroxetine withdrawal. The scores for paroxetine, 
fluoxetine and sertraline before discontinuation were 37.2, 39.1 and 40.6, and after 1 week 
discontinuation in the study reported here were 38.7, 38.6 and 39.4 respectively. In 
comparison the scores reported in the Hindmarch et al. (2000a) study were similar at 38.3, 
40.9 and 38.3 before discontinuation but 48.6, 42.8 and 40.6 after 5-7 days o f 
discontinuation for paroxetine, fluoxetine and sertraline, respectively, showing that 
paroxetine had caused a significant effect (Figure 5.33) although not clinically significant.
Figure 3 Mean change in Zung Depression Rating Scale 
sco res following treatmefit discontinuation. Vertical bars 
re p re se n t!  1 SEM. * P <  0.05 paroxetine versus fluoxe­
tine. sertraline and citalopram.
Figure 5.33: Effect o f treatment discontinuation on ZUNG questionnaire (Hindmarch et al ,  2000a)
5.6.4. Subjective sleep and Leeds Sleep Evaluation Questionnaire (LSEQ)
Using the validated sleep visual analogue scale LSEQ in the current study it was possible to 
obtain a more refined overview o f subjective change in sleep behaviour with antidepressant 
treatm ent compared with the crude items in MADRS and HAMD. The LSEQ was utilised in 
order to capture and quantify subjective ratings data on the actual quality o f  sleep and the
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various aspects o f  ‘getting to sleep’ GTS, ‘quality o f  sleep’ QOS, ‘awakening ftom sleep’ 
AFS and ‘behaviour following wakening’ BFW were determined.
5.6.4.1. Effect o f  treatment on LSEQ
In the present study analysis for the 12 weeks o f treatment showed that GTS
‘getting to sleep’ was significantly improved overall, however, there was no difference 
between treatments, which suggested that patients all felt that the time taken to fall asleep 
was reduced as shown in Figure 5.23. The reduction in scores following sertraline treatment
was not as prom inent as paroxetine or fluoxetine where scores dropped by week 2 and then 
appeared to plateau. The delay in the improvement with sertraline in GTS was also observed 
by Kasper gr a/. (2010) and it was found that patients did not find it as easy to get to sleep 
when treated with sertraline compared with agomelatine. The improvement in GTS during 
the first weeks o f  treatment with fluoxetine also confirms the data by Stephenson et al. 
(2000) whereby patients felt that it was easier to get to sleep by week 4; therefore verifying 
that fluoxetine did not im pair patients’ sleep but instead improved efforts to get to sleep. 
Paroxetine also showed a greater trend to improve GTS at weeks 1 and 2; this effect was also 
reported by Alexander g/ a/. (1997). In contrast according to Bennie gr a/, (1995) patients 
treated with sertraline tended to have less trouble getting to sleep than those treated with 
fluoxetine. However this was not the case in the current study. Moreover none o f  the 
treatments impaired or adversely affected the patients’ ability to get to sleep and 
improvements were consistent with the depression scale evidence o f M ADRS and HAMD 
that symptoms o f  depression were alleviated.
For ‘quality o f  sleep’ QOS scores were significantly improved overall in the present study 
for the 12 week data, with a significant improvement and reduction o f  scores for paroxetine 
for the 12 week data set. This result indicates that patients treated with paroxetine felt that 
their sleep quality during the night had improved more than the other treatments, although in 
general all treatments improved subjective sleep quality. In fact by week 1 scores had 
dropped dramatically ftom baseline for paroxetine so that the effect on QOS was almost 
immediate. Most o f  the other studies reported compare the SSRIs with sedating 
antidepressants so it is difficult to draw distinct conclusions with regards to differences 
between the treatments. Improvements in QOS, however, were shown in the study from 
Stephenson gr a/. (2000) whereby QOS was improved with fluoxetine for the 6 weeks o f  
treatment.
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According to Bennie a/. (1995) patients treated with fluoxetine or sertraline showed 
similar significant improvement in QOS over the 6 week study. Fairweather g/ a/. (1993) 
also showed that depressed elderly patients also reported improvements in QOS over the 6 
weeks o f  the study in those patients on fluoxetine treatment. Kerr gr a/. (1997) reported that 
over six weeks o f  treatment the ‘quality o f  sleep’ o f  depressed patients improved in the 
paroxetine treated group, in comparison to dothiepin, with a similar marked improvement to 
the current study at week 2. The current study in which patients treated with paroxetine 
showed a significant improvement in QOS was also consistent with the study by Alexander 
et a l (1997). A lthough statistical analysis o f  the current study shows that there was a limited 
difference between treatments, from the charts o f the raw data there were different effects. 
A lthough there was a difference in the time profile o f the treatments, as with GTS, no 
treatm ent adversely affected patients’ improvement in QOS.
There was no effect o f  treatment or between treatments for ‘awakening from sleep’ AFS, on
the current study. None o f the treatments affected the patients’ ability to wake up during the 
12 week treatment although there was a trend for improvement following paroxetine 
treatment. The studies by A lexander et a l (1997) and Kerr et a l (1997) showed that AFS 
was improved w ith depressed patients following paroxetine treatment, whereas other studies 
(Fairweather g/ a/., 1993; Aguglia gr a/., 1993 and Kasper gr a/., 2010) have shown similar, 
even though not significant, improvements in depressed patients treated with fluoxetine or 
sertraline.
There was a significant reduction in scores for ‘behaviour following wakening’ BFW for all 
patients overall, w ith a trend for those patients treated with paroxetine. Patients on 
paroxetine felt more alert and less clumsy, by the end o f  the 12-week treatment. In addition, 
Alexander g^  a/. (1997) and Kerr gr a/. (1997) both reported that paroxetine had no 
‘/züfMgovgr’ effect the following day compared with dothiepin. A  ‘/Margma/ Mor 
difference was recorded in fluoxetine treated-patients compared with patients 
treated with dothiepin in ‘Aawgovgr' effects, which are related to BFW. Stephenson g/ a/. 
(2000) and Aguglia gr a/. (1993) reported improvement in BFW following both sertraline 
and fluoxetine treatment. In the current study, however, although scores improved from 
baseline the change was not significant.
In general all baseline LSEQ scores were higher for the paroxetine treated patients compared 
with either fluoxetine or sertraline. As sleep appeared worse in the paroxetine group as 
opposed to patients in the fluoxetine and sertraline groups at the start o f  treatment this
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difference could account for the significant effects seen in those patients even though the 
trend for all treatments was improving. M oreover this was the case in the Alexander et al, 
(1997) study where patients assigned to paroxetine had significantly more sleep problems 
than the participants assigned to dothiepin. General improvements for all treatments seen in 
all aspects o f sleep from the LSEQ, however, could be the effect o f  the respective drugs or 
signs o f  their anti depressant action. If, in the current study, depression was relieved as was 
shown in the M ADRS, HAMD and ZUNG this might have led to better general well-being 
and mood which in turn encouraged a positive attitude and increased activity leading to 
prom oting better sleep.
The LSEQ data in the current study were calculated only from  those patients that wore the 
Actiwatch as the purpose o f the study was to review the subjective and objective data. This is 
in contrast to the Kasper et al. (2010) study in which data for all patients including those not 
wearing the Actiwatch were analysed for the LSEQ as shown in Figure 5.34. Nevertheless 
both studies indicated improvements in the LSEQ subjective ratings for sleep following 
sertraline treatment.
A. Getting to  sleep 
75-,
B. Quality o f sleep 
75 -,♦  A gom elatine 
□  Sertraline
70 - 7 0 -
6 5 - 6 5 -
6 0 - 6 0 -
5 5 - 5 5 -
5 0 -
5 0 -
6
Week
Figure 5.34; LSEQ variables GTS and QOS (Kasper et al, 2010)
5.6.4.2. Effect o f treatment discontinuation on LSEQ
As previously discussed in Section 1.6.10 discontinuation symptoms are troublesome and 
can lead to a recurrence or increase in depression symptoms, therefore it might be expected 
that discontinuation would also affect subjective sleep.
The results o f the current study show that although there was no significant difference in 
GTS between the treatments, scores for paroxetine increased which indicated that it was 
more difficult to get to sleep following paroxetine withdrawal. In contrast the scores from 
patients discontinued from fluoxetine or sertraline treatment continued to decrease indicating
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that discontinuation did not affect them getting to sleep. Only one other study by Hindmarch 
er a/. (2000a) has reported on the effect on LSEQ items following withdrawal o f treatment. 
The direction o f  impairment following paroxetine withdrawal in the Hindmarch a/. 
(2000a) study was also seen in the current study, with an increase, although not significant, 
in scores. Interestingly in contrast to the current study this impairment was also seen 
following fluoxetine and sertraline withdrawal in the Hindmarch 6/ a/. (2000a) study.
The direction o f change in QOS was similar to GTS in the current study following 
withdrawal. Paroxetine scores increased showing a worsening o f  effect, whereas fluoxetine 
and sertraline scores significantly decreased indicating that patients felt that their QOS was
improved. These findings contrasted with the Hindmarch et al. (2000a) study following 
discontinuation. The direction o f  change agreed with scores for paroxetine significantly 
increasing with worsening QOS and with sertraline scores reducing and improving in QOS. 
In contrast, however, the QOS was adversely affected by fluoxetine withdrawal as scores 
increased in the study by Hindmarch er a/. (2000a). This could be due to the end o f  the half- 
life o f  fluoxetine (up to 4 days) in the Hindmarch a/. (2000a) study as treatment was 
disrupted for 4-7 days com pared to 7 days in the current study therefore allowing the active 
metabolite (7-15 days) to continue to have an improving effect.
Discontinuation fi"om treatment on AFS variables was not statistically significant. The
direction o f the scores, however, showed that in the current study paroxetine withdrawal led 
to an increase in scores for AFS with a worsening o f effect leaving patients feeling less 
refi-eshed. Scores following both fluoxetine and sertraline withdrawal reduced, indicating 
that there was little effect on AFS. This direction o f effect was different to the Hindmarch e/ 
a/. (2000a) study in which both paroxetine and sertraline scores increased and worsened, 
whereas fluoxetine scores similarly decreased. As with QOS this effect could be due to the 
half-lives o f the antidepressants.
The effect o f discontinuation on BFW  in the current study only showed an improvement, but 
not significant, with sertraline treatment. Scores for both paroxetine and fluoxetine showed 
an increase in scores indicating that patients felt worse upon awakening and that their 
behaviour and functioning was impaired. Similarly, in the Hindmarch gr a/. (2000a) study, 
there was also an increase in paroxetine and fluoxetine scores but discontinuation from 
sertraline showed no change.
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In the current study there was no overall statistical difference between treatments during 
discontinuation. However in comparing both studies there is a suggestion from the scores 
that although not significant, withdrawal from paroxetine caused disruption in GTS, QOS, 
AFS and BFW, whereas discontinuation from fluoxetine or sertraline did not affect patients 
to the same degree. Indeed there was a significant improvement in QOS scores in the current 
study during fluoxetine or sertraline withdrawal compared with a significant impairment in 
the Hindm arch et al. (2000) following paroxetine withdrawal. Perhaps fluoxetine and 
sertraline were having some negative effects which were alleviated when medication was 
stopped or that the half-life o f  the m edication meant that both treatments continued to exert a 
therapeutic effect. It would be advisable to conduct further discontinuation studies with 
greater numbers o f  patients and maybe with a subset o f  poor sleepers to tease out the actual 
im provement or worsening o f  treatment in the subjective sleep profile. Only the Hindmarch 
er 6z/. (2000a) study showed any statistical difference between treatments after 
discontinuation in LSEQ, with the QOS component being poorer following paroxetine 
withdrawal.
5.6.5. Actigraphy
Actigraphy was used in Chapters 3 and 4 to assess short term changes and effects on activity 
and actigraphic derived sleep variables o f psychoactive compounds in highly controlled 
laboratory conditions over 1 or 2 nights. In the present study described here the objective 
was to assess whether actigraphy would provide a suitable objective tool to measure drug 
induced changes in activity and actigraphic sleep over the time course o f  long-term treatment 
'in the field, real-life' situations with antidepressants, with patients in their own home 
environments over 14 weeks which included one week o f abrupt discontinuation. Changes in 
the ‘sleep’ and activity profile and hence the time-course during treatm ent for depression 
was measured continuously with actigraphy. At the same time actigraphy provided a means 
o f  assessing the long term 24 h circadian patterns o f rest and activity and thereby any dose 
response in changes o f  behaviour patterns. As previously discussed changes in mood and 
depression rating symptoms as well as subjective ratings o f  sleep were also measured 
simultaneously.
5.6.5.1. Actigraphic sleep variables
Few long term patient studies have been conducted with the same SSRIs used to treat 
patients in the current study on sleep and PSG variables, in fact most compare the sleep 
factors from LSEQ or HAMD. PSG variables have been reported in the literature and those 
which could be correlated with actigraphy are TST, sleep latency, sleep efficiency, and
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number o f  wake/sleep bouts. It has been established that in major depressive disorder 
(MDD) paroxetine increases PSG SOL and NAW  (Hicks gr a/., 2002) reduces TST and SE 
(Staner gf üi/., 1995; Sharpley ef a/., 1996); fluoxetine increases number o f  awakenings and 
reduces sleep efficiency (Gillin et a l, 1997) and sertraline increases sleep latency, reduces 
sleep efficiency and decreases total sleep time (Jindal e/ a/., 2003). The SSRIs in the present 
study, as shown in reviews (Fava, 2004; Mendlewicz, 2009),
zzzcz"eajgz7 /z^ z'gMcy, rg /^zzce /^ ^czezzcy azzc/ zMcrea.yzMg in MDD, so
this effect might be replicated in the actigraphic sleep variables in the current study. 
Furthermore, as depression is associated with a reduction in SWS, reduced REM latency and 
increased REM, that if  sleep was abnormal to start with, with treatment this might be 
reflected in an increase in actigraphic activity levels, which could suggest that SSRIs were 
norm alising sleep architecture.
The current study was the first to report on a 14 week actigraphy study comprising 12 weeks
o f antidepressant treatment, I week o f  abrupt discontinuation followed by I week 
réintroduction (Dawson et a l,  2010). M achado-Vieira et a l  (2008) stated that standard 
antidepressants usually require approximately one month or more for antidepressant effects 
to manifest, and commonly, patients remain symptomatic and functionally impaired during 
this initial period o f treatment. So it would be interesting to see what the data showed during 
the treatment and whether actigraphy was able to track the course o f  treatment in comparison 
to the cognitive and psychom etric data. In general, in the current study, following 12 weeks 
o f treatment with SSRIs, depressed patients subjectively rated their depression significantly 
improved in MADRS, HAM D and ZUNG. In addition they rated their sleep better, 
according to improved LSEQ scores for ‘quality o f  sleep’ as well as improvements in the 
sleep components and overall depressive symptoms in line with the outcomes o f the 
MADRS, HAMD and ZUNG questionnaires. It was therefore interesting to assess whether 
these changes could be replicated in the objective actigraphic data. In contrast to the 
subjective sleep improvements reported earlier in the M ADRS, HAM D (Section 5.6.3.3 and 
5.6.4.6) and LSEQ (Section 5.6.4.1) data, actigraphy sleep variables in the current study 
worsened and indicated that objective actigraphic sleep was actually poorer. These results 
were consistent with published reports o f  other studies Eom Hicks e/ a/. (2002) and 
Argyropoulos a/. (2003) and reviewed in Wilson and Argyropoulos, (2005).
Actigraphy data were first analysed for sleep variables from Day 1 to week 14 (Day 98 
approximately) continuously. As there was no placebo run in or baseline period, 
day 1/night 1 was treated as the baseline for analysis purposes o f  the tests and
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questionnaires. However, medication commenced aAer the first visit to the GP surgery and it 
may be the case that some patients commenced on the day o f  the GP visit and therefore took 
the medication that first evening, whereas others may have started treatment the next
morning. So for actigraphy. Day 1 cannot therefore be considered as a true baseline. Day 1 
however is a true baseline o f  depression symptoms using the M ADRS and HAM D and the 
psychom etric tests which were conducted prior to treatment commencing. Patients received 
medication for 12 weeks after which there was a 1 week abrupt discontinuation followed by 
reinstatement o f treatment for 1 week. Therefore whilst an analysis o f  the 14 weeks o f  data 
were performed analysis o f  the data were also conducted from week 1 to week 12
inclusive but with removal o f  night 1 to investigate the effect o f  treatment. W eek 12 to 13 
was used to investigate the effect o f  discontinuation. This discussion, o f  the actigraphic sleep 
variables, will therefore focus on the overall 12 weeks o f  treatment. As the 14 week analysis 
also includes the discontinuation this adds no value to the interpretation o f tracking treatm ent 
progress and may impact on the significance. In addition in order to aid interpretation o f the 
results non-significant results are also discussed as they reveal trends in the direction o f  
change throughout the course o f treatment and similarities to other reported studies. The raw 
data for the actigraphic sleep variables for the full 14 weeks is presented in results.
The chart o f  the raw data for sleep latency suggests a trend that SOL increased during 
treatment with paroxetine and sertraline demonstrating that patients took longer to get to 
sleep. A lthough not significant for the 12 week study, there was a trend for an increase in 
time taken to get to sleep increasing during the first 4 weeks from 23 minutes at week 1 to 25 
min at week 12 with a peak o f  37 min for paroxetine at week 4. This compared with a 
change from 18 to 24 min for fluoxetine (week 1 to week 12) and 22 to 27 min (week 1 to 
week 12) following sertraline treatment. Furthermore this supports clinical PSG findings o f 
increased sleep latency as one o f  the effects o f  SSRIs on depressed patients as they are 
activating compounds (Abies and Baughman, 2003; Hicks ef a/., 2002; Trivedi gr a/., 1999; 
Oswald and Adam, 1986; Vasar a/., 1994; Jindal gr a/., 2003). Paradoxically, as previously 
alluded to, this was again in contradiction to the HAM D early insomnia whereby patients in 
the current study did not complain o f problems getting to sleep but instead reported that this 
was in fact improved. Additionally in accord with the HAM D and opposed to the actigraphy, 
patients felt no impact o f  medication on the ‘getting to sleep’ component o f  the LSEQ in the 
current study. It was reported that night-time dosing with paroxetine does not increase sleep 
latency as the medication is not fully absorbed (Gursky and Krahn, 2000), and since there 
was an increase in sleep latency during the first 4 weeks it could suggest that patients in the 
current study had administered in the morning.
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The current study was in agreement with Staner et al. (1995) who reported that whilst 
patients subjective rating o f quality o f  sleep was improved with a reduction in the HAM D 
sleep items, they experienced increased SOL and ‘increased awakenings’ during the sub­
chronic phase at days 34 and 35 observed &om PSG following paroxetine (30 mg/day) 
compared with baseline. This factor was also supported by the report on paroxetine, which 
showed that SOL was positively correlated with subjective SOL from the St Mary’s Hospital 
Sleep Questionnaire (SMHSQ) and objective SOL from LEG on nights 3 and 10 
(Argyropoulos a/., 2003) in a patient study.
The 12 week treatment analysis, using week 1 as the baseline and with change 6"om week 1 
over time, showed a deterioration in sleep quality in all treatments overall with significant 
reductions in sleep efficiency overall (P < 0.05) and increased number o f  sleep bouts overall 
(P < 0.0001). These effects showed significant trends following both paroxetine and 
fluoxetine treatment for sleep efficiency. There was a rapid decline in SE for patients taking 
paroxetine to the nadir at week 5 o f  77.2% which did not recover substantially over the 12 
weeks from the baseline week o f 81.9%. W hen considering that patients treated with 
paroxetine also showed a significant reduction in TST, this indicated that paroxetine in 
particular had a detrimental effect on sleep. A lthough there was also a trend towards reduced 
sleep efficiency for fluoxetine the effect was much m ore gradual w ith a higher value in the 
first week o f  83.6% reducing to 80.5%, and with only week 11 below 80%. The higher value 
for week 1 indicated that fluoxetine actually improved sleep efficiency during the first week 
compared with the first night. Sertraline did not show any overall deterioration in actigraphic 
sleep efficiency with values remaining fairly constant between 80% to 82 % in comparison 
to the Kasper gf a/. (2010) study where SE for sertraline decreased from baseline 76.5% to 
75.7% at week 6. The higher SE values in the current study compared to the Kasper e/ 
(2010) study also show that sleep was not as poor.
The number o f  sleep bouts and conversely number o f  wake bouts significantly increased 
from week 1 to week 12 for all treatments, which indicated more disrupted sleep with more 
transitions from sleep into wake. For patients treated with paroxetine the number o f sleep 
bouts increased more rapidly than patients treated with either fluoxetine or sertraline with an 
increase from 16 at week 1 to 19 at week 12 with a peak o f  21 bouts at week 5. Sleep bout 
numbers for fluoxetine treated patients rose gradually from 14 at week 1 to 18 at week 12, 
whereas although sleep bouts for sertraline treated patients at week 1 was 14 they rose more 
gradually to a peak at week 12 o f  16. This data clearly shows that paroxetine induced more
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sleep disruption during the early weeks o f  treatment than fluoxetine or sertraline and that this 
trend did not recover. It is expected that as patients develop tolerance to the effects o f
m edication their sleep profile should normalise but this was not the case for paroxetine.
Although not significant, sleep bout times, the mean length o f  the sleep bout, for paroxetine 
treated patients reduced from 35 min at week 1 to 29 min at week 12, with a nadir at weeks 5 
and 10 o f  just 24 min showing more transitions from sleep to wake. Sleep bout times for 
fluoxetine treated patients reduced &om 38 min at week 1 to 31 min at week 12, with a nadir 
at week 11 o f 29 min, similarly sleep bout times for sertraline treated patients reduced from 
41 m in at week 1 to 33 min at week 12, w ith a nadir at weeks 2 and 7 o f 32 min. The 
increase in sleep/wake bouts correlates w ith the increase in total activity counts in sleep, 
which whilst not significant, the data showed a considerable trend towards increased num ber 
o f  total activity counts in sleep for all SSRls but in particular for paroxetine.
The data suggests a trend towards an increase in number o f  sleep bouts, and an increase in 
the total activity counts in sleep demonstrating that sleep was more disrupted. Moreover 
although not significant the increase in W ASO, appears to show an effect following 
treatment with paroxetine. Although this substantiates clinical PSG findings from other 
studies o f  sleep impairment, patients in this study subjectively felt that their sleep improved 
as shown by significant improvement in LSEQ ‘quality o f  sleep’ as well as the M ADRS and 
HAMD sleep items. The reason for this discord is unclear but it may be that the impression 
that sleep was improved is likely to be due to the effect o f  the antidepressants on patients’ 
perception or the improvement in mood on patients’ perception than on actual improvement 
or that the additional m ovem ent did not actually im pair their sleep or cause them to wake, 
they just moved more. Or as suggested by Winokur g/ a/. (2001) do SSRIs have a calming 
anxiolytic effect which encourages the perception o f  improved sleep coupled w ith an 
activating effect reported by W ichniak et al. (2012). A lthough the detrimental effects o f 
actigraphic reduced sleep efficiency, increased sleep latency, increased sleep fragmentation 
are contrary to the subjective ratings o f  improved sleep they are in agreement with the 
findings o f  the (Mendlewicz, 2009; Fava, 2004) reviews on whether the sleep disturbances 
seen in depression are core symptoms o f  the underlying MDD, or a co-existing problem, or 
moreover the result o f  movement disorders, agitation or akathisia brought on by the 
antidepressant medication as suggested by Volkers et a/. (2002).
The only other reported comparable study to the present one, with continuous actigraphy,
was conducted by Kasper et al. (2010) which was a 6 week double-blind parallel design
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efficacy study o f  the effects o f agomelatine and sertraline treatment in M DD patients 
(n = 313) using actigraphy and other measures including LSEQ and HAMD. In contrast to 
the present study where there was no baseline or washout, the Kasper et a l (2010) study 
started with 2 weeks placebo washout following which patients were randomised to receive 
agomelatine (n =  154) (25-50 mg/day) or sertraline (n = 159) (50-100 mg/day). As with the 
present study actigraphy was m easured continuously with a 2 min epoch in conjunction with 
sleep diaries. The LSEQ and HAM D were completed at baseline plus weeks 2, 4 and 6 in 
contrast to the current study o f  baseline plus weeks 2, 4, 8, 10, 11, 12, 13 and 14. Patients 
were recruited with HAMD scores o f  > 22 in addition to a seore o f > 3 for items 5 and 6 
relating to insomnia. At the end o f 6 weeks the HAM D scores improved to 10.3 ± 7.0 and 
12.1 ± 8.3 for agomelatine and sertraline, respectively. In comparison the current study 
recorded the HAMD scores o f 7.8 ± 1.3 and 5.9 ± 1 . 4  (SEM ) at weeks 4 and 8, respectively. 
Subjective sleep scores for LSEQ GTS and QOS also showed a sim ilar but not significant 
trend for improvement following sertraline treatment which agreed with the Kasper et a l 
(2010) 6 weeks study.
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Figure 5.35: Actigraphy charts for SE and SOL (Kasper et al ,  2010)
W ith regards to the Kasper et a l (2010) study few variables were reported, but those that 
were showed that sertraline had a negative effect on actigraphic sleep variables. SE 
decreased from baseline 76.5% to 75.7% at week 6 in comparison to the current study with 
baseline at 81.9% and 81.3% at week 6. Sleep latency increased from ~ 24 min at baseline to 
~ 28 min at week 6, in com parison to the current study o f  17 min at baseline to 26 min at 
week 6 confinning that patients treated with sertraline took longer to get to sleep as 
treatment progressed. A factor w hich did not improve for the 12 week data. The m ean length 
o f  wake bouts increased following sertraline treatment in the Kasper et a l  (2010) study 
which compares with the current study which showed a significant increase in the num ber o f 
sleep bouts with a reduction in the sleep bout time. However these variables show similar
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traits and are indicative o f  a disrupted sleep pattern w ith more transitions from sleep and 
wake. For ease o f  reference the figures from the (Kasper <3/., 2010) study for SE and SOL 
are shown in Figure 5.35.
The average wake movement, which is the daytime activity following sleep offset to the 
following sleep onset, even with poorer sleep showed that was there an indication o f an 
increase in activity levels from week 1 for all treatments. However the values for paroxetine 
were much lower than either o f  the other treatments indicating that patients treated with 
paroxetine were less active during the day. This reduced daytime activity could be related to 
daytime tiredness due to the loss o f sleep, particularly so for the first 4 weeks o f  treatment, 
whilst patients were becoming tolerant to the medication or that paroxetine tends to be more 
sedating compared with other SSRIs (Abies and Baughman, 2003).
Interestingly, for all treatments in the current study, there was a trend towards a significant 
improvement in ‘behaviour following w ake’ from the LSEQ which indicated a correlation 
with the increase in average wake movement from the actigraphic variables. Lemke e/ a/. 
(1997), showed that paroxetine treated depressed patients (n = 16) were more active in the 
morning in an actigraphic study whereby the pooled mean o f  72 h o f  activity was measured 
with an Actometer (Zak, Germany). Data showed that depressed patients were more active in 
the morning compared with the evening which negatively correlated with subjective 
symptoms from the Multiple Affective A(^ective Checklist (MACCL) being worse in the 
morning. This might therefore signify increased daytime activity levels and improved 
daytime functioning and mood which will be discussed more fully with the circadian 
analysis data and cognitive performance. This is also in agreement with studies previously 
alluded to whereby antidepressants increased daytime activity as shown in actigraphic 
studies (Raoux er a/., 1994; Royant-Parola a/., 1986; Benoit gr a/., 1985). Even if  sleep 
variables are not improved, i f  patients actually felt that they slept better, they might be in a 
more productive mood the following day with increased activity which is shown in Figure 
5.36 from Raoux a/. (1994).
5.6.5.2. Actigraphic variables during discontinuation
Following the 12 weeks o f  stable dosing in the current study, medication was abruptly 
discontinued for a mean o f  7 ± 2 days on matching placebo. With regards to actigraphic 
sleep variables there was a statistically significant reduction in sleep timing overall for TIB, 
SPT and TST which from analysis was significant for sertraline. Caution should be
taken however with these effects o f  reduced sleep period time, as it is not necessarily
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inevitably comparable to better or worse sleep, indeed it may be that patients actually want 
or need less sleep.
Fig. 2. Hourly distribution of activity level a t DO and Dd (n  =  26)
140
DAY disehargv
^  80
12 3 4 0 8 10 12 2 4 6 8 10
HOURS
p .m .
DO =  (he 2 days preceding the InstlluBon ol anUdepressant trealment and day 1 of antidepressant treatment Dd =  the 
last 3 days before discharge pd) from noon to noon. Statistical DO/Dd comparison: area under the curve, WIicoxon lest
p  <  0.0001
Figure 5.36: Actigraphic 24h activity profile (Raoux et ai ,  1994)
Difference between 24 h profile mean of 3days before treatment compared with 3 days at discharge 
showing increased daytime activity.
Statistically, although there was no significant change for any treatment in actigraphic sleep 
latency, there was a reduction in SOL, indicating that patients took less time to get to sleep 
following withdrawal o f fluoxetine or sertraline, but there was little change in SOL after 
withdrawal o f paroxetine. W hilst this did not reach significance, it confirmed the trend 
towards an im provem ent in the perceived ease o f getting to sleep with LSEQ GTS for 
patients following discontinuation o f sertraline and fluoxetine, whereby lower scores showed 
an improvement. Conversely in the current study, the GTS for paroxetine indicated a 
worsening effect w ith patients feeling that it was harder for them to get to sleep. Furthem iore 
this is continued by the HAM D early insoiunia whereby patients reported more difficulty 
getting to sleep following withdrawal o f paroxetine treatment.
The direction o f LSEQ GTS scores for both fluoxetine and sertraline in the current study 
disagreed with the Hindmarch et al. (2000a) study which showed that scores increased 
following withdrawal from any o f the treatments in their study, indicating that it took longer 
to get to sleep. It m ust be stated that in the current study no direction o f change for SOL or 
GTS was statistically significant, and therefore no direct conclusions can be made from the 
data. These observed changes, however, are worthy o f further investigation. In both studies 
patients reported that GTS was worst following paroxetine withdrawal. Further, the HAM D
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early insomnia score in the present study was also shown to worsen following both 
paroxetine and sertraline disruption, whereas with fluoxetine there was a hint o f
improvement.
With reference to actigraphic sleep quality in the current study, sleep efficiency failed to
show any trend o f direction for any treatment, remaining fairly constant throughout the 
discontinuation week although it appeared to decline following réintroduction o f paroxetine 
treatment. The number o f  sleep bouts remained fairly stable throughout discontinuation for 
all SSRIs, although the num ber increased for paroxetine following réintroduction. The sleep 
bout time was reduced in both paroxetine and sertraline during discontinuation and further 
reduced during réintroduction. Interestingly WASO appeared to decrease for paroxetine 
during discontinuation as did the total activity counts in sleep indicating that sleep was less 
disturbed, but increased for fluoxetine during discontinuation.
It m ight be considered that these factors are indicative o f  poorer sleep, a pharmacological 
effect or patients normalising to their sleep pattern during discontinuation as the medication 
wears off. Paradoxically patients LSEQ QOS scores improved significantly following both 
fluoxetine and sertraline withdrawal. Whilst for paroxetine LSEQ QOS scores in the current 
study failed to show a statistically significant effect o f  withdrawal o f  treatment, the increase 
in scores would suggest a worsening o f  sleep quality. This is in agreement with the 
Hindmarch and colleagues study (Hindmarch ef a/., 2000a) which reported a significant 
im pairm ent o f QOS during the abrupt discontinuation o f  paroxetine. Additionally according 
to the MADRS sleep component patients, in the current study, felt that their sleep had 
worsened following paroxetine and sertraline withdrawal with scores increasing. This effect 
was replicated with increased early insom nia and poorer sleep on the HAMD sleep 
components following paroxetine and sertraline withdrawal. In contrast, patients treated with 
fluoxetine did not report a worsening o f  their sleep during discontinuation on the depression 
scales.
With regards to actigraphy in the current study, this pattern o f  subjective poorer sleep on 
abrupt discontinuation from the antidepressants paroxetine or sertraline was not reflected in 
the actigraphic sleep variables, nevertheless small changes were observed. Actigraphic sleep 
variables in combination indicated that discontinuation o f  treatment did not greatly affect 
actigraphic sleep variables by either improving or adversely affecting the sleep. Some trends 
however are worthy o f  further investigation as they suggest that discontinuation had a 
clinical effect. This fact may be due to the differences between the drugs whereby paroxetine
204
has a short T% and therefore likely to show a faster response following removal o f  treatment. 
For fluoxetine, with the longer T!4 this indicates that the applicable discontinuation emergent 
symptoms o f  sleep-disturbances and fatigue are less likely to occur if  patients miss a few  
doses.
Interestingly following abrupt discontinuation daytime AWM significantly increased, 
particularly in favour o f fluoxetine and sertraline, indicating that the patients were more 
active during the day. This might suggest that throughout treatment the antidepressants were 
having a calming effect by reducing daytime activity but on discontinuation patients were 
more active, or maybe removal o f  medication led to hyper-arousal and activation. In terms o f 
the LSEQ, patients did not report a worsening o f either AES or BFW  although there was a 
worsening trend towards these variables following paroxetine withdrawal in both the current 
and the Hindmarch study (Hindmarch a/., 2000a). Additionally patients discontinued from 
paroxetine treatment felt more sedated according to the LARS sedation component compared 
with fluoxetine or sertraline, in both the Hindmarch gr <3/. (2000a) and the current study, 
which might help to explain the differences in the LSEQ and actigraphic variables.
Without obvious directions in the actigraphic variables it may be that there are different 
conclusions to be drawn on what the results o f discontinuation indicate. It could be that 
patients in the current study had insufficient time on the medication to normalise their sleep 
wake pattern. O ther discontinuation studies (Hindmarch et a l,  2000a; Rosenbaum et a l, 
1998; Michelson gr a/., 2000) have been conducted on patients who were receiving 
maintenance therapy for longer than the 12 weeks in the current study. It could also be 
related to the length o f  the discontinuation with a longer period in the current study, as 
indicated by (Michelson gr a/., 2000) Section 1.6.10 whereby discontinuation symptoms 
emerged within 2 days o f  discontinuation following paroxetine withdrawal. M ore m ovement 
in sleep may indicate more disrupted sleep, less sedated sleep or even the reverse as has been 
discussed with fluoxetine which appears to have an effect o f  agitation. Alternatively the 
changes in activity could be related to changes in sleep architecture and REM in particular.
There appears to be more activity in the sleep o f  patients when fluoxetine is withdrawn and 
yet they did not report worsening. On the other hand patients whose paroxetine treatment 
was withdrawn reported worsening o f  sleep but their activity appears to fall causing less 
disruption. Perhaps fluoxetine and sertraline were having some negative effects when 
patients were on maintenance therapy which was alleviated when medication was stopped or 
that the half-life o f the medication or its active metabolite meant the therapeutic effect
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continued to have an effect. A PSG study by (Staner a/., 1995) showed that fbllowing 
withdrawal o f  paroxetine treatment there was an increase in REM showing a rebound effect 
which might have shown as a reduction in actigraphic activity, as was observed in the 
current study in the total activity counts in sleep. Paroxetine has a short half-life which could 
account for the opposite direction and rebound effect with a worsening o f  REM, SOL and 
GTS. These effects are worthy o f further investigation possibly with a subset o f  sleep 
diagnosed poor sleepers to tease out the actual improvement or worsening o f  treatment in the 
subjective sleep profile.
5.6.5.3. Circadian analysis
In order to reduce day-to-day variability approximately seven days o f  continuous activity 
data, including weekends was combined to provide the arithmetic means on a week by week
basis. The dates were adjusted to account for the allowable visit windows but were 
synchronised with the actual visit dates for the purpose o f  comparison with the other 
measures recorded at the visits. These means were then compared with subsequent weeks 
and relative changes were computed. For both cosinor analysis and NPCRA the weekly data 
were adjusted according to the visit dates in order to ensure that the means reflected the 
corresponding visit dates so that they could be compared with the other cognitive and 
psychom etric variables. The start and end o f  the discontinuation period was also aligned with 
the visit dates; to ensure that an accurate assessment during discontinuation could be 
obtained.
5.6.5.4. Cosinor (parametric) analysis and treatment
To the author’s knowledge no other study has investigated the impact o f  SSRI antidepressant 
treatment on the cosinor rhythms o f  depressed patients. Analysis o f  the current study 
revealed that there was an overall significant improvement o f  the percentage rhythm over 
time for all treatments for the 12 week data, with the percentage rhythm increasing. This
indicates that the sleep wake rhythm, which is a measure o f  the percentage o f data points that 
can be accounted for by the cosine curve, was increasing and stabilising with treatment and 
becom ing less fragmented and more organised. This m ight be beneficial for the patient, with 
their sleep wake pattern being more regulated.
Although there were increases in the mean activity for amplitude and mesor, with patients 
being more active overall, these did not reach significance for any treatment during the 12 
week analysis but the data did suggest that patients were becoming more active as treatment
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progressed. M oreover this confirms the trend in increasing data seen in the actigraphic 
variable AW M  which focuses on daytime activity and not the 24 h mean.
A trend for a delay in timing occurring in the cosinor acrophase time was observed overall 
for the 12 weeks study with the acrophase time occurring slightly later in the biological day. 
This trend appeared to occur after 4 weeks o f fluoxetine treatment but almost from the start 
o f treatment with paroxetine. After an initial delay in time as treatment progressed, the data 
suggests that this then began to advance &om week 4 onwards for paroxetine. These aspects 
are however very small in time, being less than 30 minutes, but could be an indication that as 
treatment took effect patients felt better and were more active later in the day as treatment 
initially took effect and then earlier with a phase advancement as treatm ent with paroxetine 
progressed.
To compare data fiom the current study a study in patients suffering from Seasonal Affective 
Disorder (SAD) showed a circadian misalignment to healthy controls with a phase delay and 
lower amplitude (Teicher er a/., 1997). A  further study o f  SAD patients showed that at
baseline their amplitude was reduced and phase delayed com pared to healthy controls 
(W inkler et a l,  2005). Following 4 weeks o f  Bright Light Therapy (BLT), as depression 
improved, patients’ amplitude increased and normalised to almost healthy control levels, in 
addition BLT led to a phase advance in acrophase time occurring earlier in the biological 
day. W ith regards to actigraphic variables after 4 weeks o f treatm ent AW M  and SE had 
improved to healthy control levels. In an inpatient study o f MDD patients (n = 26) 6 shifted 
their acrophase time by more than 1 h, following treatment with TCAs (Raoux et a l, 1994). 
Interestingly in that study the 2 patients who had the earliest phase delayed, and the patient 
with the latest phase advanced, the direction o f  the others was not reported.
5.6.5.5. Cosinor (parametric) analysis during discontinuation
The trait o f  the clock advancing occurring earlier in the day in the current study was reversed 
during the discontinuation week for all treatments, with an abrupt delay o f  approximately 30 
min in the acrophase time. This was statistically significant fbllowing fluoxetine withdrawal. 
In addition during this week there was also an increase in amplitude and mesor activity 
overall, which was again significant for fluoxetine. There was also a significant increase in 
percentage rhythm which was also statistically improved fbllowing fluoxetine withdrawal. 
Why this happened is unclear but worthy o f  further examination as to the true meaning o f  
fluoxetine abrupt discontinuation on cosinor variables. These effects are positive effects and
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are associated with the improvement in subjective outcomes o f  MADRS and HAMD  
depression scales as well as the direction o f  change in psychomotor function.
One theory could be that as REM sleep in depression is increased, activity would be reduced, 
then as depression improves REM sleep is reduced and activity during the other stages is 
therefore increased. This appears to be happening with all treatments during the 12 week
chronic phase in the current study with an increase in total activity counts in sleep and an 
increase in sleep bouts indicating more movement. W ith discontinuation the reverse occurs 
with possibly the recurrence o f more REM associated with less activity as seen fbllowing 
paroxetine withdrawal. This was also linked to a worsening effect with an increase in 
MADRS and MADRS sleep scores and an increase in HAMD early insomnia showing a 
possible rebound effect. However, during withdrawal fiom fluoxetine more activity is 
recorded in total activity counts in sleep and M ADRS score is improved although the L5 
(NPCRA) activity was reduced. The reason for this might indicate that the effect o f  
fluoxetine continued or that withdrawal o f  the drug was having a true effect and depression 
had been alleviated with a further reduction in REM. This theory assumes that although the 
depressed patients in the current study complained o f  sleep problems according to MADRS 
sleep what is not known is whether they actually had the altered sleep architecture associated 
with depression as they were not fbrmally diagnosed with a PSG recording.
5.6.5.6. NPCRA variables
For the purpose o f  this study the data were grouped into weeks which were aligned with the 
visit dates to allow for visit windows. Overall for the 12 week analysis in the present study, 
the NPCRA data analysis failed to show any significant differences between the treatment 
groups or treatment by time for any variable. In terms o f  activity levels throughout the 12 
weeks o f  chronic treatment there was no significant difference between treatments or over 
time recorded for average activity, amplitude, MIO or L5.
The activity levels for paroxetine, however, were much lower than either fluoxetine or 
sertraline treatment throughout except for L5 activity where the levels were sim ilar to 
fluoxetine treated patients. Patients treated with paroxetine or fluoxetine also increased their 
activity levels in MIO and 24 h average whereas activity levels fbr patients treated with 
sertraline showed a slight decline throughout the 12 week period. The increase in average 
activity and the MIO activity, however, do agree with increases in the actigraphic sleep 
variable ‘average wake movement’.
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One other antidepressant and actigraphy study has reported on NPCRA variables (Kasper e/
a l,  2010). Mean MIO activity increased in patients treated with agom elatine (a melatonergic 
antidepressant) but decreased in those treated with sertraline between week 1 and week 6 
which confirms the effect o f  sertraline in the current study. L5 activity showed a similar
decline for sertraline in both studies although individual weekly results were not presented in 
the Kasper et a/. (2010) study so cannot be directly compared with the current study.
A  mechanism fbr evaluating the resumption to normality is calculated as the RA where 
values close to 1 are indicative o f  a healthy non-depressed circadian cycle. The baseline RA
o f patients in the current study was higher com pared with the Kasper et al. (2010) study. At 
baseline the RA was 0.90, 0.94 and 0.93 for paroxetine, fluoxetine and sertraline 
respectively, which com pared with 0.87 and 0.85 for agomelatine and sertraline respectively. 
This suggests that patients in the current study had a higher initial baseline am plitude than 
the Kasper e/ a/. (2010) study and a less disrupted rhythm. The patients in the Kasper a/. 
(2010) study had an inclusion HAM D score mean o f 26.3 (HAM D moderate 16 - 27) which 
was more severe in comparison to the current study mean o f  26.5 (MADRS moderate 18 -  
34) (Müller er a/., 2000; Muller, 2003).
It is theorised that the RA would rise as daytime activity levels increase and night-time
activity levels decrease with the im provem ent in depression. In the current study the RA 
remained fairly constant throughout, albeit that for patients on paroxetine RA levels were 
consistently lower, this could indicate that overall patients were sleeping better and more 
active during the day with the stable ratios seen in RA levels. Com pared to the current study 
the mean RA was lower in the Kasper a/. (2010) study so it could be feasible that these 
were more severely depressed patients. The RA was stable over the 6 weeks o f  treatment 
with agomelatine whereas it decreased in the first week o f  sertraline treatment and was then 
comparable to agomelatine.
A  delay in timing was observed in the current study. There was a trend towards a significant 
delay in the MIO onset time fbr all treatments occurring later in the day by a mean o f  
approximately 30 minutes, with a trend towards a significant delay fbr the sertraline group. 
The MIO onset time appears to follow and confirm the same effect o f  a trend in delay as the 
acrophase time in the Cosinor analysis. These outcomes suggest that patients were more 
active during the day as treatment took effect but that the onset occurred later, and compared 
favourably with improvements in the depression scales, as depression lifted activity 
increased.
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Interestingly activity levels were similar fbr all patients during L5 time; with paroxetine a 
little higher in the current study indicating that paroxetine had a disrupting influence on 
activity during sleep. In comparison to the (Kasper a/., 2010) study patient numbers in the 
current study were much smaller but nevertheless similar trends are reported with increasing 
daytime activity as treatment progressed and decreasing night-time activity. Even though 
these results are not significant the current data trends are worthy of further investigation as 
suggested in line with differences in the types of depression and the differences between 
anxious agitated and melancholic retarded depression.
Although these results differ from the Kasper et ai (2010) study which found that, following 
6 weeks of treatment sertraline decreased MIO and L5 activity compared with agomelatine, 
no onset time fbr these variables was reported. There were similarities in that sleep latency 
was increased, yet quality of sleep was improved as were HAMD scores, fbllowing sertraline 
administration over 6 weeks, compared with agomelatine.
The reason for the improvement in mood and alertness in the current study could be 
connected to a delay of the circadian clock as shown by the delays observed in the onset 
times, and increased MIO activity levels. Todder et al. (2009) studied daytime (08:00 to 
20:00 h) and night-time (00.00 to 06.00b) activity levels in depressed patients on a 4 week 
course of quetiapine, and found that responders increased daytime activity levels in relation 
to improvements in HAMD. It is unclear what comes first, whether depression affects the 
activity and sleep and wake timing mechanisms due to its adverse effect on sleep; that 
depression leads to desynchrony or whether the irregularity causes the depression.
The Interdaily Stability (IS) (Van Someren a/., 1999) which ranges fiom 0-1 and the 
closer the value is to 1, or shows an increase in value, is indicative of an improvement to a 
more stable rhythm and is a measure of the coimection with external environmental cues. 
There was no significant improvement in the IS over the 12 weeks of chronic treatment 
overall or fbr any individual treatment in the current study. Comparing values presented 
from other studies indicated that even at baseline the current data showed that patients’ 
rhythms were reasonably stable with the mean values of 0.57, 0.64 and 0.65 fbr paroxetine, 
fluoxetine and sertraline respectively. These values compare favourably with other studies 
who have reported values of 0.62 (Baune gr a/., 2006) fbr depressed participants, 0.65 (Van 
Someren g/ 6z/., 1999) during bright light treatment of demented patients and 0.62 (Berle gr 
al., 2010) for schizophrenic patients treated with clozapine. However there was a trend
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between treatments with paroxetine exhibiting lower values during early treatment than 
either fluoxetine or sertraline but which was comparable by week 12.
Intradaily Variability (IV) (Van Someren g/ a/., 1999) indicates how fragmented the 
circadian rhythm is, ranging from 0 to 2 whereby a value of 0 represents a perfect fit to a 
sine wave, it represents the frequency of transitions between rest and activity. The higher the 
value the more fragmented the rhythm. In the current study the mean baseline values were 
0.81, 0.65 and 0.70 fbr paroxetine, fluoxetine and sertraline respectively, which indicated 
that the IV fbr the paroxetine group was more fragmented and agreed with the IS. Values fbr 
both fluoxetine group and sertraline group were fairly stable throughout the 12 weeks and 
values fbr paroxetine treated patients fell to comparable levels which indicated a trend fbr an 
improvement with treatment. In comparison with other studies the baseline values here are 
reasonably normal. A comparable study reported values of 1.06 for depressed patients 
(Baune et a l, 2006).
5.6.5.7. NPCRA during discontinuation
For the NPCRA variables during discontinuation there was an overall significant effect with 
increases in average activity, amplitude and MIO activity coupled with an advance of the L5 
onset time, occurring earlier in the night. These factors were also significant for fluoxetine 
and might indicate that circadian de-synchronisation was normalising on withdrawal and that 
patients were no longer depressed as the MADR and HAMD scores did not rise significantly.
IS values decreased with a significant trend P = 0.08 overall during the abrupt 
discontinuation week showing a possible disruption of the stability. Although IV values 
decreased in the current study during the abrupt discontinuation week this was not 
significant.
5.6.5.8. Circadian summary
To recap circadian rhythm analysis allows for a mechanism of observing whether the 24 h 
cycle has improved fbllowing treatment fbr depression to a more robust rhythm. Not only fbr 
higher activity levels during the day and lower activity during sleep but also the timing of 
these events and the strength of the rhythm. The NPCRA analysis produces an average day 
fbr 7 days and changes in timing and activity levels can be observed. It has been shown in 
the current study that daytime activity increased over the course of treatment as well as 
improvements in subjective ratings of depression and yet sleep variables were not improved.
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Therefore recording circadian rhythms could provide a tool to aid diagnosis, record the time 
course of recovery and further stabilisation of the 24 h rhythm.
As has been previously shown, fiom the actigraphic data, the impact of changes in sleep 
patterns was correlated with changes in increased daytime activity overall during the 
progress of 12 weeks of treatment. Therefore to explore whether 24 h rest-activity patterns 
were affected the activity data were further analysed using the cosinor program developed by 
Minors e/ a/. (1986) and the NPCRA analysis program developed by Van Someren er a/. 
(1999).
Changes can best be understood and described as differences in subsequent 24 h 7 day 
rhythms which show whether variables have changed, to what degree and whether those 
changes indicate an improvement. Patients with weak rhythms might exhibit changed onset 
times for MIO and L5 activity, improved higher IS, lower IV and a higher RA value with 
improvement in depression. Lower values for IS indicate a less stable rhythm and higher IV 
values indicate a more fragmented rhythm. Changes in these rhythm values including the 
timing of these events can show improvement in the 24 h cycle over a period of weeks. 
Although daytime activity levels increased over the course of treatment, which were 
associated with significant improvements in subjective ratings of depression, they were not 
significant fbr any treatment in the current study. Furthermore sleep variables were not 
improved. However recording circadian rhythms could provide a tool to aid diagnosis, 
record the time course of recovery and further stabilisation of the 24 h rhythm. It is likely 
that most of the patients in the current study had regular lifestyles either by being employed 
or having children with school runs and timetables etc., with key triggers or zeitgebers in 
their biological day, that their activity was to some extent controlled therefore it would be 
difficult to see obvious changes in circadian NPCRA compared with in-patients or 
Alzheimer’s patients whose activity is not so controlled. Raoux ef a/. (1994) showed that 
different patients delayed or advanced their 24 h rhythms in response to antidepressant 
therapy so to review the circadian cycle outcomes in conjunction with whether patients were 
responders or not and what types of depression they had is worthy of further investigation.
5.6.6. Line Analogue Rating Scale (LARS)
5.6.6.1. Effect of treatment on LARS
At baseline. Visit 1, the mean score fbr the three treatment groups was in the range 59 -  68 
mm, 9 - 1 8  mm above the mid-line or ‘normal’ point i.e. as depressed patients they felt more 
tired and sedated or lethargic than before they were depressed. Analysis of the change in
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LARS score &om Visit 1 to Visit 12, i.e. after 12 weeks of treatment, showed no significant 
difference between the three treatment groups. The scores were all significantly improved 
overall fbr the 12 weeks analysis which indicated that all patients felt more alert as treatment 
progressed, f  ojf-Aoc analysis showed that feelings of alertness were significantly improved 
fbr both paroxetine and fluoxetine during the 12 weeks of treatment. Interestingly in contrast 
to expected outcomes of the sedating reports of paroxetine, patients in the current study rated 
their sedation less and more improved than either fluoxetine or sertraline.
5.6.6.2. LARS during discontinuation
Treatment discontinuation from fluoxetine or sertraline showed little change whilst 
discontinuation from paroxetine showed a substantial increase in LARS sedation scores. 
Subjective sedation worsened after paroxetine withdrawal showing that patients felt more 
tired and lethargic during the 1 week discontinuation phase. This was, however, still much 
lower than their baseline. The subjective feelings of sedation after treatment withdrawal from 
paroxetine were not reflected in actigraphy variables as there was no reduction in daytime 
activity. Instead activity counts increased, perhaps an increase in activity made the patients 
feel more tired or their disrupted sleep increased fatigue, the worsening of LARS is also 
associated with the worsening of QOS in LSEQ.
This worsening trend during withdrawal confirmed the findings of Hindmarch et al. (2000a) 
who also reported an increase in sedation scores fbllowing paroxetine withdrawal. 
Rosenbaum er a/. (1998) similarly reported that paroxetine caused more ‘fatigue’ than either 
sertraline or fluoxetine during placebo substitution. Interestingly, although not analysed in 
the current study, both Hindmarch er a/. (2000a) and Rosenbaum er a/. (1998) report worse 
effects of anxiety, agitation and irritability from the DESS from both sertraline and 
paroxetine withdrawal compared with fluoxetine. Perhaps an increase in anxiety and 
agitation had a negative impact on sleep and therefore increased daytime sedation levels.
5.6.7. CFQ
5.6.7.1. Effect of treatment on CFQ
The baseline CFQ values in the current study of 59, 58 and 66 fbr paroxetine, fluoxetine and 
sertraline, respectively, were comparable to the baselines of other patient studies 
(Fairweather er a/., 1999; Preiss e/ a/., 2013; Farrin e/ a/., 2003) indicating that patients had 
similar cognitive impairment. Results from the current study showed that the mean 
percentage improvement in CFQ scores was 35% with scores reducing to 34, 41 and 43 by 
week 12 fbr paroxetine, fluoxetine and sertraline respectively, with a statistically significant
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improvement. The scores at week 12 are comparable to the scores recorded by control 
participants from other patient studies (Fairweather er a/., 1999; Preiss e/ a/., 2013; Farrin
al, 2003) which indicate that patients improved in the current study.
These results again showed significant improvements fbr all treatments over time from 
baseline with similar improvement to the self-completion ZUNG. Patients felt more co-
ordinated and alert with an increased ability to concentrate and think straight, were less 
clumsy, and more able to perfbrm simple everyday tasks without impairment in memory, 
attention and motor function.
5.6.7.2. CFQ during discontinuation
During the discontinuation week although scores increased fbllowing paroxetine withdrawal
this was not significant in the current study. In fact further reductions in scores were 
recorded during the discontinuation week for both fluoxetine and sertraline compared with 
week 12 fbllowing chronic dosing. This could indicate that patients were not adversely 
affected in their ability to maintain normal functioning as there was no significant impact on 
the CFQ scores during the period of discontinuation of treatment. These outcomes compare 
favourably with the increase in daytime activity, hr contrast, the study by Hindmarch et 
a/. (2000a), showed a significant increase in the CFQ scores during the week fbllowing 
abrupt discontinuation from paroxetine. There was also a trend for impairment following 
sertraline withdrawal.
5.6.8. Psychometric assessments
5.6.8.1. Critical Flicker Fusion (CFF) and Choice Reaction Time (CRT)
The present study showed that both CFF and CRT were improved significantly for all 
treatments from baseline with most of the effect occurring in the first 8 weeks of treatment 
after which the effect plateaued. These findings are in agreement with those of Fairweather 
er a/. (1993), and Kerr a/. (1993) who showed that fluoxetine (20 mg/day), improved CFF 
performance compared with tricyclic antidepressants (TCAs) in depressed patients over 6 
weeks. A study by Alexander et a l (1997) demonstrated that paroxetine significantly 
improved CFF threshold compared with dothiepin and this improvement was maintained
over 6 weeks. There is limited evidence of the effects of long term use of sertraline in
depressed patients on CFF or CRT. A review from Amado-Boccara et al (1995) reported 
that sertraline CFF wfr/z and also
improved CRT however the study referred to was by Hindmarch and Bhatti. (1988) was 
conducted on healthy participants over 8 h. This study therefbre addresses this gap in
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knowledge and shows that sertraline had a statistically significantly positive effect on CFF 
with an elevation in threshold and a reduction in reaction time.
5.6.8.2. CFF and CRT during discontinuation
Only one other study by Hindmarch et al. (2000a) has investigated the effect of brief 
discontinuation of paroxetine, fluoxetine, sertraline treatment on cognitive functioning of 
depressed patients and the effect of time on CRT and CFF. The brief treatment 
discontinuation of 4-7 days by Hindmarch gr a/. (2000a) had no overall effect on CFF fbr 
any treatment, although a slight non-significant decrease in threshold was observed 
fbllowing paroxetine withdrawal. This was in contrast to the current study, where although a 
similar trend and decrease in CFF was observed fbllowing paroxetine disruption, there was 
also a significant decrease in CFF threshold fbr sertraline also suggesting that cognitive 
processing was reduced during the discontinuation period. In addition in the Hindmarch et 
al. (2000a) study discontinuation of all 4 treatments increased reaction time, with a greater 
increase in the patients when they were not being given paroxetine. In contrast, in the current 
study reaction times were only increased in the paroxetine treated patients which were 
significantly increased in the within group analysis, whereas the reaction times for both 
fluoxetine and sertraline treated patients improved.
The results from both studies suggest that the consequence of abrupt paroxetine withdrawal 
causes a worsening of cognitive perfbrmance and mood symptoms. This may be related to 
the shorter half-life of paroxetine. Results of the current study add to the limited information 
available of the cognitive and psychomotor data outcome aspects of SSRI discontinuation.
5.6.9. Limitations
This study is the first to compare the SSRIs, and to show the effect of paroxetine in activity 
and sleep variables compared with fluoxetine and sertraline over 12 weeks of continuous 
monitoring combined with 1 week abrupt discontinuation. In addition the use of actigraphy 
has provided additional infbrmation of the circadian behaviour of patients fbllowing 
treatment and during abrupt discontinuation. There are many limitations to the study, which 
will be discussed in this section, to consider and improve future studies and to facilitate 
better data collection. The data collected provides insights into the positive direction of 
action of the medication as seen in the improvements in the depression scales and subjective 
assessments.
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The effect of SSRIs is well documented as previously discussed but there is little data on the 
use of actigraphy in long-term studies of depression. For future studies amendments to the 
study design are advised, to ensure that the effects seen are actual, more robust and not just 
by chance. The main limitations to the study were the small sample size, no placebo or non­
treatment baseline and no placebo comparator. Sample size was restricted to the number of 
compliant patients who wore the actiwatch throughout the study, which was approximately 
33% of the patients recruited. In addition of the original 99 recruited 26 withdrew before 
Visit 12 prior to abrupt discontinuation. Although fewer patients may have withdrawn from 
the study compared with standard GP treatment due to regular and routine contact with the 
GP surgery having an effect similar to cognitive behavioural effect CBT Lejoyeux and Adès.
(1997).
Although baseline data were not available for actigraphic variables it was for available for 
the cognitive and psychometric assessments as well as the subjective scales, as they were 
recorded at the very first visit. Therefbre changes in these variables could be accurately 
calculated. Even though there was no baseline data fbr actigraphy, as SSRIs supposedly have 
a delayed onset and may take at least 2 weeks to take effect, it was possible to calculate 
weekly changes from the start of medication, although adverse side effects might have 
occurred sooner (Mackay a/., 1999; Ferguson, 2001; Taylor a/., 2006). To have 
actigraphy data from placebo controls in depressed patients would have been valuable but 
would not have been considered ethical (Wilson et al, 2000).
5.6.9.1. Patients
The inclusion criteria stated that patients would be recruited into the study provided that in 
the opinion of the investigator they required antidepressant medication. However in order to 
ensure that there were no medication conflicts they were excluded if they had received any 
drug treatment fbr depression in the previous 3 months. Patients diagnosed as moderate to 
severely depressed, defined as requiring treatment with a score > 20 from the MADRS at 
screening Visit 1 were recruited. The mean MADRS score was 26.5 (18 - 34), which was on 
the lower side of the moderate depression spectrum. As suggested by Fava er a/. (2002) it 
could be considered more difficult to ascertain differences in treatment effects in patients 
with milder symptoms. In fact by Week 1 the mean MADRS value showed that patients 
were in the mild range of 9 -  17. There were more females than males at approximately 
78.6%, which could have biased the outcome. In the Kasper e/ a/. (2010) study, there were 
70.6% females, and although more females are treated fbr depression it is likely that they
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seek treatment more often than males as well as there being more hormonal differences 
(Grigoriadis and Roblockson, 2007).
The question of severity might be worth review as the significant improvements in the
MADRS and HAMD scores occurred within the first 2 weeks for any of the treatments. 
Maybe the patients were not sufficiently depressed as has been shown in the MADRS scores 
at inclusion. Perhaps the sleep of patients was not severely disrupted at the start to show 
improvements in their sleep variables. The changes seen in actigraphy are very subtle 
compared with the objective assessments but do offer suggestions in the direction of 
improvement in increased daytime activity. Nevertheless all patients who fulfilled the 
criteria of wearing the actiwatch and completed the abrupt discontinuation were included in 
the analysis. All patients were included in the analysis as no account was taken regarding the 
individual improvement by patient, so this aspect might be worthy of further investigation to 
expose the effects of treatment in those patients that responded more to treatment than 
others. Various studies have adopted this approach for example Baune et al. (2006) 
conducted a study of rest-activity rhythm. As only half the patients (n = 5) showed clinical 
improvement of > 30% on the HAMD after 4 weeks of treatment with quetiapine, data were 
presented in 2 groups, clinical improvement and non-improvement (Baune ef a/., 2006). 
However this would defeat the object if the actigraph is to be used in general practice as it 
assumes a pre-selection process to show significance.
There was no placebo arm, neither was there a comparator or verum medication with known 
effect, so only comparisons between the three SSRIs could be made. It might have been 
useful to include a sedating antidepressant such as one of the TCAs e.g. dothiepin or 
amitriptyline which are often used as verum in studies and produce known sedating effects. 
It is worthy to note that, in the present study, even without a drug free baseline or placebo 
run in (7 day) improvements in patients from their own depressed baselines were observed.
Current treatment for depressed patients includes Cognitive Behaviour Therapy (CBT) and 
Mindfulness Therapy so there may have been an effect of this with the visits to the doctor 
which could be considered similar to CBT thereby improving patient’s feelings of self- 
worth. It has been shown that depressed patients, (n = 31) without medication, but given a 
personalized cognitive training program, exhibited statistically significant improvements in 
the CFQ which were correlated with improvements in the Becks Depression Inventory (BDI) 
(Preiss a/., 2013). The use of CBT is an interesting aspect since although this was not part 
of the treatment patients were assessed regularly, and their symptoms discussed with their
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GP with 1:1 support, so the fact that they were in a clinical trial and receiving more attention 
might have affected the outcomes.
There are many types of depression, but it is assumed that no allowance fbr the type of 
depression was made. Patients may suffer from different types of depression which can be 
retarded and melancholic with reduced activity or anxious and agitated, or even bi-polar and 
exhibit different profiles (Haynes gf <3/., 2006; Salvatore e/ a/., 2008). The aspect of 
retardation in depression was discussed in a review of studies by Dantchev and Widlocher,
(1998) which disclosed that depressed anxious agitated patients improved more than those 
with retarded depression fbllowing fluoxetine treatment. No allowance was made fbr these 
different types of depression, so the effects that might otherwise have been seen with 
actigraphy, which uses activity levels, might have been cancelled out.
Another factor to consider is timing, as the present study was conducted in the winter and 
spring months when the amount of daylight was limited but gradually increasing, so it is 
unclear whether timing of the study affected patients who may have been suffering with 
SAD. The first patient first visit occurred in November and 22 patients completed in the 
months with a GMT clock, befbre the clocks changed to BST and when there was less 
sunlight ranging from 8 hours in January to 11 hours in March. Moreover more than half the 
patients completed their discontinuation in BST around May when there was 15 h of daylight 
so the extra daylight could have confounded the discontinuation outcomes.
The age range of the patients varied from the youngest at 21 years to the oldest at 84 years 
with nearly a third of the patients over 50. Given that depression is associated with cognitive
impairment and deficits are worse when the first onset of depression is in later life it would 
have been prudent to limit the age range studied according to Variend and Gopal. (2008). 
Further, as suggested by Fairweather er a/. (1993) depression often accompanies aging and 
the pharmacodynamic and pharmacokinetic effects of drugs are often exaggerated in older 
adults, and maybe the patients should have been stratified by age.
5.Ô.9.2. Design
As the patients were newly diagnosed and provided with medication shortly after informed 
consent, the study failed to allow fbr the collection of actigraphic data in the weeks prior to 
administration as either a drug-free baseline or placebo run-in. This is an important factor 
which would have resulted in comparative baseline data. Although actigraphy data were 
captured for depressed patients, in the Kasper gr a/. (2010) actigraphy study there was a short
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washout period prior to treatment. As previously discussed, future studies should consider 
ensuring that a pre-treatment baseline of at least 7 days is obtained.
The actigraphic sleep variables at baseline e.g. sleep efficiency and number of sleep bouts, 
are similar to healthy volunteers so the chance of seeing any relative improvement was low. 
Moreover many of the cosinor and npcra variables i.e. IV, IS and RA are relatively close to 
the normal range. Paradoxically although actigraphic sleep worsened with antidepressant 
treatment, which supported previous findings of the effects of SSRIs on sleep, this could be 
due to REM being normalised. Conducting a PSG assessment therefore, before, during and 
after treatment would have provided valuable infbrmation as to the actual sleep architecture. 
The patients were the lower end of the MADRS spectrum, therefbre to show actigraphic 
improvements it would be advisable to study patients with more severe depression.
Recruitment of patients was conducted at 12 GP centres. Investigators were trained how to 
conduct the cognitive and psychomotor tests and capture the data fbr the assessments, at the 
study initiation and start up. The testing was conducted at these centres which ranged from 
single practices in converted houses to health centres so it might be better to maybe reduce
the number of centres and standardise the test facilities.
5.6.9.3. Actigraphy
The actiwatches had a finite recording period of 45 days at 1 min epoch and 90 days at 2 min 
epoch so in order to capture the critical periods during the start of treatment and 
discontinuation 3 separate periods were recorded. Recording period 1 covered the first 4 
weeks and 1 min epoch was used; period 2 covered the maintenance of medication from 
week 4 to week 12 at 2 min epoch; and period 3 at 1 min epoch covered weeks 13 and 14 
over the discontinuation period. Prior to analysis it was necessary to normalise all the data 
files to 2 min epoch to enable the data &om the 3 files with different epochs to be 
comparable and then the actiwatch Sleepwatch data analysis was carried out. Some actiwatch 
variables, such as fiagmentation index, rely on 1 min epoch data. Analysis fbr these variables 
could not be calculated, and therefbre sleep disruption was determined through the number 
sleep/wake bouts being the number of transitions from sleep to wake and their subsequent 
length.
Each actiwatch contained a unique sensor with a slightly different sensitivity and unless data 
were derived from the same actiwatch fbr multiple recordings of the same patient there was a 
possibility that the data obtained was slightly different from each watch and might not map
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exactly. According to the later Actiwatch Manual q/"
zweaw »o Avo yfc^ zwa/c/zej^  wz// prozfzzce gxacf/y /^ze .ya/zze ozz/pzz^ ’. By 
treating all the data the same and creating weekly means it might be accepted that any
variation would be minimised.
A factor that cannot be changed is that when the clock changes from GMT to BST, the 
diurnal rhythm of the internal body clock can take over a week to adjust and affect the sleep 
wake pattern (Kantermann c/ a/., 2007), so this change in the ‘body clock’ might have 
affected the patients sleep/wake actigraphy variables and rhythm.
One other aspect of environmental time was to take account of holidays, since many patients 
were treated over Christmas and the New Year. In these cases if actograms indicated that 
there was an unusual late bedtime with subsequent late wake time the data for the full 24h 
was removed so as not to impact on the weekly means. In addition fbr one record it was 
obvious from the actogram and the diary that a holiday to USA had taken place during the 
recording. In this instance the activity data for the holiday period was treated as an outlier 
and removed 6"om the analysis as it might have skewed or influenced the data if included in 
the analysis.
It was previously presumed that all actiwatches retain time efficiently but by comparing
marker times at download with the actual time it was possible to determine any drift in the 
internal timer. Prior to download the computer clock was synchronised to a radio clock, the 
marker on the actiwatch was then pressed to act as a reference point and to confirm the 
actual time of download from the computer clock. The process of checking the internal clock 
of the actiwatch was necessary to ensure that its timing and that of the internal sensor had not 
drifted. It was ascertained at this point that the internal computer clock at the GP set-up 
centres were not synchronised with real time. By a process of deduction it was determined 
that at one centre the computer clock was out of sync by approximately 1.5 h and at the other 
1 h. To ensure parity across the data sets the *.awd files were adjusted with the mean of each 
respective centre.
Some data files when downloaded showed a reduction in activity levels which when 
compared with the other actiwatches fbr the patient indicated that the internal sensor could 
be faulty. Standard practice now includes calibration of the actiwatch, by running the 
actiwatch on a calibration jig and obtaining a certificate of validation, when a new battery is 
inserted to ensure that the actiwatch sensor is within the sensitivity range. If the actiwatch is
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returned with a suspected sensor fault, it should be re-calibrated to confirm accuracy, prior to 
the data being used in any analysis.
The Actiwatch markers were used to determine bedtimes, and the patient diaries were used 
to confirm the bedtime and wakeup time information if the marker had not been pressed. The 
diaries gave an insight into the patient’s daily activities and aided interpretation of the data 
but they were very basic and better diaries used in clinical trials are now available. Current 
diaries now also include subjective scales, to monitor daily changes in perceived sleep 
quality, sleep timing and how long patients took to get to sleep, and whether there was any 
disruption in sleep continuity fbr toilet visits. They are also now used to record dietary 
infbrmation especially regarding caffeine intake and other aspects which might impact on 
sleep such as late exercise. An example of a simple diary is shown in Appendix XIV.
For future studies over the same timescale of 12 to 14 weeks the logistics, organisation and 
management of the actiwatches must be carefully planned, to ensure that the same actiwatch 
can be dispensed to a specific patient to maintain continuity. Actiwatches are now available 
which record up to 180 days, but attention to detail and accurate recording of events should
be standard practice with checking clocks prior to setup and download.
There was a reduced analysis set for the current study compared with the full study data set 
as only patients who were compliant with wearing the actiwatch and completed all 14 weeks 
of the study were included in analysis. Approximately one third of patients were lost due to 
early withdrawal or non-compliance by not wearing the actiwatch. The mean MADRS for 
the included patients was lower than the full data set therefore the final study patients may 
have been less representative or less depressed compared with those of the total study, this 
may have contributed to the patients being more compliant.
It is likely that if depressed out-patient groups have a structured lifestyle with a regular sleep 
wake rhythm and social zeitgebers, changes in timing and circadian outcomes might be 
small, although increased activity levels might reflect a positive change, therefbre a 
combination of actigraphic variables would be desirable to any single outcome (Monteleone 
a/., 2011; Calogiuri a/., 2013).
5.6.9.4. Discontinuation
Discontinuation studies suggest that a staggered withdrawal may be preferable to abrupt 
withdrawal in order to minimise and reduce the effect of discontinuation symptoms.
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However the purpose of the study described here was to determine whether discontinuation 
symptoms would emerge if a patient missed doses, therefbre abrupt discontinuation was also 
used in this study. The study did indeed provide evidence of a worsening of symptoms upon 
discontinuation although this was not entirely in agreement with the study by Hindmarch gf 
a/. (2000).
5.6.10. Conclusions
Actigraphy remains a relatively cheap non-invasive research instrument to study circadian 
rhythms and sleep wake activity patterns (Morgenthaler et a l, 2007b) and has been 
suggested as an alternative to PSG although with some limitations (Morgenthaler a/., 
2007a; McCall and McCall, 2012). The actigraphy results from the study reported here, are 
associated with improvements in depression and cognitive and psychomotor perfbrmance, 
and are thus a useful adjunct to the effect of SSRIs on depressed patients as a continuous 
objective indicator of the outcome of treatment on sleep and activity where PSG would be 
impracticable.
The main effects found in the study were that the SSRIs did not improve actigraphic sleep 
variables indeed the change in variables showed that overall sleep efficiency reduced and the 
number of sleep bouts increased. This is in agreement with PSG findings as it is known that 
SSRIs reduce REM and increase REM latency as reported in reviews by Wilson and 
Argyropoulos. (2005) and Wichniak et al. (2012). Changes in SE and number of sleep 
bouts, which are measured from activity counts, could be due to a reduction in REM, so 
theoretically a reduction in REM would increase activity.
There was no significant difference between treatments fbr any of the actigraphic sleep 
variables; neither did any treatment improve actigraphic sleep variables during the 12 weeks 
of chronic administration. Slight differences in the actigraphic profiles of each SSRI were 
however recorded; the actigraphic sleep of patients on paroxetine and fluoxetine treatment 
was disrupted more than those treated with sertraline. There was also a significant increase in 
number of sleep bouts for all treatments and a trend for reduced sleep efficiency following 
paroxetine and fluoxetine treatment.
Circadian rhythm NPCRA and cosinor variables fbr the 12 week analysis similarly failed to 
show any significant differences between the treatment groups. Although activity levels for 
paroxetine were lower than either fluoxetine or sertraline treatment, patients treated with 
paroxetine or fluoxetine also increased their activity levels in MIO and 24 h average. There
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was a significant improvement of the percentage rhythm over time fbr all treatments fbr the 
12 week data which indicates that the sleep/wake rhythm was less fragmented. A trend fbr a
circadian delay in timing was also reported with the acrophase time occurring slightly later 
in the biological day which suggests that as depression was alleviated patients became more
active and that this occurred later in the day.
The depression questionnaires MADRS, HAMD and ZUNG all signified that depression was 
significantly relieved fbr all treatments. Furthermore, in contrast to the actigraphic sleep 
variables the sleep items from MADRS and HAMD showed that patients felt that their sleep
was improved which was also reflected in significant improvement in the LSEQ items, GTS, 
QOS and BFW. In addition LARS sedation was significantly relieved with all patients 
feeling more alert and less fatigued, which was also significant fbllowing paroxetine and 
fluoxetine treatment. The improvement in LARS although not reflected in improved sleep 
was reflected in increased daytime activity and improved circadian profile.
Patients’ cognitive skills were also improved fbr all treatments with significant reductions in 
CRT overall reaction times and significant improvement in CFF. Although no significant 
differences between treatments in CFF or CRT were fbund, significant improvements were 
recorded fbllowing treatment with sertraline in reaction times. All patients felt significantly 
less clumsy and more in control Eom the CFQ questionnaire, but there was no significant 
difference between treatments, each treatment significantly improved patients’ perception.
With regards to discontinuation from treatment, there was no significant difference between 
treatments. Only the MADRS sleep item was adversely affected and significantly worsened, 
patients felt that they had less sleep. This was confirmed with the actigraphic sleep variables 
where there was a significant reduction in timing with reduced TIB, SPT and TST and yet a 
trend fbr improved QOS was suggested with LSEQ. However, for any treatment, the daytime 
activity variables, AWM, amplitude, mesor, average activity and MIO activity all 
significantly increased fbllowing discontinuation.
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CHAPTER 6 GENERAL DISCUSSION
6.1. Introduction
Treatment of disease with psychoactive medication may impact on a patient’s well-being to a 
greater or lesser degree, either acutely fbllowing administration or chronically when 
continuously administered over longer periods of time or both. These effects may be 
manifested in a variety of different ways depending on the disease, whether it is chronic or 
acute, how severe the condition is and its impact on every day functions. Combined with the 
symptoms of the disease the medication may, in addition, cause unwanted side effects which 
may prevent the patient continuing with the recommended treatment.
Chronic long term mental diseases such as anxiety, depression, insomnia, schizophrenia, 
SAD and bipolar depression, are all likely to have an impact on sleep and daytime 
functioning and may also cause circadian desynchrony (Section 1.6.1). Psychoactive drugs, 
which are prescribed to treat these conditions, are designed to improve the symptoms, 
improve daytime functioning and may also be given to alleviate the problems of poor sleep 
which can have a negative impact on recovery. In addition disease such as fibromyalgia, 
arthritis rheumatism and painful diabetic neuropathy cause pain which may affect patients 
sleep and therefbr daytime functioning.
Psychoactive compounds including pain relief may impart positive or negative side effects, 
they may cause sedation, impair everyday functioning, reduce activity or they may be 
alerting and improve mood and increase activity (Section 1.6.2). In addition, they may 
impact on sleep by increasing or reducing the amount of sleep, or affecting the sleep profile 
and architecture all of which may influence patients’ daytime functioning, well-being and 
long term outcome of recovery. To study the effect of these psychoactive compounds on a 
patient’s or participant’s 24 h activity profiles is a useful adjunct to the set of cognitive and 
psychometric assessments usually employed fbr monitoring the effects of CNS drugs in 
Phase 1 clinical trials.
In summary the main findings of the studies conducted fbr this thesis were that:
# Actigraphy was able to follow the acute time-course of psychoactive compounds in 
healthy participants.
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• The impairing effects of the psychoactive compounds on cognitive and psychomotor 
function in acute studies were mirrored in reductions in actigraphic activity and 
increases in ‘sleep-like’ activity.
• Following acute dosing actigraphy was able to show changes in actigraphic sleep 
variables in healthy participants.
• The significant improvement in patients depression scores in the chronic 
antidepressant study was reflected in their perception of subjective improvement in 
sleep quality
• The subjective improvement in patients sleep was inversely reflected in actigraphic 
sleep variables, manifested as an increase in movement during sleep.
• The trend for a rise in daytime activity levels suggested a link in line with the 
improvement in depression scores.
• Changes in actigraphic activity were observed during the abrupt discontinuation of 
antidepressant treatment.
6.2. Actigraphic activity
By definition a psychoactive compound is one that crosses the blood brain barrier and 
therefore impacts on functioning whether that manifests itself in mood changes, alerting
effects or causes drowsiness and lack of co-ordination. Any drug effect that impacts on 
motor skills can be measured by actigraphy. By employing algorithms to calculate an 
assortment of variables the outcome of these psychoactive compounds on activity profiles 
can be measured and by dividing the 24 h day into the sleep and wake periods the effect on 
actigraphic sleep and daytime activity may be determined. In addition the effect and impact 
on the 24 h circadian rest-activity rhythm can also be measured.
Whether the effect to be measured is acute as in the case of a potent psychoactive compound 
in a single dose healthy participant controlled clinical trials Chapters 3 and 4, or chronic as in 
long term studies with patients in their own environment (Chapter 5), actigraphy may 
provide valuable additional information on the impact of medication on activity. There are 
various methods with which activity can be measured and evaluated, for example in raw 
activity counts over time or conversion of those activity counts to ‘sleep-like’ activity when 
the counts are below the sleep/wake threshold (Section 1.2.6). Time periods can be set to 
minimise or avoid the influence of alerting periods when tests are being performed to 
determine the real effect of the psychoactive compound on the activity profile (Section 3.5.2 
and Section 4.5.2).
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6.3. Actigraphic sleep
Traditionally sleep has been recorded with PSG and although this may provide an indication 
of the impact of medication on sleep architecture it is out of context with everyday life. 
Medications used to treat sleep complaints or those that affect sleep are first tested on 
healthy participants in controlled surroundings with the gold standard PSG sleep assessment 
and this may give an indication of the impact on sleep architecture. On the other hand, it is 
the effect of medication on patient’s sleep and activity in their own home environments that 
are important to define and might determine whether a patient would remain on or stop 
medication. Although not actual sleep, actigraphy provides an alternative method of 
unobtrusively examining the sleep wake profile, in both laboratory and home settings, and 
for determining effects which can be correlated with sleep architecture. The overall aim of 
the thesis was to investigate whether it was possible to identify and measure drug-induced 
changes in activity, actigraphic sleep and the rest-activity profile following acute and chronic 
administration of different classes of psychoactive drugs using actigraphy.
6.4. Comparison with cognitive and psychomotor tests
When conducted in combination with cognitive and psychomotor performance, changes in 
activity recorded by actigraphy can be correlated. By comparing the positive or negative 
effects whether in the acute phase of treatment or, during chronic dosing, the likely impact of 
the treatment medication on cognition as well as activity and actigraphic sleep can be 
determined.
Cognitive and psychomotor tests have long been established as mechanisms for assessing the 
impairment of psychoactive compounds (Section 1.3.1). Tests however, are snapshots of
time usually employed to cover the time of maximum impact on a participant or patient as in 
acute dose studies. In addition they can be used to measure hangover effects and for chronic 
studies to assess the long term effects of treatment and whether that treatment is effective. 
By comparison with subjective rating questionnaires for quality of sleep, mood, sedation and 
cognitive impairment the associated effects on actigraphic activity levels can also be 
determined.
6.5. Acute studies
6.5.1. Chapter 3
To study the acute effects of psychoactive medication on the activity and sleep profile of 
healthy participants, the benzodiazepine LZP was compared with placebo, in Chapter 3. The
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controlled study showed that there were significant differences in the actigraphy data 
between placebo and LZP. There was a statistically significant reduction in activity during 
the acute phase after dosing with LZP compared with placebo, which correlated with a 
significant performance impairment of the cognitive and psychomotor tests. In addition 
participants felt sedated according the LARS sedation rating.
Other authors (Kiang er a/., 2003; Takahashi cr a/., 2003) have also reported significant 
reductions in activity after dosing with psychoactive medication. These studies, however, 
have used larger time episodes than the LZP study and ranged from 6 to 24 post dose. The 
use of bigger time episodes may not allow for direct comparison and correlation with 
ft-equent testing of cognitive and psychomotor performance, although they do provide an 
indication of the overall effect on activity. Neither are they able to map the subtle time 
course of the medication in relation to the pharmacokinetics, pharmacodynamics or changes 
in behavioural activity following medication.
In Chapter 3, actigraphy was used to assess the impact on activity caused by the 
benzodiazepine LZP (2.5 mg) compared with placebo, in comparison with impairment in 
psychometric tests. The tests used were the choice reaction time (CRT) and continuous 
tracking task (CTT) which were performed at specific time points across the acute post 
dosing period. Actigraphic activity in the study in Chapter 3 was recorded in 1 min epochs. 
Data therefore, could be accumulated and separated into ‘controlled’ activity during the 30 
min test points and ‘spontaneous’ uncontrolled activity, between the test points, and 
therefore map the direct effect of treatment on activity. This finer analysis also allowed for 
enhanced correlation with the cognitive subjective assessment of LARS and thereby any 
feelings of sedation.
Reductions in ‘spontaneous’ activity levels during the 5 h acute post dose period closely 
followed the significant impairment in performance and suggested that actigraphy was able 
to detect the drug-induced effect seen in cognitive performance (Section 3.5.2). In addition, 
reductions in activity were also mirrored with the participants’ subjective feeling of
‘sedation’ at 4.5 h post dose.
Allen cr a/. (1993) also showed that LZP (2 mg) impaired psychomotor performance in 
healthy participants up to 5 h post dose and similarly O’Neill ef a/. (2000) showed that LZP
0.5 mg/day significantly impaired psychometric performance at 4 h post. The study in
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Chapter 3 therefore confirms these findings and that LZP (2.5 mg single dose) significantly 
impaired psychometric and cognitive effects at 4.5 h post dose.
Furthermore, the morning after dosing, actigraphy was able to detect a significant reduction 
in activity and therefore indicate a residual impairment. Although the participants did not 
feel sedated according to the LARS, the psychometric tests for CRT and CTT revealed that 
they were still significantly impaired (Section 3.5.3). Hangover effects are usually detected 
by reductions in performance or using tests such as Karolinska Drowsiness Test (KDT) or 
the Multiple Sleep Latency Test MSLT (Takahashi a/., 2003). This study has therefore 
shown that hangover effects and daytime sedation can be detected as reduced levels of 
activity. Moreover, it is important to establish the maximum duration of impairment for 
patient safety to ensure that a hypnotic taken to aid sleep has no residual or hangover effects 
the following morning.
In addition to activity counts, the data scored as ‘sleep-like’ increased, and correlated with 
the time of greatest impairment in performance on the psychometric tests when participants 
on LZP treatment actually felt more sedated and drowsy, according to the LARS (Section 
3.5.2.2). This phenomenon was also referred to as ‘inactivity’ by Roehrs a/. (2000). The 
finding confirms other researchers (Roehrs g/ <3/., 2000; Kawahara gr a/., 2002; Kiang g/ a/., 
2003) who have used similar methods to examine reductions in daytime activity.
Thus such data analysis procedures could be used to determine ‘daytime sleepiness’ as an 
overall reduction in activity levels not associated with actual sleep but in relation to feelings 
of ‘sedation’. This concept was previously described by Stanley and Hindmarch. (1997), and 
shown in studies conducted into the effects of antihistamines and sedating antidepressants.
A significant reduction of activity at the beginning of the sleep period during the first half- 
hour of the time in bed, in the LZP study, was also detected with actigraphy. These data 
confirm that of Mattmann a/. (1982) (Sections 1.4.3 and 1.4.4) who also showed that 
nocturnal motor activity was reduced and reductions in daytime activity were verified by 
subjective sleepiness and impaired performance following benzodiazepine administration. 
Borbely a/. (1983) similarly reported that night-time activity was significantly reduced 
compared with placebo showing the hypnotic and residual effects of triazolam and 
midazolam.
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During the sleep period actigraphy was able to detect the sedative effects of the anxiolytic - 
hypnotic drug LZP on changes in sleep variables, with increased sleep efficiency, a sleep 
variable common to PSG (Section 3.5.2.4). Actigraphy was also able to demonstrate a 
reduction in movement during sleep, caused by the action of the LZP, resulting in a 
significant reduction in the number of sleep bouts and increase in sleep bout time. Therefore 
actigraphy was able to provide an indication of the clinical effects of medication on sleep.
Studies have shown that LZP alters PSG sleep architecture (Section 1.4.4.1) (Grozinger et 
a/., 1998; Saletu a/., 1990) as determined by reducing sleep latency, number of 
awakenings. Stage 1 and REM sleep, whilst increasing TST and Stage 2 sleep. Although 
actigraphy is not able to identify changes in sleep stages or architecture the study in 
Chapter 3 did show an increase in actual sleep percent, longer sleep bout times, and 
reductions in the number of wake bouts (Section 3.5.2.4). This study clearly indicates 
actigraphy can provide a less expensive, non-invasive alternative for detecting changes in 
sleep due to the effect of a drug.
6.5.2. Chapter 4
Actigraphy was further used in Chapter 4 to assess the impact on activity associated with the 
impairment caused by the psychoactive antihistamine promethazine in psychometric tests in 
comparison with placebo. As in Chapter 3 the tests performed were the choice reaction time 
(CRT) (Hindmarch, 1980) and continuous tracking task (CTT) (Hindmarch a/., 1983) 
which were performed at specific time points across the 12 h day together with LARS 
(Hindmarch and Gudgeon, 1980) to measure subjective sedation. These tests have been 
shown to be sensitive to the CNS impairing effects of the antihistamine promethazine 
(Hindmarch et a l, 2001a, 1999).
Actigraphic data were treated in the same way as the methods described in Chapter 3. Data 
were accumulated and separated into ‘controlled’ activity during the test points and 
‘spontaneous’ uncontrolled activity, between the test points, to map the direct effect of 
treatment on activity. There was evidence of a significant impairment in cognitive and 
psychomotor performance up to 9 h following a single dose of promethazine (25 mg) 
compared with placebo (Section 4.5.5). Activity levels, however, although lower than 
placebo, were not statistically significantly reduced (Section 4.5.1). The performance of the 
tests coupled with the wheal and flare assessments, when activity was restricted and 
controlled, covered a large part of the time, which could therefore account for the lack of
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available spontaneous time when activity was not restricted. Moreover the alerting effects of 
the performance of the tests might have impacted on the activity levels.
To limit the effects of the tests, activity data were separated into periods when the tests were 
not being performed, and activity was not controlled. This ‘spontaneous activity’ data 
accounted for the last 15 minutes of each hour. analysis revealed a significant
reduction in activity levels between 5- 8 h post dose (Section 4.5.2). This supports the 
evidence that promethazine 25 mg reduced daytime activity measured by actigraphy at 6 h 
post dose and impaired psychomotor performance (Stanley, 1997; Hindmarch et a l, 1999). 
This reduction was also associated with significant subjective sedation, as measured by 
LARS. The participants in the Chapter 4 study similarly reported feeling sedated with a 
significant effect of LARS sedation overall and up to 9 h after dosing.
Psychometric tests, conducted at +1, +3, +6, +9, and +12 post dose, were more spread out to 
cover the pharmacokinetic effect of promethazine, than the LZP study when tests were 
conducted hourly. This regime of tests meant that participants had theoretically more 
‘spontaneous’ time. The time taken for each test point however, was greater, which restricted 
the opportunity for actigraphic assessment of spontaneous time. Nevertheless, the activity 
counts in the epochs were reduced to very low levels which were calculated as being ‘sleep­
like’ being under 40 counts per 1 min epoch.
It was also established that this ‘sleep-like’ activity during the 12 h post dose period was 
significantly increased following promethazine administration compared with placebo with 
significant effects at 5 h and 6 h post dose. This timing coincided with the T^ a* (2 -  8 h) 
(Strenkoski-Nix et a l, 2000) of the drug and when the impairment of the psychometric tests 
was greatest. From these data it was clear that promethazine increased the amount of ‘sleep- 
like’ behaviour and that this persisted for up to 6 h after dosing.
Actigraphy was therefore able to demonstrate that there was a significant increase in ‘sleep­
like’ behaviour in the acute phase of treatment immediately following day-time dosing and 
that this effect, as with the LZP study, was mirrored in the impairment of the psychometric 
tests and in LARS participant reported sedation.
When given 1 h prior to sleep at night promethazine is known to increase TST and reduce 
the number of awakenings (Adam and Oswald, 1986). Promethazine, in the Chapter 4 study, 
was administered in the morning to allow the psychometric tests and wheal and flare
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assessments to be conducted during the day. Thus it is likely that the bedtime sedating
effects had diminished and therefore no difference in the actigraphic sleep variables was 
reported compared with placebo. It is also interesting to note that although there was no 
effect on actigraphic sleep variables, there were significant reductions in activity observed at 
11 h post dose, which could indicate that if taken at night there might be a hangover effect of 
medication the following morning.
Although actigraphy was unable to detect overall significant impairment in activity levels 
associated with promethazine, significant impairment in cognitive and psychomotor tests 
was recorded. Greater reductions in spontaneous activity and increases in sleep-like activity 
may have been masked by the test regime, although an effect was detected with actigraphy 
following analysis. The study therefore supports the evidence from Stanley. (1997)
who measured actigraphic ‘sedation’ following promethazine administration with significant 
reductions in activity up to 6 h post dose. The study in Chapter 4 therefore provides 
additional evidence of the usefulness of actigraphy in studying the subtle and unobtrusive 
effects of sedating compounds.
6.6. Chronic study
The studies in Chapters 3 and 4 were performed under strictly controlled conditions, on 
healthy participants with standardised validated tests and procedures. LZP and promethazine 
were used as comparator drugs for the study drugs because of their known effect on the tests 
and actigraphy was able to show the continuous profile of the medication in association with 
the time limited tests. Participants adhered to the strict protocol sleep restrictions which 
confirmed that they were not sleep deprived so that any changes to their sleep and activity 
could be ascribed to the medication.
The psychoactive medications used in Chapters 3 and 4 are however, generally prescribed to 
patients to treat chronic conditions. LZP is prescribed to treat anxiety and promethazine for 
allergic rhinitis. Furthermore, as these compoimds have known sedating and impairing 
properties they are often used as study comparators to test the effect of new medications. 
They afforded therefore ideal opportunity and conditions in which to test the theoretical 
aspect of using actigraphy to record changes in the activity profile in association with 
psychometric tests.
To study the effect of the medication on the activity profile of the patients with these 
conditions in their own environments would be beneficial, since the sedative effects of
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medication could be hazardous and potentially lead to accidents and it is important to 
rigorously assess long term effects rather than base conclusions on a narrow time frame. 
Studying the effect of medication over longer periods of time on patients is more
problematic than acute studies.
Changes in sleep can be recorded in the patient population by PSG but it is expensive and 
time consuming. Even if the recording is conducted in the patient’s home it provides only a
portion of the 24 h picture. Whilst PSG is useful for determining the night-time effect of a 
drug it does not provide information on the effects of medication on daytime functioning and 
on the 24 h circadian sleep wake activity profile. Actigraphy may therefore provide a less 
expensive real-life alternative to PSG.
As a continuous measure actigraphy can be conducted over an extended period of time, to 
acquire activity data in the patient’s natural environment. It can provide objective 
information on sleep quality, daytime activity or inactivity and an indication of circadian 
rhythmicity. In association with subjective questionnaires and cognitive and psychomotor 
tests it is able to add to the information and evidence to deliver the complete picture of the 
effects of medication in patient groups.
Actigraphy requires little effort from patients or participants which may be particularly 
important when studying certain population groups. For example depressed patients might 
find participating in a long antidepressant sleep study with PSG onerous, and may be more
likely to withdraw or not comply with study restrictions. Actigraphy therefore provides a 
means of continuously recording the sleep and wake activity, whereby subtle changes can be 
observed.
The present study detailed in Chapter 5 investigated whether the use of actigraphs would 
provide an objective measure of the ‘in the field’ long term chronic effects of medication. In 
order to determine whether actigraphy would be able to contribute to the measurement of the 
long term chronic effect of medication it was necessary to compare the outcomes of the other 
diagnostic assessments of depression and sleep with questionnaires, as well as cognitive and 
psychomotor assessments. It was important to assess whether the outcomes described above 
showed changes with the depression status of the patients, and if any changes correlated with 
the actigraphy data.
232
The benefit of actigraphy in long-term studies was particularly evidenced in Chapter 5, the 
14 week randomised, double-blind study of the effects of paroxetine 20 mg/day, fluoxetine 
20 mg/day or sertraline 50 mg/day on depressed patients with actigraphy. This was the first 
study to investigate the effect of SSRI antidepressant treatment on the time course and 
duration of action on activity in depressed patients with actigraphy in conjunction with 
subjective questionnaires and cognitive and psychomotor performance. Patients diagnosed 
with depression with a MADRS score > 20 were recruited to the study. Assessments were 
conducted at regular defined interviews and actigraphic activity was continuously monitored. 
In addition during week 13 medication was abruptly discontinued and replaced by placebo, 
for a week, to mimic the effect of patients missing doses, followed by a further final week on 
SSRI treatment. The detailed findings and comparisons with other authors are discussed in 
full in Section 5.6.
6.6.1. Actigraphy
6.6.1.1. Actigraphic sleep variables for the 12 week actigraphy study
The current study in Chapter 5 was the first to report on a 14 week actigraphy study 
comprising 12 weeks of antidepressant treatment, 1 week of abrupt discontinuation followed 
by 1 week réintroduction (Dawson a/., 2010). Actigraphy data were analysed for sleep 
variables from Day 1 to week 14 (Day 98 approximately) continuously, week 1 to week 12
and weeks 12 and 13 to cover the discontinuation period (Section 5.4.3). Weekly means for 
the data were then calculated and analysed.
Given that the 14 week data included night 1 when it was not known whether patents had 
administered medication and the confounding discontinuation period only the results for the
12 week chronic study and the separate discontinuation period will be discussed in this 
section. Concise details of the 14 week findings and comparisons with other authors are 
discussed in full in Section 5.6.
There was no overall significant effect of time or treatment for sleep latency although the 
data suggests that there was a trend for SOL to increase during treatment with paroxetine and 
sertraline. This interestingly conflicts with patient’s perception from HAMD and LSEQ that 
insomnia early and GTS were improved, but supports clinical PSG findings that SSRIs 
increase sleep latency as they are activating compounds (Trivedi er a/., 1999; Hicks a/., 
2002; Jindal et al., 2003).
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Furthermore, there was a significant deterioration in actigraphic sleep quality during the 12 
week treatment analysis, for all treatments overall with significant reductions in sleep 
efficiency and increased number of sleep bouts across time. In addition patients treated with 
paroxetine also showed a significant reduction in TST. The reason for this discord is unclear 
but Winokur cr a/. (2001) suggested that SSRIs have a calming anxiolytic effect which 
encourages the perception of improved sleep, coupled with an activating effect, and 
additionally Wichniak e/ a/. (2012) reported that hypnotics are often co- prescribed with 
SSRIs to aid sleep.
Daytime activity as average wake movement (AWM) although not significant appeared to
increase from week 1 for all treatments. The values for paroxetine were lower which, could 
reflect that paroxetine has a more sedating effect compared with other SSRIs (Abies and 
Baughman, 2003). This increase in AWM was positively linked to a trend for improvement 
in LSEQ ‘behaviour following wake’. If patients actually felt that they slept better they 
might be in a more productive mood and more active the following day.
During discontinuation daytime actigraphic activity as average wake movement (AWM) was 
significantly increased, particularly after fluoxetine and sertraline withdrawal suggesting that
patients were more active during the day. This might imply that throughout treatment the 
antidepressants were having a calming effect by reducing daytime activity but on 
discontinuation patients were more active, or maybe removal of medication led to hyper­
arousal and activation. Patients did not report a worsening of either awakening from sleep 
(AFS) or behaviour following wake (BFW) from the sleep questionnaire LSEQ, although 
patients discontinued from paroxetine treatment felt more sedated according to the LARS 
sedation component.
There may be different conclusions to be drawn regarding the changes in actigraphic sleep 
variables during discontinuation of treatment. Without baseline, comparison of patients’
actigraphic sleep before and after treatment cannot be made. Additionally without PSG to 
confirm the changes in sleep architecture, increased movement in sleep may indicate more 
disrupted sleep or that the changes in activity could be related to changes in sleep 
architecture and REM in particular. When fluoxetine is withdrawn there appears to be more 
activity in sleep but patients did not report sleep worsening. In contrast patients withdrawn 
from paroxetine reported worsening but their activity appeared to fall. It could be that 
patients on fluoxetine or sertraline were having some negative effects whilst on maintenance 
therapy which was alleviated when medication was stopped or that the half-life of the
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medication continued to have an effect. Alternatively with their active metabolite it could 
have meant the therapeutic effect continued to have an effect thereby reducing the effect of 
abrupt discontinuation. Staner er a/. (1995) showed that withdrawal of paroxetine increased 
REM. This effect might be reflected as a reduction in actigraphic activity, as was observed in 
the current study in the total activity counts in sleep. In addition paroxetine has a shorter 
half-life compared with sertraline or fluoxetine which could account for a rebound effect and 
worsening of REM, SOL and GTS.
6.6.1.2. Circadian analysis
Activity data were combined into seven day weekly blocks which included weekends to 
provide the arithmetic means on a week by week basis. Weekly means were compared with 
subsequent weeks and relative changes calculated. Data were analysed by both the cosinor 
andNPCRA analysis programs (Section 1.6.9.1 and Section 1.6.9.2, respectively).
6.6.1.3. Cosinor (parametric) analysis and treatment
No other study, to the author’s knowledge, has investigated the impact of chronic SSRI 
antidepressant treatment on the cosinor rhythms of depressed patients. Analysis revealed that 
there was an overall significant improvement of the percentage rhythm over time for all 
treatments for the 12 week data, with the percentage rhythm increasing (Section 5.5.5.3). 
This indicated that the sleep wake rhythm was improving and stabilising with treatment and 
becoming less fragmented and more organised. This might be a beneficial outcome for the 
patient, with their sleep wake pattern being more regulated.
Increases in the mean activity for amplitude and mesor, suggested that patients were 
becoming more active as treatment progressed, although this did not reach statistical 
significance during the 12 week analysis for any treatment. Interestingly, this trend confirms
the increase seen in the AWM actigraphic variable, which only focuses on daytime activity 
and not the 24 h mean.
An indication that as treatment took effect, and patients felt better according to the MADRS, 
they were more active later in the day, observed by a delay in the acrophase time, which 
occurred slightly later in the biological day. However this effect appeared to reverse from 
about 4 weeks onwards as treatment with paroxetine progressed. These aspects are very 
small in time, being less than 30 minutes, but worthy of further investigation.
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There are very few studies to compare these SSRI effects and what they mean in terms of 
depression however a study of seasonally affective disorder (SAD) patients showed that 
baseline amplitude was reduced and acrophase phase delayed compared to healthy controls 
(Winkler e/ o'/., 2005). Following treatment with 4 weeks of Bright Light Therapy (BLT), 
patients’ amplitude increased and almost normalised to healthy control levels, as depression 
improved. In addition BLT led to a phase advance in acrophase time occurring earlier in the 
biological day. Actigraphic variables were also reported and after 4 weeks of treatment 
AWM and SE had also improved. A study of major depressive disorder (MDD) inpatients 
(n= 26) conducted by Raoux a/. (1994), showed that 6 patients shifted their acrophase 
time by more than 1 h, following treatment with TCAs. Interestingly, of those patients two 
with the earliest phase, delayed, and the one with the latest phase, advanced.
During the discontinuation week for all treatments, the trait of the advancing clock timing 
was reversed, with an abrupt delay of approximately 30 min in the acrophase time. This was 
statistically significant following fluoxetine withdrawal and associated with significant 
increases in amplitude, mesor and percentage rhythm. Why this happened on fluoxetine
withdrawal is unclear but worthy of further examination as to the true meaning of fluoxetine 
abrupt discontinuation on cosinor variables. These effects were associated with the
improvement in subjective outcomes of MADRS and HAMD depression scales, as well as 
improvement in psychomotor function.
In depression, in theory, as REM sleep is increased, activity would be reduced, then 
depression improves REM sleep is reduced and activity increased. During the 12 week 
chronic phase in the Chapter 5 study there was an increase in total activity counts in sleep 
and in sleep bouts indicating more movement which appeared in all treatments. Upon 
discontinuation of paroxetine less activity was seen which could mean that this effect was 
reversed with possible recurrence of REM. A worsening of MADRS and MADRS sleep 
scores also showed a possible rebound effect.
More activity was recorded in total activity counts in sleep following withdrawal from 
fluoxetine and yet MADRS score was improved. This might indicate that there was a further 
reduction in REM and as fluoxetine has a longer half-life the effect of fluoxetine continued 
or that depression had been alleviated. This explanation assumes that although the depressed
patients in the current study complained of sleep problems according to MADRS, as PSG 
was not conducted it is not known whether they actually had the altered sleep architecture 
associated with depression before treatment began.
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6.6.1.4. Non-parametric circadian rhythm analysis (NPCRA) variables
The NPCRA data analysis for the 12 week analysis, failed to show any significant 
differences between treatments for any variable. MIO activity levels for paroxetine were 
again much lower than either fluoxetine or sertraline treatment throughout. Patients treated 
with paroxetine or fluoxetine increased their MIO and 24 h average activity levels, whereas 
activity levels for patients treated with sertraline showed a slight decline throughout the 12 
week period. The increase in average activity and the MIO activity, however, agree with 
observed increases in the AWM actigraphic sleep variable. Mean MIO activity levels have 
been reported to increase in patients treated with agomelatine (a melatonergic antidepressant) 
but decrease in those treated with sertraline between week 1 and week 6 in an antidepressant 
study by Kasper er a/. (2010). This confirms the effect of sertraline seen in the study reported 
in Chapter 5.
A disturbance in the sleep-wake rhythm results in a low RA as shown in Alzheimer’s 
patients (Van Someren er a/., 1999), whereas higher values indicate a rhythm of higher
amplitude (Berle et ai, 2010; Calogiuri et a l, 2013). The RA levels would theoretically 
increase with an improvement in depression, as daytime activity levels increase. In the 
present study however, the RA levels at inclusion were already relatively high and remained 
fairly constant throughout the study. This could indicate that overall patients were more 
active during the day. Interestingly the RA levels for the patients on paroxetine were 
consistently lower than patients on fluoxetine or sertraline, which might be explained by the 
lower activity levels during the day.
Furthermore the baseline RA values of patients in the Chapter 5 study were higher than those 
in the Kasper et al (2010) study. Patients in the current study reported in this thesis had 
higher initial baseline amplitudes and less disrupted rhythms. In addition the inclusion 
HAMD scores of patients in the Kasper et a/. (2010) were, by comparison, greater than the 
MADRS score for inclusion and suggested that their patients were more depressed.
As has been reported there was a delay in cosinor acrophase time observed in the current 
study (Section 5.5.5.4). There was also a trend towards a significant delay in the NPCRA 
MIO onset time for all treatments occurring later in the day, by a mean of approximately 30 
minutes, with a trend towards a significant delay for the sertraline group. The MIO onset 
time delay confirms the delay in acrophase time reported in the cosinor analysis. This 
suggests that as treatment took effect patients were more active during the day, and that the
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onset of activity occurred later, and was associated with improvements in the depression 
scales, activity increased as depression lifted.
During the L5 time in the study reported in Chapter 5, activity levels were similar throughout 
treatment for all patients. Activity levels for patients treated with paroxetine were a little 
higher (non-significant) than fluoxetine or sertraline indicating that perhaps paroxetine had a 
dismpting influence on activity during sleep. Even though these results were not significant 
the current data trends are worthy of further investigation in conjunction with different types 
of depression.
Whether depression affects activity and the sleep / wake timing mechanism, due to its 
adverse effect on sleep, or that depression leads to desynchrony, or whether the irregularity 
causes the depression is unclear. The reason for the improvement in mood and alertness in 
the Chapter 5 study could be connected to a delay of circadian timing as shown by the delays 
observed in the onset times, which is associated with an increase in MIO activity levels.
There was an overall significant effect during discontinuation with increases in average 
activity, amplitude and MIO activity coupled with an advance of the L5 onset time, 
occurring earlier in the night. These factors were also significant for fluoxetine and might 
indicate that circadian desynchronisation was normalising on withdrawal and that patients 
were no longer depressed as the MADR and HAMD scores did not rise significantly.
There was no significant change however in the IS or IV over the 12 weeks of chronic 
treatment overall. Values reported from other studies (Section 5.6.5.6) indicated that 
patients’ rhythms in the Chapter 5 study were reasonably stable even at baseline.
6.6.1.5. Circadian summary
There was evidence that daytime activity levels as MIO, average activity and AWM 
increased in association with improvement in depression rating and sleep questionnaires. It is 
likely that the activity of most of the patients in the current study was to some extent 
controlled by external factors therefore it might be difficult to see obvious changes in 
circadian NPCRA compared with studies conducted in hospitalised patients whose activity is 
not so controlled. These analysis methods do allow for different aspects of actigraphic 
activity to be reviewed, and are worthy of further investigation.
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6.6.2. Questionnaires
6.6.2.1. Montgomery-Àsberg Depression Rating Scale (MADRS), Hamilton
Depression Rating Scale (HAMD) and ZUNG
The depression questionnaires MADRS and HAMD, administered by the local physician, 
were used to assess improvement in depressive symptoms and the ZUNG depression 
questionnaire was completed by the patient. The MADRS, HAMD and ZUNG scores 
(Section 5.5.7) all showed that patients responded well to treatment, with statistically 
significant improvement in depression scores. By week 14 patients were considered to be ‘in 
remission’ according to the MADRS score. There was no statistically significant difference 
between treatments. These findings are in agreement with similar 10 to 16 week studies with 
similar medications (Fava et a l, 2000, 2002) (Section 5.6.3).
Discontinuation symptoms are a recognised outcome of abrupt SSRI withdrawal which can 
lead to a rebound and resumption of depression symptoms. Although the SSRTs have 
different pharmacokinetics and half-lives, which could reflect their effect time, depression 
questionnaires revealed that although there was a slight increases in scores following 
paroxetine withdrawal on HAMD, and following paroxetine and sertraline withdrawal on 
MADRS, this was not statistically significant for treatment or time (Section 5.5.7). This 
differs to Rosenbaum et a l (1998) where both MADRS and HAMD scores of patients 
treated with paroxetine or sertraline, after one week treatment disruption, were significantly 
higher compared with fluoxetine.
Although the SSRIs are not prescribed for aiding sleep and PSG studies have shown that 
they have a deleterious effect on sleep, by improving depression, perception of sleep may 
improve. The MADRS and HAMD sleep-related questions indicated that for MADRS, 
patients’ sleep duration or depth of sleep was significantly improved for all treatments by 
week 12 with a significant effect for paroxetine. The HAMD sleep item also indicated that, 
patients felt that their sleep was statistically improved (again significant for paroxetine). This 
was also seen in the sleep component of HAMD in ‘early insomnia’ associated with SOL for 
all treatments overall (again significant paroxetine).
These improved sleep aspects of both questionnaires contrast with no improvement in 
actigraphic sleep variables, paradoxically these worsened. Perhaps the effect of the SSRIs 
was to normalise sleep architecture impaired by depression. The HAMD findings 
substantiate the improvements reported in the Fava c/ a/. (2002) study with the same SSRIs.
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During the abrupt discontinuation week scores were significantly worsened for the MADRS 
sleep component for paroxetine and sertraline. A  similar worsening was seen in HAMD with 
a rebound effect and an increase in scores for paroxetine and sertraline.
Patient-reported depression with the ZUNG provided similar improvements with reductions
in scores to HAM D and MADRS. This finding supports comparable data with similar 
improvements in ZUNG and M ADRS (Aguglia et a l, 1993). During discontinuation self- 
rated depression following paroxetine worsened confirming the results obtained by 
Hindm arch et a l (2000a).
6.6.2.2. Leeds Sleep Evaluation Questionnaire (LSEQ)
In Chapter 5 the Leeds Sleep Evaluation Questionnaire (LSEQ) showed that ‘getting to 
sleep’ (GTS) was significantly improved overall for the 12 weeks o f  chronic treatment
Subjective GTS is comparable to actigraphic sleep latency but this was not improved. 
‘Quality o f  sleep’ QOS was also significantly improved whereas actigraphic variables
indicated sleep was worsened with increases in sleep bouts, activity and W ASO.
N o effect o f  ‘awakening from sleep’ AFS, was observed, none o f  the treatments adversely
affected the patients’ ability to wake up indicating that there was no hangover effect. 
Reduction in ‘behaviour following wakening’ BFW  indicated a trend for improvement 
overall, all patients feeling more alert and less clumsy.
There was no overall statistical difference between treatments during discontinuation for any 
o f  the LSEQ variables apart from QOS scores with a trend for im provem ent following 
withdrawal from fluoxetine and sertraline. Although there were indications that patients 
withdrawn from paroxetine experienced a worsening o f  GTS and AFS, this was not 
significant. Discontinuation o f  sertraline treatment on indicated a trend for improvement.
Paradoxically increased actigraphic sleep latency was not associated with ease o f  ‘getting to 
sleep’ neither were increased sleep bouts and actigraphic sleep activity with ‘quality o f  
sleep’. The reason for the discord may be related to the patients’ perception o f improved 
sleep following treatment w ith LSEQ and actigraphy, or that additional m ovem ent did not 
actually impair their sleep or cause them to wake. Winokur e/ a/. (2001) suggested that 
SSRIs have a calming anxiolytic effect which encourages the perception o f  improved sleep 
and Wichniak gr a/. (2012) reported an activating effect with SSRIs.
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6.Ô.2.3. Line Analogue Rating Scale (LARS)
At baseline, patients felt more tired and sedated or lethargic than before they were depressed. 
Scores were all significantly improved for the 12 weeks analysis overall which indicated that 
all patients felt more alert as treatment progressed and no significant difference between the
three treatment groups was reported.
LARS worsened after paroxetine withdrawal, but this was still lower than baseline, whereas
discontinuation from fluoxetine or sertraline showed little change. LARS feelings o f sedation 
after paroxetine withdrawal contrasted with actigraphic variables with increased activity. 
M aybe the increase in activity made the patients feel m ore tired or their disrupted sleep 
increased fatigue. Worsening o f  LARS was associated with worsening o f  QOS in LSEQ. 
These findings confirmed those o f  Hindmarch et al. (2000a) who reported that paroxetine 
increased sedation scores.
Ô.6.2.4. Cognitive Failures Questionnaire (CFQ)
Baseline CFQ values indicated cognitive impairment, but by week 12 scores were 
significantly improved and comparable to control participants from other patient studies 
(Fairweather a/., 1999). Patients felt more co-ordinated and alert and more able to perform 
simple everyday tasks without impairment in memory, attention and motor function.
During paroxetine discontinuation scores increased, but not significantly. In contrast scores 
following fluoxetine and sertraline discontinuation reduced. As these effects were not 
significant, impact on the CFQ scores indicated that patients were not adversely affected in 
their ability to maintain normal functioning.
6.6.3. Critical Flicker Fusion (CFF) and Choice Reaction Time (CRT)
Patients’ cognitive function was significantly improved for all treatments in the 12 week 
study (Section 5.5.7). Both CFF and CRT total reaction time, were improved from baseline 
most o f  the effect occurring in the first 8 weeks o f  treatment, after which the effect 
plateaued. Fairweather et al. (1993), and Kerr et al. (1993) also showed that fluoxetine 
improved CFF performance in depressed patients over 6 weeks and Alexander g/ a/. (1997) 
demonstrated that paroxetine significantly improved CFF threshold over 6 weeks. There is 
lim ited evidence o f the effects o f  long term use o f sertraline in depressed patients on CFF or 
CRT. This study therefore addresses this gap in knowledge and shows that sertraline also had 
a statistically significantly positive effect with a CFF elevation in threshold, and a
241
statistically significant reduction in total reaction time in CRT. This clearly demonstrates that
the SSRI antidepressants improved cognitive function as depression was improved
Discontinuation from paroxetine, however, significantly worsened total reaction time o f 
CRT whereas discontinuation from sertraline significantly worsened CFF processing. A  
study by Hindmarch a;/. (2000a) investigated the effect o f  brief discontinuation o f the same 
SSRIs on CRT and CFF but no effect on CFF processing was reported for any treatment in 
contrast to the current study. A ll treatments increased reaction time, with a greater increase 
in time with patients discontinued from paroxetine. This was in contrast to the Chapter 5 
study where reaction times significantly increased only with paroxetine withdrawal, whereas 
reaction times were not impaired following fluoxetine and sertraline withdrawal. The results 
ftom both studies suggest that the consequence o f  abrupt paroxetine withdrawal causes a 
worsening o f  cognitive performance and mood symptoms which m ay be related to the 
shorter half-life o f paroxetine. Furthermore, the Chapter 5 study also adds to the limited 
information available o f  the cognitive and psychomotor performance data outcomes o f  long 
term  SSRI treatment and discontinuation.
6.6.4. Conclusions
The main effects found in the study were that the SSRIs did not improve actigraphic sleep 
variables indeed the change in variables showed that overall sleep efficiency reduced and the
num ber o f  sleep bouts increased. This is in agreem ent w ith PSG findings as it is known that 
SSRIs reduce REM and increase REM latency as reported in reviews by W ilson and 
Argyropoulos. (2005) and Wichniak et al. (2012). Changes in SE and number o f  sleep bouts, 
which are m easured from activity counts, could be due to a reduction in REM, so 
theoretically a reduction in REM would increase activity.
The study showed that there was no significant difference between treatments for any o f  the 
actigraphic sleep variables; neither did any treatm ent improve actigraphic sleep variables 
during the 12 weeks o f  chronic administration. Slight differences in the actigraphic profiles 
o f each SSRI were however recorded; the actigraphic sleep o f patients on paroxetine and 
fluoxetine treatment was disrupted more than those treated with sertraline. There was also a 
significant increase in the number o f sleep bouts for all treatments and a trend for reduced 
sleep efficiency following paroxetine and fluoxetine treatment.
Circadian rhythm NPCRA and cosinor variables for the 12 week analysis similarly failed to 
show any significant differences between the treatment groups. Although activity levels for
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paroxetine were lower than either fluoxetine or sertraline treatment, patients treated with 
paroxetine or fluoxetine also increased their activity levels in MIO and 24 h average. There 
was a significant improvement o f  the percentage rhythm over time for all treatments for the 
12 week data which indicates that the sleep/wake rhythm was less fragmented. A  trend for a 
circadian delay in timing was also reported with the acrophase time occurring slightly later 
in the biological day which suggests that as depression was alleviated patients became more 
active and that this occurred later in the day.
The depression questionnaires M ADRS, HAM D and ZUNG all demonstrated that depression 
was significantly relieved for all treatments. Furthermore, in contrast to the actigraphic sleep 
variables the sleep items from MADRS and HAMD showed that patients felt that their sleep 
was improved which was also reflected in significant im provement in the LSEQ items, 
getting to sleep, (GTS), quality o f  sleep (QOS) and behaviour following wake (BFW). In 
addition LARS sedation was significantly relieved with all patients feeling more alert and 
less fatigued, which was also significant following paroxetine and fluoxetine treatment. The 
improvement in LARS although not reflected in improved sleep was reflected in increased 
daytime activity and an im proved circadian amplitude.
Patients’ cognitive skills were also improved for all treatments with significant reductions in
CRT overall reaction times and significant improvement in CFF. Although no significant 
differences between treatments in CFF or CRT were found, significant improvements in 
reaction times were recorded following treatment with sertraline. All patients felt 
significantly less clumsy and more in control from the CFQ questionnaire, there was no 
significant difference between treatments, each treatment significantly improved patients’ 
perception.
With regards to discontinuation from treatment, there was no significant difference between 
treatments. Only the MADRS sleep item was adversely affected and significantly worsened, 
patients felt that they had less sleep. This was confirmed with the actigraphic sleep variables 
where there was a significant reduction in timing with reduced TIB, SPT and TST and yet a 
trend for improved QOS was suggested with LSEQ. However, for any treatment, the daytime 
activity variables, AWM, amplitude, mesor, average activity and MIO activity all 
significantly increased following discontinuation.
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6.7. Limitations
There are many issues surrounding the use o f actigraphy to consider, the main limitations are 
described below. Recommendations to overcome some o f  these limitations are also listed.
6.7.1. Actigraphy limitations and recom m endations
Actiwatches have sensors unique to each device; to ensure that data from one period to 
another is comparable the same watch should be used. The sensors on watches can degrade
or break; to ensure that the sensor is accurate they should be regularly calibrated and 
validated. Sensors also lose time during recording; checking internal clock time m arkers with 
computer clocks ensures that real time is recorded accurately.
Actiwatches have finite lengths o f  recording times, when using the older versions allowance 
should be made to cover the study with the least number o f  changes. Different sensors give
different activity levels therefore long term  studies should ensure that, where possible, the 
same actiwatch is used for one patient throughout.
6.7.2. Acute studies
In the acute studies in Chapters 3 and 4 data were extracted to compartmentalise the activity 
data between the tests, this lim ited the am ount o f  available data. The activating effects o f 
performing the tests could also have impacted on the activity levels and reduced impairment. 
When using actigraphy to measure acute changes in activity and actigraphic sleep, future
studies might consider including additional unrestricted time.
Actigraphy is particularly useful for ensuring participant compliance to study restrictions 
during the washout period, but they can be removed. Restricting removal ensures continuous 
record between periods.
6.7.3. Long-term studies
To cover longer studies actiwatches can be set up with larger epochs. Using larger epochs 
greater than 1 min, however, restricts the ability to calculate some variables which rely on 
the 1 min activity epoch e.g. ftagmentation index. In the case o f  the antidepressant study 
different epochs o f  1 min and 2 min were used (Section 5.6.9.3). To ensure parity the 
actiwatch files were edited to the larger 2 min epoch so that errors caused by trying to force 
2 minute data into a 1 minute epochs were not introduced. This is not an issue, however, for 
NPCRA analysis as the data are treated in whole hours.
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Actigraphy is currently unable to detect sleep from ‘quiet wake’, when the activity is set at
the medium setting, which would be especially useful in clinical situations, better algorithms 
to detect sleep and wake would be beneficial. Chronic long term studies should in addition 
incorporate diaries so that bedtimes can be clarified, when markers have not been pressed.
The depression study in Chapter 5 covered all ages from 18 to 84 years, depression occurs at 
any age; thus dividing patients into different age bands should be considered. Patient
numbers were reduced after the exclusion o f those not wearing the actigraph, coupled with 
the confounding factors o f  patients in real life environments, greater sample sizes might be 
advised in future to smooth out any outliers. No allowance was made for the type o f 
depression, i.e. whether patients were melancholic w ith psychom otor retardation, or were 
anxious with agitation, as these differing activity levels may also have confounded the 
results. Neither was allowance made for whether patients responded to treatment or not, non- 
responders again may have affected the outcomes. Depression severity at inclusion was 
moderate, perhaps in future, include patients with m ore severe depression and stratify for 
depression level. The actigraphic activity and sleep variables were not indicative o f  severely 
impaired sleep/wake schedules so changes induced by treatm ent were small.
Baseline activity recordings were not recorded in the depression study Chapter 5 neither was 
there any placebo run in; comparisons o f activity and sleep prior to treatment would be 
advisable. There was no placebo comparator or comparable sedating antidepressant used, 
this would have allowed comparisons between activating and sedating antidepressants. The 
PSG sleep architecture and diagnosis o f the patients was unknown, ideally for future studies 
a sleep PSG baseline should be recorded. In addition post study PSG at 12 weeks and 13 
weeks would provide further evidence o f  changes in sleep architecture with antidepressant 
treatment.
The study was conducted at different times o f  the year with varying lengths o f  daylight 
(Section 5.6.9.1). It would be interesting to see whether the increasing amount o f available 
sunlight effected the depression levels, as SAD patients are more depressed during the winter 
months (Winkler a/., 2005). During the current study patients’ recordings were conducted 
across the clock changes from GMT to BST, in addition holidays such as Christmas and 
N ew  Year impacted on activities and bedtimes, future consideration o f  these events is 
advised. No account was made for momingness or eveningness preferences; this may have 
affected the circadian timing aspects.
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It would be interesting to follow-up the patients after the study 12 weeks o f  chronic 
antidepressant medication could be extended after discontinuation or further recording 
without medication. Ensuring that circadian desynchrony does not re-emerge when 
pharmacological therapy has ended is important for the long term recovery ft"om depression.
6.8. Further research
The studies presented have highlighted that for both acute and chronic drug studies 
actigraphy is useful and suggestive o f  further research. Actigraphic recordings following 
administration o f  a variety o f  psychoactive compounds, and their effects on actigraphic
variables in relation to PSG, would be a useful database, not only in healthy participants but 
also o f patients. This could be used as a reference point for clinicians. Studies using 
actigraphy to measure the ‘sleep-like’ sedative activity o f  other psychoactive compounds and 
drug groups are warranted and will be necessary to further validate this method as a useful 
tool in psychopharmacology.
For depression studies one factor not considered in the current study was the extent o f 
response to treatment, and whether there were actigraphic differences between responders 
and non-responders. O ther studies have looked at this aspect and grouped the patients 
accordingly (Rosenbaum et al, 1998; Todder et al, 2009).
Further research into the circadian rest-activity rhythms o f  a variety o f mental illnesses 
including bi-polar and schizophrenia and m oreover the different types o f depression in 
patients would be desirable together with the subsequent acquisition o f reference recordings. 
These could be used to not only determine if  there are different rhythms in the varied forms 
o f depression but to also build a reference database w ith which clinicians could compare 
their patients.
Variables which indicate improvement in rest-activity rhythms could be standardised with 
ranges o f  values and a program  devised to interpret response and positive outcome 
(Maglione er a/., 2012). It has been suggested that the worse the depression the more 
disrupted is the rhythm (Burton a/., 2013; Moraes gf a:/., 2013) so to monitor this longer
term  would be useful, to ensure that not only has resynchronisation occurred but that the 
positive outcome has been maintained. M aintenance o f  the improved rhythm is im portant to 
safeguard the long term recovery from depression (Courtet and Olié, 2012). Depression is 
multi-factorial and so continual re-evaluation o f depression is essential to determine whether
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dose titrating is necessary, if  relapse is occurring, whether supplementary medication is 
required or i f  psychotherapy with CBT might be useful.
It is accepted that chronobiology (Malhi and Kuiper, 2013) plays an important part in the 
treatment o f depression and to record circadian rest-activity changes with actigraphy might
be useful in recognising remission with a return to norm alisation o f the circadian rhythm. In 
a series o f  papers (Malhi <3/., 2013a) a holistic approach is suggested which discusses a 
variety o f  aspects including diagnosis, treatment and the management o f  depression (Malhi 
a/., 2013b; Lampe e/ a/., 2013; Berk a/., 2013). It has been suggested that although
m elatonin in itself does not have an antidepressant effect, altering circadian timing with 
m elatonin might be (Boyce and Hopwood, 2013). If  used in association with SSRIs, light 
therapy or psychotherapy the clinician may find the use o f actigraphy beneficial as an
adjunct to determine restoration o f  circadian rhythm icity (Kuiper et a l,  2013).
A review o f  circadian rest-activity timing using actiwatches with associated delays and 
advances in depression in general practice would be useful to build on the limited data 
available. M ost studies have been conducted in research groups with small numbers, and 
focused on patients within drug trials so that the positive outcome o f  the medication is 
reported. Other studies have been conducted in short periods o f time (e.g. less than 6 weeks) 
when it is recognised that the depression response is longer (at least 3 months). Thus in 
future long term  actigraphy studies, with larger numbers, to track the time course o f  
treatment up to 6 months, irrespective o f the treatment or m edication would be useful. A 
greater understanding o f  the circadian rhythm and the dis-regulation o f  sleep might provide 
new strategies o f behaviour or treatment or both (Germain and Kupfer, 2008).
PSG studies have shown that the SSRIs adversely affect sleep and this was supported by the 
actigraphy data in the current study even though patients felt that their sleep was improved.
The correlation between subjective and objective actigraphic sleep is therefore w orthy o f 
further investigation.
Clinical trials o f  antidepressants are varied, with different classes o f  antidepressants, a 
variety o f  outcome variables, long-term use in patients, short-term effects in healthy 
participants as well as hospitalised patients and patients in their own homes to name but a 
few, it is difficult for the clinician to draw conclusive evidence o f which ones work best. To
aid the clinician with a simple non-invasive diagnostic tool such as circadian rest-activity
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rhythms with actigraphy might be unrealistic but might help to unravel the interpretation o f  
meta-data and clinical trials (Kirsch e/ a/., 2008; Sussman, 2007).
6.9. Conclusions
The acute studies in this thesis provide evidence that actigraphy is sensitive not only to the 
acute sedating effects o f LZP and promethazine, as measured by a reduction in behavioural 
activity, but also to the residual effects o f  the drug the morning after dosing. These studies 
also confirm  that the actiwatch is able to detect the effects o f a hypnotic on sleep and is able 
to provide an indication o f  the clinical effects o f  medication. Moreover these studies add 
further evidence that actigraphy can provide a reliable and sensitive indicator o f  the time 
course o f  action o f psychoactive drugs. In both acute studies the data also showed that it was 
possible to detect changes in daytime activity due to the psychoactive effect o f the 
medication. Actigraphy appears therefore to be a useful adjunct to clinical studies to measure 
the effect o f  sedating medication on activity even when confounding cognitive assessments 
are being performed.
Issues surrounding the use o f  actigraphy as a tool in clinical research basically centre on the
validation o f  the actigraphy devices including standard operating procedures and methods o f 
recording activity which can be interpreted and standardised as has been the case w ith PSG 
(M orgenthaler et al,  2007a). Algorithms to detect sleep and wake, especially during quiet 
wakefulness, are required as these remain an anomaly within the actigraphy community. In 
addition, in order to optimise the measurement o f  activity it is important to consider study 
design to capture the required variables without interference from confounding factors. 
Further studies are required to validate different therapeutic interventions in a variety o f 
patient groups (Peterson ef a/., 2012).
It is often difficult to draw conclusive evidence when com paring different studies because o f 
the different actigraphs used, the differences in the study protocols and methodology, time 
spans and epoch length, coupled with the development o f  the device over the last 30 years 
and the different algorithms to calculate the derived actigraphic variables. Often the 
limitations o f  the device, the logistics o f  the protocols and the patients / participants pre­
decide the methods employed, therefore it would be useful to collect normative data and data 
for specific sub-types for comparison across studies.
Actigraphy remains a relatively cheap non-invasive research instrument to study rest-activity 
in longer term chronic studies (Morgenthaler 6/ a/., 2007b) and has been suggested as an
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alternative to PSG although with some limitations (Morgenthaler gf a/., 2007a; McCall and 
M cCall, 2012). The actigraphy results from the study reported in Chapter 5, are associated 
with improvements in depression and cognitive and psychomotor performance, and are thus 
a useful adjunct to the effect o f  SSRIs on depressed patients as a continuous objective 
indicator o f  the outcome o f  treatment on sleep and activity where PSG would be 
impracticable.
It is interesting to observe that, although not statistically significant, as depression was 
alleviated there were suggestions that circadian rest-activity rhythmicity was improved and
daytime activity was increased with treatment as evidenced in the actigraphic variables o f 
MIO activity, average wake m ovement and amplitude. This m irrored clinically significant 
improvements in M ADRS and HAM D and subjective sleep quality and demonstrated a 
consistent improvement in depression. These findings suggest that as depression was lifted 
and mood improved patients became more active during the day.
Interestingly night-time actigraphy data showed that the number o f  sleep bouts increased
particularly with paroxetine treatment. This might suggest that sleep was impaired but as 
there was neither baseline nor pre-dose data, and since the sleep bout values were not 
excessive, it cannot be deduced that actigraphic sleep was worse during the 12 week chronic 
phase. It may in fact mean that patients were less restricted in their sleep. Depressed patients 
have more REM and shorter REM latency, whereas SSRIs are known to disrupt sleep by 
reducing REM and increasing REM  latency. I f  patients sleep was therefore improved with a 
reduction in REM, theoretically this might manifest as increased activity during sleep as 
sleep was normalising. Unfortunately this aspect could not be explored as the sleep 
architecture o f  the patients was unknown.
The study reported in Chapter 5 provides valuable evidence o f  the potential for actigraphy to 
continuously record and track the effect o f  m edication on depressed patients. This study was 
the first to investigate the effects o f  chronic antidepressant treatment over 12 weeks with 
actigraphy followed by a period o f  abrupt discontinuation. A positive outcome for this study 
was that patients were compliant and wore the Actiwatch for 14 weeks. However one 
beneficial aspect for further study consideration for this group o f  compounds would be to 
define the effect o f treatment on the activity profiles o f  responders and non-responders. 
Potentially these devices and standard outcomes could be used to aid clinicians as to the 
progress o f medication. The Help4 Mood EU Consortium project which ‘az/Mj /o (/gve/qp a 
/o w/zo are j^ zg^ z/zcazz/Ty z^cz'eo  ^6z// are .yri// a6/e fo
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/zve a / Aome worArmg ' is using actigraphy. However there remain six issues
to address: c/mzca/ ^rr/zer /zg/^/ /^zz^ /ze^ ; /ozzgzrzzzfzzza/ zzMy^ rovgzf
azzzz/yrzca/ z/zer/zoûk; cAamc^enjzzzg zzcrzgrqpAzc vzznarzozz zzz zfz^ r^-gzzr z)^e^ üfi^rgj j^zozz' 
(Burton e/ a/., 2013).
To summarise, this thesis has demonstrated that actigraphy has the potential o f  being a useful 
tool for drug research and clinical diagnosis and treatment, given the caveats outlined. 
Although the thesis has focused on psychoactive compounds, actigraphy has been 
successfully used and remains to be a useful objective tool for recording the impact on sleep 
and activity profiles in a m ultitude o f  situations where PSG would be unacceptable. 
Conditions such as chronic pain in arthritis, diabetic neuropathy, fibromyalgia, rheumatism 
and ME that disrupt sleep with the consequence o f  sleep loss and lead to reduced daytime 
functioning may be better understood with long-term assessment via actigraphy. In addition 
mental conditions which deteriorate over time in the aging population such as dementia, 
Alzheimer's disease and transient ischemic attacks or disorders that can abmptly deteriorate 
with subtle changes in sleep and wake patterns e.g. bipolar disorder and schizophrenia may 
be ideal diseases for actigraphy to play a role in clinical evaluation.
The studies presented in this thesis have endorsed previous findings and shown that 
psychomotor performance impairment and reduced processing skills, and subjective 
assessment o f  sedation are associated with changes in actigraphy (Stanley, 1997; Stanley and 
Hindmarch, 1997; Stanley er a/., 1999). In contrast to the psychometric tests which are a 
snapshot at a defined time actigraphy provides an unobtrusive continuous measurement o f  
activity and therefore any changes in activity associated with the effects o f  a drug or 
condition may be measured in a more time-specific manner.
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Appendix I: CRF -  MADRS
MONTGOMERY-ASBERG DEPRESSION RATING SCALE
INFORMATION NOT OBTAINED:
If this information was not obtained, place a tick (X or V) in the INFORMATION NOT OBTAINED 
box. No other information should appear under this module.
MADRS ITEMS;
Based on an interview by a qualified cHnician, tick (X or V) the one response that best describes 
the patient In reference to items 1-10. The evaluator must decide whether the rating lies on the 
defined scale steps (0,2,4,6) or between them (1,3.5).
TOTAL SCORE:
Add the responses to questions 1 -1 0  and place in Total Score box.
PLEASE NOTE THAT THE TOTAL MADRS SCORE FOR VISIT 1 
MUST BE >20 FOR PA TIENT TO BE ELIGIBLE FOR 
ENROLLMENT
THE SAME EVALUATOR SHOULD EVALUATE THE SAME PATIENT AT ALL VISITS.
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MONTGOMERY- ASBERG DEPRESSION RATING SCALE (MADRS)
INFORMATION NOT OBTAINED □
The rating should  be based  on a  clinical inter­
view m oving from broadly phrased  questions 
about sym ptom s to m ore detailed o n es which 
allow a p rec ise  rating of severity. The ra ter m ust 
decide  w h ether the  rating lies on the defined 
sca le  s te p s  (0. 2 . 4 ,6) or betw een them  (1, 3 ,5 ).
C heck th e  box which b est characterizes the 
patient a t  this time
1. APPAR ENT SADNESS
R epresen ting  despondency, gloom, and 
d e sp a ir  (m ore than Just ordinary transien t 
low spirits), reflected in sp eech , facial 
express io n , and posture. R ate by dep th  and  
Inability to brighten up.
□ p  No sa d n e ss .
□  ,
□  J Looks dispirited but d o e s  brighten up
without difficulty.
□  g
□  ^  A ppears sad  and unhappy m ost of the
tim e.
□  s
Q g  Looks m iserable all th e  time. Extremely 
despondent.
2. REPORTED SA D N ESS
R epresen ted  by reports of d e p re ssed  mood, 
regarc less of w hether it is reflected tn ap- 
p e a ra ix e  or not. Includes low spirits, d e ­
spondency. or th e  feeling of being beycr>d 
help and without hope. R ate  according to 
Intensity, duration, and the extent to which 
the  mood is reported to be  influenced by 
events.
□o
□ a
O .
□ 4
□ s
O ccasional sa d n e ss  in keeping with the 
c ircum stances.
Sad or low but brigfitens up without 
difficulty.
Pervasive feelings of s a d n e s s  o r gloomi­
n ess . T he m ood is still influenced by 
external c ircum stances.
Continuous unvarying s a d n e s s , misery 
o r despondency .
3. INNER TENSION
R epresenting feelings of lil-defined discom ­
fort, ed g in ess , inner turmoil, m ental tension 
mounting to e ither panic, d read , o r  anguish. 
R ate  according to  intensity, frequency, 
duration, and  the extent of re a ssu ran c e  
called for.
Placid. Only fleeting inner tension .
□  t
Occasional feelings of ed g in ess  and  
iU-defir*ed discomfort.
□ 3
Q  J Continuous fe e l in g  of inner tension  or 
intermittent panic  which the  patien t can 
only m aste r with so m e difficulty.
□ s
Q g  Unrelenting d read  o r anguish. 
Overwhelming panic.
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4. REDUCED SLEEP
R epfesen iirg  the experience o< r&duced 
rfuraiion o r depth oi sleep  com pared to 
the subject’s own pattern when v/ell.
S leeps as usual.
□  .
□  J, Slight pgficulty dropping oft to sicco or
slightly reduced, light cf fitful sleep.
□ 3
Q *  S leep  recf jc e d  or broken by at least two 
hours.
□ s
□  g L ess than Iwo or three hours sleep.
5. REDUCED APPETITE
R epresenting the feeling of a  loss of appetfto 
com pared with w hen well. R ate by 
loss of desire for food or the need  to force 
oneself to eat.
P j j  Normal or increased appetite
□  1
Q  J 5% h(ly reduced appetite.
Os
No appetite. Food is taslc less.
□ 5
P ç  N eeds persuasion to e a t at all.
6. CONCENTRATION DIFFICULTIES 
R eprasenling difficulties in collecting o re 's  
thoughts mounting to incapacitating 
lack of concentration.
p  J No Eâfricuîties in corccntrating.
□  ,
P j  Occasional cf'fficuHies in collecting one s 
thoughts.
O s
Difficulties in concentrating and 
sustalnrog Lhougtit which reduces ability 
to read or hold a  conv&rsebon.
□ s
p ^  Unable to read o r conversa vrthout 
g reat difficulty.
7. LASSITUDE
Representing a  tSillfculty getting started  or
slow ness ihidating and performing everyday
acbvMies.
P g  Hardly any difficulty In getting started . 
No sluggishness.
□  1
□  ^  Difficulties in sla/ting act-Vltics
□ 3
P ^  Ditflcullies in starting simple routine 
activities which are carried out with 
effort.
Ü,
P g  Com plete lassitude. Unable to do 
anything without help.
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e. INABILITY TO FEEL
flepresen ting  the subjactiv® exparienc® of 
feoucad  intenesf in tn* surroundings, or 
activHies 1bat rwrmWly givo pleasure. Tha 
abllSy to reac t vrith ad eq u a te  emoTor. to 
c ircum stances or people Is reduced.
□ g  Normal interest In the surroundings and 
other people.
□ ,
□  j  Radc-ced atâlity to enjoy usual interests, 
□ a
□ s
□«
I L o ss of interest irt the sur,'Ourvdir>gs. 
L o ss of feelings for M ends and 
acqiiaintansBS,
T h e  experience of being emotionally 
paralyzed, inability lo  feel anger, grtcf, or 
p leasu re  and a  com plete or even painful 
failure to  feel fo rc lo se  relatives and 
friends,
10. SUICIDAL THOUGHTS
Representing the (eeirng that life is not wonh 
living, that a  natural death  would ba 'r^loom e. 
sukpdal thoughts, end  preparations for suicide. 
Suicidaj anom pts should r>ot in 
them ssA/es influence the rating.
□  g Enjoys life or laKes it a s  it c o o e s .
□  t
□  g W eary of life. Only fleeting suicidal
thoughts.
□ a
Q ^ P rc tja b ly  better off d ead . Suicidal 
thoughts are  common, and  suicide 
is a>3s>dered a s  a  possible solution, but 
withom specific p b n s  o r intendcn.
ÜB
Q g  Explicit plans for suicide when there  is an  
opportunity. Active preparations for 
sitcide .
9. PESSIMISTIC THOUGHTS
R eoresentsng thoughts of guiS, inferiority, 
self-reproach, sinfulness, rem orse, and ruin
P q No pessim istic thoughta, 
D i  
□ a
Os
n *
□»
□ a
Fluctuating ideas of failure, self- 
reproacti, o rse i1*depreciation.
Persisten t se lf-accjsa tio ra , ordclirWle 
but still national ideas of guHt, or sin. 
Increasingly pessim istic about the future.
Delusions of ruin, romorse. or unredeem­
able stri. Sell "accusations whiOh are 
absurd and unshakable.
(DMDQ
Total S core .
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Appendix II; CRF - HAMD
HAMILTON DEPRESSION SCALE. IT ITEM SCALE
INFORMATION NOT OBTAINED:
M this Wormalbn was not obtained, place a lick (X or V) in the INFORMATION NOT OBTAINED 
box. No other information should appear under this module.
HAM-D ITEMS:
Tick (X or V) one appropriate response tor each of the 17 Items on this scale.
TOTAL SCORE:
Enter the score for all 17 Items.
THE SAME EVALUATOR SHOULD EVALUATE THE SAME PATIENT AT ALL VISITS.
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HAMILTON DEPRESSION SCALE 17- ITEM SCALE
INFORMATION NOT OBTAINED □
CHECK THE NUMERIC CODE which bes« descr<«!S Ihe patient.
1. DEPRESSED MOOD: 
helpless, worthless)
n .  Absent
□ ,  Those leellng s la tes indicated onPy on 
questioning 
n  j  These feeling s la tes spontanecusfy 
reported verbally 
n  j Communicates feeling sla tes non­
verbally 16, through facial expression, 
posture, voice, and tendency to weep 
□ ,  Patient reports VIRTUALLY ONLY these  
feeSr>g states in his spontaneous verbal 
and non-verbal communication
2. FEELINGS OF GUILT 
O g  Absent
□ ,  Self-reproach, feels he h as tel people 
down
□  j Jcteas of guilt or rumination over past
errors or sinful d eeds
□  ,j Present illness is a  punishment. Delu­
sions of guilt
□   ^ Hears accusatory or denunciatory voices
and*or experiences threatening visual 
hallucinations
3. SUICIDE
□  , Absent
P , Feels life is not worth living
□  j W ishes he wore dead or any thoughts of
possible death to self 
n  j Suicide ideas or gestures 
□ ,  Attempts suicide {any senwus attempt 
rales 4)
I, INSOMNIA EARLY
Q ç  No difficulty faWIng asleep 
□ ,  Complains of occasional dlflioult^f falling 
asleep, ie. more than 1/2 hour 
O  J Complains of nightly difficulty falling 
asleep
{Sadness, hopefess, s. INSOMNIA MIDDLE
n  p f4o difficutfy
□   ^ Patient complains of being reslless and
disturbed during the rilght
□  g Waking during the night •• any getting out
of bed rates 2 (except for purposes of 
voiding)
G. INSOMNIA LATE
□  ^  No difficulty
Q  , Waking in earfy hours of the morning but 
goes back to sleep 
O , Unable to fall asleep agatn if gets out of 
bed
7. WORK AND ACTIVITIES 
□ ,  No difficulty
Q   ^ Thoughts and feelings of incapacity, 
fatigue, or weakness related to aclhnties. 
work. Or hobbies
□  g Loss of interest In activity, hobbies or
work: -  either directly reported by patient, 
or indirect in lisilassness, indecision and 
vacillation {feels ho has to push sell te 
work or join activities}
□  J  Doorcase In actual time ^ e n t  in edivfties
or decrease  in productivity.-In hospital, 
rate 3 if paliertt does net spend at feast 
three hours a day in activities (hospital 
job or hobbies) exclusive of ward chores
O . Slopped working because of present 
illness. In hospital, rate 4  if paliertt 
er>gages in no activities except ward 
chores; or it patient fails to perform ward 
chores unassrsled
a. RETARDATION: Slowness ol thought and 
speech: impaired ability to corrcenirale; 
decreased  motor activity
□   ^ Normal speech and thought
□  , Slight retardation at interview
□  J, Obvious retardation at interview 
n  J  In te rv iew  difficuil
□   ^ Complete stupor
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HAMILTON DEPRESSION SCALE 17-ITEM SCALE
9. AGITATION
O o  None 
Q ,  FdgôlinBss
□ ,  'Playing with" hands, hafe-, etc,
□  J Moving a50id, c a n t  sit still
□  ^  Hand-wringing, nail-blitng. hair-pulling,
bRing of lips
10. ANXIETY/PSYCHIC
d o  No difficulty
□ ,  Subjective zensâon and irfftability 
3 ,  Worrying about minor m atters
□  3 Apprehensive attitude apparent in lace or
sp e e c h ■
□   ^ F ea rs  expressed without questioning
11. ANXIETY (SOfilATIC) : Physiologicai con­
com itants of anxiefiy, such as: gastrointesti­
nal— cry mouth, wind, indigestion, diarrhea, 
c ram ps, belching: cardiovascular—palprta- 
^ n s ,  headaches: respiratory— hyperventila- 
fion, sighing: urlrary frequency; sweating,
O ,  A bsent
□  , Mild
□  j  Moderate
□  3 Severe
O *  încapsüciraîir^
12. SOMATIC SYMFTOMS/QASTRO- 
IfTTESTfNAL
O p  None
□ ,  Loss of appetite but eating without stall 
enocuragem ent. Heav>' feelings in 
abdom en
□  g Difficulty eailng wilhout staff urging.
R equests or requires laxatives or medi- 
calien  for bowels or medicafion for G1 
sym ptoms
13. SOIMATICSYfMPTOriiS/GENERAL 
O *  None
□ ,  H eaviness In limbs, back  or head.
B ackaches, headaches, muscle aches. 
Loss of *n«igy and fatigability 
Q  J Any claar-cut syraptom rwei 2
14. GENITAL SYMPTOMS: Loss of fibido. 
menstrual dSstumaixes
O g  Abseni 
□ ,  Mild
□  g Severe
15. HYPOCHONDRIASIS
□  g Not present
Q ,  Self-ebsorptiorî (bodily)
□  J Preoccupation with health
Q , Frequart complaints, requests for help, 
etc.
□   ^ Hypochoodriacal deiusiorw
ACTUAL WEIGHT CHANGE
(since the last visW)
16. LOSS OF WEIGHT
No weight loss or weight loss NOT 
caused by present Illness 
Q , Weight loss probably caused  by present 
iiiness
n  g Definite weight less caused  by present 
Illness ,
17. INSIGHT
□  ^  Acknowledges tîeing depneaaed and ill 
n ,  A cknow ieds^ illness but a tu tu te s
cau se  to bad food, climate, overwork, 
virus, need 1er nasi. etc.
□  g Denies beirg  IE a t all
Total Scone of Ouest-orys 1-17
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Appendix III: C R F-ZU N G
Zunq Self-Rating Depression Scak
INFORMATION NOT OBTAINED:
If the Woftnation was not obtained, place a tick (Xor V) in the INFORMATION NOT OBTAINED box. No 
other Infotmatkxi should appear under this module.
This Is a patient rated scale and should be completed by the patient
Ask the patient to complete the questionnaire using a black ball point Ink pen.
The patient should fill out the form per the instructions on the CRF.
The patient must circle the appropriate number for each of the questions.
IF THE PATÎENT LEAVES BLANKS FOR SOME ANSWERS:
If the patient is still In the office, ask the patient to complete the questions.
If the patient has left the office, the Investigator or Study Coordinator must document (in the CRF visit 
comments section) that the questions were not completed by the patient.
For example: "Patient did not complete question 5 of the Zung SeB-Ratmg Depression Scale."
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ZUNG SELF-RATING DEPRESSION SCALE
INFORMATION f'IOTOBTAINED □
Listed befow are 20 statements. Please o rc o  the appropriate number in each row indîcaüng how each 
of the foUowiftg siatemente has applied to you during the past week.
STATEMENT
KOMGgq usdT
Aumi S2we A ijo s o  cut m i
gPTKG a# THE FWTCf CFTHÊrw5 ïtMÏ THE Tlwe TW6
1. 1 feel downhearted and blue 2 3 4
2. .Morning is vrhen 1 feel tha bast 2 3 4
3.1 have crying spells or feel 1 ske it 2 3 4
4. 1 have troubla sleeping at night 2 3 4
S. I eat as much as  I used to 2 3 4
6. 1 stiH anjoy sex 2 3 4
7. 1 notlci that 1 am losing weight 2 3 4
8. 1 .have trouble with const^atlon 2 3 4
9. My heart beats faster than usual 2 3 4
10, f get tired for no reason 2 3 4
11. My mind is aa d ee r  as it used to be 2 3 4
1 a, 1 find R easy to do the things 1 used to do 2 3 ’ 4
i a  1 am restless and can't keep stilt 2 3 4
14. 1 fcsl hopeful about tha tuturia 2 3 i
t5. lam  more Irritable than usual 2 3 4
19.1 find It easy to maxe decisions 2 3 4
17.1 feel that I am useful and needed 2 3 4
18 My life :s pretty iulf 2 3 4
19. 1 feel that others would ba batter off if f were dead 2 3 4
2 0 .1 still enjoy the things 1 used to do 2 3 4
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Appendix IV: CFQ
COGNITIVE FAILURES QUESTIONNAIRE
INFORMATION NOT OBTAINED:
If the information was not obtained, place a  tick (X or V) in the INFORMATION NOT OBTAINED box. No 
other information should appear under this module.
This is a  patient rated sca le  and  should  be com pleted  by the  patient.
Ask the patient to complete the questionnaire using a black ball point ink pen.
The patient should fill out the form per the instructions on the CRF as follows:
Visit 1 = "In the last three months”
Visits 2-14 = "Since the last visir
The patient must circle the appropriate nunriser for each of the quesitons.
SUBSCORE:
Add the number of the circled responses (i.e., very often, quite often, etc.) for each category questions 1- 
25 and place in the subscore box,
TOTAL SCORE:
Add the four subscores and place in the total score blank.
IF THE PATIENT LEAVES BLANKS FOR SOME ANSWERS:
If the patient is still in the office, ask the patient to complete the questions.
If the patient has left the office, the Investigator or Study Coordinator must document (in the CRF visit 
comments section) that the questions were not completed by the patient.
For example: “Patient did not complete question 5 of the Cognitive Failures Questionnaire."
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COGNITIVE FAILURES QUESTIONNAIRE
g INFCRMATHDN NOT OBTAINED □
Tha fcCowing questions a/o about minor mistakas which everyone makes frwn time to (fme, but some 
of which happen more often than others, We want lo know hovr often Lneso things have happened to
Please circle the appropriate number:
/ ' V v
1, Do you read sornethmg and find you haven't been
Ihnddng about l( and must read R again? 4 3 2 1 0
2. Do you find you forget why you went from ono part
of the bouse to tha cthar? 4 3 2 1 ' 0
3. Do you fail to noticD signposts on the road? 4 3 2 1 0
4. Do you find you confuse right and left when giving
directions? 4 3 2 1 0
5, Do you bump Into people? 4 3 2 1 0
$. Do you find you forgel whether you’ve turned off a light
o ra  fire or locked Ihe door? 4 3 2 1 0
7. Do you faB lo listen to people's names when you are
meetmg them? 4 3 2 1 0
a  Do you say  something and rcaHae afterwards that il might
bo taJcon as insuifing? 4 3 2 1 9
9. Do you fail to hear people speaking to you when you are 
doing something § 4e? 4 3 2 1 0
10, Do you lose your temper end regret H? 4 3 2 1 0
11. Do you leave important tetters unansw9red lo-r days? 4 3 2 1 0
12, Do you find you lorget which way to lurn on a  reed you
know wbR txit rerety use? 4 . 3 2 1 0
13. Do you Jail to see what you want in & supermarket
(although 1rs there)? 4 3 2 1 0
14. Do you find yourself sudderty wondering whether you
used a  word correctly? 4 3 2 t 0
15. Do you have trouble making up your mirid? 4 3 2 1 0
16. Do you find you fceget appointmerrls? 4 3 2 1 0
17. Do )"OU forget where you put somalhing like a newspaper
oralxcdc? 4 3 2 1 D
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Paga 3a c*f 8
P lease  circle the appropriate rum ber.
1B. Co you I'tnd you acsqidenify ihnyw o;my tho thing ycu 
want and keep what you moant to ihfow aw ay? in 
th* exairpM c( ihrawng asway Sid matehOscK and putting the 
m a tc h  iff your pcckDî.1
19. Do you daydream  when you ought to be  listening lo 
som ething?
20. Do you ttnd you forget people's names?
21 r Do you start domg one thing st home end get
distracted Into doing som ething e lse  (unintentionally}?
22. Do you find you canl quite remembor something 
although on the tip of your tongue?
23l Do you find you forget what you cam e  to d ie  shops 
to buy?
24. Do you drop thirds?
25. Do you find you carrt think of anything to say?
S . d  a  a c t  a
y
Total Score;,
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Appendix V: LSEQ
LEEDS SLEEP EVALUATION QUESTIONNAIRE
INFORMATION NOT OBTAINED:
If the informabqn was not obtained, place a tick (X or V) In the INFORMATION NOT OBTAINED box. No 
other Information should appear this module.
This is a patient rated scale and should be completed by the patient
Ask the patient to complete the quesdonnafre using a black ball point Ink pen.
The patient should f IN out the form per the instructions on the CRF as follows:
Visk 1 = "Compare oettlna to sleep last nkxN wkh aettma to sleep in the oast weelT
VisMs 2-14 = "Compare oettinn to sleep usina the médication with oeMino to sleeo nomnallv i.e. without 
the medlcaMon"
IF THE PATIENT LEAVES BLANKS FOR SOME ANSWERS:
If the patient is stiU in the office, ask Ae patient to complete the questions.
If the patient has left the office, the Investigator or Study Coordinator must document (in the CRF visit 
comments sectkm) that the questions were not completed by the patlenL
For example: "Patient dW not complete question 4 of the Leeds Sleep Evaluation Questionnaire."
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LEEDS SLEEP EVALUATION QUESTIONNAmE
INFORMATION NOT OBTAINED □
Each question ts answered by placing a vertical r^arlc on the line. It no change was experlefKed ^ en  
place a mark in lha mnddfe of W  lire. If a change was experienced tt%n posflion your mark according to 
the nature and extent of .the change.
1. How would you compare getling to sleep Fast night with getting to sleep the past week?
a. E asier than 
usual
Harder than 
Usual
b. Quicker than 
usual
Slower than 
usual
c. Felt m ore 
drowsy than 
usual
Fait jess 
drowsy than 
usual •
2. How would you compare the quafty of sleep last night with tt% quality of sloop Irv the past week?
More restful 
than usual
L ess nssdul 
than usual
b. Fewer periods 
of wakefulness 
than usual
More periods 
of wakofulrwss 
than usual
3. How did your awakening this morning compare with your pattern of awakening in the past week?
a. Easier ttian 
usual
More tSfjicuft 
than usual
b. Took shorter 
ifïan usual
Took longer 
than usual
4. How did you feel on waking? 
a. Afcrt ----------------- Tired
5, How was your sense of balança and coordination upon getting up?
a. L ess clumsy 
than usual
More clumsy 
than usual
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LINE ANALOGUE RATING SCALES
INFORMATION NOT OBTAINED:
II the information was not obtained, place a tick (X or V) in tfie REFORMATION NOT OBTAINED box No 
otiier information sfrould appear under this module.
This Is a patient rated scale and should be completed by the patlenL
Ask the patient to complete the questionnaire using a Mack ball point ink pen.
The patient stioukl fill out the form per the Instmctions on the CRF.
IF THE PATIENT LEAVES BLANKS FOR SOME ANSWERS:
If the patient is sdll in tfie office, ask the patient to complete the questions.
If the patient has left the office, the Investigator or Study Coordinator must documerA (in the CRF visit 
corrsnents section) that the questions were not completed by the paient.
For example: "Patient dd not complete a line of the Line Analogue Rahng Scales."
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UNE ANALOGUE RATING SCALES
INFORMATION NOT OBTAINED □
Thés# scâiéè axe designed te allow you to a s se ss  how you fool new compared to how you 
usually feel. Per each of the etoveh ânes you should place a  Venice! mark somewhere along the line 
to IndK-ate how you feet. The closer you mark towards either end of the line, the greater the change in 
your feelings. If you ere feeling no different from usual then place the mark in the middle of the line, if 
you make a  mistake, scone cut the error with a single W  and initie: and date the error. Remember 
the marks axa to show how you are feeling now.
More
anxious
Less
anxious
Less
tired
More
tired
Less
happy
More
happy
More
relaxed
Lass
relaxed
More
drov/sy
Less
drowsy
Less
dlziy
More
dizzy
Less
clumsy
More
ctomsy
Mora
alert
Less
alar;
Less
energetic
More
energetic
More
sad
Less
sad
More
depressed
Less
d e p re s s e d
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Appendix VII: CRF -  CRT and CPF Instructions
'ege 6a od 8
CRT RESULTS
INFORMATION W T  OBTAINED □
MRT <rw) T i m a  f £ 4 . t i o u '  c to r.k )
RRT {ms) 
TRT (ms) .
CRITICAL FLICKER FUSION RESULTS
INFORMATION NOT OBTAINED G
CFFrHz) Tima ( z c - tv u t dock)
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Appendix VIII: Diary over clock change patient AlO
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Appendix IX: Actiwatch actogram for patient AlO AW 1
AW  start time reset for incorrect com puter clock, matches diary
5  Actogram
File Copy Display O ptions Graphs Markers 
Light On
I 06*0
aI X I j J
Light Off
18*0
j J H L lI
Activity Scale
I 2 0 0 0
s ta rt Day
I d e n t it y :  a l O a
S t a r t  d a t e :  0 4 - J a n - 1 9 9 9  ( M o n )
S t a r t  T im e :  1 7 : 3 6
A g e :  4 1
I n t e r v a l :  1 . 0 0
S e x :  F
00:0012:00 1 8 : 0 0 00:00
04.Jan |l
iU M iàOWan
06-Jan
07^ an
.iUjftitùlluàkiJL.L0&-Jan
09-Jan
10-Jan
j... [)>iii|tfLl llliiiiiiLlillii bkiJnL..,Jii11-Jan
12^ an
ill MilUiMiiiil hi i
U.,.4lifc
13~Jan
14-Jan
15-Jan
16-Jan
17-Jan
tl . iJiJlUlLl4'lÉLkllMik^ ..Jt
I L .,
JLx|
jLu.jk
.la .jL .*  ^
.iA
18-Jan
19-Jan
Ü. ..^ JLiuyi lÉLk
h'*
20-Jan
21-Jan
22-Jan
fljJ.
, . L . .
23-Jan
24-Jan
,  I-..ÜLU.L aiijL25-Jan
26-Jan
27-Jan
2&Jan
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Appendix X: AW file for patient AlO AW2
Last 2 days after clock changed, 2 min epoch. AW  set up before clock change, downloaded 
after clock change
5  A ctogram  
File Cdpy Display O ptions Graphs Markers 
Light On
06*0
X X Z jJ
Light Off
18*0
Aj~_r_d
Activity Scale
s ta rt Day
Start Time
00*0
a 1 0 b
0 1 T e b - 1 9 9 9 ( H o n )  
1 9 : 0 0
Mennty:
n t e r v a  :S t a r t  d a t e :
S t a r t  T im e :
12:0000:00
01-Feb t,k ti..
OS-Feb
05-Feb
07-Feb
09-Feb
I ■ M i l  il I I
jéuMiajIuiHiiJilUii
11-Feb
.LltaiM ■ aJ.
i..b } ..kJ lyAhA-iA, iLiii 
iiÜ É lÉ É h  ‘1 I f
15-Feb
17-Feb
■JllU.ilfc ikil.J
19-Feb püÊLÀX
21-Feb
27-Feb
01-Mar
03-Mar
05-Mar nil iMiat
07-Mar
09-Mar
UwLhA. . . j ;
11-Mar
13-Mar
15-Mar
17-Mar
19-Mar
dL*tu4,l.iL* • ,
ua.il
21-Mar
23-Mar
25-Mar
27-Mar
29-Mar
31-Mar
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Close up view of GMT to BST patient AlO
Actogram
File Copy Display O p ^ n s  G raphs Markers
Light On I d e n t it y :  a 1 0 b
S t a r t  d a t e :  0 1  T e b - 1 9 9 9  ( M o n )
S t a r t  T im e :  1 9 : 0 0
A g e :  4 2  S e x :  F
I n t e r v a l :  2 . 0 0
Light Off 12:00 1 8 : 0 0 00:00 0 6 : 0 0 12:0000:00 0 6 : 0 0
18*0 
iIZJX J
Activity Scale 21-Mar
&22-Mar
lU Z X J
23-Mar
24-Mar
25-Mar
26-Mar
Start Day 27-Mar
28-Mar
Start Time
29-Mar
00:00
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Appendix XI: Sleep analysis during clock change from GMT to BST patient AlO
FUe Copy Summaiy Sensitivity Sleep-Wake Markers Sleq) Diary 
Idenlitjp : alOb
Start date : 01-Feb-1999 (Mon] 
Start Time : 19:00
Ape : 42 Sea : F
Interval : 2.00
Day Scale
Fri 26-Mar-1999 Sat27-M of-1999
21.00 22 HfJ—23 00*00 00 01 00 02 00 03 OP 04 00 05.00 06:00 Q7.U0 00 0fj-.09 00
r  f  »l Anatyaii end I 09:1521:00 Analytis start
Bedtime 22:36
07ÆO 188.2 % Actual awake time { 00:56 |11.8 %
Mean iengtt) of sleep bouts [ 00.21:00 
Mean length of wake bouts I 00:02:48
Sleep efficiency {% 
Sleep latency
No of minutes immobile | 306.O (T6.9 % 
Hoof ^m obile  phases j 44 
Immobility phases of 1 min | q
Total activity score | 5683^
Wake movement js îM J
Ho of minutes moving | j i o  o [ 23.1 % 
ean length of Immobility | @3 
Immobility of 1 min (%) j ô!Ô Fragmentation indexj
Mean activity score J 23.88 Mean score in srtivs periods]
File Copy Summary Sensitivity Sleep-Wake Markers Sleep Diaiy
Identity : alOb
Start date : 01-Feb-1999 (Mon) 
Start Tune : 19:00
Age : 42 Ses : F
Interval : 2.00
Sun 28-Mar-1999
Day Scale
00 22 01—73 00*mnn 01 DO 02 no 0.3:00 04 00 05-00 06 00 07 00 00 (lU^nj 00
► I Analysis
I >1 Get up
r  Sleep end | 06:50
Bedtime 22:36 Time m Bed 08-.22
Assumed sleep 07:38
00:18 \ T f  %07:20 96.1 %
Sleep efticiency ( \] |  gy.g 
Sleep latency I 00:36
Mean length of sleep bouts | 00:48:53 
Mean length of wake
Wake movement | 922.4
Ho of minutes immobile | ZdOJi 178.6 % No of minutes moving f i O " "  [21% %
Hoof immobile phases I 39 Mean length of immotMhty ) 9j
Immobility phases of 1 min I ô Immobility of 1 min (%) j ô!Ô Fragmentation index] 21.4
Total activity score | 2795 Mean activity score | 12.21 Mean score In active pehodsj 57.04
I—
File Copy Summary Sensitivity Sleep-Wake Markers Sleep Diary
Identity : alOb
Start date : 01-Feb-1999 (Mon) 
Start Time : 19:00
Sun 28-Mar-1999 Mon 29-Mor-1999
21.90 2.! Ill'—73 U0“9rj 00 01 00 02 00 0.100 04 00 05.00 06 00 07 00
Analysis21 AO Analysis start
Bedtime I 21:44 < I I » I 
AUTO Sleep Stan | 22:20
Time m Bed] Q9:10 
Assumed sleep] 08:28
Get up time 96:54
Sleep end 06:48
Actual awake time f 01:18 Il5.4 %Actual steep time j 07:10 184.6 %
Sleep efficiency (%)]78>2 
Sleep latency] 00:36
Mean length of sleep txHits j 00:20:29 
Mean length of wake bouts | 00:03:43
Woof sleep bouts | 21
Number of wake twuts j X Ï
No of minutes unmobtfe | 4OO.O |78J % No of minutes moving | 108.O 121.3 %
No of Immobile phases j 37 Mean length of immobility | 10.8
ImmotMUty phases eâ 1 min [ q Immobility of 1 mm (%) { ô!Ô
Total actrvtty score ] g084 Mean activity score
Wake movement j 92&I
Fragmentation Uidexj 21.3 
Mean score In active periods] 149.70
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Appendix XII: Actogram for patient AlO, AW3 during discontinuation week 13 and resumption of 
treatment week 14
G . A ctogram  
File Copy Display O ptions G raphs Markers 
Light On
06*0  
Light Off
I 18*0
XZLLlJ
Activify Scale
I 2 0 0 0
jlT -T X
Zero
Start Day
I T
i_
start Time
00:00
I d e n t it y :  a l O c
S t a r t  d a t e :  2 9 - M a r - 1 9 9 9 ( M o n )
S t a r t  T im e :  1 9 : 0 0
A g e :  4 2  S e x :  F
I n t e r v a l :  1 . 0 0
1 8 : 0 000:00 0 6 : 0 0 12:000 6 : 0 0 12:00 1 8 : 0 000:00
29-Mar
30-Mar
31-Mar
01-Apr
02-Apr
AW.1I11LLM Jiti iL ..\03-Apr
04-Apr
05-Apr
06>Apr
07-Apr
OS-Aor
09-Apr
J  k I k .I10-Apr
11-Apr
12-Apr
13-Apr
00:00
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X
1
I
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m ro ro
œ  (T, œ
CTi CTi 0*1 0*1 cj\ <j\ <y\ a\CTi CTi (Ti <Ti 0> (Ti en (Ti œ<n (T\ en  (Ti
•X» PO Lf) VX)LO CSJ PO LG ro PO PO 'îT
LO PO co <D00 PO oc rH  PS] <n en
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en en en en
CM LOlO  CM CM lo
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Appendix XIV; Example of sleep diary
Daily Habits and Sleep Questionnaire
Please this section in the ewnlngL before going to bed.
Today's Dale Time
1 1 1 1 1
E
s 1
E
§ g 1 1 1 : 1 .1 1 1
Ea E3 1 1 1 1
Enter. C •  GafWn: -Tea. Coffs*. Ctrta, ChocDbteï E -  Ejatfdse; A -  Atohol: M » k M a C o n ; N •  Naç>\ F -  Food 
Any atSJtlord commente
Please complete this section m the morning, wtttiln 15-25 mine of w ^ n q .
Today's D ie Time
1 .
2-
How rareshed dM you feel upon awaking up? (place a .emcal mark on tne Ine below].
UstataB----------------------------------------------------------------
How 'A3S the qualty of yoix sleep last rtgft? (place a  vertical mart on tfe  ine below]
Mery good------------------------------------------------------------------------------weryt«d
3. M ien dd  yxi go to bed last rfgnt pigfts oufi?
4. How long ddlttakeytxj to ta l asleep?
5. How many times dd  you wme up?
6. M iat was t ie  total di4i l  on of these right awakenings?
7. How many times d d  you get up to use tîR PaQtoom?
8. Mien d d  you th a ly  wake tp  tuts momng?
9. Dd you wme ip  ean^r *Jian intended?
If answer Is Yes; By how much eader?
10. Mien d d  you get ip  this mcmlng?
11. How d d  you awaken IMS morning?
e.g. ianrVdsturPance.'naluFaliy?
12. How long d d  you sleep last dgpit iTtne t i n  failng asleep
% waking m die rnomng. exdudng a'l w ^ n g  periods]?
13- Dd you lake any naps yesterday?
IT Yes, how many napa and for how long In '.dal?
Any adrfflona commente
 :____ i24 hour dock)
 Hocrs  Mns
 Times
 Hours  Mr»
 Times
 : _____|24 hour dock)
□  Y O N  
 Hoirs Mhs
 : _____(24 hour dock)
 HOUB
□  Y O N  
 Naps .
M r»
Hours M r»
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